<SEC-DOCUMENT>0001144204-13-067106.txt : 20131213
<SEC-HEADER>0001144204-13-067106.hdr.sgml : 20131213
<ACCEPTANCE-DATETIME>20131213115907
ACCESSION NUMBER:		0001144204-13-067106
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20131213
DATE AS OF CHANGE:		20131213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-189794
		FILM NUMBER:		131275510

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>v362816_424b2.htm
<DESCRIPTION>424B2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(2)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-189794</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To the Prospectus dated July 16, 2013)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>11,500,000 Shares</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="slogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;We
are offering 11,500,000 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and
the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our common stock
is listed on the NYSE MKT under the symbol &ldquo;SYN.&rdquo; On December&nbsp;10, 2013, the closing price of our common
stock was $1.35 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of December 11,
2013, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $44,922,912, based
on 44,654,414 shares of outstanding common stock, of which approximately 17,262,394 shares are held by affiliates, and a per
share price of $1.64 based on the closing sale price of our common stock on October 22, 2013. We have not offered any
securities during the past twelve months pursuant to General Instruction I.B.6 of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Our business and
an investment in our common stock involve significant risks. See &ldquo;<FONT STYLE="color: windowtext">Risk Factors</FONT>&rdquo;
beginning on page S-7 of this prospectus supplement and on page&nbsp;5 of the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Per</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">11,500,000</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Underwriting discount<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>.065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">747,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>10,752,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 13.7pt"><SUP>(1)</SUP></TD><TD>The underwriters will receive compensation in addition to the underwriting discount. See &ldquo;Underwriting&rdquo; beginning
on page S-12 of this prospectus supplement for a description of compensation payable to the underwriters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have granted a 45-day option to the underwriters
solely to cover over-allotments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriters expect to deliver the shares
against payment therefor on or about December 17, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aegis Capital Corp</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 11, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></TD>
    <TD STYLE="text-align: right">i</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="text-align: right">i</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INDUSTRY AND MARKET DATA</FONT></TD>
    <TD STYLE="text-align: right">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUPPLEMENT SUMMARY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE OFFERING</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DILUTION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDEND POLICY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CAPITALIZATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">UNDERWRITING</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE OFFERING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDEND POLICY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF CAPITAL STOCK</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATED OF CERTAIN INFORMATION BY REFERENCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document is part
of the registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo;
registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated
by reference, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the
documents incorporated by reference, gives more general information, some of which may not apply to this offering. Generally, when
we refer only to the &ldquo;prospectus,&rdquo; we are referring to both parts of this document combined. This prospectus supplement
may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus
supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If information in this
prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference that was
filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus
supplement, the accompanying prospectus and the documents incorporated into each by reference include important information about
us, the securities being offered and other information you should know before investing in our securities. You should also read
and consider information in the documents we have referred you to in the section of this prospectus supplement and the accompanying
prospectus entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You should rely only
on this prospectus supplement, the accompanying prospectus and any free writing prospectus we may provide to you in connection
with this offering and the information incorporated or deemed to be incorporated by reference therein. We have not authorized anyone
to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus
supplement and the accompanying prospectus. If anyone provides you with different or inconsistent information, you should not rely
on it. We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not
assume that the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus
is accurate as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as the case
may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery
of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition,
liquidity, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No action has been
or will be taken in any jurisdiction by us or the underwriters that would permit a public offering of the common stock or the possession
or distribution of this prospectus supplement and the accompanying prospectus in any jurisdiction, other than in the United States.
Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus
supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus
do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities
offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful
for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Some of the statements
contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus may include forward-looking
statements that reflect our current views with respect to our ongoing and planned clinical trials, business strategy, business
plan, financial performance and other future events. These statements include forward-looking statements both with respect to us,
specifically, and the biotechnology sector, in general. We make these statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Statements that include the words &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;will&rdquo; and similar statements of a future or forward-looking nature identify forward-looking
statements for purposes of the federal securities laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All forward-looking
statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results
to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, those
factors set forth under the caption &ldquo;Risk Factors&rdquo; in this prospectus supplement and in the accompanying prospectus
and under the captions &ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; in our most recent Annual Report on Form&nbsp;10-K and Quarterly Report
on Form&nbsp;10-Q, all of which you should review carefully. Please consider our forward-looking statements in light of those risks
as you read this prospectus supplement and the accompanying prospectus. We undertake no obligation to publicly update or review
any forward-looking statement, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If one or more of these
or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially
from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on
our behalf are expressly qualified in their entirety by this Note. Before purchasing any shares of common stock, you should consider
carefully all of the factors set forth or referred to in this prospectus supplement and in the accompanying prospectus that could
cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDUSTRY AND MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We obtained the industry
and market data in this prospectus supplement from our own research as well as from industry and general publications, surveys
and studies conducted by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to
give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future
performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety
of factors, including those described in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement. These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: center"><B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: left; text-indent: 0.5in"><I>The items
in the following summary are described in more detail elsewhere in this prospectus supplement and in the documents incorporated
by reference herein. This summary provides an overview of selected information and does not contain all the information you should
consider before investing in our common stock. Therefore, you should read the entire prospectus supplement and any free writing
prospectus that we have authorized for use in connection with this offering carefully, including the &ldquo;Risk Factors&rdquo;
section and other documents or information included or incorporated by reference in this prospectus supplement before making any
investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a biotechnology
company focused on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing
an oral enzyme for the prevention of <I>C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment
of Pertussis and <I>Acinetobacter</I> infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting
multiple sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product Pipeline:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 700"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Summary of Infectious Disease Programs:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B><I>Clostridium difficile
(C. difficile, C. diff)</I>&nbsp;infections:</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="color: black">We
are in preclinical development with</FONT> SYN-004, a novel second-generation oral enzyme drug candidate, for co-administration
with commonly used IV antibiotics intended to prevent the development of severe effects of <I>C. diff</I> infections<FONT STYLE="color: black">,
the leading cause of hospital acquired infections, that generally occur secondary to treatment with intravenous antibiotics.</FONT>
Designed to be given orally to protect the gut while certain IV beta-lactam antibiotics (penicillins and cephalosporins) fight
the primary infection, SYN-004 is believed to have a similar profile to its first-generation predecessor, which demonstrated favorable
protection of the gut flora (microbiome) during <FONT STYLE="color: black">treatment with certain penicillins, with the potentially
added ability to act against</FONT> a broader spectrum of IV beta-lactam antibiotics. <FONT STYLE="color: black">Beta-lactam antibiotics
are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.</FONT>
Roughly 14.4 million patients are administered &quot;SYN-004 target&quot; IV beta-lactam antibiotics annually, representing an
estimated target market for SYN-004 of 117.6 million beta-lactam doses purchased by U.S. hospitals. While the final dosing regimen
for SYN-004 is yet to be determined, the addressable market is extremely significant. Currently there are no approved treatments
designed to protect the microbiome from the damaging effects of IV antibiotics. This worldwide opportunity could represent a potential
multi-billion dollar market.<FONT STYLE="color: black">* In October 2013, we initiated</FONT> manufacturing of SYN-004 material
to support our planned preclinical and clinical studies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 1.25in">*This information is an estimate derived from the use of information
under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly
reserves all rights, including rights of copying, distribution and republication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 1.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt 1.25in; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>Pertussis:</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="color: black">In December 2012, in collaboration with Intrexon Corporation (NYSE: XON) (&ldquo;Intrexon&rdquo;), we
initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as
whooping cough. We are developing a mAb therapy, SYN-005, designed to target and neutralize the pertussis toxin, in order to reduce
the mortality rate in infants and potentially shorten the duration of chronic cough in afflicted adults. To further the development
of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin to license the rights
to certain research and pending patents related to pertussis antibodies. According to the World Health Organization, each year,
<I>B. pertussis</I> infection causes an estimated 300,000 deaths worldwide, primarily among young, unvaccinated infants.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 29.7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B><I>Acinetobacter</I>&nbsp;infections:</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="color: black">In September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for
the treatment of <I>Acinetobacter</I> infections. Many strains of <I>Acinetobacter</I> are multidrug-resistant and pose an increasing
global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. A treatment for <I>Acinetobacter</I>
infections represents a billion dollar market opportunity.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 29.7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 31.9pt"><B><I>Summary of Multiple
Sclerosis Program:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 29.7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Trimesta<SUP>TM</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="color: black">(oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting multiple sclerosis
(&ldquo;MS&rdquo;) in women. Patient enrollment is complete in this two-year, randomized, double-blind, placebo-controlled Phase
II clinical trial being conducted at 15 centers in the United States. The primary endpoint is relapse rate at two years, with top-line
results expected in 1H 2014. This trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial
through completion. Annual worldwide sales of current MS therapies are estimated at $14.1 billion.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Trimesta</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="color: black">is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month
randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at the University of California, Los Angeles
(&ldquo;UCLA&rdquo;). The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test
(&ldquo;PASAT&rdquo;). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations
and charitable organizations and we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three
years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently
no approved treatment.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: -15.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>Summary of Fibromyalgia
Program:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Effirma<SUP>TM</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="color: black">(flupirtine) is being developed for the treatment of fibromyalgia by Meda AB (Meda), a multi-billion
dollar international pharmaceutical company. On May 6, 2010, we entered into a sublicense agreement with Meda covering all of our
patents&rsquo; rights on the use of flupirtine for fibromyalgia in the United States, Canada and Japan. The sublicense agreement
provides that all ongoing and future development costs are to be borne by Meda and we are entitled to receive certain payments
if milestones are achieved and royalties on sales. According to Meda&rsquo;s 2012 Year-End Report filed in February 2013, Meda
has received the go-ahead from the United States Food and Drug Administration (&ldquo;FDA&rdquo;) to conduct a Phase II proof of
concept study for the treatment of fibromyalgia. Meda also announced that the randomized, double-blind, placebo and active-controlled
study of patients with fibromyalgia will be conducted at 25 clinics in the United States Based on an estimated annual price of
$1,200 per fibromyalgia patient, we estimate that the total market potential in the United States is $6 billion.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: left; text-indent: 0.5in">In order to further
prioritize our focus, we elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis.
However, we are seeking development partners for our zinc-based intellectual property and assets including, AEN-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 29.7pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 5, 2013,
we, through our newly formed, majority owned subsidiary, Synthetic Biomics, Inc. (&ldquo;SYN Biomics&rdquo;), entered into a worldwide
exclusive license agreement (the &ldquo;CSMC License Agreement&rdquo;) and option agreement (the &ldquo;CSMC Option Agreement&rdquo;)
with Cedars-Sinai Medical Center (&ldquo;CSMC&rdquo;) for the right to develop, manufacture, use, and sell products for the human
and veterinary therapeutic and prophylactic treatments for acute and chronic diseases discovered by an investigational team led
by Mark Pimentel, M.D. at CSMC to be associated with pathogenic gastrointestinal microorganisms, including for example, irritable
bowel syndrome (IBS), obesity and type 2 diabetes. The portfolio of intellectual property licensed to SYN Biomics under the License
Agreement includes 9 issued U.S. patents, 1 issued European patent validated in 18 countries, 1 issued European patent validated
in 3 countries, 2 issued Australian patents, and 1 issued Japanese patent as well as 13 pending U.S. and international patent
applications for most fields of use and modalities (subject to certain agreed-upon exceptions); two pending U.S. patent applications
are optioned to SYN Biomics under the Option Agreement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The CSMC License
Agreement provides that we will issue to CSMC 291,569 unregistered shares of Company common stock, subject to approval by the
NYSE MKT, LLC, or in the event such shares are not issued within 30 days, pay to CSMC in the form of cash, an initial license
fee and patent reimbursement fee of $150,000 and $220,000, respectively. The parties also entered into a Stock Purchase
Agreement with respect to such stock issuance and other issuances of our unregistered shares of common stock that may be
issued to CSMC in lieu of cash, including license fees, milestone payments expense reimbursements and options fees under the
CSMC License Agreement or CSMC Option Agreement. Any and all such stock issuances by us shall be subject to the prior
approval of the NYSE MKT, LLC. The CSMC License Agreement also provides that commencing on the second anniversary of the CSMC
License Agreement, SYN Biomics will pay an annual maintenance fee, which payment shall be creditable against
annual royalty payments owed under the CSMC License Agreement. In addition to royalty payments which are a percentage of Net
Sales (as defined in the CSMC License Agreement) of Licensed Products (as defined in the CSMC License Agreement) and Licensed
Technology products (as defined in the CSMC License Agreement), SYN Biomics is obligated to pay CMSC  a percentage of any
non-royalty sublicense revenues as well as additional consideration upon the achievement of the following milestones (the
first two of which are payable in cash or our unregistered shares of stock at our option): (i) successful Phase I trial
completion of the first Licensed Product or first Licensed Technology Product; (ii) successful Phase II trial completion of
the first Licensed Product or first Licensed Technology Product; (iii) initiation of Phase III dosing for each additional
indication of a Licensed Product or Licensed Technology Product; (iv) successful Phase III trial completion for each Licensed
Product and each Licensed Technology Product; (v) the FDA&rsquo;s acceptance of a New Drug Application for each Licensed
Product and each Licensed Technology Product; (vi) regulatory approval for each Licensed Product and each Licensed Technology
Product; and (vii) the first commercial sale of each Licensed Product and each Licensed Technology Product. The stock
issuances are subject to prior approval of the NYSE MKT, LLC. The CSMC License Agreement automatically terminates upon the
occurrence of certain events and SYN Biomics has the right to terminate the CSMC License Agreement without cause, upon 6
months notice to CSMC however, upon such termination, SYN Biomics is obligated to pay a termination fee with the amount
of such fee reduced: (i) if such termination occurs after an IND submission to the FDA but prior to completion of a Phase
II clinical trial; (ii) reduced further if such termination is after completion of Phase II clinical trial but prior to
completion of a Phase II clinical trial; and (iii) reduced to zero if such termination occurs after completion of a Phase III
clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Prior to the
execution of the License Agreement, we issued shares of common stock of SYN Biomics to each of CSMC and Mark Pimentel, M.D.
(the primary inventor of the intellectual property), representing 11.5% and 8.5%, respectively, of the outstanding shares of
SYN Biomics (the &ldquo;SYN Biomics Shares&rdquo;). The Stock Purchase Agreements for the SYN Biomics Shares provide for
certain anti-dilution protection until such time as an aggregate of $3,000,000 in proceeds from equity financings are
received by SYN Biomics as well as a right, under certain circumstances in the event that the SYN Biomics Shares are not then
freely tradeable, and subject to NYSE MKT, LLC approval, as of the 18 and 36 month anniversary date of the
effective date of the Stock Purchase Agreements, for each of CSMC and the Mark Pimentel to exchange up to 50% of their SYN
Biomics shares for unregistered shares of our common stock, with the rate of exchange based upon the relative contribution of
the valuation of SYN Biomics to our public market valuation at the time of each exchange. The Stock Purchase Agreements also
provide for tag-along rights in the event of the sale by us of our shares of SYN Biomics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: left; text-indent: 0.5in">Pursuant to
the terms of the CSMC Option Agreement, SYN Biomics has a period of six months to negotiate an exclusive license to develop,
manufacture, use, and sell biologic products relating to the prevention, acute treatment and chronic treatment of irritable
bowel syndrome or other indications utilized or derived from certain optioned patent applications pending completion of
certain limited testing of technology embodied in the patents applications. The CSMC Option Agreement provides that, within
30 days of the execution of the CSMC Option Agreement, we are obligated to pay to CSMC a non-refundable option fee of 43,342
shares of our unregistered stock, or $50,000 cash in the event such issuance is not approved by NYSE MKT, LLC. In addition,
SYN Biomics has the right to extend the option period for an additional six months, for an additional non&ndash;refundable
extension fee of $25,000, payable in our unregistered shares of common stock having a market value of 110% of such amount,
subject to approval of NYSE MKT, LLC, or in cash. At any time during the 6 or 12 month option period (if so extended) SYN
Biomics has the right to exercise the option and negotiate an exclusive license to be optioned patent applications, which
shall provide for (i) a $50,000 license issue fee plus reimbursement of patent expenses incurred by CSMC prior to the
exclusive license payable to CSMC in our unregistered shares of stock having a market value of 110% of such amount, subject
to approval of the NYSE MKT, LLC, or in cash, (ii) the same milestone payments, royalties and sublicense fees as are payable
under the CSMC License Agreement, and (iii) such other customary terms and conditions CSMC typically includes in its license
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: left; text-indent: 0.5in">In
collaboration with Intrexon Corporation, and partially utilizing the intellectual property optioned or licensed from
CSMC described in the CSMC Option Agreement, we and SYN Biomics intend to develop biologic approaches for the prevention,
and acute and chronic treatment of a subset of irritable bowel syndrome (IBS) pathologies specifically caused by
auto-antibodies. During the option period, we, SYN Biomics and Intrexon will seek to create and test a variety of biologic
candidates for the treatment of IBS. This biologic program has been selected as the third target under our exclusive channel
collaboration with Intrexon Corporation dated August 6, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On July 3, 2013, we
entered into a Controlled Equity Offering<SUP>SM<B> </B></SUP>Sales Agreement with Cantor Fitzgerald &amp; Co.<B><SUP> </SUP></B>pursuant
to which we may offer and sell shares of our common stock in an at-the-market public offering for up to $15,000,000 of shares of
our common stock from time to time through Cantor Fitzgerald&nbsp;&amp; Co., acting as agent (the &ldquo;ATM&rdquo;)<FONT STYLE="color: black">.
As of the date of this filing, we have not sold any shares under the ATM. We amended the </FONT>Controlled Equity Offering<SUP>SM
</SUP>Sales Agreement on December 10, 2013 to limit our ability to sell shares of our common stock under such agreement to the
lesser of $15,000,000 or the amount that we can sell under General Instruction I.B.6 of Form S-3, if still applicable, after this
offering. We will not use the ATM unless and until we file an updated prospectus supplement reflecting the number or dollar amount
of shares which we may sell under the ATM after taking into account the foregoing amendment, but only if such amount is less than
$15,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 19, 2012,
we entered into a Patent License Agreement (the &ldquo;License Agreement&rdquo;) with The University of Texas at Austin (the &ldquo;University&rdquo;)
for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related
to Pertussis antibodies developed in the lab of Dr. Jennifer A. Maynard, Assistant Professor of Chemical Engineering. In connection
with the License Agreement, we and the University also entered into a Sponsored Research Agreement pursuant to which the University&nbsp;is
performing certain research work related to pertussis under the direction of Dr. Jennifer Maynard and we will obtain certain rights
to patents and technology developed during the course of such research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November 28, 2012,
a closing was held for the transaction contemplated by the Asset Purchase Agreement (the &ldquo;Prev Agreement&rdquo;) we entered
into with Prev ABR LLC (&ldquo;Prev&rdquo;), pursuant to which we acquired the <I>C. diff</I> program assets of Prev, including
pre-Investigational New Drug (&ldquo;IND&rdquo;) package, Phase I and Phase II clinical data, manufacturing process data and all
issued and pending United States and international patents. Pursuant to the Prev Agreement, we paid Prev an initial cash payment
of $100,000 upon execution of the Prev Agreement, and at closing paid an additional cash payment of $135,000 and issued 625,000
unregistered shares of our common stock to Prev. In addition, upon the achievement of the milestones set forth below, Prev may
be entitled to receive additional consideration payable 50% in cash and 50% in our stock, subject to Prev&rsquo;s option to receive
the entire payment in shares of our stock, with the exception of the first milestone payments to be paid in cash: (i) upon commencement
of an IND; (ii) upon commencement of a Phase I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon
commencement of a Phase III clinical trial; (v) upon Biologic License Application (&ldquo;BLA&rdquo;) filing in the United States
and for territories outside of the United States (as defined in the Prev Agreement); and (vi) upon BLA approval in the United States
and upon approval in territories outside the United States. The future stock issuances are subject to prior approval of the NYSE
MKT, LLC. No royalties are payable to Prev under the Prev Agreement. The Prev Agreement also provides that Prev has a right to
the return to it of all assets acquired by us under the Prev Agreement if on or prior to the date that is (i) thirty (30) months
after the execution of the Prev Agreement, we have not initiated toxicology studies in non-rodent models or (ii) thirty-six (36)
months after the execution of the Prev Agreement, we have not filed an IND under the program related to the assets and such failure
is not due to action or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of
control as defined in the Prev Agreement and after such change of control the assets are not further developed; provided, however
that such thirty (30) and thirty-six (36) month periods can be extended by us for an additional twelve (12) months upon payment
of a cash milestone payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: left; text-indent: 0.5in">On October 30, 2012,
we completed a private placement (the &ldquo;October 2012 Private Placement&rdquo;) with certain accredited investors, pursuant
to which we sold an aggregate of 6,750,000 shares of our common stock at a price per share of $1.60 (the &ldquo;Common Shares&rdquo;)
for aggregate gross proceeds of $10.8 million and net proceeds of $10.1 million. In connection with the October 2012 Private Placement,
we filed a registration statement with the SEC which was declared effective on December 20, 2012 for the resale of our common stock
owned by certain of the purchasers in the October 2012 Private Placement. In connection with the October 2012 Private Placement,
we also entered into an agreement with a certain purchaser that is an affiliate of Intrexon (the &ldquo;Joinder Agreement&rdquo;)
pursuant to which such purchaser agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement
with us entered into in connection with the Second Channel Agreement (the &ldquo;First Amendment to Registration Rights Agreement&rdquo;)
and we registered the shares issued to such purchaser in accordance with the First Amendment to Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: left; text-indent: 0.5in">Griffin Securities,
Inc. (&ldquo;Griffin&rdquo;) served as the placement agent for the October 2012 Private Placement. In consideration for services
rendered by Griffin in the October 2012 Private Placement, we (i) paid to Griffin cash commissions equal to 6.0% of the gross proceeds
received in the October 2012 Private Placement, (ii) issued to Griffin, or its designee, warrants, which are five-year warrants
to purchase 635,855 shares of our common stock with an exercise price of $1.60 per share (the &ldquo;Agent Warrants&rdquo;); and
(iii) reimbursed Griffin for its reasonable actual out-of-pocket expenses incurred in connection with the October 2012 Private
Placement, including reasonable legal fees and disbursements. The common stock underlying the Agent Warrants was registered under
the registration statement declared effective on December 20, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On August 6, 2012,
we expanded our relationship with Intrexon and entered into a Second Channel Agreement with Intrexon (the &ldquo;Second Channel
Agreement&rdquo;) that governs an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we will use Intrexon&rsquo;s
technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization
of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases (the &ldquo;Program&rdquo;).
The Second Channel Agreement establishes committees comprised of our and Intrexon&rsquo;s representatives that will govern activities
related to the Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters,
commercialization efforts and intellectual property. On October 16, 2012, a closing was held for the transaction contemplated by
the Second Channel Agreement. Pursuant to the terms of a Stock Issuance Agreement with Intrexon (the &ldquo;Second Stock Purchase
Agreement&rdquo;), we issued 3,552,210 shares of our common stock, $0.001 par value, which issuance is also deemed paid in consideration
for the execution and delivery of the Second Channel Agreement, dated August 6, 2012, between ourselves and Intrexon. We registered
the shares issued to Intrexon in accordance with the First Amendment to Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On February 15, 2012,
upon stockholder approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common
stock continues trade on the NYSE MKT (formerly the NYSE Amex and American Stock Exchange) under the symbol &ldquo;SYN.&rdquo;
Prior to this time and since October 16, 2008, our name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE MKT stock exchange
under the symbol &ldquo;AEN.&rdquo; We are incorporated in the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 21, 2011, we announced that the Board of Directors had taken several actions to prioritize our focus on our entry into
the emerging field of synthetic biology. In connection with the change in business focus on March 8, 2012, we entered into a Membership
Interest Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the Adeona Clinical
Laboratory (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s former owner, in consideration for
(i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable up through the date of closing, plus (ii) Seven
Hundred Thousand Dollars ($700,000) payable pursuant to the terms of a two-year non-recourse promissory note secured by all of
the assets of the Lab.</FONT><FONT STYLE="background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif">During
the three month period ended September 30, 2013, the note receivable and associated interest receivable were deemed uncollectible.
Accordingly, we recorded bad debt expense of $763,000.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November 18, 2011,
we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon 3,123,558 shares of our common
stock at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed paid in consideration for the
execution and delivery of the channel agreement, which was entered into on November 18, 2011 and terminated on April 16, 2013.
We also agreed to an equity participation right in future securities offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: left; text-indent: 0.5in">Our predecessor,
Sheffield Pharmaceuticals, Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc.,
a Delaware corporation formed in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008
we changed our name to Adeona Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary
for the purpose of reincorporating in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics
and entering into our first collaboration with Intrexon, we amended our Articles of Incorporation to change our name to Synthetic
Biologics, Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left">&nbsp;<BR>
&nbsp;</P>

</DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75pt; text-align: left; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 4.2pt; text-indent: -4.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common stock offered by us</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 11,500,000 shares of common stock</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 4.2pt; text-indent: -4.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="width: 60%">56,154,414 shares of common stock</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 4.2pt; text-align: left; text-indent: -4.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds</FONT></TD>
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We intend to use the net proceeds from this offering, if any, for general corporate purposes, which may include, among other things, increasing our working capital and funding research and development, and capital expenditures. In addition, we may use a portion of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development programs, and to fund possible investments in and acquisitions of complementary businesses or partnerships. See &ldquo;Use of Proceeds&rdquo; on page S-8.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 4.2pt; text-align: left; text-indent: -4.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></TD>
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-7 of this prospectus supplement and page&nbsp;5 of the accompanying prospectus for a discussion of factors you should read and consider carefully before investing in our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 4.2pt; text-indent: -4.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NYSE MKT symbol</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYN</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 22.3pt">Except as otherwise indicated,
all information in this prospectus supplement is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">based on 44,654,414 shares outstanding on December 10, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">assumes no exercise by the underwriters of their over-allotment option to purchase up to an additional&nbsp;shares
to cover over-allotments, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">excludes 3,879,580 shares of our common stock subject to options outstanding as of December 10,
2013 having a weighted-average exercise price of $1.79&nbsp;per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">excludes 4,107,321 shares of our common stock that have been reserved for issuance in connection
with future grants under our stock option plans as of December 10, 2013; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">excludes 1,632,501 shares of our common stock that have been reserved for issuance upon exercise
of outstanding warrants as of December 10, 2013 having a weighted-average exercise price of $1.99 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>You should consider
carefully the risks discussed under the section captioned &ldquo;Risk Factors&rdquo; contained in our annual report on Form 10-K
for the year ended December&nbsp;31, 2012 and in our subsequent quarterly reports on Form 10-Q, as updated by our subsequent filings
under the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;), each of which is incorporated by reference
in this prospectus in its entirety, together with other information in this prospectus, and the information and documents incorporated
by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering
before you make a decision to invest in our common stock. If any of these events actually occur, our business, operating results,
prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock
to decline and you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Additional Risks Relating To The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>Our management
team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant
return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management will
have broad discretion over the use of proceeds from this offering. The net proceeds from this offering will be used for general
corporate purposes, which may include, among other things, increasing our working capital and funding research and development,
and capital expenditures. In addition, we may use a portion of the net proceeds for licensing or acquiring intellectual property
to incorporate into our products and product candidates or our research and development programs, and to fund possible investments
in and acquisitions of complementary businesses or partnerships. Our management will have considerable discretion in the application
of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds
are being used appropriately. The net proceeds may be used for corporate purposes that do not increase our operating results or
enhance the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>If you purchase
common stock sold in this offering, you will experience immediate dilution in your investment. You will experience further dilution
if we issue additional equity securities in future fundraising transactions and if shares of our common stock underlying our significant
number of outstanding warrants and options are purchased by the holders thereof.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The portion
of the public offering price per share in this offering attributable to our common stock exceeds the net tangible book value
per share of our common stock outstanding prior to this offering. Assuming we sell shares of common stock in this offering at
a public offering price of <FONT STYLE="color: black">$1.00 </FONT> per share, after deducting
the estimated underwriting discount and estimated offering expenses payable by us, you will experience immediate dilution
of approximately <FONT STYLE="color: black">$0.70 </FONT> per share (or immediate dilution
of approximately <FONT STYLE="color: black">$</FONT>0.68 per share if the underwriters exercise in full their option to
purchase additional shares in this offering), representing the difference between our as adjusted net tangible book value per
share as of September 30, 2013 after giving effect to this offering and the public offering price. See the section entitled
&ldquo;Dilution&rdquo; below for a more detailed illustration of the dilution you would incur if you participate in this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If in the future we
issue additional common stock, or securities convertible into or exchangeable or exercisable for common stock, our stockholders,
including investors who purchase shares offered under this prospectus supplement, will experience additional dilution, and any
such issuances may result in downward pressure on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, we have
a significant number of outstanding securities convertible into, or allowing the purchase of our Common Stock. Investors will be
subject to increased dilution upon the exercise of outstanding stock options and warrants. There were 44,654,414 shares of our
common stock outstanding as of December 10, 2013. As of that date, stock options and warrants outstanding represented 5,512,081
shares of our common stock that could be issued in the future. Most of the outstanding shares of our common stock, as well as the
vast majority of the shares of our common stock that may be issued under our outstanding options and warrants, are not restricted
from trading. Also, the issuance of additional shares as a result of such conversion or purchase, or their subsequent sale, could
adversely affect the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We estimate that
the net proceeds of this offering, after deducting the underwriting discount and the estimated offering expenses payable by
us, will be approximately $10,487,500 million (or approximately $12,100,375 million if the underwriters exercise the
over-allotment option in full).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We intend to use the
net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, increasing our
working capital and funding research and development, and capital expenditures. In addition, we may use a portion of the net proceeds
for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development
programs. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products;
however, we have no current commitments or obligations to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The amounts and timing
of our actual expenditures will depend on numerous factors, including our development and commercialization efforts, as well as
the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for
the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have
broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from
this offering in short-term, investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If you invest in our
common stock, your interest will be diluted immediately to the extent of the difference between the public offering price and the
adjusted net tangible book value per share of our common stock after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our net tangible book
value on September 30, 2013 was approximately $6.4 million, or $0.14 per share. &quot;Net tangible book value&quot; is total assets
minus the sum of liabilities and intangible assets. &quot;Net tangible book value per share&quot; is net tangible book value divided
by the total number of shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">After giving
effect to the sale of $11.5 million of common stock in this offering at a public offering price of $1.00 per share, and
after deducting estimated offering commissions and expenses payable by us, our as adjusted net tangible book value as of
September 30, 2013 would have been approximately $16.9 million, or $0.30 per share of common stock. This represents an
immediate increase in net tangible book value of $0.16 per share to our existing stockholders and an immediate dilution in
net tangible book value of $0.70 per share to investors participating in this offering.
The following table illustrates this dilution per share to investors participating in this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Assumed offering price per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net tangible book value per share as of September 30, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Increase in net tangible book value per share attributable to new investors in offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">As adjusted net tangible book value per share after
    giving effect to the offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Dilution per share to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The above illustration
of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase our common
stock or outstanding warrants to purchase shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The above discussion
and table are based on shares of our common stock issued and outstanding as of September 30, 2013, which does not include the following,
all as of September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&bull;&nbsp;3,804,580 shares issuable
upon the exercise of outstanding stock options with a weighted-average exercise price of $1.79 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&bull; 1,182,321 shares of common
stock which were reserved for future equity awards that may be granted in the future under our equity incentive plans; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.85pt; text-align: left">&bull;&nbsp;1,632,501 shares of our
common stock reserved for issuance upon the exercise of outstanding warrants, each with a weighted-average exercise price of $1.99
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To the extent that
any of these outstanding options are exercised, there will be further dilution to new investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The
information above assumes that the underwriters do not exercise their over-allotment option. If the underwriters exercise
their over-allotment option in full, the as adjusted net tangible book value will increase to
$0.32 per share, representing an immediate increase in as adjusted net tangible book value of
$0.18 per share to our existing stockholders and an immediate dilution in net tangible book value
of $0.68 per share to investors participating in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have never declared
or paid cash dividends on our capital stock. We currently intend to retain our future earnings, if any, for use in our business
and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at
the discretion of our board of directors after taking into account various factors, including our financial condition, operating
results, current and anticipated cash needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table
sets forth our capitalization as of September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>on an actual basis, without giving effect to this offering and the use of net proceeds as discussed in &ldquo;Use of
                                                                    Proceeds;&rdquo; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>on  an as adjusted basis to reflect this offering and the use of net proceeds as discussed in &ldquo;Use of
                                                                    Proceeds.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 40.5pt">This capitalization
table should be read in conjunction with management's discussion and analysis of results of operations and our consolidated financial
statements and related notes included in our annual report on Form 10-K for the year ended December 31, 2012 and in our Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013 and September 30, 2013, and the other financial information
included and incorporated by reference in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">As of September 30, 2013</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; padding-bottom: 2.5pt; padding-left: 0">Cash</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">5,145</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">15,633</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preferred stock, par value $0.001, 10,000,000 shares authorized, <FONT STYLE="color: black">none issued and outstanding</FONT></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Common stock, par value $0.001, 100,000,000 shares authorized, 44,735,896
    issued and 44,654,414 shares outstanding, actual and 56,235,896 issued and 56,154,414 outstanding shares, as adjusted <SUP>(1)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">83,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">93,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(77,034</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(77,034</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,857</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,369</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,857</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Outstanding shares of common stock as of September 30, 2013 excludes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27.35pt">&bull;</TD><TD STYLE="text-align: left">3,804,580 shares issuable upon the exercise of outstanding stock options with a weighted average exercise price of $1.79 per
share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27.35pt">&bull;</TD><TD STYLE="text-align: left">1,182,321 shares of common stock which were reserved for future equity awards that may be granted in the future under our equity
incentive plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27.35pt">&bull;</TD><TD STYLE="text-align: left">1,632,501 shares of common stock reserved for issuance upon the exercise of outstanding warrants, each with a weighted average
exercise price of $1.99 per share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27.35pt">&bull;</TD><TD>the underwriters' over-allotment option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Aegis Capital Corp.
is acting as the representative of the underwriters of the offering. We have entered into an underwriting agreement, dated
December 11 , 2013, with the representative. Subject to the terms and conditions of the underwriting agreement, we
have agreed to sell to each underwriter named below and each underwriter named below has severally agreed to purchase, at
the public offering price less the underwriting discounts and commissions set forth on the cover page of this
prospectus supplement, the number of shares of common stock listed next to its name in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 80%; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Aegis Capital Corp.</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"></TD><TD STYLE="width: 17%; border-bottom: Black 1pt solid; text-align: right">11,500,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The underwriters are
committed to purchase all the shares of common stock offered by us other than those covered by the option to purchase additional
shares described below. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in
the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters' obligations are subject to customary
conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers'
certificates and legal opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have agreed to indemnify
the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments
the underwriters may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The underwriters are
offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters
by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The underwriters
propose to offer the shares offered by us to the public at the public offering price set forth on the cover of this
prospectus supplement. In addition, the underwriters may offer some of the shares to other securities dealers at such price
less a concession of $0.0318 per share. After the initial offering, the public offering price and concession to dealers may
be changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have granted the
underwriters an over-allotment option. This option, which is exercisable for up to forty-five (45) days after the date
of this prospectus, permits the underwriters to purchase a maximum of 1,725,000 additional shares from us. If the
underwriters exercise all or part of this option, they will purchase shares covered by the option at the public offering
price that appears on the cover page of this prospectus supplement, less the underwriting discount. If this option is
exercised in full, the total price to the public will be approximately $13,225,000 and the total proceeds to
us, before expenses, will be approximately $12,365,375.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Discounts and Commissions</I>.
The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information
assumes either no exercise or full exercise by the underwriters of their option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Per&nbsp;Share</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total&nbsp;Without<BR> Option</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total&nbsp;With<BR> Option</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; padding-left: 1.5pt">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">11,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">13,225,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt">Underwriting discount (6.5%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(747,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(859,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 1.5pt">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.935</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,752,500</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,365,375</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accountable expense allowance (1%)<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(115,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(115,000</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: left">The expense allowance of 1% is not payable with respect to the shares sold upon exercise of the
underwriters&rsquo; over-allotment option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Griffin Securities,
Inc. (&ldquo;Griffin&rdquo;) is acting as a financial advisor in connection with this offering and will be paid fees out of the
underwriting commission of up to a maximum of $140,000; provided, however, that Griffin&rsquo;s compensation will be reduced pro
rata to the extent the aggregate gross proceeds to us in the offering are less than $10 million (<I>i.e</I>., Griffin shall be
entitled to receive 21.54% of the aggregate underwriting discount or spread); provided, further, however, that Griffin&rsquo;s compensation
shall be reduced by its pro rata portion (<I>i.e.,</I> 21.54%) of the underwriters&rsquo; reasonably incurred expenses of the offering,
including, but not limited to, the reasonable fees and expenses of counsel to the underwriters in an amount not to exceed $10,000.
In August 2012, as amended in December 2012, we entered into an agreement with Griffin, terminable by either party upon thirty
(30) days prior written notice, pursuant to which Griffin acts as an advisor to us and is paid a monthly fee of $10,000 for such
services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have paid an expense
deposit of $25,000 to the representative, which will be applied against the accountable expenses that will be paid by us to the
representative in connection with this offering. The underwriting agreement provides that in the event the offering is terminated,
the $25,000 expense deposit paid to the representative will be returned to us to the extent that offering expenses are not actually
incurred by the representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have agreed to pay
certain of the underwriters' expenses relating to the offering, including (a) all fees incurred in clearing this offering with
FINRA; (b) all fees, expenses and disbursements relating to the registration, qualification or exemption of securities offered
under the securities laws of such foreign jurisdictions as the underwriters may reasonably designate; (c) the fees and expenses
of counsel to the underwriters not to exceed $25,000; (d) <FONT STYLE="color: black">$21,775 for the underwriters&rsquo; use of
Ipreo&rsquo;s book-building, prospectus tracking and compliance software for this offering; and (e) up to $10,000 of the representative&rsquo;s
actual accountable road show expenses for the offering</FONT>. The total of any advanced payments will be refundable to the extent
not actually incurred in compliance with FINRA Rule 5110(f)(2)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We estimate that the
total expenses of the offering payable by us, excluding the underwriting discount and expense reimbursement, will be approximately
$100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Discretionary Accounts</I>.
The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Lock-Up Agreements</I>.
Each of our directors and executive officers, subject to certain exceptions, have agreed with the underwriter not to dispose of
or hedge any of our shares of common stock or securities convertible into or exercisable or exchangeable for common stock for ninety
(90) days after the date of this prospectus supplement without first obtaining the written consent of Aegis Capital Corp., other
than the issuance of common stock pursuant to the valid exercises, vesting or settlements of options, warrants or rights outstanding
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any of the securities
subject to the lock-up agreement may be released in whole or part from the terms thereof only upon the approval of the representative;
provided, however, that we must announce any such release through a major news service and such release will only be effective
two business days after the publication date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Electronic Offer,
Sale and Distribution Shares</I>. A prospectus supplement in electronic format may be made available on the websites maintained
by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters
participating in this offering may distribute prospectus supplements electronically. The representative may agree to allocate a
number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions
will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other
allocations. Other than the prospectus supplement in electronic format, the information on these websites is not part of this prospectus
supplement or the registration statement of which this prospectus supplement forms a part, has not been approved or endorsed by
us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Other Relationships</I>.
Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial
banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary
fees; however, except as disclosed in this prospectus supplement, we have no present arrangements with any of the underwriters
for any further services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Stabilization</I>.
In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate
covering transactions, penalty bids and purchases to cover positions created by short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not
exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the
shares while the offering is in progress.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Overallotment transactions involve sales by the underwriters of shares in excess of the number
of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short
position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not
greater than the number of shares that they may purchase pursuant to their option to purchase additional shares. In a naked short
position, the number of shares involved is greater than the number of shares pursuant to their option to purchase additional shares.
The underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares
in the open market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Syndicate covering transactions involve purchases of shares in the open market after the distribution
has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position,
the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with
the price at which they may purchase shares through exercise of their option to purchase additional shares. If the underwriters
sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short
position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be
created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the
open market that could adversely affect investors who purchase in the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Penalty bids permit the representative to reclaim a selling concession from a syndicate member
when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover
syndicate short positions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">These stabilizing transactions,
syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our shares or
common stock or preventing or retarding a decline in the market price of our shares or common stock. As a result, the price of
our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price
of our common stock. These transactions may be effected on the NYSE MKT, in the over-the-counter market or otherwise and, if commenced,
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Passive market making</I>.
In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our
common stock on the NYSE MKT in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display
its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered
below the passive market maker's bid, that bid must then be lowered when specified purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offer restrictions outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other than in the United
States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this
prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus
supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons
into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating
to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to
sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such
an offer or a solicitation is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B><I>Australia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This prospectus supplement
is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities
and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of
the Australian Corporations Act. Accordingly, (i) the offer of the common stock under this prospectus supplement is only made to
persons to whom it is lawful to offer the common stock without disclosure under Chapter 6D of the Australian Corporations Act under
one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia
only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by
accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted
under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the common stock sold to the
offeree within twelve (12) months after its transfer to the offeree under this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>China</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The information in
this document does not constitute a public offer of the common stock, whether by way of sale or subscription, in the People's Republic
of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The common stock may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than
directly to &ldquo;qualified domestic institutional investors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>European Economic Area-Belgium, Germany, Luxembourg and
Netherlands</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The information in
this document has been prepared on the basis that all offers of common stock will be made pursuant to an exemption under the Directive
2003/71/EC (&ldquo;Prospectus Directive&rdquo;), as implemented in Member States of the European Economic Area (each, a &ldquo;Relevant
Member State&rdquo;), from the requirement to produce a prospectus for offers of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">An offer to the public
of common stock has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions
under the Prospectus Directive as implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a) to legal entities
that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose
is solely to invest in securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b) to any legal entity
that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more
than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net
turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c) to fewer than 100
natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject
to obtaining the prior consent of the Company or any underwriter for any such offer; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d) in any other circumstances
falling within Article 3(2) of the Prospectus Directive, provided that no such offer of common stock shall result in a requirement
for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>France</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document is not
being distributed in the context of a public offering of financial securities (<I>offre au public de titres financiers</I>) in
France within the meaning of Article L.411-1 of the French Monetary and Financial Code (<I>Code mon&eacute;taire et financier</I>)
and Articles 211-1 et seq. of the General Regulation of the French <I>Autorit&eacute; des march&eacute;s financiers</I> (&ldquo;AMF&rdquo;).
The common stock has not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document and any
other offering material relating to the common stock have not been, and will not be, submitted to the AMF for approval in France
and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Such offers, sales
and distributions have been and shall only be made in France to (i) qualified investors (<I>investisseurs qualifi&eacute;s</I>)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D. 744-1,
D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of
non-qualified investors (<I>cercle restreint d'investisseurs</I>) acting for their own account, as defined in and in accordance
with Articles L.411-2-II-2&deg; and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing
regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to Article
211-3 of the General Regulation of the AMF, investors in France are informed that the common stock cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8
to L.621-8-3 of the French Monetary and Financial Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ireland</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The information in
this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or
approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;).
The common stock has not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by
way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii)
fewer than 100 natural or legal persons who are not qualified investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Israel</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The common stock offered
by this prospectus supplement has not been approved or disapproved by the Israeli Securities Authority, or &ldquo;ISA,&rdquo; nor
has such common stock been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the
public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with
the offering or publishing the prospectus supplement; nor has it authenticated the details included herein, confirmed their reliability
or completeness, or rendered an opinion as to the quality of the common stock being offered. Any resale in Israel, directly or
indirectly, to the public of the common stock offered by this prospectus supplement is subject to restrictions on transferability
and must be effected only in compliance with the Israeli securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Italy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The offering of the
common stock in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (<I>Commissione
Nazionale per le Societ&agrave; e la Borsa</I>, &ldquo;CONSOB&rdquo;) pursuant to the Italian securities legislation and, accordingly,
no offering material relating to the common stock may be distributed in Italy and such securities may not be offered or sold in
Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&ldquo;Decree No.
58&rdquo;), other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">to Italian qualified investors, as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation
no. 11971 of 14 May 1999 (&ldquo;Regulation no. 1197l&rdquo;) as amended (&ldquo;Qualified Investors&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article
34-ter of Regulation No. 11971 as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any offer, sale or
delivery of the common stock or distribution of any offer document relating to the common stock in Italy (excluding placements
where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with
Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and
any other applicable laws; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any subsequent distribution
of the common stock in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree
No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules
may result in the sale of such common stock being declared null and void and in the liability of the entity transferring the common
stock for any damages suffered by the investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Japan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The common stock have
not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.
25 of 1948), as amended (the &ldquo;FIEL&rdquo;) pursuant to an exemption from the registration requirements applicable to a private
placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the
FIEL and the regulations promulgated thereunder). Accordingly, the common stock may not be offered or sold, directly or indirectly,
in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional
Investor who acquires common stock may not resell them to any person in Japan that is not a Qualified Institutional Investor, and
acquisition by any such person of common stock is conditional upon the execution of an agreement to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Portugal</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document is not
being distributed in the context of a public offer of financial securities (<I>oferta p&uacute;blica de valores mobili&aacute;rios</I>)
in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (<I>C&oacute;digo dos Valores Mobili&aacute;rios</I>).
The common stock has not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal.
This document and any other offering material relating to the common stock have not been, and will not be, submitted to the Portuguese
Securities Market Commission (<I>Comiss&atilde;o do Mercado de Valores Mobili&aacute;rios</I>) for approval in Portugal and, accordingly,
may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances
that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of
common stock in Portugal are limited to persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities
Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sweden</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document has not
been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly,
this document may not be made available, nor may the common stock be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980)
<I>om handel med finansiella instrument</I> )). Any offering of common stock in Sweden is limited to persons who are &ldquo;qualified
investors&rdquo; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they
may not distribute it or the information contained in it to any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Switzerland</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The common stock may
not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering material relating to the common stock may be publicly distributed
or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Neither this document
nor any other offering material relating to the common stock have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of common stock will not be supervised by, the Swiss
Financial Market Supervisory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This document is personal
to the recipient only and not for general circulation in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>United Arab Emirates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Neither this document
nor the common stock has been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or
any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the
Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the
common stock within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer
or invitation. No services relating to the common stock, including the receipt of applications and/or the allotment or redemption
of such shares, may be rendered within the United Arab Emirates by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No offer or invitation
to subscribe for common stock is valid or permitted in the Dubai International Financial Centre.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>United Kingdom</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Neither the information
in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority
in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended
(&ldquo;FSMA&rdquo;)) has been published or is intended to be published in respect of the common stock. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom,
and the common stock may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any
other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This
document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients
to any other person in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any invitation or inducement
to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the
common stock has only been communicated or caused to be communicated and will only be communicated or caused to be communicated
in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the United Kingdom,
this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating
to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005 (&ldquo;FPO&rdquo;); (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d)
(high net worth companies, unincorporated associations, etc.) of the FPO; or (iii) to whom it may otherwise be lawfully communicated
(together &ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation,
offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not
act or rely on this document or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Parsons Behle &amp;
Latimer, Reno, Nevada will pass upon certain legal matters relating to the issuance and sale of the common stock offered hereby
on behalf of Synthetic Biologics, Inc. Certain legal matters in connection with this offering will be passed upon for the underwriters
by Reed Smith LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The financial statements
as of December 31, 2012 and for the year ended December 31, 2012 incorporated by reference in this prospectus have been so incorporated
in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference,
given on authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The financial statements
as of December 31, 2011 and for the year ended December 31, 2011 incorporated by reference in this prospectus have been so incorporated
in reliance on the report of Berman &amp; Company, P.A. an independent registered public accounting firm, incorporated herein by
reference, given on authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have filed with
the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules
and regulations of the SEC allow us to omit from this prospectus supplement certain information included in the registration statement.
For further information about us and the securities we are offering under this prospectus supplement, you should refer to the registration
statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this
prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects
by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We file reports, proxy
statements and other information with the SEC under the Exchange Act. You may read and copy this information from the Public Reference
Room of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains
reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that
website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The SEC allows us to
&ldquo;incorporate by reference&rdquo; the information we file with it which means that we can disclose important information to
you by referring you to those documents instead of having to repeat the information in this prospectus supplement. The information
incorporated by reference is considered to be part of this prospectus supplement, and later information that we file with the SEC
will automatically update and supersede this information. We incorporate by reference the documents listed below and any future
filings made with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus
supplement and the termination of the offering however, we are not incorporating by reference any documents or portions thereof,
whether specifically listed below or filed in the future, that are not deemed &ldquo;filed&rdquo; with the SEC, or any information
furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Our annual report on Form&nbsp;10-K for the fiscal year ended December 31, 2012 filed with the
SEC on April 16, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Our quarterly reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013 and September
30, 2013 filed with the SEC on May 15, 2013, August 14, 2013 and November 14, 2013, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Our current reports on Form 8-K filed with the SEC on April 19, 2013, October 15, 2013, October
25, 2013 and December 10, 2013<FONT STYLE="color: #1F497D">;</FONT> and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">The description of our common stock set forth in our registration statement on Form&nbsp;8-A12B,
filed with the SEC on June 20, 2007 (File No.&nbsp;000-12584).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may obtain, free of charge, a copy of
any of these documents (other than exhibits to these documents unless the exhibits are specifically incorporated by reference into
these documents or referred to in this prospectus supplement) by writing or calling us at the following address and telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="slogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">155 Gibbs Street, Ste. 412<BR>
Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(734)&nbsp;332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="slogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 22%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 22%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may offer and sell up to $50 million
in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with
a general description of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each time we offer and sell securities,
we will provide a supplement to this prospectus (which includes, but is not limited to, the sales agreement prospectus) that contains
specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update
or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and
the applicable prospectus supplement before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may offer and sell the securities described
in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers,
or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities,
their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth,
or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus
entitled &ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information. No securities may be
sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering
of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 22%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>This prospectus may not be used to sell securities unless
it is accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>INVESTING IN OUR SECURITIES INVOLVES
RISKS. SEE THE &ldquo;RISK FACTORS&rdquo; ON PAGE 6 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS
SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NYSE MKT under the symbol
&ldquo;SYN.&rdquo; On July 1, 2013, the last reported sale price of our common stock on the NYSE MKT was $1.67 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of July 2, 2013, the aggregate market
value of our outstanding common stock held by non-affiliates was approximately $45,744,673, based on 44,654,414 shares of outstanding
common stock, of which approximately 17,262,394 shares are held by affiliates, and a per share price of $1.67 based on the closing
sale price of our common stock on July 1, 2013. We have not offered any securities during the past twelve months pursuant to General
Instruction I.B.6 of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is July 16,
2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE OFFERING</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDEND POLICY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF CAPITAL STOCK</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">You should rely only on the information
we have provided or incorporated by reference in this prospectus or in any prospectus supplement. We have not authorized anyone
to provide you with information different from that contained or incorporated by reference in this prospectus or in any prospectus
supplement. This prospectus and any prospectus supplement is an offer to sell only the securities offered hereby, but only under
circumstances and in jurisdictions where it is lawful to do so. You should assume that the information contained in this prospectus
and in any prospectus supplement is accurate only as of their respective dates and that any information we have incorporated by
reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this
prospectus or any prospective supplement or any sale of securities. The registration statement, including the exhibits and the
documents incorporated herein by reference, can be read on the Securities and Exchange Commission website or at the Securities
and Exchange Commission offices mentioned under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This prospectus is part of a registration
statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration
process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a
total dollar amount of $50 million of securities from time to time as described in this prospectus. Each time that we offer and
sell securities, we will provide a prospectus supplement to this prospectus (which term includes, as applicable, the sales agreement
prospectus filed with the registration statement of which this prospectus forms a part) that contains specific information about
the securities being offered and sold and the specific terms of that offering. The prospectus supplement may also add, update or
change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information
in this prospectus and the applicable prospectus supplement, you should rely on the prospectus supplement. Before purchasing any
securities, you should carefully read both this prospectus and the applicable prospectus supplement, together with the additional
information described under the heading &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">You should rely only on the information
incorporated by reference or provided in this prospectus. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely on it. We will not make an
offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information
appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate as of the date on its respective
cover, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference,
unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those
dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Unless otherwise stated or the context
otherwise requires, references in this prospectus to &ldquo;Synthetic,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo;
and &ldquo;us&rdquo; refer to Synthetic Biologics, Inc., a Nevada corporation and its consolidated subsidiaries, unless otherwise
specified. When we refer to &ldquo;you,&rdquo; we mean the holders of the applicable series of securities.</P>


<!-- Field: Page; Sequence: 26; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>The items in the following summary are
described in more detail elsewhere in this prospectus and in the documents incorporated by reference herein. This summary provides
an overview of selected information and does not contain all the information you should consider before investing in our common
stock. Therefore, you should read the entire prospectus and any free writing prospectus that we have authorized for use in connection
with this offering carefully, including the &ldquo;Risk Factors&rdquo; section and other documents or information included or incorporated
by reference in this prospectus before making any investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Our Business</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are a biotechnology company focused
on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing an oral enzyme
for the prevention of <I>C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis
and <I>Acinetobacter</I> infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting multiple
sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tpg27.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>Summary of Infectious Disease Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left"><B><I>Clostridium difficile (C. difficile)</I> infections:</B> In November 2012, we acquired a
series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention <I>of C. difficile</I> infections
(CDI), the leading cause of hospital acquired infections (HAI), that generally occurs secondary to treatment with intravenous antibiotics.
The acquired assets include a pre-Investigational New Drug (IND) package for P3A (SYN-004), Phase I and Phase II clinical data
for P1A, manufacturing processes and data, and a portfolio of issued and pending U.S. and international patents intended to support
an IND and Biologic License Application (BLA) with the FDA. Utilizing this portfolio of assets, we intend to develop a proprietary
oral beta-lactamase enzyme product candidate, SYN-004, previously known as IPSAT P3A. When co-administered with certain intravenous
beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract,
thus preserving the natural balance of the patient's microflora, and preventing opportunistic infections including CDI. Beta-lactam
antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes
of antibiotics. In 2012, 15 million Americans were administered beta-lactam antibiotics.*</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">*This information is an estimate
derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital
database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left"><B>Pertussis:</B> In December 2012, in collaboration with Intrexon, we initiated development of
a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough. We are developing
a mAb therapy, SYN-005, designed to target and neutralize the pertussis toxin, in order to reduce the mortality rate in infants
and potentially shorten the duration of chronic cough in afflicted adults. To further the development of this potential therapy
for Pertussis, we entered into an agreement with The University of Texas at Austin to license the rights to certain research and
pending patents related to pertussis antibodies. According to the World Health Organization, each year, <I>B. pertussis</I> infection
causes an estimated 300,000 deaths worldwide, primarily among young, unvaccinated infants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left"><B><I>Acinetobacter</I> infections:</B> In September 2012, in collaboration with Intrexon, we initiated
efforts to develop a mAb therapy for the treatment of <I>Acinetobacter</I> infections. Many strains of <I>Acinetobacter</I> are
multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected
by natural disasters. A treatment for <I>Acinetobacter</I> infections represents a billion dollar market opportunity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27.5pt"><I>Summary of Multiple
Sclerosis Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">Trimesta <SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting
multiple sclerosis (MS) in women. Patient enrollment is complete in this two-year, randomized, double-blind, placebo-controlled
Phase II clinical trial being conducted at 15 centers in the U.S. The primary endpoint is relapse rate at two years, with top-line
results expected in 1H 2014. This trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial
through completion. Annual worldwide sales of current MS therapies are estimated at $14.1 billion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">Trimesta <SUP>TM</SUP> is also being developed for the treatment of cognitive dysfunction in female
MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at the University
of California, Los Angeles (UCLA). The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial
Addition Test (PASAT). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations
and charitable organizations, and we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three
years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently
no approved treatment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.6pt; text-align: left; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: left"><I>Summary of Fibromyalgia Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: left">Effirma <SUP>TM</SUP> (flupirtine) is being developed for the treatment of fibromyalgia by Meda
AB (Meda), a multi-billion dollar international pharmaceutical company. On May 6, 2010, we entered into a sublicense agreement
with Meda covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. The
sublicense agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive
certain payments if milestones are achieved and royalties on sales. According to Meda&rsquo;s 2012 Year-End Report filed in February
2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia.
Meda also announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be
conducted at 25 clinics in the U.S. Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the
total market potential in the U.S. is $6 billion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In order to further prioritize our focus,
we have elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, we are
currently seeking development partners for our zinc-based intellectual property and assets including, AEN-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Recent Developments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 19, 2012, we entered into a
Patent License Agreement (the &ldquo;License Agreement&rdquo;) with The University of Texas at Austin (the &ldquo;University&rdquo;)
for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related
to Pertussis (more commonly known as whooping cough) antibodies developed in the lab of Dr. Jennifer A. Maynard, Assistant Professor
of Chemical Engineering. In connection with the License Agreement, we and the University also entered into a Sponsored Research
Agreement pursuant to which the University will perform certain research work related to pertussis under the direction of Dr. Jennifer
Maynard and we will obtain certain rights to patents and technology developed during the course of such research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 28, 2012, a closing was held
for the transaction contemplated by the Asset Purchase Agreement (the &ldquo;Prev Agreement&rdquo;) we entered into with Prev ABR
LLC (&ldquo;Prev&rdquo;), pursuant to which we acquired the <I>C. diff</I> program assets of Prev, including pre-Investigational
New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international
patents. Pursuant to the Prev Agreement, we paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement
and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev.
In addition, upon the achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable
50% in cash and 50% in our stock, subject to Prev&rsquo;s option to receive the entire payment in shares of our stock, with the
exception of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase
I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial; (v)
upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement);
and (vi) upon BLA approval in the U.S. and upon approval in territories outside the-U.S.&nbsp; The future stock issuances are subject
to prior approval of the NYSE MKT, LLC. No royalties are payable to Prev under the Prev Agreement. The Prev Agreement also provides
that Prev has a right to the return to it of all assets acquired by us under the Prev Agreement if on or prior to the date that
is (i) thirty (30) months after the execution of the Prev Agreement, we have not initiated toxicology studies in non-rodent models
or (ii) thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action
or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in
the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty (30)
and thirty six (36) month periods can be extended by us for an additional twelve (12) months upon payment of a cash milestone payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 30, 2012, we completed a private
placement (the &ldquo;October 2012 Private Placement&rdquo;) with certain accredited investors, pursuant to which we sold an aggregate
of 6,750,000 shares of our common stock at a price per share of $1.60 (the &ldquo;Common Shares&rdquo;) for aggregate gross proceeds
of $10.8 million and net proceeds of $10.1 million. In connection with the October 2012 Private Placement, we filed a registration
statement with the SEC which was declared effective on December 20, 2012 for the resale of our common stock owned by certain of
the purchasers in the October 2012 Private Placement. In connection with the October 2012 Private Placement, we also entered into
an agreement with a certain purchaser that is an affiliate of Intrexon (the &ldquo;Joinder Agreement&rdquo;) pursuant to which
such purchaser agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement with us entered
into in connection with the Second Channel Agreement (the &ldquo;First Amendment to Registration Rights Agreement&rdquo;) and we
registered the shares issued to such purchaser in accordance with the First Amendment to Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Griffin Securities, Inc. (&ldquo;Griffin&rdquo;)
served as the placement agent for the October 2012 Private Placement. In consideration for services rendered by Griffin in the
October 2012 Private Placement, we (i) paid to Griffin cash commissions equal to 6.0% of the gross proceeds received in the October
2012 Private Placement, (ii) issued to Griffin, or its designee, warrants, which are five-year warrants to purchase 635,855 shares
of our common stock with an exercise price of $1.60 per share (the &ldquo;Agent Warrants&rdquo;); and (iii) reimbursed Griffin
for its reasonable actual out-of-pocket expenses incurred in connection with the October 2012 Private Placement, including reasonable
legal fees and disbursements. The common stock underlying the Agent Warrants was registered under the registration statement declared
effective on December 20, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 6, 2012, we expanded our relationship
with Intrexon and entered into a Second Channel Agreement with Intrexon (the &ldquo;Second Channel Agreement&rdquo;) that governs
an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we will use Intrexon&rsquo;s technology relating to the identification,
design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody
therapies for the treatment of certain serious infectious diseases (the &ldquo;Program&rdquo;). The Second Channel Agreement establishes
committees comprised of our and Intrexon representatives that will govern activities related to the Program in the areas of project
establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual
property. On October 16, 2012, a closing was held for the transaction contemplated by the Second Channel Agreement. Pursuant to
the terms of a Stock Issuance Agreement with Intrexon (the &ldquo;Second Stock Purchase Agreement&rdquo;), we issued 3,552,210
shares of our common stock, $0.001 par value, which issuance is also deemed paid in consideration for the execution and delivery
of the Second Channel Agreement, dated August 6, 2012, between ourselves and Intrexon. We registered the shares issued to Intrexon
in accordance with the First Amendment to Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 15, 2012, upon stockholder
approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues trade
on the NYSE MKT (formerly the NYSE Amex and American Stock Exchange), under the symbol &ldquo;SYN&rdquo;. Prior to this time and
since October 16, 2008, our name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE MKT stock exchange under the symbol
&ldquo;AEN&rdquo;. We are incorporated in the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 21, 2011, we announced that
the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic biology.
In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement, and
certain related agreements, pursuant to which we sold all of our interest in the Adeona Clinical Laboratory (the &ldquo;Lab&rdquo;)
to Hartlab, LLC, an entity controlled by the Lab&rsquo;s former owner, in consideration for (i) the immediate assignment of the
Lab&rsquo;s outstanding accounts receivable up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000)
payable pursuant to the terms of a two-year non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 18, 2011, we entered into a
Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon 3,123,558 shares of our common stock at a purchase
price equal to the $0.001 par value of such shares, which issuance was deemed paid in consideration for the execution and delivery
of the channel agreement which was entered into on November 18, 2011 and terminated on April 16, 2013. We also agreed to an equity
participation right in future securities offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Company Information</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our predecessor, Sheffield Pharmaceuticals,
Inc. was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we reincorporated in the State of Nevada. After reprioritizing our focus on the emerging
area of synthetic biologics and entering into our first collaboration with Intrexon, we amended our Articles of Incorporation to
change our name to Synthetic Biologics, Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our principal executive offices are located
at 155 Gibbs Street, Suite 412, Rockville, Maryland 20850. We also maintain an administrative and finance office in Ann Arbor,
Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: left">We may offer shares of our common
stock, warrants to purchase any of such securities, either individually or in combination, and/or units consisting of some or all
of such securities for total gross proceeds of up to $50 million, from time to time under this prospectus, together with the applicable
prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at
the time of any offering. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus
supplement that will describe the specific amounts, prices and other important terms of the securities being offered. Below is
a summary of the securities we may offer under this prospectus (together with the applicable prospectus supplement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: left">We may sell the securities directly
to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept
or reject all or part of any proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters,
dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission
or discount arrangements with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS THAT MAY AFFECT FUTURE RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>You should consider carefully the risks
discussed under the section captioned &ldquo;Risk Factors&rdquo; contained in our annual report on Form 10-K for the year ended
December&nbsp;31, 2012 and in our subsequent quarterly reports on Form 10-Q, as updated by our subsequent filings under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, each of which is incorporated by reference in this prospectus in its entirety,
together with other information in this prospectus, and the information and documents incorporated by reference in this prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to
invest in our common stock. If any of these events actually occur, our business, operating results, prospects or financial condition
could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose
all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This prospectus, including the documents
incorporated by reference in it, contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act
of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934 as amended, or the Exchange
Act.&nbsp;These statements may be made directly in this document or they may be made part of this document by reference to other
documents filed with the SEC, which is known as &ldquo;incorporation by reference.&rdquo;&nbsp;You can find many (but not all)
of these statements by looking for words such as &ldquo;approximates,&rdquo; &ldquo;believes,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;may&rdquo;
or other similar expressions in this prospectus or the documents incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We caution investors that any forward-looking
statements presented in this prospectus or the documents incorporated by reference, or those which we may make orally or in writing
from time to time, are based on our beliefs and assumptions, as well as information currently available to us.&nbsp;Such statements
are based on assumptions and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors
that are beyond our control or ability to predict.&nbsp;Although we believe that our assumptions are reasonable, they are not guarantees
of future performance and some will inevitably prove to be incorrect.&nbsp;As a result, our actual future results can be expected
to differ from our expectations, and those differences may be material.&nbsp;Accordingly, investors should use caution in relying
on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future
results or trends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Some of the risks and uncertainties that
may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking
statements include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a failure to continue to undertake preclinical development and clinical trials for our product
candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a failure to expand our research activities with Intrexon relating to monoclonal antibodies for
infectious diseases;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a failure of our product candidates to be demonstrably safe and effective;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a failure to obtain regulatory approval for our products or to comply with ongoing regulatory requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a lack of acceptance of our product candidates in the marketplace;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a failure by us to become or remain profitable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">an inability by us to obtain the capital necessary to fund our research and development activities;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a loss of any of our key scientists or management personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This prospectus and all subsequent written
and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety
by the cautionary statements contained or referred to in this section.&nbsp;We do not undertake any obligation to release publicly
any revisions to our forward-looking statements to reflect events or circumstances after the dates that such statements are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For more information on the uncertainty
of forward-looking statements, see &ldquo;Risk Factors&rdquo; in our Annual Reports on Form 10-K and our Quarterly Reports on Form
10-Q and any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We intend to use the net proceeds, if any,
from the sales of securities offered by this prospectus for general corporate purposes, which may include, among other things,
increasing our working capital and funding research and development, and capital expenditures. In addition, we may use a portion
of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product candidates or
our research and development programs. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary
businesses or products; however, we have no current commitments or obligations to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The amounts and timing of our actual expenditures
will depend on numerous factors, including our development and commercialization efforts, as well as the amount of cash used in
our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above.
We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application
of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have never paid cash dividends on our
common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. We
intend to use all available cash and liquid assets in the operation and growth of our business. Any future determination about
the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital
requirements, operating and financial conditions and on such other factors as our board of directors deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our authorized capital consists of 100
million shares of common stock, par value $0.001 per share, and 10 million shares of preferred stock, par value $0.001 per share.
As of July 2, 2013, 44,654,414 shares of common stock and no shares of preferred stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may issue shares of our common stock
from time to time. Holders of shares of common stock have the right to cast one vote for each share of common stock in their name
on the books of our company, whether represented in person or by proxy, on all matters submitted to a vote of holders of common
stock, including election of directors. There is no right to cumulative voting in election of directors. Except where a greater
requirement is provided by statute, by our articles of incorporation, or by our bylaws, the presence, in person or by proxy duly
authorized, of the one or more holders of a majority of the outstanding shares of our common stock constitutes a quorum for the
transaction of business. The vote by the holders of a majority of outstanding shares is required to effect certain fundamental
corporate changes such as liquidation, merger, or amendment of our articles of incorporation. Upon our liquidation, dissolution
or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and
the liquidation preferences of any outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There are no restrictions in our articles
of incorporation or bylaws that prevent us from declaring dividends. We have not declared any dividends, and we do not plan to
declare any dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Holders of shares of our common stock are
not entitled to preemptive or subscription or conversion rights, and no redemption or sinking fund provisions are applicable to
our common stock. All outstanding shares of common stock are, and the shares of common stock sold in the offering will when issued
be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may issue warrants for the purchase
of common stock. We may issue warrants independently or in combination with common stock. In this prospectus, we have summarized
certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any related free
writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as
well as any warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits to the
registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the
SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular
series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any warrants issued under this prospectus
may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into
with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating
to the particular series of warrants being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following description, together with
the additional information that we include in any applicable prospectus supplement and in any related free writing prospectus that
we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under
this prospectus, which may be issued in one or more series. While the terms we have summarized below will apply generally to any
warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail
in the applicable prospectus supplement and in any related free writing prospectus that we may authorize to be distributed to you.
The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the
applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different
or additional terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series
of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The summary below and that contained in
any prospectus supplement is qualified in its entirety by reference to all of the provisions of the warrant and/or the warrant
agreement and warrant certificate, as applicable, applicable to a particular series of debt securities. We urge you to read the
applicable prospectus supplements and any related free writing prospectuses related to the warrants that we may offer under this
prospectus, as well as the complete warrant and/or the warrant agreement and warrant certificate, as applicable, that contains
the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms of the series of warrants being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the offering price and aggregate number of warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the currency for which the warrants may be purchased;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">if applicable, &nbsp;the number of warrants issued with each such security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the number of shares of common stock, as the case may be, purchasable upon the exercise of one
warrant and the price at which these shares may be purchased upon such exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the effect of any merger, consolidation, sale or other disposition of our business on the warrant
agreements and the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the terms of any rights to redeem or call the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">any provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the dates on which the right to exercise the warrants will commence and expire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the manner in which the warrant agreements and warrants may be modified;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a discussion of any material or special U.S. federal income tax considerations of holding or exercising
the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the terms of the securities issuable upon exercise of the warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if
any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Exercise of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered.
Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the close of business
on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business
on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Upon receipt of payment and the warrant
or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent,
if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and
deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants represented by such warrant
certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Enforceability of Rights by Holders of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each warrant agent, if any, will act solely
as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with
any holder of any warrant. A warrant agent may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or
responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without
the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise,
and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Governing Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Unless we otherwise specify in the applicable
prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of
the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may issue units consisting of any combination
of our common stock and warrants. We will issue each unit so that the holder of the unit is also the holder of each security included
in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each included security. The
unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The summary below and that contained in
any prospectus supplement is qualified in its entirety by reference to all of the provisions of the unit agreement and/or unit
certificate, and depositary arrangements, if applicable. We urge you to read the applicable prospectus supplements and any related
free writing prospectuses related to the units that we may offer under this prospectus, as well as the complete unit agreement
and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the particular
series of units we are offering, and any supplemental agreements, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The applicable prospectus supplement, information
incorporated by reference or free writing prospectus may describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the designation and terms of the units and of the securities comprising the units, including whether
and under what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of
the securities composing the units;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">whether the units will be issued in fully registered or global form; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">any other terms of the units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The applicable provisions described in
this section, as well as those described under &ldquo;Common Stock&rdquo; and &ldquo;Warrants&rdquo; above, will apply to each
unit and to each security included in each unit, respectively</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may sell the securities from time to
time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods or through
underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time
to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>at a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>at prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each time that we sell securities covered
by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set
forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds
to us, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Offers to purchase the securities being
offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities
from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If a dealer is utilized in the sale of
the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell
the securities to the public at varying prices to be determined by the dealer at the time of resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an underwriter is utilized in the sale
of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time
of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales
of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the
underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions
or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated
in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal,
and may then resell the securities at varying prices to be determined by the dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any compensation paid to underwriters,
dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters
to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating
in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts
and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts
and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including
liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse
those persons for certain expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any common stock will be listed on the
NYSE MKT, but any other securities may or may not be listed on a national securities exchange. To facilitate the offering of securities,
certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price
of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating
in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments
or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these
persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by
imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities
sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize
or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If indicated in the applicable prospectus
supplement, underwriters or other persons acting as agents may be authorized to solicit offers by institutions or other suitable
purchasers to purchase the securities at the public offering price set forth in the prospectus supplement, pursuant to delayed
delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These purchasers
may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational
and charitable institutions. Delayed delivery contracts will be subject to the condition that the purchase of the securities covered
by the delayed delivery contracts will not at the time of delivery be prohibited under the laws of any jurisdiction in the United
States to which the purchaser is subject. The underwriters and agents will not have any responsibility with respect to the validity
or performance of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may engage in at the market offerings
into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative
transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities
covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party
may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings
of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of
stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named
in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities
to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable
prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in
our securities or in connection with a concurrent offering of other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The specific terms of any lock-up provisions
in respect of any given offering will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The underwriters, dealers and agents may
engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Gracin &amp; Marlow, LLP, New York, New
York will pass upon certain legal matters relating to the issuance and sale of the warrants and units offered hereby on behalf
of Synthetic Biologics, Inc. and Parsons Behle &amp; Latimer, Reno, Nevada will pass upon certain legal matters relating to the
issuance and sale of the common stock and the common stock underlying the warrants offered hereby on behalf of Synthetic Biologics,
Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in
the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The financial statements as of December
31, 2012 and for the year ended December 31, 2012 incorporated by reference in this prospectus have been so incorporated in reliance
on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on authority
of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The financial statements as of December
31, 2011 and for the year ended December 31, 2011 incorporated by reference in this prospectus have been so incorporated in reliance
on the report of Berman &amp; Company, P.A. an independent registered public accounting firm, incorporated herein by reference,
given on authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We file annual, quarterly and special reports,
proxy statements and other information with the Securities and Exchange Commission. You may read and copy any document we file
at the SEC&rsquo;s public reference room located at 100&nbsp;F&nbsp;Street N.E., Washington,&nbsp;D.C. 20549. Please call the SEC
at 1-800-SEC-0330 for further information on the operation of the public reference room. Our public filings are also available
to the public at the SEC&rsquo;s web site at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This prospectus is part of a registration
statement on Form&nbsp;S-3 that we have filed with the SEC under the Securities Act. This prospectus does not contain all of the
information in the registration statement. We have omitted certain parts of the registration statement, as permitted by the rules
and regulations of the SEC. You may inspect and copy the registration statement, including exhibits, at the SEC&rsquo;s public
reference room or Internet site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additional information about Synthetic
Biologics. Inc. is contained at our website, <U>www.syntheticbiologics.com</U>. Information on our website is not incorporated
by reference into this report. We make available on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate
Governance documents are also posted on our website: Code of Conduct, Code of Ethics for Financial Management and the Charters
for the Audit Committee, Compensation Committee and Nominations Committee of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference
is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede
this information. We incorporate by reference the documents listed below and any future filings made with the SEC under Sections&nbsp;13(a),
13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the termination of the offering, however, we are
not incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that
are not deemed &ldquo;filed&rdquo; with the SEC, or any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related
exhibits furnished pursuant to Item 9.01 of Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Our annual report on Form&nbsp;10-K for the fiscal year ended December 31, 2012 filed with the SEC on April 16, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Our quarterly report on Form 10-Q for the quarter ended
March 31, 2013 filed with the SEC on May 15, 2013;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Our current report on Form 8-K filed with the SEC on April 19, 2013, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">The description of our common stock set forth in our registration statement on Form&nbsp;8-A12B, filed with the SEC on June
20, 2007 (File No.&nbsp;000-12584).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain, free of charge, a copy of any of these documents
(other than exhibits to these documents unless the exhibits are specifically incorporated by reference into these documents or
referred to in this prospectus) by writing or calling us at the following address and telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="slogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">155 Gibbs Street, Ste. 412<BR>
Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(734)&nbsp;332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>11,500,000
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="slogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Aegis Capital Corp</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>December 11,
2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -4.5pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>slogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 slogo1.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_X1$J17AI9@``34T`*@````@`!0$2``,`
M```!``$```$Q``(````<```(5@$R``(````4```(<H=I``0````!```(ANH<
M``<```@,````2@`````<Z@````@`````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````$%D;V)E(%!H;W1O<VAO<"!#4S,@5VEN9&]W<P`R,#$Q.C$R.C$X(#$P
M.C(X.C$U```(D`,``@```!0``!#XD`0``@```!0``!$,DI$``@````,P,```
MDI(``@````,P,```H`$``P````$``0``H`(`!`````$```)/H`,`!`````$`
M``&*ZAP`!P``"`P```CL`````!SJ````"```````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````,C`Q,3HQ,CHQ."`Q,#HR.#HQ-0`R,#$Q.C$R.C$X(#$P.C(X
M.C$U````_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!8
M65H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`````````````
M``$``/;6``$`````TRU(4"`@````````````````````````````````````
M```````````````````````````18W!R=````5`````S9&5S8P```80```!L
M=W1P=````?`````48FMP=````@0````4<EA96@```A@````49UA96@```BP`
M```48EA96@```D`````49&UN9````E0```!P9&UD9````L0```"(=G5E9```
M`TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C
M:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,
M=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ````````````
M```2<U)'0B!)14,V,3DV-BTR+C$`````````````````````````````````
M`````````````````````````````````%A96B````````#S40`!`````1;,
M6%E:(`````````````````````!865H@````````;Z(``#CU```#D%A96B``
M``````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C````````
M`!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@`````````````````````````````````````````````
M````````````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````
M`````````````````&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````
M``````````````````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<
MG@````%865H@``````!,"58`4````%<?YVUE87,``````````0``````````
M``````````````*/`````G-I9R``````0U)4(&-U<G8````````$``````4`
M"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W
M`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`
MZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U
M`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"
M+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+
M`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$
M(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058
M!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&
MT0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN
M"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*
M5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<
M#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.
MM@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q
M$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44
M!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z
M%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:
M41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#
M'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74A
MH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67
M)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J
M`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"
M+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S
M?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,
M.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^
M(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`
M1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)
M\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G
M4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6
M]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)
M7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE
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MCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67
MX)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'
MH;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K
M=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*
MM@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`
M<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LV
MR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76
MV-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3
MXMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCN
MM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG
M^W?\!_R8_2G]NOY+_MS_;?___^$)VFAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U
M,3@R9C%B(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/CQX;7`Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3,R!7:6YD
M;W=S/"]X;7`Z0W)E871O<E1O;VP^/'AM<#I#<F5A=&5$871E/C(P,3$M,3(M
M,3A4,3`Z,C@Z,34\+WAM<#I#<F5A=&5$871E/CPO<F1F.D1E<V-R:7!T:6]N
M/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/#]X<&%C:V5T(&5N9#TG=R<_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@(!`0(!`0$"`@("`@("`@(!`@("`@("`@("
M`O_;`$,!`0$!`0$!`0$!`0(!`0$"`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@("`O_``!$(`(P"*P,!(@`"$0$#$0'_
MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#
M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!
M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<`
M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`**P_$'B;P[X4L'U3Q+K>EZ%IZ9!NM4O8+.)V&/W4)G<&>8D@+&@9
MV+`*I)`KYI\2?MD_";1WDAT=/$'BJ9=P673=-%C8%EXP]SK,T$H3/\202`@$
MC(QEJ,I;*XFTMW8^LJ*^+_"7[65]XZU2\LM%\`V>EZ=I-C<:SK6M:WXKDE:P
MT:RCDFO;BWT'2_#TEWJ]V(HV\N"T\Z1V&TA5.\?'WC+_`(*L/IGQ`O;?P=\+
MX=<^'NGQ3V$3:]JMUX<\4:QJ<=U$7U4216-Y%HVG_9XKF..TEMIKAC,L\\L+
M!K1?SGQ"\5^!/"VEEM3C;/(Y4\UFX4*<:5;$5I*-N>JZ.'A4JJE3NN>;A:[4
M8\TVHO\`1.`/"OCKQ.J9C3X,R26:1RJ"G6J2JT</2BY7Y*?ML1.G3=6I9\L.
M:]DY2Y8)R7[(T5^2&@_\%9O!=P8_^$G^#OBC2%+8E.@^*-)\1LBYEP8UU'3=
M*$K8$/!*<NXSA%,GTAX-_P""A_[+OBTPQ7/C'5/!EW.`4M?&7A[4;%58_P`$
MNIZ4M[8PD`'E[I5X."2"*\#(_I!^"W$4X4\N\1<NA4G9)8N=3+VV]DECZ>&;
MDWHH[MZ6N>[G7@#XR\/PG4S#P]S"=.&\L+"GCTDMVW@*F)5DM7+9+5NQ]OT5
MROA3QUX*\=V/]I>"?%WAKQ=8`*6N_#>N:;K4$9<`A9I-.N9!!)S@J^U@000"
M,5U5?KF&Q6%QM"EBL'B:>+PM97A4I3C4IS3V<9P;C)>:;1^38G"XG!5ZF%QF
M'J83$T7:=.K"5.I!]I0DE*+\FDPHHHKH,`HHHH`****`"BBB@`HHKS?XL_&#
MX7?`CP)K?Q-^,?CWPQ\-_`7AV'SM6\4>+=5MM)TR!F5S!9P/.X?4-4G9"EM9
MVZ2W=U*5AMH9965"`>D45_,3\??^#G_]F;P3J=]H_P"S[\#OB/\`'7['))`G
MBCQ/K5E\'/"6H$2!$O='2\T;6M9N;+RR6V7^D:7.S+Y9C0,)1\8K_P`'4OQ:
M&J23/^R#\.FT4J!%IR_%+Q,FJI)Y,8+R:P?";0RIYXE;:+%#L=4W$J9'I1D]
M;`?VB45_+[\#O^#H;]F[Q;?V&F?'KX`?$WX-?:Y%@F\1>#M?T?XO>&]/.Y@;
M[5(SIN@:I#8^6FYEL].U&>-G$8CE`,M?T1_`[X_?!C]I7X?Z;\4O@1\1_#'Q
M.\":H[00Z]X9O3.+.^CA@GGTC6]-N8X[SPYKT,-S;-/I^H6]K>VXN$\ZWCWK
ME--;H#U^BOY_/VC?^#A#X$_LM_&WXB_`3XK_`+-/[1FF>./AMX@N=#U06T?P
MUET[5+4QQ7FC>(M%N)/'*-=:#J>C7>GWUC*Z1N]MJ$?FQQ2[XUYWX._\')_[
M&OQ7^*G@'X9ZC\-?C/\`#6W\>>*-*\*KXZ\;1^`H_"/AFZUNZ2PT_4?$USI/
MC&XFT_1?M\]JD]T(FBMHYS<3E+>.212SWMH!_1+1112`**^5OVS?VO\`X3_L
M-_`7Q+^T!\89M1E\/:)>Z7HFC^'="%E+XG\9^*=<G>+2O#'AFUU"\MX;K5'M
MX+^ZDWS(D%EI-W=R,(K=S7X<C_@Z/_9#Z?\`#/G[1XX!YA^&(ZXP.?'O7D>W
MOCFG9O97`_IOHK\2_"'_``6]^$/BW]C[XN?MMK^SQ\?=%^#/PI\:>#O`"3ZO
M%\/X=6\<^)/%.KZ?I-];^#X(O&3Q7-II+ZSHSZA/<2P1%M2$%JUQ<0W,</R)
M_P`11_[(G'_&/?[2&22`##\,0=P&2O\`R/W6E9[6U`_IOHKXL_82_;L^#7_!
M0/X+M\9?@\NLZ/#IOB/5/"GBOP3XL_LJ'QAX/UO3W$MK%K5IH^I74'V2^TF:
MSO;*>*9XYH;HQDK<V]S!#]IT`%%%?S('_@Z/_9#[?L^?M('U(@^&7'.._CWZ
M?G32;VU`_IOHK\9_A[_P6N^`GQ%_8C^/G[<^E_"GXO6/P]_9]\=>$_`7B7PC
MJ$?@P>,]:U+Q=KGP_P!!LKO0TM_%#V1LHKGXB:8TOVB[ADV6,^Q&/EA_B@_\
M'1_[(8_YM\_:0_[\_#`^_;Q]Z$?@0>]*SVMJ!_3?17\Q_P#Q%(?LA_\`1OG[
M2'_?GX8__-[1_P`12'[(?_1OG[2'_?GX8_\`S>T[/LP/Z<**_F/_`.(I#]D/
M_HWS]I#_`+\_#'_YO:/^(I#]D/\`Z-\_:0_[\_#'\S_Q7O`HL^P'].%%?CUK
M_P#P69^!7A_]@GP3_P`%`KKX6_%J;X:^./B==_"W3_!<,?@__A.;/5[34_%V
MER:C>I)XF%@--,W@^^8>7>/+MN8LQYWA?A7_`(BD/V0^#_PSW^TC@]#Y/PQP
M?7'_`!7O8\?A2L][:`?TWT5X]^SY\9M!_:)^!_PI^.WA?2]7T3P[\6_`GAWQ
M[HND:\+(:UING>)-.AU*UL]4&G74\'VV.*=5D\F:2/<IVNPYKV&@`HKQ[]H/
MXS:#^SM\#_BM\=O%&EZOK?AWX2>!/$7CW6M(T$61UK4M.\-Z=-J5U9Z6-1NH
M(/MLD4#+'YTT<>YAN=1S7\^/_$4A^R'R?^&>_P!I'`ZGR?AC@=<9_P"*][GC
M\:`/Z;Z*^%OV)?V]OAS^W-^SKXB_:1^'O@[QMX2\*^'/$_B_PM=:%XR30E\0
M7%YX.T32-<OKFW71-7N[<VTMOK$"0[IU??$^]5&"?QX_XBD/V0_^C?/VD.W_
M`"Q^&![>WC[KFG9OIL!_3A17\Q__`!%(?LA_]&^?M(?]^?AC_P#-[1_Q%(?L
MA_\`1OG[2'_?GX8__-[19]F!_3A17\Q__$4A^R'_`-&^?M(?]^?AC_\`-[1_
MQ%(?LA_]&^?M(<\#]S\,>IZ#_D?:+/L!_3A17X6?MD?\%[/V<OV+/VD/B-^S
M1X\^#OQL\5>*_AM_PB']JZ]X1C\"-X>O_P#A,?`GA?Q]8_V>=9\76MR1%IOB
MJS@E\V"/]_;2A-\85V^8O^(I#]D/_HWS]I#_`+\_#'_YO:+/L!_3A17\Q_\`
MQ%(?LA_]&^?M(?\`?GX8_P#S>T?\12'[(?\`T;Y^TA_WY^&/_P`WM%GV8'].
M%%?S'_\`$4A^R'_T;Y^TA_WY^&/_`,WM?1/[)W_!P#^S9^UU^T-\,_V<O!/P
M8^./AKQ1\4-3U32](USQ3%X"70-/FTKP[K/B2:34CI/C"YN!$UIHMQ&OE02'
MS)4R`NY@6?8#]YZ*_"O]LC_@O9^SE^Q9^TA\1OV:/'OP<^-GBKQ7\-O^$0_M
M77O",7@1O#U__P`)CX#\+^/['^SCK/BZUN2(M-\56<$OF0)^_MI0FY`KL?L;
M_P#!>S]G+]M+]I#X<_LS^`_@[\;/"OBSXE?\)?\`V5KWBZ+P(OAZP_X0[P'X
MH\?WW]H'1O%UU<CS=-\*WD,7EP/^_N(M^V/>ZEGO;0#]U***X7XD_$_X=?!S
MP;K/Q#^*WC?PO\._`WAZW-SK/BKQAK5AH.B6*8/EQR7VHSQH]U*X"00(6FGE
M98H8Y)&5"@.ZHK^:S]H/_@YN_9&^'6J7VA_`?X7?$C]H>ZL9+B/_`(2*YN[7
MX1^`]1,<CQ0OI6J^(-+U'69HG*%BT_AZV`C=&3S"65/A"Z_X.I/BR^J0RV7[
M'_P\MM&10;K3[OXJ>);S5)2))2S0:M#X1@BM@8FMP`UC+AD=B2'"QTHR>M@/
M[0J*_EP^!W_!T5^S]XIOK#3/C_\`L\_$3X1+</%;3^)O`WB;2?BQH%J^P++J
M.H6%WI7A_4;+3_,#DQVMOJ<T8(5?/(+G^BGX%?M#_!']IKP'9?$SX"?$SPK\
M4?!-\_D?VQX9O_.ETZ]$:3/I7B#2+J.*^\,ZVD4D3R6.HVUK>1K,C20*KJ2F
MFMT![-1112`*^6OV@?VC;'X5QGPUX=BMM6\<W=J)2LK++I_AR"8?N;K5(XW#
M37SI\\-KE<J5FF*Q-&D_NOQ`\6V_@3P5XF\77*I(NA:3<WD,$C,J75\5$.FV
M;,O*B;4);6+(Y'G9%?AGK.L:EXAU?4=<UB[EOM4U6\GOKZ[F(:2XNKB0O(^%
MX5-QPJJ`$5`BC:JJ-:4%)WE\*_%D2E;1;FUK7B#QE\1M>%[K>HZGXFUR]<K%
M]HD,QB5CEH;6W`$6GVBX)V1K'#&`6("[J]U^'7[-VM>*I5:Z22ZV%?M,5K(+
M;3;,M@E+W5'!+R[6SY<(\SC<A<<UWGP)^$RW=[8:=-'Y5_>PF^U^]"J9;'3H
MVC9[&W)4B-@SPQ9P0TTH=MRJH'Z1:7I=AHUA;:9IEM':65I&(X88QP!DEG=C
MS)*SEF=V)9F8LQ))-7.IR^['1(F,>:[;/FCPK^RSX1T403WLD"W41213I-I$
MLT$J$,IBU34DFE?#C(.R,\`C!`(]!UOX!_#+Q-92VGB/0CK<TH&-6O;ATUR,
M@#&W6+,13R(,+^[D>2+Y`"A4L#[+17@YYD&1\3Y?6RGB3)\+GV5XC2>&QF'I
M8FA/MS4JT9P;71\MUT:/1R_,<PRK$PQF5XZMEV+I_#5H5)TJBZZ2@XR2\KV/
MC\_L/?`>>SEM=1T;4-2D::=H[^ZNH&O%MY0?*MI4-H;>81%I`C"W0LI`D$A#
M,_CWBW_@FA\&]865O#VIZCHDK;V1;RRM[N)6;YA&IT6;3=B;@`"RR;0>5<YS
M^D-%?C^/^C+X#YAA(X*IX:9?A*4%RJ6$]O@:UN[KX.M0K2E_>E4;;W;/T/+O
M&GQ5RJO]8P/'>84ZE[VE6]I#_P`%U5."7DHI'Y#_``X_X)[^,?A1\:/A[XXT
M;7XKO1=`\5:;J>ISZ;JHWG2[2X$]S:WEE?0V<QBFBB\MTBEO,B8%ED`*#YE\
M._MM_MP?LZ:[-I'Q@\+0?%SPW;7)EO=+UK3+OP_XVTNQDE9S#8:G%8I>*HS(
M!)J-CJHVQ`>>%&^OZ$L?Y_K7'^,OA_X*^(6F'2/&OAK2?$5CAO*34+96N+5G
M&&EL+Z(K/IT^,CS()(WP2-V#7Z#X*^&O`W@IE^?Y+D>`Q.99-Q%BH8J=/&8G
MZQ4PLX4E2Y,)4=.%54Y12<O:5)U'+>KRI17L9QXR9IQKC:&(\1LLP_$ZHX>G
MAHU%3C1KPIPJ5:CG&<6G[24JSNX2I:1BE;6_RY^SO^WM^SW^T5]BTC1/$O\`
MPAOCVYV1-\/_`!N]MI&M7%VV%,&@WIF:S\2$R"39':3-=[(_,FM(`<5]IU^-
M?[2O_!+G0O$<5]XD^$LLKZ@-]Q_8UU/;6NNJXR0+#5G6.#6XU)7$-\([@)#A
M+V25@#\T?"/]M_\`:/\`V1-;B\!?'S3]=^*OPQTZ\ATN2^U47$7Q`\(HA,:P
M6^I:HXDG9(W0C3]6=PXBCALK^VB5MW[55X;P6:49XOAG&>WY5>6%JM1JP\HO
M2_9<UD[.U26QY6(X(RG/\/4S#@7,OK<H+FG@,1)1Q$/*G-\JEKI%32O9\M6H
MS^BNBO+?A!\:/AK\=O!MGXZ^%_BBP\3:%<D0W(MV,.I:-J`17FTG7M*FQ/H^
MIHK*QBF12\;I-"9()(I7]2]?;_`'^M?&U:=2C4G1K4Y4JM-VE&2<91:W33LT
M_)GYE7H5\+6JX?$T98>O1;C.$XN,HR6ZE%I--=F@HHHJ#(****`$9E16=V5$
M52S,Q"JJJ,LS,>`H`))/I7^:;_P5A_X*)>./V^OVD?$]_;Z_>K^S_P##GQ!K
M?AWX$^#(9)(-)7P[:7+Z>_CW4;%6`G\6Z]':QWDTLH:6UMI[?38I/*M0TO\`
MHX?%W2]:UOX3_$_1O#8G/B+5_AYXUTO0!:RR071UJ_\`#>IVFEBVGB.Z&?[=
M+!L=?F5L$<@5_DD20RP2212H\4T#R1RQ2(8WB>-L2(Z,`8G5]V5(4@J01G(J
MHI-Z@?97[%O[`O[2?[?/CO5_`W[/?A.QU&+PO:V%_P"-?&OB?4U\/^!/!%CJ
MD]Q:Z5-XCUQ;>:1KNZEM;S[-8V-M>ZC<I8W,\%G);VEU-#^TM]_P:W_M;1:%
M%<Z?^T)^SK>>)3#.UQHUT?B58Z*DR!_L\%MXAC\&3S7$;J(U9WTV'8'.%?;E
MNB_X-YO^"B_[+O[+?A;XO?`#]H3QA8_"?5/B'\0=,\>>#OB'XCBDC\%ZIGP]
MIWAR\\+:_P"(+>!E\+SVS:9'=VMS?F/3I4U*Z5[JWGCC2[_M!\&^./!7Q%T"
MR\6?#[QAX7\=>%M27=IWB7P;X@TGQ/H%^H56+66LZ)=SVUTNUT.4D;AP>XIR
MDTVD]$!_EM_M=_L0_M(?L->/K+X>_M%>`Y?"U[KEI=ZCX1\1:=>VVO>#?&VF
MV$MO#?7OA;Q)8,8KY[=[FT%S:R""^M#?6_VRU@%S#YGI?_!./]O;XF?\$_\`
M]H;PU\2O"FJZE<_#?6]4T;1_C9\/8)O-TOQWX!2^_P")@HL9V\J+Q786MQ>W
M&C7PV2VUSNB:1K&[OH+G^]?_`(*D?\$];#_@HY\`-`^$D7C#2_AQXM\(_$/2
M/'GA;Q[J'AR7Q(VEBWTK6=$US1S8VNIV4LEE?:=K`,B"Y6,SZ;:3R)(UO&!_
M/U_Q"K>/QC'[9W@[(&,GX*:UGVQ_Q<CC`Z=<?E@NG'7XD!]I?\%^_P!@C2/V
MK/V>/#W[</P-LK?7OB!\(?!<&M^(YM#MI)IOB7^S[J%O_P`)"NKP!(MUU>^'
MH[ZXU:V+"/=I&IZL)6DD@L8D_A?'&,C`QWP"/FP6SC.X-GMD8[U_K$_LX?"+
M4/@K^SA\%?@3XI\06?CZ\^%?PB\#_"O5/$?]D_V?9>*+?P;X6T_PJM[)H]U=
M7)BAN+'3X]\<LT[-N;S9)&9F/^?U_P`%H?\`@GK+^PA^U+?7/@O1Y;7]GKXV
M2ZMXU^$$\,;_`-G^&YTN()/%WPR$F,1R:+?7]L;)22QTC5M-+2R3I<E%&UTG
ML!_4C_P05_X*'C]KO]FU/@I\2=>^V_M`?LXZ7I?A_59M0N8WU3QW\+HECTSP
M9XWW23&;4M2M$CATC69B'<W-O8WUU,T^KA1^]%?Y5_[$_P"UGX]_8F_:1^''
M[0O@)Y+FX\)ZF+3Q7X;-RUK9^-O`.JO':^+O!E^<%4CN]-60V\KQRBSOK:TO
MDC:>TB6O[&O^"Q/_``5J\!>`?V&/`EM^S3XUM=7\?_ML^`S=>"=8TZ[@35O`
M_P`&M9M9+#QKXLO[>UN'ET3Q4\\EWX<M(6\N>TU1-6FCE6\T&6%AQULNH'\_
MO_!=;_@H6W[9G[3MQ\-OA[K9O/V?OV=KW6/"?A%[.96T[QIX[6<V7CCXB*\0
MQ>V<EU:Q:;I$@:6(Z?I7VZV:/^U+A3^8W[)G[,?Q$_;$_:!^&_[//PQMP?$7
MC[7([6\UJ6UGNM)\(>&K4-=^)_&>NBV`*Z/INC0W-S(`RM.\4=I`6N;B%&^<
MR!N.``,_*"P'4$X//3C].#@@G^^O_@W^_P""=8_9:_9_/[2?Q,T,VGQV_:.T
M'3;ZPL]2ME35/A]\&Y98]5\,^',2Q"6QU76W2PUG58RP(CBTBTGAANM/G5JN
MHJW5`,_X+&_`CX>_LQ_\$3?$GP'^%FE_V5X&^&E[\#O#^D12"(WNH2I\5O#-
MWJ^OZQ-#&BW6NZGK5SJ&H7\RH@FO-2FD"H&"C^!4GT`'&".H/?D'J.GY<Y/)
M_P!$_P#X.$O^46WQJ_['#X,_^K4\+5_G7@$G`Y/IW/T]3_A1'9>OZ`?J=_P2
M/_X*"ZI_P3__`&I-%\5:[?ZC)\"?B2UCX*^.7A^V,US&/#T]Q)_9'CNSL(XY
M#<:YX>U*[DO8Q'&UQ<6$VI:;"R/?[Q_I0:/K&D^(M(TKQ!H&IV&M:%KFFV.L
M:+K.E7<&H:7JVDZG:Q7NG:GIM_:R-%>V$]G/#+#-&S1R1RJZ,58$_P"1?X@\
M,>(O"=[:Z;XFT;4="U"^T/PUXFM+/4K66VFN?#WC+P]I7BSPIK,4<BYDT_4/
M#>MZ3?6L@&V6VU"&5"0XK^S;_@W*_P""CA\?^$)/V"_BSK0?Q?\`#W2+_7OV
M?]7U"Z)N/$/P_LBUYK_PY\VX<FXU705EDO=.B5W=M$DN84CBMM$!=26[6J`_
MJLK_`"`"<X^F".<$9R1@=!GICIU'/-?Z_P#7^/\`T0W?H!_2Q_P3_P#A!\3/
MCU_P0C_X*(?"CX.^#=8^('Q&\5_M(?"?_A'/"&@1PS:MJW]A>*?V<O$FK_9(
M[B:-6%OH6CZG=29<?NK)R,D`'\R6_P""0O\`P4O.!_PQQ\8#@=?[-TKG/)_Y
MB_J2?7D].`/Z;O\`@UO_`.30_P!H/_LY";_U6/@*OZ<*.9INW<#_`"X/BC_P
M36_;M^"G@+Q'\4?BM^S'\2_`WP^\(VUM>>)/%>N6.G0Z5H]M>:A::5:S7DD.
MI.R(^HW]G"I"GY[A<X&2/B#;QGVS[>O4>Q'OE@,=Q_I7_P#!;+_E%O\`M=?]
MB=X0_7XI^!!_6O\`-.[>ASG(Z_@>W?IZ_2J4F]6[:@?:'P<_X)W?MM?M!>`=
M+^*/P7_9P^(OQ%^'^MW.IV>E>*O#UEI\^E7USHVH3Z5JD,$D^HQL9(-1M;F&
M0%!AX2!FO41_P2$_X*7<D_L;_&#CD$:=I0.?;&K\'W[8[]#_`&7_`/!O<<_\
M$MO@KGD_\)A\9N>Y_P"+J>*NOJ?\GFOVPJ.=VL!_$E^U;\%?BI^SW_P;P?`_
MX7?&CP/K?P[^(&B_M;SWFJ^%/$,4-OJME:ZUKOQHU73)9X[>:142?3KNWE3#
M'Y)ATZ5_+:#@8(R!G'XXZY!R<#O^.0,5_?A_P<N_\HZM%_[./^&?_J+_`!&K
M^`\`GIC]?\.N<`>I(%5&S3OMK^@'^H?_`,$O/^4=7[%?4_\`&-_PKZDD_P#(
MK6'<U]X5\'_\$O/^4=7[%7_9M_PK_P#46L*^\*S`^#_^"H?_`"CJ_;4ZC_C&
M_P"*G0D'_D5K_N*_R\"<C`&`<9_#/3`&#@]OPP#BO]0__@J'_P`HZOVU?^S;
M_BI_ZBU_7^7@01UQ^O\`AUSD'T((JX)-N^X']X/_``;S$'_@E9\4^./^%O\`
MQRXSG`_X5[X&P,GVK^#[.>"0,#T)Z#N22<`#\`.YZ_W@?\&\O_**OXI?]E?^
M.7_JO?`U?P?@'J!TY^GOQW[_`(>E./QR^?Y@?3/[/_[&O[4/[5%GXFU#]GGX
M*^,_BQ9>#;G2[3Q1<>%+:SN(]$N=:COIM*AO?M-Y$4>>+3;]DP#D6K9QQGZ&
M_P"'0G_!2_\`Z,X^,'_@MTG_`.6]?T)?\&JO_)/_`-L[@`_\)C\%<XQC_D"?
M$8=1P3W."?O?A7]9U$IM-H#_`#'_`/AT)_P4O_Z,X^,'_@MTG_Y;TH_X)"?\
M%+L'/[''Q@Z<?\2W23SU[ZM@CC'?K^(_TWZ*3FV!_"Q_P60_X)Q_MQ_'K_@I
M!^T9\6/@]^S5\2/B!\.?%9^$7_".^+=`LM/FTG5O["^`_P`+_#>KFTDGU&-F
M\C7='U.UDR@Q+8N!D`$_F./^"0?_``4N)Y_8X^,`]_[-TG_Y;U_IOT4E-I6`
M_P`DCXN_!_XF?`7XA>(/A1\8?!NL?#_XC>%?[*_X2+PCK\<,.K:3_;FB:;XD
MTC[7'!-(J_:-"UC2[J/#G,5ZF<-E0?"+X/\`Q,^/7Q"\/_"CX/>#=8^('Q&\
M5?VK_P`([X1T".&;5M6_L/1-2\2:O]DCGFC5OL^A:/JEU)EQB*R?&6PI_3C_
M`(+V'_C;%^U8/3_A1G3N3^S9\'>3[]/P`H_X()G_`(VQ?LICU_X7GU[$?LV?
M&+D>_7\":T;?)=/4#Q\_\$@_^"EP/'[''Q@/O_9ND_\`RWK]$?\`@D[_`,$U
M_P!NWX)_\%"_V:/BC\5OV8_B7X&^'WA+Q/XGO/$OBO6['3HM*T>VO/AWXQTJ
MUGO)(=2=E1]0O[2$81OFN0.,Y']YU%9N3:LP/\X#_@O8?^-L7[5@_P"R&'\3
M^S9\'??T`I/^""?_`"EC_92_[KI_ZS9\8J/^"]G_`"EC_:M_[H9_ZS9\'?\`
M/XT?\$$_^4L?[*?M_P`+TS_XC9\8A_.KWAW`_P!"OXX_&GX>_LZ_"/X@?&_X
MK:T/#_P^^&OAR\\2^)=2$?GW/V6V*0VNGZ;:!U-_K-[J,]G9V-LI#W-Y?P0(
M=T@K_-C_`."B7_!1WXX?\%#?BS>^+?'>I7OA[X7:%J%VOPI^#>GZE-)X6\#:
M/^\@@OKF!66/7O'%S:;CJ6KRQ^;,TI@M5M=/CMK.'^A#_@Z'_:CU32-&^`G[
M'WA[5'M;3Q5%??'+XG6$,C12ZCI&EZC=^%/AC8W#1MF?2GUVR\>74L+YC:Z\
M/6$P!>W4K_'_`.&/#NL^,?$F@>$O#>GS:IXA\3ZUI7AS0-,M^9]0UK7+^WTS
M2;"'<P'G37]U!&O3+2\8[0HW5]@/3O@1^SI\<_VG/'-M\-O@%\+_`!9\4_&=
MRB3OI7A?33<6^EV32Q0#5/$>M7,D=CX8T-9Y(D:^U.ZM;-'=$:X!<*?UXT[_
M`(-Q?^"EE[X;.NW/ASX.:1J:HKCP;?\`Q8T^3Q*S,L!\I+O2M.NM'$BF:4$G
M50/]'<JS`Q^9_9K_`,$]_P!AKX:?L#?L[>%?A#X+TW39_&-W8:=K'Q?\?06R
MC5/B%\07M,ZIJ=S=O&)?[!M;B>YM='LSB.SL47Y6NI[NXN/N:AS?31`?Y1O[
M2/[)7[1W[(?C*+P-^T5\)_%'PQUN\%W+H\VKV]M>^'O$MM92)!=7?A7Q9I$]
MQI?BBUC,L(E>QNYQ";A!-Y;/BNR_8J_;9^-_["?QGT7XP?!KQ!=11K/96WCO
MP)=WETG@_P")OA:WN':Y\->*].C)2=6BN;PV=YY9N=-N;C[59R1S`AO])C]L
M[]DOX9_MK_L]>/O@)\3=+L[BU\2Z5<3>%/$<EM')JW@/QQ:02R>&/&F@7>PR
M65_9ZCY1F6-E6\LI;K3[D26EW/%)_G^S_P#!$C_@J1#/+$/V2O%DXBDDC\Z+
MQG\+&BEV.Z>;"[>.E9HFY9<A20PRM/FO;FZ`?Z&O[,W[0G@+]JOX#?##]H/X
M9W+S^#_B?X8M=?L;:>2&2_T34$EFT[Q#X8U8VSM&NM:5XALM4TV]$;,@NM+E
M",R;6/NM?@I_P0&^`G[7/[+_`.S[\8/@G^U'\*]>^&ECIWQ.LO&_PQ77-:\,
M:RM]9>,-!2Q\6:=II\-ZW>K9V=KJGA:PNFCD:,&;Q-+)&&+R$?O74/UN!\P?
MM?7$T/P4U:.)RJ7>M^'[>X'.)(5OUNE1L=OM%M`WU05^6?@RR34/%.AVLBAH
MFU&"613]UX[;-TR,"<$%(2I'?<<<XS^OG[1OAJ7Q3\&?&]C;Q&6[L=/BUZU5
M5+R;M!NX-4N%B0<M(]A;7<8`R3YV`"3BOR%\%W:V'BK0;EV"(-1@A=N,*EUF
MU8L2#A0LV3T..>.#712^"2]?R7_!,I[H_5G]G^VB/_"3WA`,P_LJV0G.4B87
MTLF"3T9TCSZ>2,=Q7TA7R=\"M9CLO$=_I,KA5UJQ4P9/^LN]-:2:.,`CG-K-
M>G.<_N\<YX^L:QENRX[(****DH****`"BBB@`KY^^.W[.'P]^/6AW-EXCT^W
MLO$`M);73O%$%G#/=P(P.RSU.UD(37-'+</;3$85W,$L$CF2OH&BM\-B:^#K
M0Q&&JRHUJ;TE%V:\NS3ZIW3ZIG5@L=B\NQ-+&8'$2PN)HN\9P=FO)]&GLXM.
M,EHTT['\MWC/P)^T!_P3V^+MQXQ^&][<:3%%&LNJ:2&N=3\*^*?#@N&(:YMG
M*#7?#9;?G>8[_3926#PRJ98_W@_9+_:X\`?M7^!VUWP\$T'QGHJ00^-O`5W>
MI<ZEX?NI<K%>6DWE1G5?#MPR.;:\6-`2K0S)%.CQCL/VD/A!>?&7X?S^'M+A
M\+MK-K(]YI5QXBLK]I8+C8%*:9J^GWJ'1WD50LQEMKV"=`(Y(4.RXA_FG\?^
M$OC1^PY\9](^(/A2TU;P+JUC>G;:31F32;F&9\WVBSF*1K?Q#X0OHX74&.22
M)6A94>.:W@<?HU.&"XVP%ZCIX7B'#)I23LZB25N:.[A+NN9TWLVKQE^W4899
MXIY0E7E1R_C/!Q:C43LZZ@M%4C\4J<EM)*;HR>C:YH3_`*V:*^5OV-_CYXF_
M:5^"EC\5O%'AC2?"=SJOB+Q!IFGZ;HUW>WMI+INB7$5A]M>:^0,)VU&/44*C
M<H6W4YW%@OU37YSB<-5P>(K86NDJV'DX32::4HNS5U=.S['XEC\%B,MQN*R_
M%Q4,5@YRIU$I*24XNTES1;B[/2Z;04445@<@5_$?_P`%C?\`@A]\6O"'Q.\>
M_M2?LA^"]2^)7PK\>:QJ?C7Q]\*O"%D;WQO\,O$FK74VH^(K_P`+^&+)/.\5
M>!;G4;B>YAATV.6\TG[7)`UE_9MLMVG]G7Q"^)?PX^$?A:]\<_%?X@>"?ACX
M)TV:RMM1\8?$+Q7H7@OPM87&I745CIT%[X@\27]M:6LUQ?3P0PK),K2RS)&@
M9V`/SK_P\*_8%Y_XSA_8_P"!D_\`&2_P7X'')_XK7IR/SIIM.Z`_RRKNSNM/
MN[JRO;6:RO;.>>TO+.[ADMKFVNK>1XKBUGMI@&@GCE1U>-@K*5VLH)P>T^'O
MQ4^)_P`)=;7Q-\*OB/X[^&7B1/*VZ_\`#[Q?X@\&:RODLSP8U7PYJ%M.NR1V
M*_O/D+_+MYK_`$\_BI^Q]^PM^VQX?TKQS\1/@Q\$/CEI7BO2+74=`^*6CV>D
M7>JZ]H%]`LMA?>'_`(K>"+J'4+W1Y8'5X);34VA8,'C8\-7Y'?&W_@V5_8I\
M<_:[WX-?$'XP?`C5)O,^RZ?_`&I8?$_P59[@VP_V/XIBAUFX*EL?-XB&5&#R
M2U6I)O7^OU`_G5^"?_!>[_@I?\&GTZWO?C/IGQC\/:>\3'P]\:/!^A^*?MB(
MR^9'>>,-(ATWQ'=&2.(*2^M.5)9TVL68_P!*O_!/C_@X,_9^_:L\0^'_`(2?
M'S0;?]G'XRZ_/;:7X>O[O6?[4^$?C?6[F58+32M*\3WD4,_A#7;F5PMM9:JA
MMI9"EM;ZO<WD\%M)_-O^WW_P0Z_:M_88\+:S\6(M0\.?'+X%Z))&=:^('@6V
MOM,UWPG93S0VL&H^._`&HF6;1=->ZF"FYL+S5[*W&TWMU:F2-6_%WM@<=,G<
M.K#'X#'7\CVH?*TVMP/]?ZOAG_@HI^Q/X1_;V_9<\=?`S7?L&G>*VA/BCX3>
M+[V$/_PAGQ.T6UNCX<U625;:62/1KG[1<Z=JJQ(TLFF:Q=K$!/Y+I\Z?\$1/
MVJO%7[6?[`'P[\4>/]6G\0?$'X7Z_K_P3\9>(;RYDN]0UZ\\%6VCZCX>U;5;
MB=FEN-9F\#>)/"9O)I7>6YNA-=2-OG('ZXUGL!_D8?$#P'XO^%GCGQ;\-_'V
MA7WACQOX$\1:OX2\5^'M101W^CZ]H%[+INIV$^UF5F2YMY`)(V>.12'C=T8,
M>9N+^]O(K"WO+RZN;;2[1K#3()[B66+3;&2^O-3EL]/BD<I:6K:EJ.HW!BC"
MH9[^:4J9)79OZG?^#GW]F?X=^!?BE\"OVF_"MJND>-/C?:^*_!WQ*L[:W5;+
MQ#J'PVT_PJOASQ=/()<KKAT'6HM,N#L*S6VA6!&R2*5I_P"5@=>A.<C@D<$8
M/(Z<?AZ\5M'5*3W_`*0'[<_\$./^"=S?MK_M.V_COXAZ&;S]GC]GV]TCQ7X]
MCO;=FTOQQXM\R2Z\%?#0-<0/%J%I/>V?VW68"&4Z1ILEI,87U2SE;_1%5515
M1%5$50JJH"JJJ,*JJ.`H```'I7Q9_P`$]OV4O`'[&G[)GPG^"_@&-+GRM!L?
M%WC;Q,UJEK>^-OB'XJTZPOO%'BJ_C5F*>9,MM:V<3R2M::9I-A8^;(MJKG[4
MK)N[;[@?B?\`\'"7_*+;XU?]CA\&?_5J>%:_SK__`*X_`\$?E7^BA_P<)?\`
M*+;XU?\`8X?!G_U:GA6O\Z^KCLO7]`/ZW_\`@HM_P3D'QQ_X)5_L-_MH?"G1
MC+\6/@9^P]^S5:?%'2=-M5:Y\<_!NT^#OA"\FUMTC&;C7/"\MQ=W98@-+HEU
MJ"RR2?V?86Y_E>^%OQ-\<_!GXB^"OBO\-M?O/#/CWX?>(]*\6>%=<LG(N-/U
M?1[R.\MF>-ODN[*1T,5Q;RAK>Z@GEMITDCD>,_Z?G_!/VWM[S_@GY^Q):7<$
M-U:W7['/[-MO<VUQ$D]O<6\_P4\&1303PRJ5FA>-F5E8%65B""#7\*?_``6C
M_P""==Y^PC^TW?:GX(T9X/V=?C?<:OXN^$ES:Q$V'A6\2>*7Q7\+YV*XMIM'
MO+ZWDT_=D2Z/JEB1-+<PWRPJ,MD]@/[H/V`OVS_`W[>/[,W@?X]>#_LVG:O?
M0GP_\2?!\4S2S^!?B3I%O;?\)+X<D\QR[V!:YMKW3IG.ZXTS5K.=PDKR11_Y
M:17&.0<^F2..,@D=,@_E7[$_\$7?^"B=U^P=^TY9Z?XUU1HOV=_CA=:+X.^+
MMO.P%IX6NENIH?"?Q2@!8>2VBWNHW2ZAM+>9HVJ:@!!-=PV7E?CL>W3H/\/3
MV^OU&"7&+3OT`_N/_P"#6_\`Y-#_`&@_^SD)O_58^`J_IPK^8_\`X-;_`/DT
M/]H/_LY";_U6/@*OZ<*B6[]0/RP_X+9_\HM_VNO^Q.\'_P#JT_`=?YIU?Z6/
M_!;/_E%O^UU_V)W@_P#]6GX#K_-.JH[+_$!_HH?\&]O_`"BV^"O_`&.'QF_]
M6IXJK]L*_$__`(-[?^46WP5_['#XS?\`JU/%5?MA4`?SX?\`!R[_`,HZM%_[
M./\`AG_ZB_Q&K^`\9[=N?3VZ]NOMR0<CJ/[\/^#EW_E'5HO_`&<?\,__`%%_
MB-7\!X.`1ZC'^??!(^A-:0_S_0#U+3/C?\:M"TZRT?1?C!\4=(TC3+:*QT[2
M]+^('BNPTW3[2V0116EC96>K)%:6T:*%2-$554```5=_X:%^/O\`T7'XP?\`
MAR_&G_R[K^T3]AC_`((@?\$Z?CA^QS^S/\8/B+\)?%&K>._B5\&/`7C+Q=J=
MK\5_B1I5M?:_KN@VE]J5U!ING>)(X+&)[B5RL4*)&@.U%``%?5G_`!#V_P#!
M+;_HBOC#_P`/-\5/_FII-QOIM_PP'\`6I_&_XU:[IU[H^M?&#XHZOI&IVTMC
MJ.EZI\0/%=_INH6ERABEM+ZRO-6>*[MI$8J\;HRLI(((KRTY[]^?7VZ]^GOR
M"<GJ?[H_VZ/^"('_``3I^!_['/[3'Q@^'7PE\4:3X[^&OP8\>^,O".IW7Q7^
M)&JVUCK^A:#=WVFW4^FZCXDD@OHDN(D+13(\;@;74@D5_"X3D`>@Q_\`K]\`
M#Z`5<;/;=`?W@?\`!O+_`,HJ_BE_V5_XY?\`JO?`U?P?@$GZ=<]/8'T!/?@<
M\D5_>!_P;R_\HJ_BE_V5_P".7_JO?`U?P?Y_/((/IC/MZX_*IC\<OG^8'T!\
M%?VK/VE/V;[7Q!9?`3XX_$SX0V?BRXTZ[\2V_@#Q9JOAJ'7;G28KJ+3)]433
M;A!=SV\6H7BQE\E/M4@!^8Y]P_X>B?\`!17_`*/4_:/_`/#I^*/_`)/K]6_^
M""O_``3F_90_;L\(_M)ZM^TEX&UGQ???#?Q'\,]-\)2:3XW\6^$EL+3Q)IGC
M.ZU:.:/PUJ]LM\SS:/8%6F#LGE':1O;/]`G_`!#V_P#!+;_HBOC#_P`/-\5/
M_FIHDU=W7Y?Y`?Q0?\/1/^"BO_1ZG[1__AT_%'_R?7ZV_P#!$#]NG]L?XX?\
M%%/A/\.OC!^TQ\9_B5X$U;PM\5;O4_"7C'QWKNNZ!?7&D_#CQ'J.FSW6G7MV
MT4TD%_;V\T1924DA5E((%?OE_P`0]O\`P2V_Z(KXP_\`#S?%3_YJ:]Z_9J_X
M)!_L)_LD?%S0OCC\#?AGXB\-?$;PW8Z[IVD:OJ/Q)\>^([6"T\1Z1=Z%JR/I
M.NZ]/;3M)IM]<HK/&Q0N'0A@");5MOR_R`_3:BBBI`_S?_\`@O9_REC_`&K?
M^Z%_^LV?!VC_`(()_P#*6/\`92_[KI_ZS9\8J/\`@O9_REC_`&K?^Z%_^LV?
M!VC_`(()_P#*6/\`92_[KI_ZS9\8JT_Y=_UW`_T@****S`_S?_\`@O9_REC_
M`&K?^Z%_^LV?!VE_X()G_C;%^RGQU_X7G^'_`!C9\8O\^GMTPG_!>S_E+'^U
M;_W0O_UFSX.TO_!!+_E+%^RGQG_DN?X#_AFWXQ<]?H/QK3_EW_7<#U'_`(.+
M/$5[K?\`P4V\=Z9=M(T'@_X6_"+PYI@>8R*EE<^%U\72+$A0?9X_[1\4WYV@
ML"[,^[+E5^3_`/@D%X2L?&O_``4P_8XT;48K::WL_B]I_BV-+I"\:WW@#2-8
M\=Z7*BC_`)>8]2\-VCPGHLL:.<!21]W?\'*GPUO?"'_!0G3_`!NULR:7\6O@
M?X!\16]\%?R)M5\,WFO>!-2LF=G.;R&Q\-Z+(X50!%J$!P27-?EU_P`$\_C'
MI7[/W[</[+?Q=\07RZ7X:\(_&7P8?%FJ23RV\6E^$-=U&/PUXNU*9X9%+PV_
MAS6M2G=-VR1(2D@:-V4O[&G]=P/]36BD5E=5=&5T90RLI#*RL,JRL."I!!!'
MK2UD`44C,J*SNRHBJ69F(5551EF9CP%`!))]*_E1\6?\'2GPMT'Q3XET/1OV
M3?%/B?1]%\0:QI.E>);3XR:':VGB'3=/U&YL['7+:W/@&46\%W:PQW"1^=*$
M6?`DD`WEI-[`?U7T5^1G_!+[_@JYI'_!3+4/C-;:!\"M>^$ME\'+/P)<7VIZ
MKXWL?%]OK%SX[G\61V5A$EIX:T\V$\47A*]D.3+O63HFT%_USH::=F`R2-)4
M>*5$DBD1HY(Y%#I(C@JZ.C`AD*D@@C!!P:_$[XV_#B[^%GQ"U?01'*NE33-J
MWAFZ.X"XT6[FD>U59<?-/;R+);R\#+VC,`%9<_MI7C'QJ^#FD?&#0;&RN6CL
M]:T:]2[T?4W$F$AFE@&J:;<&+YOL=U;0J"5RT<L,,H#;"CU3ERRUV9,E=61X
MW8_#3QAHD7AK5--U+2]1U\Z9IFM_V=%<1V.K+.D%M/=R1Z=>2#[1:)<LZ-M<
ME@-I0$[#]9Z#JKZSIEO>S6=SIUT5$=]87<,D,]G>(`)X&25060,0R/C#QNCC
M[V!^1G[;WQ@E\)_M)^&=%^V3PZ'IGP\T.*^\F21'TO5]0USQ#>KJEMY3YC=;
M!],$@4!FC&2',<('8^#OVG?B7X9CM@=9@\6:241T@\0*]^[P."P>WU>*1;ER
MRE=A>69``,(1D'^6\Z^E'PWPOQSGW"'$V1XFA@LIQ+P]/,,-*&(C+EC#VGM\
M.U2G3]G4<XMTIUY-)/V:=T>10SG"U<3B\,KJ>#J>SELW=)6E;>SL]5U370_5
MJBOGWX1?'VS^*CFT3P?XETF[AREU?0VLFK>&89@F\0RZ[!#&+6X9"C+'-$F1
M(-K.`37T%7]`\,<4Y#QCE-#/.',P69Y9B;J-50J4[M6NG"K"G4BU?52BFCUJ
M=2%6*G"7-%]0HHHKZ`L****`"BBB@`Q7XS_\%G5^)?P_^!.B?M#>"++2O'?@
MSX=ZS8^'/CC\'/&45W?>#_%OPZ\9:I9:9IWBG2Y;.ZCOO!/CK1_%\VCI;:QH
MD]G=M;>()O[3:^T^R2R/[,5\Y?M?^![#XE?LI_M'^!=1@AG@\2?!+XF6$'G-
MM2#4AX0U:XT>_#[6V2VVKP6-Q&Q5@KVJDJP!4^=FT<2\NQDL%BJF!QU.G*="
MM3FX3IUJ:YZ<HR3NO>BE);2BY1E=2:/T?PASW`\.^)O!&9YME]+-<E68X:CC
M\-7@ITZ^!Q-2.'QD+.SA56'JU)X>M%QJ8?$1I8BE*-6E"2_F!^#_`/P7$^$W
MPP\>_L$^`/AMIOCKX??`CP[#\8/`'[5?@CX@RZ9K;Z#=_$_Q7X2UCPCX[TCQ
MAH]I:P>)K+P[K\6OW,=^+"QNIM(U/5;>XTN&XNH)$_L)5E=0R,K*P#*RD,K*
MPRK`CJ",8-?Y3GB_0474Q*HP;JVCDD(!Y=-\+<`$D^5''P>>HQG!K_0W_P""
M0OQ\O?VAO^"?WP&\3ZY?OJ/BWP7HMY\)/%UQ*3)<2:G\-+V3PYI-U=SD#[3?
M7?@^#PQ?3R'+/-J;EF9MS'\YX`XUS'B/,\UP^<8CZQC:\5B5*W+>24*=;39<
M[<*EDDN9U9)).R_NWZ=OT7N'/"3ASA#C;@G!U,-ED<;BLLS#VDY5JE2IC:V+
MS3!XBK5DN>I*$I8O"RJUG.HZ*P-&4Y.FG+]+J***_5S_`#+/S(_X+'?!'7_C
M]_P3=_:>\$>%+&;4O%&D^$M(^)6B6%L'DN;Y_A3XKT+XAZO86EK&X-]?7/AO
MPYK5M;P`,\L]W$L2/+Y:G_,Y9<$C.0J\@#G&,AB1C=S@Y/'`SS\M?Z_M?Q>?
M\%6_^"`/Q$TGQMXL_:#_`&$O"J>,O`WB:]O_`!)XN_9\TI[>V\4^"=8O9Y;S
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MHOA^5&CFT/2/%_B&PTB2)T$312Z;::@D,BM$JJ5*$,!MQ@[:IPN[K8#_`$9_
M^"L_[;_[.?[-/[)7QZ\%?$#QMX5U7XG?$_X2^._AUX(^#UKJVGZAXR\0ZKX[
M\,ZCX8M;^_\`#T)FFTKPK:'5?M5[?W<45L(K4P1227DUM!+_`)K:C@CC`7."
M.5ZD;0#DC!SZ=\'C-@FZOKDR.T]Y?7EP79V,EQ=W5S<2'+L[$M/.\[DY))9V
MZDEJ_>#_`()M?\$+/VB_VLO%7AOQ]\?O"_B7X"_LVVE[8ZGJEYXNTJ\T#XA_
M$O3(I8;Q]#\">$]1$-[IVG7UHZI_;]['#910WIN=-759(C;TK*.^M_Z^8']%
MO_!N)\*M;^&__!.&P\0ZU;7=HOQH^-?Q'^*NC0WB^7(VB+8>$OAC9W,<+1J\
M=K/+\-+F>%G+^=%<K<1NT$T1K]Z:YOP;X/\`#'P]\)>&?`G@K1+#PUX/\&Z#
MI/ACPOX>TN+R-.T30-#L8--TG2[*(DE+:"QMH(UR2Q$>68L23TE0]6WW`_DP
M_P"#JO\`Y)_^QC_V./QJ_P#3)\.*_C.[8]?\YQZ]>N>IK^S+_@ZJ&?A_^QE_
MV./QJQ[_`/$D^'/`QU/I_P#JK^,['N.F3[<<9]NF<9ZXZ\5K%KE2[?Y@?ZY_
MP\_Y$#P-_P!B?X9_],MEZUV%<?\`#W_D0/`__8G^&?\`TRV5=A60'XG_`/!P
ME_RBV^-7_8X?!G_U:GA6O\Z^O]%'_@X1&?\`@EO\:AG'_%8?!GG_`+JIX5K_
M`#L-O3D$G/`(.,`<$DXSD\XZ#GI6D6K;[/\`0#_4^_X)Z_\`)@G[#O\`V9_^
MS1_ZI?P56=^W[^QAX%_;Q_9F\<?`7QC]FT_5KZ$>(/AMXOFA,LW@7XDZ1;W7
M_"->(X_+1G>P+W-S9ZC$@WW&F:M>01F.5XY8]'_@GKC_`(8$_8=QR/\`AC_]
MFC!]O^%+^"J^P*S`_P`C[XH_#+QS\&/B+XT^%/Q)T&\\,>/?A[XEU7PKXIT*
M^&V;3]9T>[EM;H(X^6[LI#$LMO<Q%X+FWFCN())(94<\"PP>.A_+\/;!!ZG@
MCDU_:G_P<:_\$Y&\?>#T_;T^$NBK)XP^'FCV&@_'_2-/MB;CQ%\/[(K::!\1
M?*MUS<:IH0DALM1D96=M$>VF>2*VT0I)_%:PRV<CD`\'C!(`&>PY&,]`1WK:
M,DTKO4#^X[_@UO\`^30_V@_^SD)O_58^`J_IPK^8_P#X-;_^30_V@_\`LY";
MN._PP\`G\#@BOZ<*REN_,#\L/^"V?_*+?]KK_L3O!_\`ZM/P'7^:=7^EC_P6
MS_Y1;_M=?]B=X/\`8?\`)4_`G4]A7^:AMXSN7K@#D9.,XSC`;IP>W/3DU'9>
M3N!_HG?\&]O_`"BV^"O_`&.'QF_]6IXJK]L*_%#_`(-[AC_@EO\`!49S_P`5
MA\9N?^ZJ>*J_:^H`_GP_X.7?^4=6B_\`9Q_PS_\`47^(U?P'5_?E_P`'+@S_
M`,$ZM&Y`_P",C_AIU.,X\+_$<XR>]?P'8YQD<].<>XZ],CUQUSTK2'^?Z`?Z
MA_\`P2\_Y1U?L5?]FW_"O_U%K"OO"OA#_@EZ,?\`!.O]BL'M^S?\*QZ?\RM8
M>M?=]9@?!_\`P5#_`.4=7[:O_9M_Q4_]1:_K_+OK_41_X*A#/_!.O]M0#O\`
MLW_%0>O_`#*U_P"E?Y=^.<9''7G/N>G7`],],]*N#2OY@?W@?\&\O_**OXI?
M]E?^.7_JO?`U?P?@$YQR?3G)_(>N!]2*_O!_X-YAC_@E7\4AP3_PM_XX]#GK
M\/?`W&1U-?P?$8Z\\>HYXZC_`&<_R(X.0"+7,WW_`,P/ZF/^#=7]LG]E[]E;
MP5^U/8?M#?&OP7\)[SQIXH^%-YX6M_%5S>6\FM6VB:3XYAU:6R%M92[T@EU*
MP63.,&Z7&><?TC_\/>_^":'_`$>/\'__``9:M_\`*BO\R`DG`/88'?OZGM[=
M./K24VDW?77_`(`'^G!_P][_`.":'_1X_P`'_P#P9:M_\J*/^'O?_!-#_H\C
MX/\`_@RU;_Y4U_F/TH/;IGC/IP1U`Z<\^M+E7FON\O,#_7D\->(]#\8^'/#_
M`(N\,:E;:UX:\4Z)I7B/P]K%FS-::MH>N6$&IZ3J5JSJI:VGL+JWE0D`E91D
M`\5MU\X?L<_\FB?LKYZ_\,X?`_\`]5EX8]J^CZ@#_-__`."]G_*6/]JW_NA?
M_K-GP=H_X()_\I8_V4O^ZZ?^LV?&*E_X+VC_`(VQ?M6'U_X49^G[-GP=_P`?
MK[8P2?\`!!(?\;8OV4SZ?\+S_7]FSXQ?Y]?;&2-+^Y;K_P`$#_1_HHHK,#_-
M_P#^"]G_`"EC_:M_[H7_`.LV?!VC_@@G_P`I8_V4O^ZZ?^LV?&*E_P""]H_X
MVQ?M6'U_X49^G[-GP=_Q^OMC!)_P02'_`!MB_93/I_PO/]?V;/C%_GU]L9(T
MO[ENO_!`_J+_`.#@[]B#6/VH_P!DO3OB[\/M'FUCXI?LO7FN^,X=-LH7GU'7
M_A9K=G9+\2])LK>$!KN^M$T/0-9B4EF\GPW>P6Z-/=J&_P`_8Y'.,@`9.WJI
MRN-_.5QQ@D>P&./]?QE5U9'571E*LK`,K*PPRLIX*D$@@^M?R&?\%7O^#?K6
M]?\`$GBC]HO]@G0=*D_ME[K7?'?[--L]GHGE:FQDN-4USX.3W4T=G]FN"TDT
MGAJ4VP@E61=$EFCGM=%MU&5K)[`>E_\`!(/_`(+L_"35?A;X._9K_;6\<6?P
MY^('@#2-/\*^!OC3XIE>'P5X]\+:5#%8:)8>.O$+*4\*^,K+3HH8)=1U!H]/
MU*&S6YN;Z+4I)$NOZ5M.^.GP2UC0?^$JTGXQ?"S5/#'D_:/^$CT[XA>$KW0?
ML_EQR^?_`&Q;:NUOY/E2Q-N\S;MD4YP03_E!^._A]X[^%_B;4?!?Q)\%^*_A
M]XOTF5H=6\*^-O#VJ^%O$6ES!G41WVC:[:07-J=R,N7C7.TD<$9Y$')`8`GD
M$$`!<9SDD\L223SWZYQM?*GML_N_S`_NB_X*^_\`!;GX$_#CX+^/_P!GG]E#
MXD:-\5OCC\1]"U+P9J_CGX?ZE'K/@?X5>&M<M)=/\0ZI;>-]+F-IK?CF33)[
MNVTV'2KB<Z9=2/?7UQ:S6=O:7O\`"X!M.>0>N02#@#)'3C@]>G!ZUJZ)H>N^
M)]7T[P_X<T;5?$6OZM<QV6F:%HFG7NKZOJEY*28[2QTVPADFOKEMH`CC1G.W
M&WBOZFO^"47_``0#\?>*/%GAC]H#]NWPE/X+^'F@W-KKGA+]GK7T\KQCXYU*
MUECN-/NOBEI8^;PMX0CF17ET:Y*ZEJ,D7D:A;V5BK1WQI%?W@/U__P"#?C]D
MK6/V:OV&-.\;>--*FTCQ_P#M*^(!\6;ZQO(7M]1TSP(--M](^&>FWD+QKY?G
M:)#>:U&O+(GC01OL=&C3]T*9'''#&D42)%%$BQQQQJJ1QQHH5$1%`"(%```&
M`!@4^H;;=V`4445+OT`_);]J#]ASXP?&OXI_$WXK:/X@\*6UO+8:+#X&\)S7
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M4*/ME7:S^7-&RS()"4D7<<_J!\(?VD_`7Q52VTW[2GAKQ@X5)/#6J7"*UW-@
M[CH=\ZHFK1G#$(%CN5"DM`%`=OY[?B5\._CS^Q[X@71_'NA2ZCX+OKN6+2=;
MLGGO/".N(K2-YNC:QY.='U5HHW=[.Y2.<*3)+;%"DU=!X9^)/AOQE$DND:@(
M]01/,ETRZ98-2MRN"SK&'_>Q+P?-A+(O&YE;(K^;.!O$;Q&\#LRKY'BL+4Q6
M34*C]OE>-4Z:IN3NYT)-2EA:D[W4X1GAZJESRIU7RR7CX3BFOA*TL/7H/#XB
MF[5,/5O%K;6#MK?=-)IK6S5F?T\T5^*'PU_;0^*GP]%KIVM3Q>/O#MNJQBQU
M^:1-8@MT"@+9>(HT>4,`N%%TEVJKPJ*-NW[R\`_MM_`WQD+>UU;6KGP%J\H5
M7L_%D!@T\2X!<Q>(+4R6BVP)X>Y>U9@,F->17]N<%^/OAUQC3HTWFRX>S.:7
M-ALP<:#YM-*>(;^KU4W=12J1JRT;I1O8^KP?$^48NT)8E86L_LU6H:[:3?N.
M[V5U)_RH^O:*S-(UO1M?LH]2T'5],UO3IO\`57^D7]KJ5E+P&_=W5G*Z/P0>
M&/!%:=?M%.I3K0C5I5%5I32<91:E&2>S35TT^C3L?01E&24HR4HRU33NFO)A
M117'_$+QMH_PV\"^,/'^OOLT;P9X;UCQ)J(5U226WT>PGOFM8"_!NIC"L42X
M)>69%`)(%;T*-7$UJ.'P]-UJ^(E&$(Q5W*<VHQBEU<FTEYG/C<9A<NP>+S#'
M5XX7!8&E4K5JLW:%.E2BYU*DWTC"$7*3Z)-G8'G@\YK\M/\`@J]\%_&OQ`_9
MZU;X@_!SQ5KGA7XS_#'0?%]Q8V/AO4Y;&_\`B7\+-9T<P_%OX;WVEPR9\4V+
M^&;8ZK%9/#=;KCPXL4,227)E7U.__P""D/[,FE?!WP[\5K[Q6TFI^(](DO+7
MX7Z2(M6^(5KK%J7@U#0=2TN"14T<Q7T,\:7M]):65S'&MQ;S21R1[OYS?CY_
MP45^-WB?]I[X?_M0WY7PYX;^"6LR7G@GX:VU_)_8EEX3OPMCXOT35+\6X;4M
M7U_1'N;*_O#"'*W4<=I%&D%O&OZEP[]'_C#Q#H9]EF+PE3AW"8>CBH*OB82I
M.>,I1DJ%'#IN+G)8F$5.M%NE1C&4G*4U&G/\2K_3Y\*_H[\9^&O&?#^>8/C[
M/9X_+<5'+L'.GBZ53*<3.E]<EF"C&K&%'$Y=6JTXX2<5BL3[:$:<*<7*O2_!
M#Q;9*UU;1A,%+<LY(!'SROA6R.P3/)QCDC&:_L(_X-PYM27]COXP6$T;G2K3
M]I/7Y=.G99"#>7?PQ^%HU*U25G*[$CM].D**HVM>,[%O,&/RH^,_[&G_``3W
MUKQMKOQSO/\`@H]\%?@Q\#_B<--^)7@3X8Z9X?E^)WQA\(>'O%ND6?B";P?K
MG@3PEKZWGARXT[4;O4K"VA:VNIX8=.ACN$>[6:,?T"_\$]/^"<GP4_9@TCPU
M\7_@Q\:?VD=?TWXC>&M&\53Z!XNUR+PEX'\3Z=KNC176C:CK_P`)1X3LI[#4
MUTZ^BDBCU1GU*P:0PLT#B6*OY`X4\,?$3@[B*GFO$'#&(RS+(SQ&&5:O^ZC5
ME&\9NES7=3ELI.-HNS3NM#_H(^EQ],KZ*WC[X#8K@SP^\3Z6<\9YC#*LVC@\
M/@,77EA91Y,0L+C*_+2P]"K)3G0E4IU,3"-2,X\K3YU^L=%%%?M)_C:%%%?B
M[H/_``7A_8A\4Z,_B/PQX>_:=\1>'HVN5DUW0OV=O&VKZ.C68)O%?4]/62%&
MB4$R@N"@^]C(H`_4CXH_`/X&?'"TCL/C/\&OA9\6;.&'[/;P?$GX?^%/&R6L
M/F-,J6G_``DFE7)M-L[-(IB*%)#YBD/\U?)5S_P28_X)M7>H_P!J2_L:?`];
MG?!)Y5MX7-EIN;=8UC4:/9W4=H(B(DWIY&R0EFD5R[EO7/V2_P!N#]FO]MSP
MOXA\3_L\>/\`_A*O^$-U*VT?QMX;U71-:\+>,/!NJ7B7$EE;>(/#?B"QM[B"
M*=+2\$%S$)K.=[&YABN'FM;F.+ZSH`^=_A7^R+^RM\#KF&_^#O[.'P/^&>JP
M,[IK?@KX7>#/#_B`N\C2%I=?T[1DO9V!;"EYV*(JQIM1%4?1%%%`!117SQX#
M_:?^%7Q&_:"^.W[,OAJ[UN7XI?LYV'PZU+XEVEYHTUIHMK:_%+PS;^+?"9T?
M6'D*:N[Z/<Q&<(J^1)F-LD4`>XZKH&A:\L":YHFD:RELSM;+JNFV>HK;M*%$
MC0+>0N(F8(@8KC.P9Z"L7_A7O@'_`*$?P?\`^$SHO_R%7844`(JJBJB*J(JA
M550%5548554<!0```/2EHHH`I:CIFFZO:O8ZMI]CJEE*R-)9ZC:07MK(T;B2
M-GM[F-D=E=5921P5!'(KG/\`A7O@#_H1_!_;_F6=%[=/^7*OE']K;_@H9^S'
M^Q==^&/#OQ=\4:[JOQ)\<Q-<>"?@]\-?#.I>/OBGXIM%GDMC?6'A?2%Q8:<U
MQ#<QPW.H3V<%S+9SPVTDTL$J)Y5\!_\`@K)^RE\<OB[I?P$O8/B]\!?C'XDB
M2;P7X`_:3^%VM?"/6/'*2!O+C\*W&IS3VE[>R2(\=O:RW,%W>21NEE!<,C``
M'Z6V]O;VEO!:6D$-K:VL,5O;6UO$D-O;V\*+'#!!#&H6*%(U5550%55```%3
M444`0W%O;WEO/:7<$-U:W4,MO<VUQ$D]O<6\Z-%-!/#*I6:%XV965@596(((
M-<K_`,*\\`?]"-X/YZ_\4SHO_P`A>Y_.NPHH`S-*T31=#ADM]$TC2]'MYI3/
M-!I5A::?#+,55#-)%:1(KR[$4;B"<*!G`%:=?-7[5'[6'PA_8Y^'FB_$_P"-
M-YKUCX5U_P`>>'/AQI\OAW0Y]?OF\3>*HM2FTF*6R@E1HK,II5YYDV2(]JY'
M-?2M`%6^L;'4[6:QU*SM=0LKA0MQ9WUO#=VLZJZNJS6\Z,DJAT4@,#@J#U`K
MF?\`A7O@#K_P@_@_/K_PC.B]^O\`RY5V%%`%+3M,TW2+5+'2=/L=+LHF=H[/
M3K2"RM8VD<R2,EO;1JB,SLS,0.2Q)Y-7:**`,[4](TG6[86>LZ7IVK6@E286
MNIV5M?VPFC#*DP@NHG42JKN`V,@.<'DU@?\`"O/`'_0C>#^__,LZ+WZ_\N5<
M3\??VA/@W^R_\,=>^,7QW\>:/\//A[X>\F.]UO5C<SRW=_=;Q8Z-HFDZ?!->
M>(->N&CE^SV-E!/=2B&1TB*1R,OYFV/_``72_8S4:'K7C#P=^U-\,/AGXDU!
M-/T7XV?$3]GCQ;H_PDO_`+1<-;V-[;^)=/GO)Y;&=E+1LMF6103.D)5PH!^R
M-K:VMC;06=E;6]G:6T20VUK:PQV]M;PQ@*D4$$*A8HE4`!5```P!4]9.@:_H
M?BK0]'\3>&-8TOQ#X<\0Z98ZUH.OZ)?VNJ:-K6CZI;17NFZKI6I64KPZAIUQ
M9S0RPS1.\<L<JNC%2#6M0!!=6MK?6T]G>VUO>6ES$\-S:W4,=Q;7$,@*O%/!
M,I66)E)!5@00<$5RW_"O/`'_`$(W@_\`\)G1>W3_`)<J["B@#-T[1M'T>T>P
MTG2M-TNQD>21[+3K&ULK1Y)55)9'M[:)49V15#$KDA0#D"L'_A7O@#_H1_!_
M_A,Z+_\`(5=A7Y??&C_@KG^RA\(OB[X@^!.A6'QJ_:#^*?@PR1>/?"W[-/PG
MUKXMR^!;N)A'+I_B34-/N+>UCU&*<M#<PVL]T]E<Q/:WHMKF-X5`/T1_X5YX
M`_Z$;P?_`.$SHO\`\A4?\*\\`?\`0C>#_P#PF=%_^0J^7/V0_P!O_P#9H_;:
MMO%-O\%O%6KP^-/`<D<7C[X5^/O#NH>"/B?X+::9K>.76O"VK#,]C]H7RFN[
M&:\M(IR+:6>.X_=5]IT`<?\`\*\\`?\`0C>#_P#PF=%_^0J/^%>>`/\`H1O!
M_P#X3.B__(5=A10!%###;0Q6]O#%;V]O%'#!!#&D4,,,2".*&**,!8XE1555
M4``*```*EHKYYUS]I_X5>'OVF?!7[)6I7>MK\8/'_P`--:^+'AVRBT>6709?
M"&@:E?:5J$UUK@E"6U^+O3KD)`4+,H#9&10![%?^#?"&JW<M_JGA7PWJ5_<>
M7Y][?Z'I=Y=S>5$D,7FW-Q:L\FV&.-%RQPL:J,``46'@WPAI5W%?Z7X5\-Z;
M?V_F>1>V&AZ79W</FQ/#+Y5S;VJO'NADD1L,,K(RG()%=)10`4444`<W?^#?
M"&JW<M_JGA7PWJ5_<>7Y][?Z'I=Y=S>5$D,7FW-Q:L\FV&.-%RQPL:J,``46
M'@WPAI5W%?Z7X5\-Z;?V_F>1>V&AZ79W</FQ/#+Y5S;VJO'NADD1L,,K(RG(
M)%>#?M4_MB_L\_L7>`K7XB?M"^/[7P=I&K:C_8WAG2;:QU#7_%OC'6MJ,=*\
M*>%=%MYKW6;A!-`9Y4B%K:+<1O>3V\<BN?BSP;_P6F_8_P!:\:^$/!'Q)\/_
M`+0_[-=Q\0+F"P\$>)/VD_@GX@^&/@KQ)J-R\206=IXIDNKNVLD/GP,UU>-;
M6,2S*9;J/<,@'ZX4444`>;?$CX-?!_XR:;%HWQ>^%/PV^*ND0,6@TKXD>!?"
M_CG386;.YHK'Q/I=U%&QR<D*.IKX\N/^"3?_``3;N=2CU63]C/X&)<Q2V\JQ
M6WA..STTM:[/*$FC6DZ6<T1V#S$>!DF#,)5<,V?T,HH`\4^$_P"S7^SQ\!XW
MC^"?P+^$7PF,T(M[FX^'7PZ\)>#[V^B"HI&HW^@Z3!/J+L(X][SR2.Y0%V)Y
MKVNO,OC)\9?AC^S[\-/%OQA^,?C'2O`?PX\#Z:VJ^)/$VL-,;>S@,L=M;6UM
M:6D,EQJFJW-[/;VUG96L,UW>75U%;6L,L\L<;?EM9?\`!=#]C+=X?UCQ3X1_
M:B^'/PO\4:C#I^A?'/Q_^SWXLT3X.Z@MW,T-AJ-OXHMYKB>73)V7*2)9,47+
MSI$J2%`#]EJ*H:5JFFZYIFFZWHU_9ZKH^L6%GJFDZIIUQ%>:?J6FZA;QW=C?
MV-W`[)=6<UK-%)%(C,CI(K*2"#5^@`HHHH`****`,;Q!X=T#Q9HVH>'?%&BZ
M5XBT'58&M=3T76["UU32[^W8@F&[L;V)XYX\@$!E."H(P0#7Y#_M!?\`!)GP
MOKDEUXI_9R\42^`-?1WNXO!GB.\U"]\+2SC<ZIHWB&(2ZCX=?<3M$HU"/<0J
M&VC&1^R-%?)\5<#\+\:8587B'*:>.<$U3JVY,12O_P`^JT;5(J^KA=TY-+GC
M):'EYGDV6YO35/'X6-9Q^&>U2'7W9JTEKK:_*WNF?R-_$/3OVE_V:;X:5\;O
MAOK:Z4)Q;VOB&ZA6XTF^W$^4NF^--(\^PU&5D!?RI'>Z4,JRB(C:,?2_CGX#
MUH!)]0ET.Z;AH-8B,$0.=I(O8F>`)DCYI'1B"/E'./Z\;^PL=4LKK3M3LK34
M=/OH)+:]L+^VAN[*\MIE*2V]U:W",EQ`R$AD=2K`X((KX)^+_P#P3'_9"^+K
M75X_P]E^'&MW19GUKX5WZ^$RK$=5\.O:W.BJ=W)8:8)"2<O7\N\3?147/5Q'
M"V<1JP>L:.*7LJL5V5:E"5*I)^=&A;^:[N?G.:>'F/2F\IS&.(I]*>(O&:\E
M4BFI/UC!>9^)&B>-=0TV3^UO!WBB]T^;"A-2\-:W/:R[0=R8O-*N5)&1GACS
MGI7K&F_M>?M(^'D5-/\`C!XOE2/`4ZU<6GB1^-N"\GB*TNVD^X,[B2<G/5B>
M[^(7_!#GQ79R3WWP<_:"TV:8[_L>F>//#>HZ!+;J2I59O$_A6]O3<,?FRRZ7
M$!M'RMGCY-\3_P#!+G_@H]X5=XO#UOI?CB*)U$;^&_BSH<<$@_=`-#'X^U#2
M65/WCY#(A_<-A>4W_G<?"?Q<X5E*.6+,<#%:_P"PU:LD]=[X*K._SBGW2;L?
M!XGASCC+7-8;"XN@^^&J2E?S3P\F_P`+^2U/HF[_`&^_VLMCQCXL%0ZLC%/!
M'PXC<!EP621/!X9'QG#*05."".M?3G[<7Q-\=^!?V0/A1\)O'WB>]UWXJ_&+
M[-XC\?W-Z(+6ZMM!TN:V\0W.BS6ME:QQV,<&KWOANQ`18EN%T2\XD+S5^-FI
M_L2?\%.=)"7O_"HOB4)(;F(PR:1KO@V_NHKF)S-%+$FC>()9417BR)`-@.,M
MEE!^^/`-M_P5_P#$5G9^"OCW^R5\._VG_`L:0Q/9_'B3X-:3K&EV;M'";K2?
M&6G^*;2XAU5%=F:YGM=3O@I=E0R!2O\`27T:^)<^\/O$#"<2>*&!XEXLP>#=
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M>_\`!+JZ^`'QVU#4/CC\+?AO\>/"5U:QWGP^^)MKJ[W$?PZUO23<7?\`Q5'P
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M0`!@=L4BJJ@*H"HH4*J@!0H&%"@#@`8X[8IU?Q)XA^(>=^(V=O-LU:P^&PZ<
M,+A:;;I8>DVFTF[.=2;2=6JTG.222A3C"$?]CO"WPPR+PKX;IY%E$I8S$U>6
M>+QE5)5<562LI.*;5.E!-QHT8MJG%MN4ZDZE291117P1^E!7\B__``18_;)^
M/'P2_8;T/P1\/OV`OVA?VB?#5M\1_B)JD?Q)^&VI^#K3PU=76H:A:2W6D06N
ML7:W/VVU9%64;,%I`$S7]=%?S(?\$Y++_@K%_P`$_P#]FC3/V=O^'50^+7]F
M^,/%OBL>,!^W'^S9X"$__"47<%U]@_X1_?K7E>0(-OF_;6\W?DQQ\T`=_P#\
M$D?'EA\8O^"@/_!1[XU_$GPS?_LZ_M&_$7_A6<-_^Q[K^@^(]$\5>"?AOX.T
M+0]"B^)?B"^UOP_IT'B;4]9U-M%GN9;&';!<:T]Y,S1:U9-7]&%?B_\`L6_L
MV?M:^-_VYOC!_P`%$OVR/AQX/_9_\2:]\'--_9]^$GP"\(^.](^(VIZ)X/AU
M_2?$FK>(_'GC7PI,VFZYJ7VO1X8K-HI6\\:O=&:PTX6&GF;]H*`"BBB@`K\3
M_P!D#/\`P^A_X*^#M_PA_P"Q#^?_``H;1>_>OVPK\N_V</V=?C)X"_X*<_\`
M!1W]H;Q9X._LGX/_`!Z\-_LL6'PG\7_\)!X6OO\`A*[OX<?"33/#'C2+^P--
MUR;5-"^Q:Y;S0;M2LK-;C9YMHT\)$A`/U$HHHH`****`/P)_X)CZ%IWQH_X*
M(?\`!5O]I_XA0G7?BA\.?VBM3_9?^'5UJ>RZ_P"$$^%_P]U'Q%X<6W\-JZ*-
M,.JV'AGP^;@QQJ<:?*5ED:^OI+CV;_@NS\)/"7CK_@GG\5?B5?16VE?$?]GR
M_P#!GQ8^$WCR`M9>(?"'B?3?&_AO3;Q-'UBT47%M]NT;4KZV$2.(FO38W3*9
MK.W>/@OBY^SM^V!^Q1^V1\6_VT?V(?AGH_[2/PK_`&G+70+C]I?]E^Y\6:5X
M!\76OC?PT#!8?$GX:>(=7C-M=W4L=]K4]Q;R"XG^T:]J"_9+J.XM)M)\O^.O
MA+_@H+_P5D3P?^S]\1/V7M5_88_8W'C#P_XJ^._B#Q_\2/#OB?XK_%?2_"NL
M6FK:=X%\+>&?#MO')X?M_P"TK2.Y$MW;R6[75E97POE%G]@OCY7`_;[]GOQM
MK'Q*^`?P/^(WB)H6\0>/_A!\-/&VN-;Q1P6[:QXJ\%Z+KNIM!#$BK#";V_GV
MJJJJK@*``!7K]9^D:3IN@:3IFA:-96^FZ/HNG66DZ5IUI&(K6PTW3K:*SL;*
MVB'$=O%:PQ1HHZ+&!6A0`4444`?A%_P<,''[%7PLXS_QF!\#?S^P^.<'\#@_
MA7[NU^1G_!:/]FSX]?M1_LG^#_`?[.?P\_X6?\0/#O[0GPR^(DWA;_A+?!O@
MKSO#WA73_%PU*Y.N>.M=T^RC`N=1T^/8LTDY^U;XX)%1]M,?MF?\%8N?^-+Q
M'I_QL6_9LY]/^97X/3]>?5]NX'Z_T5C^'KW5M2T#0]1U_1?^$;UV_P!'TR]U
MKP[_`&C;:Q_8&K75E!/J.B_VO9*L.J?9;R2:#[3$HBG\CS8P$8"MBD`4444`
M?@5^WMH>F_M!_P#!7K_@FK^R]\3H%U7X*>'/!7Q7_:*NO!UYB70_''Q"\.:5
MXKF\.VNMZ?./(U2#3I_`>FS&*9+@/9:MJ5H8HXKZ:0_N+X]\`>#/B?X'\4?#
M;Q_X<TKQ5X&\9Z#J'AGQ-X9U>TBN]*U;1-3MGM+NQN+:12NPPO\`(RX:-T62
M-E=%8?G'_P`%'_V,_BY\<-8^`7[3_P"REKWAOPU^UY^R3XJU+Q)\-8?%YE@\
M(_$GPEXBAM[3QK\+O%%[#(IL;;4+"W>.WG=EC5+^^LVFL1J+:E9?/'C#]L?_
M`(*X?%'P9?\`PE^%W_!,K5O@C\;==L/^$<U'XS_$+XY_#[6/A%\-KN\BCM-1
M\;Z"+*T5O&/V9'NKBTMX)[LP2I"QAUD1FTN3]`-C_@@CK&NP?LC?&'X1ZEX@
ME\3:#^S7^V/\>?@)X`U66[>_\WP1X:A\&>*+`0W<D:&6U.K^,];>'"HJQ3(J
M)&@6-/V[KXI_X)\_L=:-^PM^RWX#^`=EK0\5>(["34_%?Q)\9A)HQXP^)'BJ
MX6_\3ZS"MS^\&G1LEI86)E`G-AHUJ;C-P96/VM0`4444`?-'[9_Q*\1?!O\`
M9#_:@^*_A`78\6_#GX`?%WQEX7GL[?[5+8^(O#_@/7=2T34Y8O,7_0;34[>U
MN;E\_N[>UEDP=F#^>O\`P2VT'X:?L?\`_!*+X7_&C2_!OBCQMJGC#X=I\>OB
MO-\-O#C^-_BG\2/%OC*]>^F@@TVVECG\3:UIVGWMCI<%OY@:.'0VW%IS<2R_
MKYXT\(>'OB%X.\6>`?%VG1:OX4\<>&M=\(>)])F++#JGA[Q+I=UHNM:=,R$$
M13Z;>W,3$$$"4X(-?@;\!+?_`(*1?\$LO#&J?LSZ=^RQJW[>_P"S-X7UG7[W
M]GSXH_#;XD>&_"OQ+\+>&=;U:\U>#P%\0_"7B"VFGN?(N[V:19[6W^RV1NY8
M;6[O;06UGIP!N_![]IC]A_XV?\%/_@]\2M'^"W[9_P`"OVM/BM\,O'OPST1O
MB7\'[3X0?#KXH>$_!OA#7_&^NWOCJVU&YDO?%.JV6C:#9Q6UY&[F.31=$M9@
M(;>#;^_5?SR^!O@1_P`%)OC]_P`%-?V-_P!NK]HKX,>%/@]\'?AO9?'OPA:_
M!G1_B7X2\7^)O@GX3U_X+^,M&\-^*O'.IV^H0KXQ\3>*?&/B^VM)8]#@GDTR
M#P[:C4+*PC624_T-4`%%%%`!7XH?%G/_``_I_93';_AA#XJ''K_Q6_BWK7[7
MU^7GQ#_9U^,FN_\`!6_]G[]IW2O!WVKX'>"/V3/'_P`,O%'C?_A(/"T']F>-
M];\5>(M2TS1/^$:N=<35[WS;*^M7^TV^GS6B>;MDN$=64/34#]0Z***0!111
M0!^"*Z%I?[07_!?_`,2:=\3[;^V="_8X_8\T+Q3\%O"VIPK/HEOXV\<Z[X7?
M5_B%!I]W(\-UJ4%MX[O[47"P!TNM(TJ82QSZ5;%OU@_:Q_9H^#/[6_P+\8?!
M'X\V#7/P]\0C3M1O-3M;RQTK6O#&HZ#?PZIIWB7P[KVH6<Z:!J]O)`Z?:1&0
MUM=W-K,'MKB>-_SY_;E_92_:=\,_M6_"O_@HQ^PQHWA;QS\9/!'@*[^$/QJ^
M`WBK7;7PC9_'/X23:E)JUM9Z)XFO9(K33/%MM=3MMDOIXXR=)TJXC,[:8=-U
M'YZ_:'\7?\%,O^"DOPSNOV3]%_8BU?\`8G^'/Q*U#2=&^/'QS^+_`,3_``EX
MQFT7P+::C8ZEKFA>`O"&BVMC>>([R\:U2(7,:/#<P>99NVG+<OJ%H`?O/\.?
M#&F>"?A[X$\&:)K6J^)-&\(^#/"_AC2/$6NZC;ZQK>OZ9H&B6.E6&M:QJ]I;
MPQ:IJMU:6D4]Q<Q111SS3O*D:*P4=E7#?##X>^'OA)\-?AY\*?",4T'A/X8^
M!O"7P]\,07#I)<0^'O!>@:?X;T6*>2-%629=-TVV#,JJ"P)"@<#N:`"BBB@#
M\TO^"LG['?Q#_;>_9`UOX0_"C6M"TSX@Z+XW\'?$KPUI?BN1X?"GC&\\'3WQ
ME\'^(IQ!*L-C=6NI7$D)FBDMS>V-JMQY4#23Q?`'QC_X*'^/;;X'^-?@A_P5
M(_X)@_M"?"KX3>+/"%QX!^*'Q-^"L>B_&#X.Z3:WT4=@?$]KK.E3K;^![.TO
M#:7NFO'JNKWEE/8PR6C7EQ;KG](?^"D_[-7QQ_:-^"'A63]F7X@GX>?M`_!3
MXK^#?C;\,+F\UO5-%\,^*]8\&M?";P3XMDL',<^C7D-\)D6ZAFMFO-)M8;@P
MVDUS*OQ5XU_:^_X*F?%'X9>+/@4/^"3.J:#\6O&?@_7O`6O>-O$7QX^&E_\`
M`729=>TR3P_J7BR.6Y@>/Q)H0AOKFY&CC4)Y7C`MA=7^)&=K70#]4OV04^"D
M/[,/P,M/V</%-QXS^!&G_#CP[I?PI\17>H7>IWEWX+TJT&G:/:WMS?VL%PE[
M:06OV.:"Y@AN;66P>UN8HYX9$7Z.KXN_X)W_`++>K?L6_L9?`O\`9I\0>(K#
MQ5XC^'.@Z]+XFUO28YTT>;Q-XV\:>)?B'XCL]$:Z@AENM$L];\67]G9W$T%O
M-<VMA%<36UO+*\$?VC2`****`"BBB@!C/M]/?/:JSW00D9Y`S@#_`.M4\B;C
MG&?\_7_.*J26Q<D_/[#J!P!T(H`IS:F8Q\S*G4$LRKV]\?K6+<>+-/M<_:=5
ML8-O4RW$*`=SR3SQ5N\T>.Z5EFA#J<C^+)SD#&TY/4]N,UYYK7PD\(:ZK)J6
MC&X#@AAYDPSD8YVN*/6Z^X#:E^)GA2$D2^+-%C/(P^I6:\Y&!DR]3V-30?$7
MPS<D"W\3Z1*>``FHVLC<`=A)SWSUKY\UG]BWX!^()#+J_P`/K*^8MNS</=L=
MV0<_Z[@Y%;&@?LE_!?PR5_L;P5;V(3&P0R70"X]`9L#CVI^[_,_N]";R[*Q]
M%VWB.UN<&"_M9QV\N>)LY!`Z'YO\FM:+4&<+C'8DYW#!Z\`<CK@_2N`TCX>Z
M!I`5;#3#"(\`9:5@!@@<$\]:[>VTWRL!4VJO.`,DY]"3Z#K2TZ;%>IK).'`P
M<\X[CD8(Y[_UYJP#NP<].H_.JD<!0$$''7'<GN21^'Y5:1=HQ_GO_C0'D/HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
<@`HHHH`****`"BBB@`HHHH`****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`'>`X0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T7XE>(]5\
M-Z;I\VDRQ1R3W/E.70-D;<CK[URW_"2?$@'_`%NF_P#?M:UOC-_R!]'_`.OX
M?R--/4US8[%RPT(."3O??RL<=:4E.R9E_P#"2_$C_GKIO_?M:/\`A)?B1_SU
MTW_OVM:=%>=_;%;^6/W&7//N9G_"2_$C_GKIO_?M:/\`A)?B1_SUTW_OVM:=
M%']L5OY8_<'//N9G_"2_$C_GKIO_`'[6C_A)?B1_SUTW_OVM:=%']L5OY8_<
M'//N9G_"2_$C_GKIO_?M:/\`A)?B1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_
M$C_GKIO_`'[6C_A)?B1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_$C_GKIO_?M
M:/\`A)?B1_SUTW_OVM:=+1_;%;^6/W!SS[F7_P`)+\2/^>NF_P#?M:/^$E^)
M'_/73?\`OVM:=%']L5OY8_<'//N9G_"2_$C_`)ZZ;_W[6C_A)?B1_P`]=-_[
M]K6G11_;%;^6/W!SS[F9_P`)+\2/^>NF_P#?M:/^$E^)'_/73?\`OVM:=%']
ML5OY8_<'//N9G_"2_$C_`)ZZ;_W[6H8_%OQ#DNYK99M/,D2JS#RUP`<X_E6S
M69:_\C%J/_7&'_V:M:>;59*3<8Z+MYH.>?</^$E^)'_/73?^_:T?\)+\2/\`
MGKIO_?M:TZ*R_MBM_+'[@YY]S,_X27XD?\]=-_[]K1_PDOQ(_P">NF_]^UJG
M>:[J$>JWEE9:=%.+6,2NSS;3@CL,59@\1Z;)86]W-<"V$Z%U63J,'!&?K73+
M&XQ14N1._97WU#VDNX__`(27XD?\]=-_[]K1_P`)+\2/^>NF_P#?M:=<Z[I=
MFD3W%]'&)E#QYR20>^!SBII=3L8+%;V2ZC%LWW9<\'Z>M9_VEB]/W:UVT#GE
MW*__``DOQ(_YZZ;_`-^UH_X27XD?\]=-_P"_:U3L=>2[UF^"W4;Z=#;+*CJ.
MGKD]:U3J5FL-M,;A?+NF"PM@_.3TQ55,?BZ;2<%KY>5PYY=RM_PDOQ(_YZZ;
M_P!^UH_X27XD?\]=-_[]K4D^LZ;;7BV<U[$ERQ`$9)SD]`?2JNG>);'4=1FL
MHVPZ-B,DY\T#J1QQCWH6/QCBY>S5EKL'M)=R;_A)?B1_SUTW_OVM'_"2_$C_
M`)ZZ;_W[6M.BL/[8K?RQ^X.>?<QF\7?$-+V.U,VG^9(C.H\I<8&,\_C4W_"2
M_$C_`)ZZ;_W[6BX_Y&:Q_P"O6;_T)*TZUJ9M5BHM1CJNWFPYY]S,_P"$E^)'
M_/73?^_:T?\`"2_$C_GKIO\`W[6I-:U%M*TJ:\2)96CV@(S8!R0.OXU3LM9O
M'U5=.U"Q2WEDA,T;12[U('KZ5<,?BITW4C"-EY!SR[EC_A)?B1_SUTW_`+]K
M1_PDOQ(_YZZ;_P!^UJ/3M45=%:]U'4+:11(RF:,%5X/`P1R:<^M6MSI5Y<Z=
M=1S/#$S<#[IQQD&AX_%<S2@M[7MH'/+N._X27XD?\]=-_P"_:T?\)+\2/^>N
MF_\`?M:9:ZU!#H5E>ZE<QQ-/&"2>-Q/H!5J+5;":Q:]CNXFMD^])NP%^M3+,
M<5%_`M[;:7#GEW(/^$E^)'_/73?^_:T?\)+\2/\`GKIO_?M:C/B#3[NWN%L-
M0A,Z0M("RMA<=SQT%/CUBVM-(M+G4KZ`-*@/F*"!(?51C./PI_7\7;^&K]N5
MW#GGW%_X27XD?\]=-_[]K1_PDOQ(_P">NF_]^UJ_!/%=6Z3P2"2*0;E=>A%8
ML_B/R=?73_LX-OYBPO<;ONR$9QBE2S'%56XPA&Z\@YY=RW_PDOQ(_P">NF_]
M^UH_X27XD?\`/73?^_:U8OM4L=,"&]NDAWG"ALY/X"HUUK3&L&OA>1_9E;:9
M#D#/ISR:2S+%R2DJ::?D'/+N1_\`"2_$C_GKIO\`W[6C_A)?B1_SUTW_`+]K
M4L>LZ=-8R7L5Y&]M%]]QGY?J.M);ZUIEU<M;P7T4DJKN*J>W?Z_A1_:.+U_=
MK3^Z'/+N1_\`"2_$C_GKIO\`W[6C_A)?B1_SUTW_`+]K46D^([+5[F:WB.V1
M&.P$Y\Q1_$..!2VUW<7GB:[B24BRM(PC(.CR'G]!5O'XJ+DIQBK*^P<\^Y)_
MPDOQ(_YZZ;_W[6H;GQ;\0[5$:6?3P'D6,8C4\DX%;-9FN?\`'K:_]?D/_H51
M1S:K.HHN,?N#GGW#_A)/B0#_`*W3?^_:T?\`"2_$C_GKIO\`W[6M0]:2LO[9
MK?RQ^X.>?<S/^$E^)'_/73?^_:T?\)+\2/\`GKIO_?M:TZ*/[8K?RQ^X.>?<
MS/\`A)?B1_SUTW_OVM'_``DOQ(_YZZ;_`-^UK3HH_MBM_+'[@YY]S,_X27XD
M?\]=-_[]K1_PDOQ(_P">NF_]^UK3HH_MBM_+'[@YY]S,_P"$E^)'_/73?^_:
MT?\`"2_$C_GKIO\`W[6M.BC^V*W\L?N#GGW,S_A)?B1_SUTW_OVM0W7BSXB6
MMK+<2S:>(XUW,5C4G%;-9^N_\@"^_P"N)K2EFU64U%QCJ^P<\^Y&OB;XCE01
M-IN",C]VM+_PDOQ(_P">NF_]^UK1C_U,?^Z/Y4ZH><5D[<L?N#GGW,S_`(27
MXD?\]=-_[]K1_P`)+\2/^>NF_P#?M:TZ*7]L5OY8_<'//N9G_"2_$C_GKIO_
M`'[6C_A)?B1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_$C_GKIO_?M:/\`A)?B
M1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_$C_GKIO_`'[6C_A)?B1_SUTW_OVM
M:E)1_;%;^6/W!SS[F9_PDOQ(_P">NF_]^UH_X27XD?\`/73?^_:UJ4E']L5O
MY8_<'//N9A\2_$<`GS=-X_Z9K4-IXM^(=W:17,4VGF.1=REHE!(K8;[C?0UG
M>'O^1>T__K@M:K-JOLW+ECNNGJ'/+N)_PDOQ(_YZZ;_W[6C_`(27XD?\]=-_
M[]K6G167]L5OY8_<'//N9G_"2_$C_GKIO_?M:/\`A)?B1_SUTW_OVM:=%']L
M5OY8_<'//N9G_"2_$C_GKIO_`'[6C_A)?B1_SUTW_OVM:=%']L5OY8_<'//N
M9G_"2_$C_GKIO_?M:/\`A)?B1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_$C_G
MKIO_`'[6C_A)/B1_SUTW_OVM:=*.HH_MBM_+'[@YY]S%MO%OQ#NHV>*;3RJR
M,AS$HY!P:F_X27XD?\]=-_[]K2Z)_P`><_\`U]3?^A5I5I6S:K";BHQ^X.>?
M<S/^$E^)'_/73?\`OVM'_"2_$C_GKIO_`'[6M.BL_P"V*W\L?N#GGW,S_A)?
MB1_SUTW_`+]K1_PDOQ(_YZZ;_P!^UK3HH_MBM_+'[@YY]S,_X27XD?\`/73?
M^_:T?\)+\2/^>NF_]^UK3HH_MBM_+'[@YY]S,_X27XD?\]=-_P"_:T?\)+\2
M/^>NF_\`?M:TZ*/[8K?RQ^X.>?<S/^$E^)'_`#UTW_OVM0P^+?B'--<1)-IY
M:!PCYB7@E0>/P-;-9VG?\A/6/^OA/_1:UI#-JTHR?+'3R\PYY]QO_"2_$C_G
MKIO_`'[6C_A)?B1_SUTW_OVM:=%9_P!L5OY8_<'//N9G_"2_$C_GKIO_`'[6
MC_A)?B1_SUTW_OVM:=%']L5OY8_<'//N9G_"2_$C_GKIO_?M:/\`A)?B1_SU
MTW_OVM:=%']L5OY8_<'//N9G_"2_$C_GKIO_`'[6C_A)?B1_SUTW_OVM:=%'
M]L5OY8_<'//N9G_"2_$C_GKIO_?M:/\`A)?B1_SUTW_OVM:=%']L5OY8_</G
MGW.2U#XE>-=.O7M;B[M%E3&0L"D<C-%<WXR_Y&>Y^B?^@BBOJL/!5:49M+57
M(]I/N>J?&;_D#Z1_U_#^1IIZFG?&;_D#Z1_U_#^1IIZFOF\X^"E_V]^AM7^,
MK7MR]I;^;':SW3;@/+A`+?7FLJS\2_;BXATJ]54+*\K[=B,!G#8-;PZCZUS/
MAL_\2O6.?^7J;^5<&'C2E2DY1NTUU[LQ-/1M674M-MKB8PQ3S`D1*_/4C@'G
MM5^2X@A*B6:.,M]W>X&?IFN`CLK6'PCI>H1Q*MV;I/WW\7WL8SZ>U2:PBR>)
M-26_NK*W#8$+7D+/E,?P$=#7;_9U*=5\LK+7IV:V$CNWFAC.))40XW89P./7
MZ4TW5L)%C-Q"';!53(,G/3%<>+*&YU/PY:W3B[B-J^2P($@'(R#SCIUK)UR6
MW,NH*D5E:R0S!4B\IC,P'\0;L/TJ*66PG)1YNG;SL!Z0\\,98231H4`+!G`V
M@^OI2^9'Y7F^8OEXSOW#&/7-<;>OI8\7,VL!6MS91_?!*[L=\?CBLYEG'A2W
M/S)8&_8@R*641?PE@.2N:(Y8FE[S5[=._;ST"YZ"+B!H3,L\;1#JX<%1^/2E
M,T0V9E3]Y]SYA\WT]:XBUM4;3M<-G>6ET)+7!BLX61`>Q`/&?I4HU*TOY_#$
M-O)YC0NHD`4X0[<8)]:EY:N9J+;2OT\K_P#`'<Z2'6;2[>[AM)%>>VR-K,`'
M('8YY'O4MC>/)ID5U>^1;NXRP64%`?\`>SBN7TZ*PM=5UZW,445TN_[,FWY@
MFTYV^U5+<VRV/AIM24'2Q$^[>,H),G&ZM)8"F[J-[:=-?A;T`[Y'21`Z,&4C
M(93D&LN[\06EGK$.G2)(7DV@R#&U"W0&K&FOIXTU'L-JV0W%2H(7&3DC/;K7
M&O'J6K:9J%[%IZO'=3>>EQYP#($Z87OQFL,)A85)R]IHEIKIK_P`9WCS11G$
MDJ(<$X9@#@=32/<V\:*[SQ(K_=9I``WT/>N1N9K?7K[PU),H>.='\Q">I`Y!
M_$55UF"./Q'-#<RV5K;+`BV_VN$O&%QT7'0]:NGER;49RL[-O3L[:=_N`[F2
M:*%0\LJ1J>C.P`_6G(Z2('1PRL,AE.0?QKA+IHH-+T:UEDLYHF60K>W<3-&H
MSTVG^M;/@ELZ+.H8,JW+A<#`QQT'8>U17P"I4'5OU_"[7Z!<Z2LNU_Y&+4?^
MN,/_`+-6I67:_P#(Q:C_`-<8?_9JY*7PS]/U0&I114,]W;6S*MQ<0Q%ONB1P
MI/YUBHN3LD!S,FEW%_XLU-1=75I"T*!GB7B4=UR?Z5)<:7%;:]H-M!;DVL"2
M#E=P'<$GUS74`\#!X[<T5VO,*FW1*UOE:X'+32C2?$M_=7EA/<0W,2B%X8?,
MP`.4QVK/&G7=EI.EW$]G(\4-XT\EL@W,B,>./;T]Z[G)'?\`6JTM_;V][;VC
MN5GN,^4`IYP.>>U:T\=/11C=Z7WU237RW$<Q;127VK:W+!930)<V0$0DCV;R
M>_L3Z572>>YL]!M!87:-9W$8G=XB%4CCCU^M==8ZC;:E#)):R&1$D,;9!&&'
M7K2C4(#J)L`[?:%C\PK@XV_6J>,ES-.GJO-Z65@.<L9?[+U/4;:\TZXGFNKK
MS(I$AWJZD\<]L58TO=9^*=5@EMI0;F020R"+Y-H!S\W:NDSQC/ZT@8,"%8$#
MK@UC+&N2E[NZL]0"EHHK@&9=Q_R,]C_UZS?^A)6I67<?\C/8_P#7K-_Z$E:E
M;UOAAZ?JP,3Q9&\OANZ2-&=B4PJJ23\P["L;2K=!KUM+I%I>P6XB*WC7"L`W
M'`&[OFNJ?4K&*4QO>VZ2`X*M*`0?IFK6<\YS[YKHI8J="C[-QWOWMK_PPFC@
M[>TN8]#TVXDLY98K6^DDGAV'=MSP=O>KC1R:C>:MJ5O9SPV[6+0@21;&E?UV
MUV&??Z<T9.>OZUH\R;=W'7U\[_TPL<7"DMBV@ZA<6<\UM%9^4X2,LT3GOMZU
M6OH9/[*U:_\`LS6T-W=1-!$XVG@_>V]_I7>YYSGFJ.JVEE>V134&"PJ0WF&3
M84(Z$'L:NEF/[Q<T?^&O?;OYA8YBSE%S#K33LW]I3VW^H%LT7R@8!`/)-+"L
MFGS:)J%S93S6R67E$)$6:-_=:Z#2=,TZT+75E(UP\@V^>\YE.!V!K4S@YSS]
M:*N/BIN,8W7GITMIV"Q3AND&EB[6WDB01F182F&'4XVCN?3WKCO['UNY\/33
M%K<>=(;PQLC>=N!XY]:[WO1WS7+0QKHW<4M7?7\AG"ZEJ-S+J5C=P0D7$E@5
MD1X#*5R<'Y!R/K1<VPET#1Y-.DN)K:TE83/%'^\1NYVGTKI[[0[/4+D7$OGQ
MS[=A>"4H67T..M6[&RM].M5M[5/+C7GKDD]R3ZUVRS&G&G!P6JZ=.O\`GH*Q
MQYM`^AZW<0'4IY)XT4M<P!"Y!_A4=:T9+3R]3\--%;;51")"L>`HV#KQQ^-=
M/DYSGFC_`#UKGEF$GT[_`(JWX!8Y72KD:1>:VEU;2H1*]PLAC^0H!_>_I6AX
M8MGAT=;B;/VB\<W$A/\`M=!^5:EW:PWUJ]M<)OA?[R;B,_E4=W=V^F637$Y\
MNWB`!(7.!T'%14Q/MH\J7O2M^"TM\]1EJLO7/^/:U_Z^X?\`T*M)&#H&'((!
M%9NN_P#'M:_]?</_`*%6&&5JT0-3O6+=^(1;ZE-8Q:;>74L*AG,(!`!&?6MK
MO7*#4K+3?&FIR7MRD"M!&%+=SC/%:8.E&HY7CS66P&FVNBZT=KW3(TE=9`C1
MW#^7M.>0<GK6FUQ#&R)+-&DCXPC.`3]/6N#O%:;1=8U$1-';W=Y$T0<8W`'[
MV/>I]<:SMM:FN-UK>3,8T>SG1O-4X',;"N]Y?3D^6'GY]%HWY7$=K)<00LJR
MS1QLWW0[@$_3-$MQ!`0)IHXRW0.X7/YUR$KZ4/$>J'7T3+!/LPF!/R8Z+CO]
M*;,VDIK6K_V\J[V`^R^<I/[O;QL]^E8QR^+=FWM?1;[;:ZVOJ,[/S8Q((S(O
MF$;@FX;B/7'I2":(F0"5#Y?W_F'R_7TKB56;3-%T/6+A7W6LA1PWWO)8G`/^
M>]17,%Q_PB@OF&/MU[Y]PQ!("<[<@=5JEEL6U[^C=OG?_(+G=)<021-*D\;1
MK]YU<%1]32"[MBP7[3#N)``\P9.>G>N)M((%MM8EM]0LIT-DP>*SA9$!['GC
M-6FT>`>"[>\LX%6\B2.Z\P?>8KR<GZ9I2P%.+2<GJTMN_>X'7^;'YOE>8OF8
MSLW#=CUQUJCKW_(`O_\`KB:S/#;G4[Z_UQTVB8B&$'LJ]?UK3U[_`)`%_P#]
M<37,Z7L<1&%]4U?UTT`O1_ZF/_<'\JK:IJ,6DV$EY,CNB$#:F,G)QWJU'_J8
M_P#<'\JP_&7_`"+%P3_>3_T*LZ$(U*\82V;`GL=?AN[PVDUK<6<YC\Q4N`!O
M7U!K32>&0XCFC<[=V%<'CU^E<_'I%UF34]1O(YY4LVCA2*/:JJ5[^IK(CLEC
M^'BW5G#_`*1,@\Z1>6*;N1].G%=LL)0G+W)6U2\KOS=G8#MXIX9P3#-'*!P=
MCAL?E44UY"D<^R6-Y8D9C&'!/`ST'-<;I$*?;VET_4+&2?[)(!#9P-'GY>-W
M;(.*ET-M$_LE454&KB"7S,J?,!P=VX^E$L!"#;3;M;I^?EH*YMV.KWE]!I4R
MVUN$NPQES+@ICIM!Y:M7[7;94?:8<L=H_>#D]P*XS3,%O"!X^[+C]:JBQM)/
M"NLWKQ*US'<OLD)Y3#=O3K6M3`TI2WMK;1=Y-:ZC.U^TW/\`;/V7R8OLWD[_
M`#/,&_=Z;>N/>K*7$$DC1I-&TB_>17!(^H[5RDQG;Q!(T&3<G1LH1U)Q4.E3
M:'%HN;:W275$M)/-C`82'CY@QK.>!3BI+RV7?OJ!V,=S!,66*:*1E&2$<$C\
MJHZ'J;ZMIQN9(UC;S73:I)&%.*Y#0I(CXDTUX9++,D3[TM(B@7C[K$_>(KH?
M!O\`R`3C_GXE_P#0JG$X*%"G+J_=_4#H&^XWT-9OA[_D7M/_`.N"UI-]QOH:
MS?#W_(O:?_UP6N)?P)>J_4#3K#N_$L=K?7-JNGWEP;90TKQ`$*",YK<KCC;7
MUYXJUJ"QNH;??&BRL\>X[2,<>];8*E2FY.KLE?\`%`S7.OQOJ&FQVX1K6\C>
M0RL<%0OZ5K+-$\7FK*C1XSO5@5_/I7)W6D6D&MZ!I;KYL$<,@(?^+OS^-5&>
M+3].\0Q1VL<EO'>HJPMG8@/<@=A75+!4:B7LG_7-;ON!V\4\,ZEH9HY`."4<
M-C\J(IX9RPAFCD*G!".&Q^5<'I7V;[9J\?VN!;9[$;YK*(H@YZA?4>M/T^3;
M9ZI:Z=%:S2QV?RWEDI7>/1A_>QFB66)-I2?3IW_R[;BN=RD\,KLD<T;LOWE1
MP2/J!574-3BTY[19(W<W,PA7;C@GN?:N.T&&W?4M-DAU"P69/O0P0.LK#'(<
M]_J:WO$^!/HN3_R_+6<L%3IXB-*]TT_+N%]#H:!U%!ZF@=17F#,S0_\`CSG_
M`.OJ;_T*M.LS0_\`CSG_`.OJ;_T*M,=16V(_BR`YYO%UNK2LUA>?9H93%)<!
M044YQSSFK<>LJVN3V3^2EM'`DRS%\9W?7BN<TO2[S5X-3M5O(X;%[UO.01YD
M;!SP>U71IME=>,KJWN(%EBBLHPJ/R!VR?>O5J8;")RBMTO6VW>VNK%=G4-/$
MD7FO*BQ]=Y8`?G0LT31>:LJ-'UWA@5_.N"2X1/"VFQ2QV[1M=R()KI2\<(!Z
MD#K^-)8+;3:#JL,U]%!;_;$VRK$?*SC(RO4*:C^RURN3D][;=+V'<[Z.:&6/
MS(Y4=/[R,"/SHBGAG4M#*D@'!*,&`_*N#EG:?PO?):VT$4:72":2U5O*E7NP
M'ITSBM#PU#`-;>6VU&QF!@(>&SA9%Z\$YXS6=3+XPIRFY;?\#?[Q7.CEU**+
M5[;33&YDG1G5QC:`/6DTS4XM4BFDBC=!%*T1#XY([\=JS;S_`)'K2O\`KWDI
M/")!LK_!_P"7V2LYX>FJ'M%O9/[VT/J=#6;IW_(3UC_KX3_T6M:59NG?\A/6
M/^OA/_1:US4O@G_74"W>7*65G-<R!F2)"[!>IQ659>)H+JYMH9;.ZM?M0_</
M,!MD^A%6]=_Y`&H?]<&_E6-H>D75Y!I%Y>WD;6]J@>WACCP03_>/>NG#TJ#H
M.=7O;\/\P9J:1K*ZA!*]QY,#+</"B[\;MOU[UHRW$$!`FFCC)Z;W"Y_.N!^P
M6;^%-8O7A5KF.Y?9+W3##IZ=:GU^>*6^$4Z643"R1A-<Q-(TQ(^ZF.AYZUU/
M+J=2K:#LNOEM]^XKG<230PH'EE2-#T9W`!H>:*.+S9)42/\`OLP`_.N#E^S-
MH6BSW%Y;+-%;L5@O$+1RC/MWHU&4SPZ'))%#96)@;"W,;20HV>XZ].F:B.6)
MM+FZM;=K[=P.^5E=`Z,&4C(93D&LQM=@7^U/W,O_`!+O]9R/GX[?_7JIX3A2
M&QN?*O(;F)ILJ8$943CD*#VK-D(QXPYZ#^E94\+3]K.#U2MY;M#9OC6X#-IL
M?E2YU!2T9R/EXSS_`/6K3KD%(^W>$N>L)_\`0177UABZ,*?+R=;_`)L#RWQE
M_P`C/=?1/_0111XR_P"1GNOHG_H(HK[K`_[M3]%^1)ZI\9O^0/I'_7\/Y&FG
MJ:=\9O\`D#Z/_P!?P_\`0333U/UKY;./@I?/]#HK_&%-"HN0JJ,\G"XS3J*\
M1.QB,\N/:%\M-HZ+M&!^%*T<<F/,1'QTW*#BG4478#2JE@Q52PZ''(_&D:*-
MB2T:%B,$E0213Z*$VG<#/&DQ?VS+J)?=YD(A,3*"N`>M7]J[=N!MQC&.*6BJ
ME4E*UWMM\@&HB1C:BJH]%7%((HUP!&@P<C"@8/K3Z*GF?<!I1"VXHI8C!;:,
MD?6D,<9C\O8FS^[M&/RI]%',P&[5Q@`!>F,<4!55=JJ`H&``,#\J=12NV`P1
M1KMQ&@V_=PH&/IZ4K1QR`!T1P.@90<4ZBG?J`UD1UVNBLHZ`J"*4*J_=4#/)
MP,9-+12N^X!67:_\C%J/_7&'_P!FK4K+M?\`D8M1_P"N,/\`[-6]+X9^GZH#
M4[UR>@6=KJUSJUSJ$"7%P+EH]LHW;%'0`'I765D7?ARQNKQ[L/<V\\@_>-;3
M%-_UK3"UHPC.+=K]4!D:S=364YL=-N[U!:VX/DVT`<(,<%V/;I]*5M3U.].@
MK#="![V)C*0@(R!U`]?2M.?PQIT[JV;B/$8B81S$>8H[-ZU/%H=G"]@R&7-B
MI6'+=CZ\<UV?6L,J<4E=Z]%V_P`P,-M9U'3],UJ.2X^TSV<RQQ3.H!.[N0/2
ME-M>VWB?0Q>7[7>]792R!2IV\CCJ*W#HMD_V\.C.M\P:96;C('&/2H+3PU86
M=U!<H]R\T&=CRREN,8Q]!1'%X9)M*S=^BZJWRLQ&''K&H?V.J13A;BYU%K99
MB@_=KGL*F@6?3_%=Y]LOO.:+3RPN'0`@9XW`=<5L'PYI[:=)8LLC1/,9\E_F
M5SW![46WAS3[::24":1Y8C#(99"V]3US[TWC,/:7*K7OT[VZ^@&%IFJZC)K%
ME";N]DM[Q6`>X@5!T.&3']:;HAN--L=;O_M3RK;RR`Q,HVN_'SDCO[5NVGAF
MPLKNWN8Y+IY+<GRO,F+!0>V/2I8M"LH;NZG42D7082PE\QG/4[?6JJ8S#.\8
M+1VZ+6S_`,@U,+2=1UR2^LY)!?SP3G]_YML%C4$=4([?6NQK(L_#MG8W$<L4
MMX5B.8XGN"R)]!6O7#C:M*K-.DK+TL!EW'_(SV/_`%ZS?^A)6G69<?\`(S6/
M_7K-_P"A)6I65;X8>GZL9RVEZ=97^L^(!=VL4P%P!N=<E01V/:LNTO[ZVT2"
M*SNBJC4C;Q.PW`IVSZC-=%/X8LI[JXN#/>(;A]TJ1SE5;\`*M2:)8R6MK;+&
M8H;602QK&<?,/7UKTOKM&_O7DG;1K160BBLMY:>(]-TZ6^DN$>"1I"R@;V!X
MX'I6?/K5_#I^L2+<\Q7PA1V`/E(>I`[XK>U+1[75)(9)S,DL).R2&38P!ZC/
MI65JGAOR]*>WTJ+=YEPLTD;288X_NL>A]S4X>KAI./.M=+Z*VCOOY@.\.SW=
MU?WKMJ<][8Q!5BD>,*'8]>W44S5(TO\`QG865V-]JL#2I$WW7?GJ.]2^'K'4
MK6ZG>X$T-HR@)!-<><V[^]D=!6GJ6D6FJK']H5P\1S'+&VUT^AJ:E:G2Q;:>
MEK7733?2VH&;JRKHL,,.E1QVDM_<+$7"_*G'4#IFHTN-1TW5YM.GOVO$>S>>
M.1T"NC#/IVJ[_P`(Y8FRDM93<3B1@YDEF+.&'0@]L5)::%9V1G9#/++,AC>6
M>0N^WT![4HXB@H<LO>?FM^S\K=@.;34-<72M+U+^TP[74@A\IHAM&<@,?4U>
M6]U&RNM9L9KYK@V]IY\4S(%921TXXK6&A60L+.RS-Y-I()(SNYR/7CFFWVDQ
MR?VC=PAS=W5L8<%OE/'&*U>+H3E;E5K]EW5OP&88O]8MK/2-4FU'SH[J1(WM
M_+`7![^I/K5@SZKJDFJW-OJ9LX[*1HXXE0$-M&26)]:L:1X8MK>"QGN4F^T0
MH#Y32[HT?N0.F:M77AK3[NZEG8W$9F_UJ0RE4D_WA3GB<,IV73KRKOM;TZB*
M%IK-W>7V@$OL2[AD::-?NLP[U!>:M?1VGB*1+E@UK.BP'CY!QD"MN]T*ROH;
M:-EDA^S<0M`^QD'H#42^&M.6RN[11,L-T5,G[SG(]#6<<1A;\S7RM_>O^*T`
MHP7.IV>MZ?%=7WVJ*]B9VC\L*$(&?EK'OYM3U/PM>ZG+?XMWD*?9/+&T*&P,
M'KFNQ?3+>2\L[HE_,M%*Q_-Q@C!SZUG2^$M+E,P(N%CF)8Q+*0BM_>`]:JEC
M,/&2FU9Z=%T;T^ZVH&S;?\>L/_7-?Y"J&N_\>UK_`-?</_H5:4:B.-4'10`,
M^U9NN?\`'M:_]?</_H5<%%WKI^8S4[U&T,3MN>*-B>[(":D[T5SIM;`-95<8
M958>A&12>7'O#E$+CHQ49_.GT478#6C1R"Z(Q'0E0<4-&CD%T5B.A90<4ZBB
M[`:RJZE74,#U!&11@;=N!MZ8QQCZ4ZBD`P11JI540*>H"@`TRY@\ZTE@C?R=
MZ%`RJ#MSQP*FHJE)IW`J:;81:9IT-G$2RQ+C<>K'N34.O?\`(`O_`/KB:T:S
MM>_Y`%__`-<36M*3G7C*6[?ZB+T?^IC_`-P?RI657&&56'HPR*2/_4Q_[H_E
M3ZR;M*Z&)@8Q@8]*1555"J`JCH`,`4ZBIOI8!BQQQDF-$3/7:H&:7RXPQ81H
M&;J=HR?K3J*?,P&".,;<(@V_=PH^7Z>E'EQ[2OEIM/5=HP:?12;8#=BA]P5=
MP&,XYQZ9H5$5BRH@8]2%P3]33J*=P&"*)>5C12#G(4"E5508554=<*,4ZBAR
M;W`1ON-]#6;X>_Y%[3_^N"UHM]QOH:SO#_\`R+VG_P#7!:VC_`EZK]0-.FA$
M#%@JACU8#DTZBL+@-*J6#%5+#H2.11L3YOE4;_O87[WU]:=13N`P1QK]V-!Q
MCA0./2E5$081%0>BKBG44FV]P&".-6++&BL>I"@$TI16QN56(.1D9Q3J*?,V
M[W`*!U%%`ZBD!F:'_P`><_\`U]3?^A5IUF:'_P`><_\`U]3?^A5IUMB/XL@&
MJB)G:JKGDX&,FC:N[=M7<>"V.3^-.HK*[`9Y4>S9Y:;/[NT8_*CRX\,/+3#=
M1M'-/HHYGW`:%55VJJJOH!@4B1I'Q&B(#UVJ!FGT4<S[@-*J6#%1N'`..1^-
M"JJ9"JJYY.!BG44KOJ`5FZ=_R$]8_P"OA/\`T6M:59NG?\A/6/\`KX3_`-%K
M6]+X)_UU`T2`P((!!Z@CB@`*H"@`#H`.!2T5A?2P#/*CVE=B;3U&T8/X4I1&
MV[D0[>F5!Q]*=13YFG>X$9AB*A3%&5'0%`0/I3F577:ZJR^A&13J*+L!JJJJ
M%50JCH`,"C8GS?(OS?>^4?-]?6G447>X#?+3*G8OR_=^4?+]/2G4447;W`\M
M\9?\C/=?1/\`T$44>,O^1GN?HG_H(HK]$P/^ZT_1$GJ?QH\PZ1HXC`+&]P,^
MNTXK(_L/XD_]`_3_`/OZG^-;?QA_Y!NB?]A%?Y5Z37FSC"5.//%/?<[G3C.;
MN>-_V'\2/^@?8?\`?U/\:/[#^)'_`$#[#_OZG^->H:WK*Z,EJ!97%W+=3>3'
M%!MW%L$_Q$#H#WI-(UN'51<(;>>TN;5PD]O<`!X\C(/!(((YR#6?L*-K^S7W
M"]A"]KGF']A_$G_H'6'_`']3_&C^P_B1_P!`_3_^_J?XUZAJ>MVUEH5YJL#1
MW<=K&SLL4@.<=LC.#5O[?:HL(FN(8I)E!1'D`+9],]:7L:/_`#[C]P>P@>2_
MV'\2/^@?I_\`W]3_`!I/[#^)'_0/T_\`[^I_C7KTUW:VP8SW$,04`DR.%QG@
M=:)KNVMHA+/<111DX#2.%!/U-'L:/_/N/W#]A`\A_L/XD_\`0.L/^_J?XT?V
M'\2/^@?I_P#W]3_&O53?L-4:V,*BW6W\XW)E7&<XQMZ].<]*LQW5M-(T<4\4
MDB`%E5P2`>F11[&C_P`^X_<'L('D7]A_$C_H'Z?_`-_4_P`:/[#^)'_0/T__
M`+^I_C7K7]HV)N/L_P!LMO/W;?*\U=V?3&<YJ=Y(XP"[HH)`!8XY/:CV-'_G
MW'[@]A`\>_L/XD?]`_3_`/OZG^-)_8?Q(_Z!^G_]_4_QKUQK^R6`3M=VXA)V
MB0R#:3Z9Z9I\ES;PKNEFB0;2V68#Y1U/TH]C1_Y]Q^X/80/(/[#^)/\`T#[#
M_OZG^-']A_$G_H'6'_?U/\:]<^VVA\H"YAS,,Q#S!^\_W?7\*SKS7XM-_M"7
M4(Q!:V80B;S%8R[AG`7J".G/7M0J-%[4X_<+V$#S3^P_B3_T#K#_`+^I_C1_
M8?Q)_P"@=8?]_4_QKTZ;Q'I,%Q:0O?0;KO=Y3"12IVCG)SQZ?6I[;4#+<WD<
M\2P)!*L<;M*I\W(!!P/N\G&#S1["C_S[C]P>P@>5?V'\2/\`H'Z?_P!_4_QI
M?[#^)'_0/T__`+^I_C7KT5S;W"%X9HI54D%D8,`1U'%1P:A8W,ACM[RWF<#)
M6.4,<?0&CV-'_GW'[A_5X'DAT/XD?]`_3_\`OZG^-9]OI'CMM;O8H[*S-XL4
M1G4R)@*<[<<_6O=.,5SFF_\`(]ZY_P!>UM_[/3C2HV?[N/W"=")Y]_8?Q(_Z
M!^G_`/?U/\:/[#^)'_0/T_\`[^I_C7LF/:BI]C0_Y]Q^X?U>!XW_`&'\2/\`
MH'Z?_P!_4_QH_L/XD?\`0/T__OZG^->R48]J/8T/^?<?N#ZO`\;_`+#^)/\`
MT#]/_P"_J?XT?V'\2/\`H'Z?_P!_4_QKV2CBCV-#_GW'[@^KP/&_[#^)'_0/
MT_\`[^I_C1_8?Q(_Z!^G_P#?U/\`&O9,44>QH?\`/N/W!]7@>-_V'\2/^@?I
M_P#W]3_&C^P_B1_T#]/_`._J?XU[)1Q1[&A_S[C]P?5X'C?]A_$C_H'Z?_W]
M3_&C^P_B1_T#]/\`^_J?XU[)BBCV-#_GW'[@^KP/#)M)\=C7K2*2QLA?-;RM
M$HD3!0%=W?U*U?\`[#^)'_0/T_\`[^I_C7H-[_R4+2/^P?=?^AQ5T>/:KE2H
MZ7IK;L)4(GC?]A_$C_H'Z?\`]_4_QH_L/XD?]`_3_P#OZG^->R8]J,>U1[&A
M_P`^X_</ZO`\;_L/XD?]`_3_`/OZG^-']A_$C_H'Z?\`]_4_QKV3'M1Q1[&A
M_P`^X_<'U>!XW_8?Q(_Z!^G_`/?U/\:/[#^)'_0/T_\`[^I_C7LE&*/8T/\`
MGW'[@^KP/&_[#^)/_0/T_P#[^I_C1_8?Q(_Z!^G_`/?U/\:]DXHQ]*/8T/\`
MGW'[@^KP/&_[#^)'_0/T_P#[^I_C1_8?Q(_Z!^G_`/?U/\:]DXHXH]C0_P"?
M<?N#ZO`\;_L/XD?]`_3_`/OZG^-']A_$C_H'Z?\`]_4_QKV3\*,4>QH?\^X_
M<'U>!XW_`&'\2/\`H'Z?_P!_4_QH_L/XD?\`0/T__OZG^->R<48H]C0_Y]Q^
MX/J\#QO^P_B1_P!`_3_^_J?XT?V'\2/^@?I__?U/\:]DQ[48]J/8T/\`GW'[
M@^KP/&_[#^)'_0/T_P#[^I_C6?JVD>.X8(#?65DB&YC6,I(G,A;Y1UZ9KW3'
MM7.>,O\`CPT__L)VW_HP54*5!235./W"=""1Y]_8?Q(_Z!VG_P#?U/\`&E_L
M/XD?]`_3_P#OZG^->QT<5/LJ'_/N/W#^KP/'/[#^)'_0/T__`+^I_C1_8?Q(
M_P"@?I__`']3_&O8Z*/94/\`GW'[@^KP/&_[#^)'_0/T_P#[^I_C2_V'\2/^
M@?I__?U/\:]CHXH]E0_Y]Q^X/J\#QS^P_B1_T#]/_P"_J?XT?V'\2/\`H'Z?
M_P!_4_QKV.BCV5#_`)]Q^X/J\#QO^P_B1_T#]/\`^_J?XTO]A_$C_H'Z?_W]
M3_&O8Z*/94/^?<?N#ZO`\;_L/XD?]`_3_P#OZG^-4M8TCQ[#H]W)?V-DMHL1
M,S+(F0O?'->X_A6#XT_Y$O5_^O9JJ-*CS+]W'[A.A%*YYO'HGQ',:%=/L"NT
M8_>IT_.G_P!A_$C_`*!^G_\`?U/\:]>MO^/6'_<7^52TG2H7_AQ^X?U>!XW_
M`&'\2/\`H'Z?_P!_4_QI?[#^)'_0/T__`+^I_C7L=%+V5#_GW'[@^KP/'/[#
M^)'_`$#]/_[^I_C1_8?Q(_Z!^G_]_4_QKV.BCV5#_GW'[@^KP/'/[#^)'_0/
MT_\`[^I_C1_8?Q(_Z!^G_P#?U/\`&O8^**/94/\`GW'[@^KP/'/[#^)'_0/T
M_P#[^I_C2?V'\2/^@?I__?U/\:]DHH]E0_Y]Q^X/J\#QS^P_B1_T#]/_`._J
M?XT?V'\2/^@?I_\`W]3_`!KV.BCV5#_GW'[@^KP/&VT/XCA3G3[#&.?WJ?XU
M1T72/'DVBV<FGV-D]FT0,+/(@)7MG)KV^7_5/_NFL+P-_P`B-HO_`%Z)_*J]
ME1Y?X<=UT%["-['G?]A_$G_H'Z?_`-_4_P`:7^P_B1_T#]/_`._J?XU['^%%
M3[*A_P`^X_</ZO`\<_L/XD?]`_3_`/OZG^-']A_$C_H'Z?\`]_4_QKV/BBCV
M5#_GW'[@^KP/'/[#^)'_`$#]/_[^I_C1_8?Q(_Z!^G_]_4_QKV.BCV5#_GW'
M[@^KP/'/[#^)'_0/T_\`[^I_C1_8?Q(_Z!^G_P#?U/\`&O8Z.*/94/\`GW'[
M@^KP/'/[#^)'_0/T_P#[^I_C1_8?Q)_Z!^G_`/?U/\:]CHH]E0_Y]Q^X/J\#
MPW2=(\>2VTQL;&R:,7$BN6D0$.&^8=>F:O\`]A_$C_H'Z?\`]_4_QKT+P?\`
M\@N\_P"PA<_^C#70U<Z=%R;=./W"5"-CQS^P_B1_T#]/_P"_J?XT?V'\2/\`
MH'Z?_P!_4_QKV.F32QP0R32LJ1QJ6=CT`')-1[*A_P`^X_</ZO`\?_L/XD?]
M`_3_`/OZG^-']A_$C_H'Z?\`]_4_QKUVVNK:\MDN+6>*:"0922-@RD>Q%3<4
M_94/^?<?N#ZO`\;_`+#^)'_0/T__`+^I_C2_V'\2/^@?I_\`W]3_`!KV/%&/
M:CV5#_GW'[@^KP/'/[#^)'_0/T__`+^I_C1_8?Q(_P"@?I__`']3_&O8\>U&
M/:CV5#_GW'[@^KP/&_[#^)'_`$#]/_[^I_C5&QTGQX^H:DEO8V1G29!<AI$P
MK>6I`'/]TBO<L>U<]H/_`",?B?\`Z_(O_1$=-4J-G^[C]PO81N>>?V'\2/\`
MH'Z?_P!_4_QH_L/XD?\`0/T__OZG^->R48]JGV5#_GW'[A_5X'CG]A_$C_H'
MZ?\`]_4_QH_L/XD?]`_3_P#OZG^->QX]J,>U/V5#_GW'[@^KP/'/[#^)'_0/
MT_\`[^I_C1_8?Q(_Z!^G_P#?U/\`&O8\>U&/:CV5#_GW'[@^KP/&_P"P_B1_
MT#]/_P"_J?XTO]A_$C_H'Z?_`-_4_P`:]CQ[48]J/94/^?<?N#ZO`\<_L/XD
M?]`_3_\`OZG^-)_8?Q(_Z!^G_P#?U/\`&O9,>U%+V5#_`)]Q^X/J\#Y9\4P:
MA:Z_/%K<<<=^`N]8B"H&T8Z>U%;/Q7'_`!<._P#]R+_T!:*]JB[4XI)6MV.2
M44FT>B?&'_D&:)_V$4_E7I(KS;XP_P#(,T3_`+"*?RKTD5YLOX<?F=T?CE\C
ME_&,$]S=:!%;W+VTK7_RSHBL4_=OSA@1^=<Y>07T.B>)].9Y9]66:*6XN=A+
M7-N2,$(,<!0RE5QT/K7I9ICRQQGYW5>">3CIUJ5-K0;C<\L,-FV@^);FPU2Q
MNE;32CPZ?8&WC!Y*D\D%L$C'7%/\8S0R37UK+%I]O*FGH86GL6GGNSL/^K((
MV[3QD9(/->G?:+?"$2QXD^YAA\WT]:=YB9*[EW`9(SR/K3]IY"Y#SNYGT6+Q
M+9S>(5C>#^Q(</<(70,6/WN",GL3^%49(;6T\-Z-/?W$$$\,<[6MGJ=LTD<L
M+/E4(ZJX7;CN`>E=G+/96_C2.0ES)<::Q\S>OEJD;@_F2_7..*M)KL-UI]I>
MZ=&;R&XE1#M<*8U;^)@?3TZTW)Z60K')W3F>>[F^QM:[_"K?N".8N3\OX5-;
M:;9Z3?\`A26PM%@>6SF69HQAI!Y(;#'N=PSS7=>?"&"F2,,Q*@;ADD=1]:SH
M[^'4M2U727@8"V2,2,3PXD4GCTP!2YWL/E//?"*6$^IZ/+=?8X9H5?R&%A(D
MMQ(P_CE8;68<GY2<GD5T'B:QU)]!\C5[Z"\BEOK50L%L82H,JYR=QSQ]*T=-
M\,VT<EH_]L7E_:63#[+;O(ACB(&%Y4`L0.!DFNBDGAA4&61$4G`+L!G\Z)3]
MZZ",?=LSSWQ78VUAKUBKMIUAI"VCK%]IL/.MUE+?-\H("L1CD]<&BTTFTEO?
M"%I/(-1M5BO'1WA*(R_*5&QL_*.P.>`*]"DGAB`\V1(\G`WL!D_C5&RU5+S5
M-3LO+*&P=$9R1A]R[LCTQ1S.P<JN<!/HEA;^%O$5U#91K<6NIN+:0+\T(61=
MH3^Z.3P.*NZ[:"Y/C@&V\XK%;.J^7N.1&>1[@9Z5WZ7$#Q>8DL;1]-P8$?G1
M]H@",YEC"(<,VX8!]S1SN]PY$<'J3>&FG\-:DMO8'2-\T33"W!C!*?*",<?-
MGKWJMJEO'<IXAAD0F*77+,,!D94B+N/:O1C-"(O-+H(\9WY&,?6JTU\4N[.*
M&W,T5P6W3HZ[8P!D$]SGIQ0IL'$X;7;2WTNX\36]C`+:V?2H7:.W78N[>ZEL
M#V`SCDBK/@N+3VUV\N0+&"^>W5%MK6QDMAY:DY<"103DD`XX&!76:G8V>MV$
M^G2RY!(W>4X#QL#D'V((SS5;3?#_`-BOS?76HW>H70C,227)4>6A()`"@#D@
M9/6GSKELPY7<VJYS3?\`D>]<_P"O:V_]GKHZYS3?^1[US_KVMO\`V>H6S+>Z
M.DK"\1>(+C0(7N?[(N+NUCCWRS12QJ$YQC#$$]N@K=KGO'`+^"]655+,8.`!
MDGD4HVOJ$MM"S9:X'@:34[8:4PP52YN(R64]&^5CQGCGO4UIJGFB<W*P6XCN
M6@C_`-(5MX'0\=">?EZC%8<VGVU[X]LGNK59EBTDE/,3<JMYBCZ9Q6%/9K=0
M-;SV[212>*R70J<,O/)]JM139',SO!K.FFW2X&H6GD._EI)YZ[6;^Z#G!/M4
MMUJ%K8QK)=W,%NC':&FD"`GTR>]<6V@:8VL^+@VF0%!:1^6OE#:"8FW;1T!.
M!R.>!63>K()=$N]1O$MK1]'BC2:YT_[4@EZNI'\+$8Y[X-'(NX^9GI5UJ%G9
M(CW5W;P)(<(TLH4,?09/-4W\1Z7%K2Z1)=PI=M&)`K2*`<G`7K]X]<>E<-?V
M]AI>E:1(+[S[F"S=(([[3G>.ZC+9";<$HW``QSC':MC=9P>,M*NK^P2U-WIJ
MQQ!H=VR?>IV;@.&`[G'2ERH')G5+J5D]XUFEY;-=*,M")5+CZKG-8TNMZG:K
M))+':RI'>>0PC5E.P+N9N2><=O:N-29[GQ#IK>7!;W$>K#S+*#3BC0+EAN>;
MONZ^AS7IYLX&R3!&<N9#D?Q$8)^N.*&E$$VRGI6JOJ5U>C8@MXF7R'4Y,BD'
MYC^(./:M2H8+2"U4"WACB`54`10!M48`^@J>H9:.<O?^2AZ1_P!@^Y_]#BKH
MZYR]_P"2AZ1_V#[G_P!#BKHZN6R]/U8EU"BBBH&%96KZW'I1MX5MYKN\N6*P
M6T(&Y\#).20%4=R?45JGI7*ZY+_9'BK3]:N8Y#8"VEMII40OY!+*RLP'(4X(
MS]*:5V)NQ>T[Q$MW>36-Y93Z=>Q1^<8;@J0T><;E9200._/%76UG3421VU&S
M5(\;V,Z@)GIGGC/:N5NKI/$.KR:CIZR-8V>FW$9N#&RK+(X'RKD9.`N2?7%9
M\T-KI/A#PVD5G9VL<T2?:+V:R\_R&\O.2O4LQR,GI5\B9/,SLK_78[4:8T*I
M<QW]TMNDD<@*@,"=P(Z]*TI)DAB:21U2-!EF8X`'J37FFD1R?V9I0VNRCQ(S
M*?LYB&TAB&"?P#GI[UTOCV&XGT.W,1(@CNXY+DB#SL1C.24_B`."1[4G!)I`
MI:7.@CU&SFLS>17=N]L,DS+*"@`Z_-TJE>^)M)L+6VN9;Z!H+F4112)*I5B3
MC.<XP.Y[5Q4%GI4FAZK<2:TTEM+/`S3P:88X8Y$/!,>"&!XW<8Z4^66*[\*6
M][<:;;?9K35HV:>"T*I+$&`:4(1D`]#]/2FHJXN9V.]_M6P549KVU`DV[29E
M^;=]W'/.>WK4-IJPDTZ2\OA!:)'(Z,3<*R@*Q`)8<#/IVZ5@V-GI]_XYFO%M
M8Y8$TRW-LS1?*H+O]T$<'`'N*PK=(H+'2;K4[=WTJ'4[YK@&(NJL7;RW9<<C
M.>?4BCD0.3.UU/7H;+3;>]M_+NXI[F*!6CE!7YW"Y!&<XS6S7F4L*2VU[=:?
M;/'I=QK-D]LHC*AB&7S'5<<*3W]B:]-%*44DBHN["BBBH*"N8\;RQP:5932N
MJ1QZC;,[L<!0'&2:Z>N(^*J/+X(FCC0N[SQJJJ,DDGH*NG\:)D[(V?\`A-/#
M/_0>T_\`[_BC_A-/#'_0>L/^_P"*^;H_#U_%$HG@D1\=&B.13O[$N?[A_P"_
M9KI6'I_S'/[:?8^C_P#A-/#'_0>L/^_XH_X33PQ_T'K#_O\`BOG#^Q+G^X?^
M_9H_L2Y_N'_OV:?U:G_,'MI]CZ/_`.$T\,?]!ZP_[_BC_A-/#'_0>L/^_P"*
M^</[$N?[A_[]FC^Q+G^X?^_9H^K4_P"8/;3['T?_`,)IX8_Z#UA_W_%'_":>
M&/\`H/6'_?\`%?.']B7/]P_]^S1_8ES_`'#_`-^S1]6I_P`P>VGV/H__`(33
MPQ_T'K#_`+_BC_A-/#'_`$'K#_O^*^</[$N?[A_[]FC^Q+G^X?\`OV:/JU/^
M8/;3['T?_P`)IX8_Z#UA_P!_Q6-XL\6>'KKPGJEO;ZS92S26[*B+,"6/H*\)
M_L2Y_N'_`+]FD;1IT0NZ[57DL4(`IK#P3NI`ZTVMCZ,@\9^&5MHE.NV`(0`C
MSAZ5)_PFGAC_`*#UA_W_`!7SA_8EQC[A_P"_9H_L2Y_N'_OV:7U>G_,'MI]C
MZ/\`^$T\,?\`0>L/^_XH_P"$T\,?]!ZP_P"_XKYP_L2Y_N'_`+]FC^Q+G^X?
M^_9H^K4_Y@]M/L?1_P#PFGAC_H/6'_?\4?\`":>&/^@]8?\`?\5\X?V)<_W#
M_P!^S1_8ES_</_?LT?5J?\P>VGV/H_\`X33PQ_T'K#_O^*/^$T\,?]!ZP_[_
M`(KYP_L2Y_N'_OV:/[$N?[A_[]FCZO3_`)@]M/L?1_\`PFGAC_H/6'_?\4?\
M)IX8_P"@]8?]_P`5\X?V)<_W#_W[-']B7/\`</\`W[-'U:G_`#![:?8^C_\`
MA-/#'_0>L/\`O^*/^$T\,?\`0>L/^_XKYP_L2Y_N'_OV:/[$N?[A_P"_9H^K
M4_Y@]M/L?1LGC/PR8W`UVPY4_P#+<5C>#_%?A^S\'Z3;W&LV44T=LJNCS`%3
MCH17A?\`8EQ_</\`W[--71IW0.B[E89#!"0:?U>G:W,+VL[['TC_`,)IX8_Z
M#UA_W_%'_":>&/\`H/6'_?\`%?.']B7/]P_]^S1_8ES_`'#_`-^S2^K4_P"8
M?MI]CZ/_`.$T\,?]!ZP_[_BC_A-/#'_0>L/^_P"*^</[$N?[A_[]FC^Q+G^X
M?^_9H^K4_P"8/;3['T?_`,)IX8_Z#UA_W_%'_":>&/\`H/6'_?\`%?.']B7/
M]P_]^S1_8ES_`'#_`-^S1]6I_P`P>VGV/H__`(33PQ_T'K#_`+_BC_A-/#'_
M`$'K#_O^*^</[$N?[A_[]FC^Q+G^X?\`OV:/JU/^8/;3['T?_P`)IX8_Z#UA
M_P!_Q1_PFGAC_H/6'_?\5\X?V)<_W#_W[-']B7/]P_\`?LT?5J?\P>VGV/<_
M"_BOP_:Z?=)/K-E&S7UPX#3`$J9"0?H:W/\`A-/#'_0>L/\`O^*^;ET:=QE5
MW#."0A/(IW]B7/\`</\`W[--X>G?X@56:6Q]'_\`":>&/^@]8?\`?\50UKQA
MX<FT'48H];L7=[61543#))4X%?/_`/8ES_</_?LTAT6=5+,I``R24/%+ZO3_
M`)@]M/L5?#_B36?#LOF:3?26_/S1$[HW^JGBO8/#/QJL+O9;>((/L,YX^T1Y
M:%C[]U_45X9/*D<K,F".@/K4:2S3'"1CGC@5I4ITY;D1G-/0^R+2\M[VW2XM
M9XYH7&5DC8,I^A%3U\W^!].\3Z=>)/9W\FG0,070C<K_`/;,\?CQ7T'IUV]S
M`I<?-CDXQFN&<5%V3.N,FUJ7:***@H*YW0?^1C\3_P#7Y%_Z(CKHJYW0?^1C
M\3_]?D7_`*(CIK9BZHZ*B@44AA1110`4444`%%%%`!1110!\Y?%?_DH=_P#[
MD7_H"T4?%?\`Y*'?_P"Y%_Z`M%>K2^!'FU/B9Z'\8?\`D&:)_P!A%/Y5Z2*\
MV^,/_(-T3_L(K_*O2-Z_WA^=>?+^''YG='XY?(=7)>*K*WU#Q'X9MKJ,2P//
M.70]&Q$3@^H]N]=7O7^\/SI"4/4KD=.:S3:=RWJK'F-UH6F1:%XOG2T026-R
MYM",_P"C81''EC^#YB3QBMB?5+32/$^K-J$OE&]T^#[/E23,5#AE7'WFR1P/
M6NVS'SRG/7IS03&2"2IQTZ<57/?H3R]CSK0[>.ZE\-6\L*RQR>'I%:-U!#<Q
M\$&JNFC3!X2T".Q2W2YCU6U6\6-`KK(&(^<=<_6O3P8QC!7C@=.*3]WVV<G/
M;K3]II:P<AY3J!T-H?$T<Z!M=;4)!8C!,N_Y=GE'M\W)Q^-7];6^_P"*K$1/
MG>78>>54M\F/WG"\D8SD#MFNYTW3(--:\*2^8;FZ>Y._'REL9`]N*O[D!R"N
M3UYH<^PN4XCP5#:KJUY/8ZGI4\30(KV^EVQBB4@G#'YB-V,CUZ4WQU_9\=];
M7=W<:<\T-O)LL=1C+1S@D?</:3C`(!//2NY7RT&%V*/;%!,;$9V''(SCBES:
MW';2QY]<3:&VMM+XFM$CMY-.@-A#>)O5,@^8BC_GIG;TYZ54U@3&'Q.+,&.#
M[39>=NC9ML'EKNRH(8@#J`<XS7IA,;8SM.#D9QQ1E,DY7GKS1S^0<OF>52VU
MM_PC/B*6RU/3;B"6&%7ATJ`Q1(V_[WWB-Q'ISP*W=>L-&TG5-'AOK:"#0`LI
M=73]R;C"[3)V)(W8+=_>NW`B"[0$"^@Q2DQL,,5(]#BCG#E5CS)H--DT2[/V
MRWLM'_M7S=.^V1%K60!.5*G`\LMN(Y`STJ[I]S%=7/A.:.RCLXA+>!4@SY9`
M1OFCR`=IZCBN_/EE=IV%?0XQ2YCXY7CISTHY_(.4\_\`!CZ?:Z]]BL#8:@#`
M['4+:,K,HW#Y9^Q8YX.<\'@5Z%308USMVC/7&*7>O]X?G4R=W<I:"USFF_\`
M(]ZY_P!>UM_[/71;U_O#\ZYS3F'_``G6N'(_X]K;O_OTX[,3>J.EI",FDWK_
M`'A^=&]?[P_.I*%"@48%)O7^\/SHWK_>'YT6"XNT4;1[TF]?[P_.C>O]X?G0
M+07:!Z_G1M'J:3>O]X?G1O7^\/SH&+MXQDTM-WK_`'A^=&]?[P_.@+CJ*;O7
M^\/SHWK_`'A^=`'/7O\`R4/2/^P?<_\`H<5='7-7K#_A86D'(_Y!]SW_`-N*
MNCWK_>'YU<MEZ?J2NHZBF[U_O#\Z-Z_WA^=04.I,4F]?[P_.C>O]X?G0`NVC
M'UI-Z_WA^=&]?[P_.@!=M&*3>O\`>'YT;U_O#\Z`N+MYSDT8I-Z_WA^=&]?[
MP_.@-!=H]Z-ON:3>O]X?G1O7^\/SH`7;SG)I0,#%-WK_`'A^=&]?[P_.@!U%
M-WK_`'A^=&]?[P_.@!U<WXQ_X\-/_P"PG;?^C!71;U_O#\ZYSQB0;#3\$?\`
M(3MN_P#TT%5#XD3+8T+W18+V4NXR:J_\(S:^E;N]?[P_.C>O]X?G4CT,+_A&
M;7TH_P"$9M?2MW>O]X?G1O7^\/SH#0PO^$9M?2C_`(1FU]*W=Z_WA^=&]?[P
M_.@-#"_X1FU]*/\`A&;7TK=WK_>'YT;U_O#\Z`T,+_A&;7TH_P"$9M?2MW>O
M]X?G1O7^\/SH#0PO^$9M?2L;Q;X=MH?"&K2`?,MNQ%=MO7^\/SK!\:,I\&:N
M`1_Q[-WJH_$A2V&P>&K4VT1Q_`O\J?\`\(S:^E;%LZ_98?F'W%[^U2[U_O#\
MZ0U8PO\`A&;7TH_X1FU]*W=Z_P!X?G1O7^\/SI!H87_",VOI1_PC-KZ5N[U_
MO#\Z-Z_WA^=`:&%_PC-KZ4?\(S:^E;N]?[P_.C>O]X?G0&AA?\(S:^E'_",V
MOI6[O7^\/SHWK_>'YT!H87_",VOI1_PC-KZ5N[U_O#\Z-Z_WA^=`:&`_AFU$
M;G'\)_E6-X.\/6TW@W1Y"/F:U0FNVE=?)?YA]T]ZP?`[*/`^B_,/^/1._M5?
M9%]H?_PC-KZ4?\(S:^E;N]?[P_.C>O\`>'YU(]#"_P"$9M?2C_A&;7TK=WK_
M`'A^=&]?[P_.@-#"_P"$9M?2C_A&;7TK=WK_`'A^=&]?[P_.@-#"_P"$9M?2
MC_A&;7TK=WK_`'A^=&]?[P_.@-#"_P"$9M?2E'AFUR.*W-Z_WA^=&]?[P_.C
M4-#AO"OAZVETVZ)'(O[@?E(:W/\`A&;7TIG@]E&F7F2/^0A<]_\`IH:Z#>O]
MX?G52W$K6,+_`(1FU]*I:SX;MTT+4&526%M(0`,Y.TUU6]?[P_.C>O\`>'YT
MDVG<>A\NZ9\/M6NA'-?0M:1,,J)1\Y'LO^->C^'O`4%KM:*W^?\`YZN,M_\`
M6KTV73[::?S9-I/UJU&D,2X3:/QJY5)2(C"*,;3_``Y!;`%U!;WK<CC2,808
M%+O7^\/SHWK_`'A^=9FEQU%-WK_>'YT;U_O#\Z`'5SN@_P#(Q^)_^OR+_P!$
M1UT&]?[P_.N>T%E_X2/Q/R/^/R+O_P!,(ZI;,5]4=&**;O7^\/SHWK_>'YU(
M[CJ*;O7^\/SHWK_>'YT`.HIN]?[P_.C>O]X?G0`ZBF[U_O#\Z-Z_WA^=`#J*
M;O7^\/SHWK_>'YT`?.GQ7_Y*'?\`^Y%_Z`M%-^*S#_A85_CGY(NG^X**]6E\
M"/-G\3/1/C&BOIFBAAD&_4'Z$<UT_P#P@GAD_P#,+7_OZ_\`\57,_&'_`)!F
MB?\`813^5=;XFO[NRLK:*P=([N]NH[6*5UR(RW5L=\`$XK@=_9Q2?<[=.:5_
M(@_X0/PS_P!`M/\`OZ__`,51_P`('X9_Z!:_]_7_`/BJ5DE\*V-UJ%[K%[?V
M<<63%.JM)YF0!L(`ZYQ@]R.:9;^)KB*\-MK&E26$CV[W$)683!U099>`,,`1
MQ^M1>?1E6CV'?\('X9_Z!:_]_7_^*H_X0/PS_P!`M?\`OZ__`,54&F^*;V_U
M:SM)-'6"&\MVN8IOMBN?+&.2H'!Y'&?QXJ/3O&,][_9L\VC2VUAJ$OD17#3*
MQ\PYP-F,[3@X;]*/?[BO`M_\('X9_P"@6O\`W]?_`.*H_P"$#\,_]`M?^_K_
M`/Q58L^N:E:6@?2H))C)KCVTOVFZ!/WL;5RORJ>W]W'>KMUKK:9JFI74UK<-
M+;V%O-/;BYW1HK.P8J,=1R2>X':G:?<+Q[%W_A`_#/\`T"U_[^O_`/%4?\('
MX9_Z!:_]_7_^*I^I^*;73;BZ5XFDAM;1;F25&'5VVH@'JW)ZTW0O$_\`:NHR
M6%Q;16]TL7G*(;M+A63.#\R]"#V]^M+W[7N/W1/^$#\,_P#0+7_OZ_\`\51_
MP@?AG_H%K_W]?_XJK6LZU-8WMK8V5B;V^N%9UB,HC547&69B#CJ`!CFL/0/$
M,\8_TV"<+>:Q/;9EDR;<XRJ'KQD$#!]*%SM7N'NWM8TO^$#\,_\`0+7_`+^O
M_P#%4?\`"!^&?^@6O_?U_P#XJJ]YXP\B22."Q$K?;390-).(HY'5=S$L1A<'
M*CKDU0\176LWM]H5B+":&.Y9WFCBU#R6+*I^7>HS@?>R.O`XIKG[B?+V-?\`
MX0/PS_T"U_[^O_\`%4?\('X9_P"@6O\`W]?_`.*HD\2I#H6IZB+1BMA<O;;#
M)R^U@N<XXZU%J'BB[M=2U&TL]$EO!I\:2S2"=478R[N,CEN.GZBE[_<=HDO_
M``@?AG_H%K_W]?\`^*H_X0/PS_T"U_[^O_\`%47'B66:6VM]%TUM0FFM5NVW
M3"%4C;[N20?F//'L:K6FM:W/XOFL)--C2S6WBD(:X7?%NW98@#DY&,9[9SS1
M[_<'R]BS_P`('X9_Z!:_]_7_`/BJ/^$#\,_]`M?^_K__`!54-+\1&/1-*@L+
M.ZOKR\$K117%R-P1'.YGD(Z=`..X%3R>,3'IXE.E3F\2^6PELU<%DD(R-K=&
M!&#GC@T[3O:X>Z6/^$#\,_\`0+7_`+^O_P#%5AV/@_0)/&&KVKZ>IABM[=D7
MS'X)W9[^PKI]%UF;4;B\L[RQ-G>V;+YD7FB12K#*L&`&>_;M533?^1[US_KV
MMO\`V>A.2NFPM%V#_A`_#/\`T"U_[^O_`/%4?\('X9_Z!:_]_7_^*KI*0G%1
MS2[CY5V.<_X0/PS_`-`M?^_K_P#Q5'_"!^&?^@6O_?U__BJZ/-&?K1S2[ARQ
M['.?\('X9_Z!:_\`?U__`(JC_A`_#/\`T"U_[^O_`/%5TE%'-+N/E78YO_A`
M_#/_`$"U_P"_K_\`Q5'_``@?AG_H%K_W]?\`^*KI**.:7<.5=CF_^$#\,_\`
M0+7_`+^O_P#%4?\`"!^&?^@6O_?U_P#XJNC)`ZTT2HQX8'\:?-+N+ECV.>_X
M0/PS_P!`M?\`OZ__`,51_P`('X9_Z!:_]_7_`/BJZ,,*6ES2[CY5V//[KP?H
M">-M-M%TY1!+97#NGF/RRM&`>ON?SK<_X0/PS_T"U_[^O_\`%4M[_P`E#TC_
M`+!]S_Z'%71U<I2LM25%:Z'-_P#"!^&?^@6O_?U__BJ/^$#\,_\`0+7_`+^O
M_P#%5TE%1S2[E<J['-_\('X9_P"@6O\`W]?_`.*H_P"$#\,_]`M?^_K_`/Q5
M=)2$XHYI=PY5V.<_X0/PS_T"U_[^O_\`%4?\('X9_P"@6O\`W]?_`.*KH\TM
M'-+N'*NQS?\`P@?AG_H%K_W]?_XJC_A`_#/_`$"U_P"_K_\`Q5='F@'(HYI=
MPY5V.<_X0/PS_P!`M?\`OZ__`,51_P`('X9_Z!:_]_7_`/BJZ2BCFEW#E78Y
MO_A`_#/_`$"U_P"_K_\`Q5'_``@?AG_H%K_W]?\`^*KHR0.M%'-+N'+'L<Y_
MP@?AG_H%K_W]?_XJC_A`_#/_`$"U_P"_K_\`Q5='F@'(S1S2[ARKL<Y_P@?A
MG_H%K_W]?_XJC_A`_#/_`$"U_P"_K_\`Q5=)11S2[ARKL<W_`,('X9_Z!:_]
M_7_^*K#\4>#]`L[.R:WT]4+W]O&W[QSE6<`CKZ5Z!7-^,?\`CPT__L)VW_HP
M5<)2YEJ3**L'_"!^&?\`H%K_`-_7_P#BJ/\`A`_#/_0+7_OZ_P#\571YHJ.:
M7<?*NQSG_"!^&?\`H%K_`-_7_P#BJ/\`A`_#/_0+7_OZ_P#\571T4<TNX<J[
M'.?\('X9_P"@6O\`W]?_`.*H_P"$#\,_]`M?^_K_`/Q5='11S2[ARKL<Y_P@
M?AG_`*!:_P#?U_\`XJC_`(0/PS_T"U_[^O\`_%5T=%'-+N'*NQSG_"!^&?\`
MH%K_`-_7_P#BJ/\`A`_#/_0+7_OZ_P#\571T4<TNX<J['.?\('X9_P"@6O\`
MW]?_`.*K'\5>#?#]GX5U.YM].5)HX&9&$CG!_.N[K!\:'_BC-7_Z]FJH2ES+
M44HJS*T'@7PTUO$QTM22@)_>OZ?[U2?\('X9_P"@6O\`W]?_`.*K>MO^/6'_
M`'%_E4M)REW&HQ['.?\`"!^&?^@6O_?U_P#XJC_A`_#/_0+7_OZ__P`571T4
MN:7<.5=CG/\`A`_#/_0+7_OZ_P#\51_P@?AG_H%K_P!_7_\`BJZ.BCFEW#E7
M8YS_`(0/PS_T"U_[^O\`_%4?\('X9_Z!:_\`?U__`(JNCHHYI=PY8]CG/^$#
M\,_]`M?^_K__`!5'_"!^&?\`H%K_`-_7_P#BJZ.BCFEW#E78YS_A`_#/_0+7
M_OZ__P`51_P@?AG_`*!:_P#?U_\`XJNCHHYI=PY5V.:D\">&A&Q&EKPI_P"6
MK_\`Q58_A'P=X?O?"&E7-SIRO-+;*SMYCC)/T-=W+_JG_P!TU@^!O^1'T7_K
MT3^55S2Y=Q<JYAG_``@?AG_H%K_W]?\`^*H_X0/PS_T"U_[^O_\`%5T=%3S2
M[CY4<Y_P@?AG_H%K_P!_7_\`BJ/^$#\,_P#0+7_OZ_\`\571T4<TNX<J['.?
M\('X9_Z!:_\`?U__`(JC_A`_#/\`T"U_[^O_`/%5T=%'-+N'*NQSG_"!^&?^
M@6O_`']?_P"*H_X0/PS_`-`M?^_K_P#Q5='11S2[ARKL<Y_P@?AG_H%K_P!_
M7_\`BJ/^$#\,_P#0+7_OZ_\`\571T4<TNX<J."\,>#M`O-/NGGTY79;V=`?,
M?A0Y`'7TK:_X0/PS_P!`M?\`OZ__`,53O!__`""[S_L(7/\`Z,-=#52E*^XH
MQ5CG/^$#\,_]`M?^_K__`!5'_"!^&?\`H%K_`-_7_P#BJZ.J&MR/%H.HR1LR
M2):R,K*<$$*<$5/-+N/ECV,O_A!/#7_0+7_OZ_\`\51_P@?AG_H%K_W]?_XJ
MO(_"_P`9M6T](X-<B_M*W''GIA9E'OV;]#7L?A_Q?HGB:#S-+ODE<#YX6^61
M?JIYK2<:D=V3%PEL0?\`"!^&?^@6O_?U_P#XJC_A`_#/_0+7_OZ__P`571@Y
MI:SYI=R^5=CF_P#A`_#/_0+7_OZ__P`51_P@?AG_`*!:_P#?U_\`XJNDHHYI
M=PY5V.;_`.$#\,_]`M?^_K__`!58NC^#M`GUSQ!#+IRM'!=1K$OF/\H,*$]_
M4FN^KG=!_P"1C\3_`/7Y%_Z(CJE*5GJ2XJZT&_\`"!^&?^@6O_?U_P#XJC_A
M`_#/_0+7_OZ__P`572"BIYI=Q\J['-_\('X9_P"@6O\`W]?_`.*H_P"$#\,_
M]`M?^_K_`/Q5=)11S2[CY5V.;_X0/PS_`-`M?^_K_P#Q5'_"!^&?^@6O_?U_
M_BJZ2BCFEW#E78YO_A`_#/\`T"U_[^O_`/%4?\('X9_Z!:_]_7_^*KI**.:7
M<.5=CF_^$#\,_P#0+7_OZ_\`\52_\('X9_Z!:?\`?U__`(JNCHHYI=PY5V/F
MCXCV%MI?C>\M+*/R8$6,J@8G&4!/6BK7Q7_Y*'?_`.Y%_P"@+17K4G[B/.G;
MF>AZ'\8?^09HG_813^5=IKVD'6;!8H[AK:XAE6>WG"[O+D4Y!([CL1Z&N+^,
M/_(,T3_L(I_*O2:\YNU.+]3N2O.7R.9GT;6M9TVZM-9O[2,2(!$+*)OD<,&#
MDL<DY`XZ54O=*UJ2"YU/5IH9Y[2QGCM8=.C92S.N"V6S\V!@`5?O]32P\1W)
M8W3F#2GN3$)0(F"O_=Q][W]*;I?BJ2_O;*"XTFXLHM0B,EI+*ZG?A0Q!4<J<
M'(SU'I4KF2N@TV.8\&21VNJVMMILFFW@N(B+UK2P:![?"Y!9\D'+<8X]:Z2W
M\,W$.@Z%IYN(C)IUU'/(X!PX4MD#W^:M#7-<_L060%G-=R7D_D1QQ$`[MK$=
M>W'X=:QV\;7217N[P[=^=IQS?*)4VQ+C<"K?QG;S@4/FEJ@7*M&/D\+WHTN:
M&"Z@%T-5;48&="4^_N",!STSR*NQZ'--JM]>W[PNEY81VLL48(&X;MQ&>QW<
M=ZMVVMQ76L-81Q-@6:7:RYX*L2`,?A^M8*Z]<:GJ?AZ[M(Y4CNK>[<VGFX$C
M*`%!/3KT/;-'O,?NH2R\%3#PQ?Z9J%\L]U=,NVX5,A5C`$0*GK@*,CODUIZ!
MI%[87$DEW;Z-#E`J_P!GVIC+>[$_R%85MXAU*^\)17NJ6\]L3>1(DUI<(&ES
M-MQ@#@#@'U&:U;SQ?+;SZDD&BW5S#ILFVZE1U`5=H;*@_>(!^Z/3WIM3V$G%
M%O6M)OI]3M-5TJXMX[R"-X62Y1FCDC;!/W>000"*Q=1T:?2?!.L?:[P371N'
MOHITBP1+N5DPO^\`/H:LGQ!%:Z_JU]-<R/IL.FV\Z(#D?,7Y4>I^45>T;Q-_
M:FH-I]S9?9+GRO.C47"3!TS@\J>""1Q2]Y('RME5=!U"+PM9:=`NG3R[2UVE
M_"725V^9CQT.XFI-/\,W%BF@*;M9?[-\TR$J?FWJ0`O)P!G`SV%7-;U]M)NK
M.RM[(W=Y=[C'&9EB4A<9^9N,\C`J*\\17,5Q#9V6CSW=\T`N)8#*D8A0G'S,
M>,YR`!Z&DN9C]U&5J'A75YX=4T^UU"TCTZ^N#<_O(F,JL2"R9SC;D=>M;`T6
M87^NW'FIMU&)(XQ@_(50KS^=9:Z^;#6->O+\SI;6]M:.MLS`E'<-\H&<;B<"
MI4\:JEKJ+7FGF&XL[8W?DI<)*)(QP<,O`.>Q]J;4A7C<;%X=U?3?L,^EWEF+
MF.PCLKA;B)F1@GW77!!R"3P>#FKJ:1J=OXBBU&*[MY8Y+9+>\$L9#-M)(9,<
M#.>AJ-_%-REM;DZ)<"[O)"MG:F5-TBA=Q=CT0`=<^U1R>,T@T^XDN-.EAO[>
MX2U>T>50`[_</F?=VD'[U)\P_=*UMX5U+3;/2Y+"[M1J%BDL3><C&*6.1]Q!
MQR"#@Y]JFC\+W1BAEFNXI+U]334+IPA5#M&-B#K@#`&?K4USJ4SSZ"UW;7EE
M//>-&88[A2IPC'YB,[U(&>,<XJ?1?$<NM7,ABTV1+`,Z)=><A)93@AD'S+G!
MQG]*=Y;A[MRS9:9+;>(-3U%I%,=VD*H@!RNP,#GZYJCIO_(]ZY_U[6W_`+/7
M1USFF_\`(]ZY_P!>UM_[/4IWOZ#['25RGCFVGCT.\U2VU/4+6:VARB6\VU"<
MCDC')YKJZS/$&EOK.@WFG)*L37$>P.PR%Y]*(NS')71A17=[HVJ0Z/8Q7>JS
M7-O]J,M]><1`,%(SMX'/&!R?2HHO$/\`9=M=26]C<7,DNMO9^4UQN)8]U)&%
M7(^[T'K70+I+KXCBU3SEV)8FU\O;R3O#9S^%9G_"*394_:TXUK^T_N'[O]SK
MU]ZI./4FTBL?%FMJU_;_`/"/*UWIZB2Y`NQY?EE=PV-MRS$`\$`<=:DU+QM'
M;M9QV:6KRW-JMW_IEVMLJQM]T9(.6/H!VZUIG1)/MVN7'GKC4H4B5=OW-J,N
M3Z]:RI?"%U$-/GLY[%[JWLDLY5O+;S8Y%4<,!D%2#GOT-"Y>HGS"-XV:YBTL
MZ99PRR:A"TJ"YNA"ORG:45L$,^<\#L,U,VK:]_PFT=@EI;_86LUE=7GPR@L`
MS<*<D<C&<'KFG:KX>U2_TJ'3UN-*:%HBDZS6.5#'^.,!AM(SQG/2I_\`A'[R
MVU;3;RSOHRMO:BSN%N8R[21@@[@01AN.^1S1[H_>*DGBV6#7X=-O+6S2.>?[
M.@2^5YU)SM9H@.%./4XR*6?PXY$GV:UBA?[>;A'0*O`3Y#QVW=O<U4MO!%Y!
M>6O^FV9MK6^^UJPM<3RY8DAY,\]>H';FNVI-I;`DWN8FAV5W;W%Y<WD82:[\
MN5P'W!6P<J/9>!^%;=%%0]2T<Y>_\E#TC_L'W/\`Z'%71USE[_R4/2/^P?<_
M^AQ5T=7+9>GZL2ZA1114#`]*YO6Y[N]UZRT*VNY+..6"2YN)X<"0HI"A5)^[
MDGD]>*Z2L76=%N+R\M-2TZ[2UU"T#(C21[XY$;&4<9!QD`Y!SQ51M?43VT,E
M+B\\-ZY]B:_N+^RGLI;F(73!I(WCP2-^.5(/?IBI(O%&JRZ'%JK:5:VT$ZH\
M37=^L8"D9RYV\=L`9SGG%6(?#U]<7%U?:K?0S7LEJ]K"((BD4"-U(!))).,D
MGM45[X6N9M)T.""XM6N-*15`N8#)#+\FPDKD'/<<\57N]2/>Z&?+X@;6K70K
MJ+,#?VRMO,L4V]&*A\X8<,IX-=%XAUV+P_IRW4BJ[R2+#$CR"-6=NFYCPHZD
MGVK)L_!]Q;6MI$]["[0ZJ=0<I#L5@0?E"@\=:UO$.B?VW81Q)*D4\$JSPN\8
MD4.O9E/4$$@_6A\MT-<UC#3QZG]EW\[V]LUS9R11N+>[62`^8<*QE`X4<Y)'
M&*=K&N^((M(TVXMK*TCGGO4B<"[#HZD\;6V]&[G`(]ZO0:/K$6FW""?2([J1
MUPL5B1"5'4,-V3G/7/%4X_!]U#H+6L5Y;Q7GVX7\?EP$01N"#M5,Y"\>O<FA
M<MQ/F+9U[4VUQ-(BTF)YUMX[BXD^TXCB#$@@';ECQQQS[5G:=K[6VEV\&GV<
MUS>7=[<QPPSW.>$=MSLY'"CT`.,@"MVQTFYAUR;5+F>)Y)K2*!UC0J-REB2,
MD\'=T]JRD\)7EK:VLEG?Q)J%I=7$\3O$6C996)9&7.>A'(/44+E#WBGJVNW-
M[IOV>:![&_M-5M(IXXY=RD,ZD%6&,J1Z@=P:[FN4;PE<SVTLES?1/?W%]!=S
MR)$5C`B(PBKG(&!U)/6NKI2M;0J-[ZA1114%!7%?%&>6V\&27$$C1S17$;HZ
MGE6!R"*[6N7\=6\5WHUI;3H'AFU"W21#T92X!%5#XD3+8\&A\9>+I8E?^W=3
MY_Z:=:?_`,)?XN_Z#NI_]_*]<U#X=Z9YW^B62QH.``[?XU3_`.%=6_\`SP'_
M`'T:ZO;T_P"4Y_8S[GF'_"7^+O\`H.ZG_P!_*/\`A+_%W_0=U/\`[^5Z?_PK
MJW_YX#_OHT?\*ZM_^>`_[Z-'MZ?\H>QGW_$\P_X2_P`7?]!W4_\`OY2?\)?X
MN_Z#NI_]_*]0_P"%=6__`#P'_?1H_P"%=6__`#P'_?1H]O3_`)0]C/O^)YA_
MPE_B[_H.ZG_W\H_X2_Q=_P!!W4_^_E>G_P#"NK?_`)X#_OHT?\*ZM_\`G@/^
M^C1[>G_*'L9]_P`3S#_A+_%W_0=U/_OY1_PE_B[_`*#NI_\`?RO3_P#A75O_
M`,\!_P!]&C_A75O_`,\!_P!]&CV]/^4/8S[_`(GE_P#PE_B[_H.ZG_W\J.X\
M3^*+NWDM[C6=1EAD7:Z,^0P]#7JG_"NK?_G@/^^C6;K_`(&CT_P_?WD4062&
M$NK9/!IJO3OM^`.E-=3@1XN\6JH4:[J8`&`/,I?^$O\`%W_0=U/_`+^5Z9'\
M/('AC8P`EE!/S'TI_P#PKJW_`.>`_P"^C1[>GV#V,^YYA_PE_B[_`*#NI_\`
M?RC_`(2_Q=_T'=3_`._E>G_\*ZM_^>`_[Z-'_"NK?_G@/^^C2]O3_E#V,^_X
MGF'_``E_B[_H.ZG_`-_*/^$O\7?]!W4_^_E>G_\`"NK?_G@/^^C1_P`*ZM_^
M>`_[Z-'MZ?\`*'L9]_Q/+_\`A+_%W_0=U/\`[^4O_"7^+O\`H.ZG_P!_*]/_
M`.%=6_\`SP'_`'T:/^%=6_\`SP'_`'T:/;T_Y0]C/O\`B>8?\)?XN_Z#NI_]
M_*/^$O\`%W_0=U/_`+^5Z?\`\*ZM_P#G@/\`OHT?\*ZM_P#G@/\`OHT>WI_R
MA[&??\3S#_A+_%W_`$'=3_[^4?\`"7^+O^@[J?\`W\KT_P#X5U;_`//`?]]&
MC_A75O\`\\!_WT:/;T_Y0]C/O^)Y>?%WBTC!UW4_^_E16WB;Q/9VT=O;:QJ,
M4$:A4C1\!0.PKU1OAW`$8^0.`3]XUF^'?`\>H^'-.O98@TD\"NS9/)-5[>G:
M]OP%[*=]S@_^$O\`%W_0=U/_`+^4?\)?XN_Z#NI_]_*]/_X5U;_\\!_WT:/^
M%=6__/`?]]&I]O3_`)1^QGW/+_\`A+_%W_0=U/\`[^4O_"7^+O\`H.ZG_P!_
M*]/_`.%=6_\`SP'_`'T:/^%=6_\`SP'_`'T:/;T_Y0]C/O\`B>8?\)?XN_Z#
MNI_]_*/^$O\`%W_0=U/_`+^5Z?\`\*ZM_P#G@/\`OHT?\*ZM_P#G@/\`OHT>
MWI_RA[&??\3S#_A+_%W_`$'=3_[^4G_"7^+O^@[J?_?RO4/^%=6__/`?]]&C
M_A75O_SP'_?1H]O3_E#V,^_XGF'_``E_B[_H.ZG_`-_*3_A+_%W_`$'=3_[^
M5ZA_PKJW_P">`_[Z-`^'5OD?N!_WT:?MZ?\`+^`>QGW/*H/$WB>U1D@UC4(E
M9V=@KXRQ.2?J34W_``E_B[_H.ZG_`-_*[O0O!$=_93RR1;BEW-$"2>BL0!6I
M_P`*ZM_^>`_[Z-#KT[ZH%1G;<\P_X2_Q=_T'=3_[^4R7Q5XJGA>*76]2>.12
MKJ9.&!X(KU+_`(5U;_\`/`?]]&JVH^`8;;2[RX6$!HH'<'<>"%)H5>G_`"A[
M&?<\-=1;RLK'@=0>HIL5X()UGMYI(ID.4DB)5E^A%.M=.O-4F\NWB>1CR<#^
M9KM]#^'>YE>])=O^>4?]3_A6DZJ2U(5-MZ&[X*^*OB,W$=A?63ZO$<#S8P%F
M4>I/W3^./K7M]O<)<1*ZGJ.GI7!Z)X1%O&JI$L,8_A48KM[*S%I$%!)KAG)-
MZ*QUQ32U+=%%%04%<[H/_(Q^)_\`K\B_]$1UT5<[H/\`R,?B?_K\B_\`1$=-
M;,75'1"B@44AA1110`4444`%%%%`!1110!\Y?%?_`)*'?_[D7_H"T4?%?_DH
M=_\`[D7_`*`M%>K2^!'FU/B9Z'\8?^09HG_817^5>DUYI\8V*Z7HI"EL7X.!
MWP*Z;_A)[_\`Z%36/_(7_P`77`TW3C;S.Y.TW\B35-"N;[5;N[CDC5)M*DL5
M!SD.QR"?:G+H=P)_#LADCQIB,LO7Y\Q;/E_'UJ'_`(2?4/\`H5-8_*+_`.*H
M_P"$GU#_`*%36/RB_P#BJGWQ^Z7]9TN;4;W2)HG15LKO[1(&SEEV,N![_-5.
M;0;F1?$@$D7_`!-5`AZ_)^Z"?-^//%,_X2?4/^A4UC\HO_BJ/^$GU#_H5-8_
M*+_XJDE-!>-R-]"U>UO[2[TRXLQ)]A2RN!<*Q`"G(=,=3R>#C/K3=)\,7FG-
MX?,L\,G]FPSQRE0?WADQ@C\N:F_X2?4/^A4UC\HO_BJ/^$GU#_H5-8_*+_XJ
MG[X>[>Y23PQJW]A'1Y)[,P0WL<]O*NX,4$WF$.,8!QP,546RUJ_U+Q3:Z=<6
MD5M<W8BF,Z,7C!A0%DQP3@]#Z5L?\)/J'_0J:Q^4?_Q5(/$U^.GA/5_RB_\`
MBJ:<Q6B5[OP;]J_M&#SE2UN-/@LXOEW,AB+$$CH1R./K5KP[HEUIUT\MSIVA
M6O[O8K:=;E'<\9))`P..G/UXI/\`A)]0_P"A4UC\H_\`XJC_`(2?4/\`H5-8
M_*+_`.*I/G:LQ^[>Y/XGTJ]U:W2WM[;2[B`@[TOE?Y6[,I7D$<^GUJ@GA_6M
M-EM+G3+VVGN5LDL[DWJMB3:25<%><C)X/7/6K'_"3ZA_T*FL?E%_\51_PD^H
M?]"IK'Y1?_%4)32L#Y6[E:]\(W&I#6!=743-?06RJ_E9Q)%D[F7IM)(XSTS4
M2>%KZ71M4M'L=!L9KJV,"/80,N2>I8X!Q[`&KW_"3ZA_T*FL?E%_\51_PD^H
M?]"IK'Y1?_%4>^*T2?5M(O9Y--O=.EA2^L-P59P3'(K*%93CD=`0?:J:Z#JH
MM=0N)?[,N=0U"5#/#/&QMO+5=H0=SZY(Y/:I?^$GU#_H5-8_*+_XJC_A)]0_
MZ%36/RB_^*HM,?NE2P\*7MI!I*O/#_H=^]VT2;BD:LC*(X\\X!;O[]*EL/#^
MI)XF75KH:=!L1U<V*NK76>AD!XXZ]SGO4W_"3ZA_T*FL?E%_\51_PD^H?]"I
MK'Y1?_%4/G8>Z=+7.:;_`,CWKG_7M;?^STW_`(2C4/\`H5-8_P#(?_Q58ECX
M@O4\7:O./#>J,\D%NIB'E[DQOP3\V,'M]*48.S!R5T>@T5S/_"3ZA_T*FL?^
M0_\`XJC_`(2?4/\`H5-8_*+_`.*I<DBN9'345S/_``D^H?\`0J:Q^47_`,51
M_P`)/J'_`$*FL?E%_P#%4<D@YD=-17,_\)/J'_0J:Q^47_Q5'_"3ZA_T*FL?
ME%_\51R2#F1TU%<S_P`)/J'_`$*FL?E%_P#%4?\`"3ZA_P!"IK'Y1?\`Q5')
M(.9'345S/_"3ZA_T*FL?E%_\51_PD^H?]"IK'Y1?_%4<D@YD=-17,_\`"3ZA
M_P!"IK'Y1?\`Q5'_``E&H?\`0J:Q^47_`,71R2#F0Z]_Y*'I'_8/N?\`T.*N
MDKSZZ\07K>-=-N#X;U172RN%$)\O<P+1_,/FQ@8_45M_\)/J'_0J:Q^47_Q5
M5*,K(E26ITU%<S_PD^H?]"IK'Y1?_%4?\)/J'_0J:Q^47_Q53R2*YD=-17,_
M\)/J'_0J:Q^47_Q5'_"3ZA_T*FL?E%_\51R2#F1TU%<S_P`)/J'_`$*FL?E%
M_P#%4?\`"3ZA_P!"IK'Y1?\`Q5')(.9'345S/_"3ZA_T*FL?E%_\51_PD^H?
M]"IK'Y1?_%4<D@YD=-17,_\`"3ZA_P!"IK'Y1?\`Q5'_``D^H?\`0J:Q^47_
M`,51R2#F1TU%<S_PD^H?]"IK'Y1?_%4?\)/J'_0J:Q^47_Q5')(.9'345S/_
M``D^H?\`0J:Q^47_`,51_P`)/J'_`$*FL?E%_P#%4<D@YD=-17,_\)/J'_0J
M:Q^47_Q5'_"3ZA_T*FL?E%_\51R2#F1TU<WXQ_X\-/\`^PG;?^C!3?\`A)]0
M_P"A4UC\HO\`XJL3Q/X@O;FSLE?PWJD.V_MW!?R_F(<?*,-U/:JA"7,B925C
MT"C`]*YK_A*-0_Z%36/RC_\`BJ/^$GU#_H5-8_*+_P"*J>217,CI<#THP/2N
M:_X2?4/^A4UC\HO_`(JC_A)]0_Z%36/RB_\`BJ.20<R.EP*,#TKFO^$GU#_H
M5-8_*+_XJC_A)]0_Z%36/RB_^*HY)!S(Z7`]*,#TKFO^$GU#_H5-8_*+_P"*
MH_X2?4/^A4UC\HO_`(JCDD',CI<"C`]*YK_A)]0_Z%36/RB_^*H_X2?4/^A4
MUC\HO_BJ.20<R.EP*P?&@'_"%ZO_`->S5!_PD^H?]"IK'Y1?_%UD>*O$-]<>
M%M2A?PUJD"/`P,LGE[5]SAJ<8OF1,I*S.XM@/LL/^XO\JDP/2N7@\37XMXQ_
MPBNKG"#D"/T_WJ?_`,)/J'_0J:Q^47_Q5+DD-21TN!1@>E<U_P`)/J'_`$*F
ML?E%_P#%4?\`"3ZA_P!"IK'Y1?\`Q5')(?,CI<#THP/2N:_X2?4/^A4UC\HO
M_BJ/^$GU#_H5-8_*+_XJCDD',CI<#THP/2N:_P"$GU#_`*%36/RB_P#BJ/\`
MA)]0_P"A4UC\HO\`XJCDD',CI<#THP*YK_A)]0_Z%36/RB_^*H_X2?4/^A4U
MC\HO_BJ.20<R.EP/2C`]*YK_`(2?4/\`H5-8_*+_`.*H_P"$GU#_`*%36/RB
M_P#BJ.20<R.CE`\E_P#=-8/@?_D1]%_Z]$_E4+^)]0,;#_A%-7Y![1__`!58
M_A+Q#>VWA'2H8_#>J7"I;*!+'Y>U^.HRW2JY'RD\RYCOL"C`]*YK_A*-0_Z%
M36/RC_\`BJ/^$GU#_H5-8_*+_P"*J>217,CI<#THP/2N:_X2?4/^A4UC\HO_
M`(JC_A)]0_Z%36/RB_\`BJ.20<R.EP/2C`]*YK_A)]0_Z%36/RB_^*H_X2?4
M/^A4UC\HO_BJ.20<R.EP/2C`]*YK_A)]0_Z%36/RB_\`BJ/^$GU#_H5-8_*+
M_P"*HY)!S(Z7`]*,"N:_X2?4/^A4UC\HO_BJ7_A*-0_Z%36/RC_^+HY)"YD/
M\'_\@N\_["%S_P"C#70X'I7`>&?$%[;V%TB>&]4F#7L[%H_+P"7/'+=1TK:_
MX2?4/^A4UC\HO_BJJ4)7%&2L=+@>E1W-O%=6TMO,NZ*5"CC.,@C!KGO^$GU#
M_H5-8_*+_P"*H_X2?4/^A4UC\HO_`(JIY)%<R(#X0LH/+M[&VBMK9.`D:X__
M`%_C6U9:-;V@&$!/TK,_X2?4/^A4UC\HO_BJ/^$GU#_H5-8_*+_XJFXR?_#B
MYD=*JA1@"EKF?^$GU#_H5-8_*+_XJC_A)]0_Z%36/RB_^*I<DA\R.FHKF?\`
MA)]0_P"A4UC\HO\`XJC_`(2?4/\`H5-8_*+_`.*HY)!S(Z:N=T'_`)&/Q/\`
M]?D7_HB.H_\`A)]0_P"A4UC\H_\`XJL71_$-[%KFOR+X;U21I;F-F1?+S&1"
M@PWS=>,_C34)69+DKH]`HKF?^$HU#_H5-8_*/_XJC_A)]0_Z%36/RB_^*I<D
MA\R.FHKF?^$GU#_H5-8_*+_XJC_A)]0_Z%36/RB_^*HY)#YD=-17,_\`"3ZA
M_P!"IK'Y1?\`Q5'_``D^H?\`0J:Q^47_`,51R2#F1TU%<S_PD^H?]"IK'Y1?
M_%4?\)/J'_0J:Q^47_Q5')(.9'345S/_``D^H?\`0J:Q^47_`,51_P`)1J'_
M`$*FL?\`D+_XNCDD',CQCXK?\E#O_P#<B_\`0%HJK\1[MKWQM>3SVTMD[+'F
M&?&\?(/0D45ZM-/D1YT_B9Z;\8?^0;HG_817^5>DBO-OC#_R#-$_["*?RKTG
MM7FR_AQ^9W1^-_(I7^K6&F/;)>W20-<RB&$-_&YZ"KF17`>(3=:WK6I6UOI-
MS?06MK]ECDADC413MAV;YF'(Q'T]ZEEO9?$?_"*@W=S:K=B=;Q+>0HQ9$^9"
M1T^8'D<^E3R:#YCN\BJEEJ-O?O="W9B;:=H),KC#C&<>O6N3C@M[W6=674-6
MO+5-+DBBMT2\:(1IL4AVY^<L21EL],5EW5I)%IWBC6X;Z\BN++4I)($CE*QJ
M1LSE1PV>ASGVQ34$P<K'I>11D&O-_&-]*9]5GLOM:S:;`K/,=2,$<#E=RA8P
M,2>^>O04[59M7U?7Y[.)9&6WLX981'J1L]K."3)@`[^1CG@8Z<TN0.<]&R*.
M*\ZU>YN[J&VM9_/GU&WTY9[B2'5#:P)G(W@J/G)(],8K>T;5-;N=&T29+"*[
M2XM8GN+E[D1LK$<G;M.>.>HI.&EQ\RO8VYM6L(-5M],EN42]N$+Q0GJX'4U<
MR*\RU&[O[V74M<M=&NK@07:26EVDD80109##!;=@_O,X'.16GXCF9[B+6OM%
MQ/H\=JDI2SO3#);Y.?-VY`D!&.">QP#3<!<YW61C-&17#:E)):^(UU.\GNIM
M.>6&.![6\*?9F.!M>'HP8D<\G#=*I7LC7.F^(-:GU>ZM]1T^YEC@CCN"B0[/
MN*8^C;N.H.=W%"@',>C9%5+/4(;R:ZCB$H:VE\E]\94;L`\$]1SU%<DH76=9
MU$ZQJ5U9"RA@:.*&Y,`C#(&9S@C=\V1SD?+BH+C4&$.MQ32WDQEUA;6VCBNC
M$3F-"%W_`,"]2<?A1R!S'=SW,%M"\T\J11)]YW.`/QJ2O*;@2W7A+Q+:7LDR
M1Z?=1&.,7S3^5D(2IDX+#))P>GX5K:Y#=1ZOINA6(GGLOLKSJK:H\#RONQS+
MRS;0<XSW]J?LPYST#-5+'4;?4/M/D,Q^SSM!)E<8=<9^O7K7%1#4+J70=&UJ
M_EC1X[AY'MKL@S,C`(AE7!)"DDXQDBI_#-O:7&CZC&^JS>0NLNR72W`5I2I7
M`+?Q`XP1WI<ED'-J=S7.:=_R/>N?]>UM_P"SUT?:N<TW_D>]<_Z]K;_V>DMF
M4]T=)1114C"BBB@`HHHH`****`"BBB@`HHHH`YN]_P"2AZ1_V#[G_P!#BKI*
MYR]_Y*'I'_8/N?\`T.*NCJY;+T_5B74****@84444`%%%%`!1110`4444`%%
M%%`!1110`4444`%<WXQ_X\-/_P"PG;?^C!725S?C+_CPT_\`["=M_P"C!50^
M)"EL='2T45(PHHHH`****`"BBB@`HHHH`*P/&G_(EZO_`->S5OU@^-/^1+U?
M_KV:JC\2%+9FS;?\>L/^XO\`*I:BMO\`CUA_W%_E4M2-!1110`4444`%%%%`
M!1110`4444`,E_U+_P"Z:P?`_P#R(VB_]>B?RK>E_P!2_P#NFL'P/_R(VB_]
M>B?RJOLO^NY/VCH:***DH****`"BBB@`HHHH`***8TBJZJ6`+=!GDT`8/@[_
M`)!EY_V$+G_T8:Z&N>\'_P#(+O/^PA<_^C#7054MQ1V%HHHJ1A1110`4444`
M%%%%`!7.Z#_R,?B?_K\B_P#1$==%7.Z#_P`C'XG_`.OR+_T1'36S%U1T-+0*
M*0PHHHH`****`"BBB@`HHHH`^<?BN/\`BX=__N1?^@+12_%?_DH=_P#[D7_H
M"T5ZM+X$>=-OF9Z'\8?^09HG_813^5>DCI7FWQA_Y!FB?]A%/Y5Z2*\^7\./
MS.V/QR^1!;V<%KYOV>%(O-D,C[1C<QZL?>H(M)L8)4EBLH4>.1Y495P5=_O$
M>Y[U?ILF[RGV??VG;]:R-#FKZY\(7/B"**_;3Y-6A(5#*H+(>PW=`?0$UIWE
MKI=KIM\;N&!+*3=-=;U^5O5F]>@K$\'MIS>"+<W!@P6;[;YV/]?O.[?G^+=Z
M^U'B2\U*?PUKT5WI:VMNEK)Y<PN5D\ST^4#C(YJ[:V(OI<DUV;P=!?12ZVEA
M]J>',;31;F,?3K@\5/K"^%+K2[74-633YK,`"WFD4,"#T"]STZ#TK-NH]3D\
M86JZ5<6L,O\`8Z[VN86D!'F=@&'.:IZ-I<E_X?L%L;B&TU32+V=8F?\`>PS.
M"0YQP=IW=N5JN56O<GF=[6.G73_#_B&UM+U;.RO88EQ;R&,$(!Q@<<8QTK0"
M6NGV.P"*WM8$QR0J(H_D*S?#NM'4M-:2XB@MKF.YDMI4CD#(\BGDH>X/7UZU
M4\;F/^R;/[01]B.H6_VO=]WR]W\7^SG;FHLV[%W25RSH^M^&[M!I>E7=JRJA
M"V\8P-O?`/4?2F6VC^&M3??'IEI*VG2&U4O!_JBG\(SV&?I5;Q=Y3?V&L00W
MO]I0FU"XW;0?G(_V=N<]JYV:-H-/\4ZM!K%S;W-CJ,SPPQR[8PWRX#)_%NZ<
M_A5J-U=$\VMCNI-"TF35!J;Z;;-?+@B<Q@OQT.?6DGT+2+G4EU&?3;62\3&)
MWC!88Z<^U<7J<_B#5M<U.*S2Z5[)(Q"(=06W6(L@;>Z$?.,GOQA<5;U634;:
M_AU35)[O[#'%!N;3[O:+:4_>+Q_\M%)(YYX[5/*^X^9=C>N8O#VJWTT]]:VT
ML^FR+&TUS%C8Q`(`9A@CD?C5Z?1M-N(+F">Q@DBN7\R='0$2-@#<??@?E7#^
M(=]_I_BA+BZN?+M=2M_*59BH4%8\CZ<DX]>:UM4O&\'W\4[W-S-I\ME)&JW$
MS2'STRR\GNP)'O@4W%]&+F74Z&#1-+M;2:T@T^VBMYEVRQ)&`KC&.1WXKGS<
M^#+IK?P^UG!);Q3&*!6M6\@2\Y57QMW=>`:W-'AN--\-V_VZ:6>YCA\R=V.Y
MBQ&YA^'0?2O.X;UM*L;?7-1^;0YV>\TZ")MR6UPV2JR=VR2<8X4D@^M$%>X2
M=CT>?0-)NM.AL)M-M7M(2#'"T8VICT':G_V+IIM_L_V"W\GS1-Y?EC;Y@QAL
M>HP/RJQ823S:=:RW(07#Q*T@3[H8@9Q[9JQ479=D]1*YS3?^1[US_KVMO_9Z
MZ2N;TW_D>]<_Z]K;_P!GIK9@]T=)4-U=065M+<W,JQ0Q*7=V.`H'4FIJSM;@
ML;K1[NWU*18K.6/9*[/MV@\9SVYI+<'L4H_&&D26DUT7N8H8=A=IK62/"N<*
MWS`97/<<"KUWK5C977V::4B7[.]R0JEL1IU8XZ>WK7.Z//-=WM[X9O[VWUBS
M^QAA=1@!@K';LDV_+NQR",9P>*SM#M'7PAXAO+F<W%TL4]D)6'(BA5E4?S)]
M2:OE1',SK(O$VDS:%%K,=R6L9655<(<Y+;0",9!R<5JO(D4;22,%1`69B<``
M=37E&K*=%T:TA&18ZP+.6/`XCN5*;A[;E&?JIKK?%*Z_<:+K<`M[+[&UI*(F
MCE<S-\O`V[<>O>AP5QJ3-'3O%>D:I>):VT\OF2J7A,D#QK,HZE"P`8?2K-OK
MVF76LSZ3;W2RWL$?F2QH"=@SCD],\].M<U=7UCJ=UX1CTRXAFD6<3@1,"4A$
M1#$XZ#D#GOQ4T,VG6_Q$2."6TC4Z<R[4=1^\,P)'^\?SHY4+F9JW?B_1;&^D
MM9[EPT3!)I%A=HX6/0.X&U3R.I[TW5_%6G:+>V]K=-())F`&$/(()^7CYSD`
M87)RPKEQ?65MX-\3V%Y/&+PW5VC0,P\QVD8^7A>IR&7%=(?"MAJ-M82:E;[[
MJ&&-9"3G=A"I!].23Q@Y`]*;C%;AS2>QOQN'0.`0&&0",'\J?38T6*-40850
M`!GL*=61H<Y>_P#)0](_[!]S_P"AQ5T=<Y>_\E#TC_L'W/\`Z'%71U<MEZ?J
MQ+J%%%%0,****`,?4?$VF:9=_9)7GEN0N]HK:W>9D7L6"`X!]ZNZ?J5GJEFE
MW93K-`^=KKZC@@^A!XP:YS0KZSL-<\16U[<0V]X]]YW[YPA>(HH0C/4#!'X&
ML!U%];2S6TTL5AJ'B2/R9(6V%T*A792.S$'G\:TY$]".9GIA/'>J*:I!)K,V
MEJ)/M$4"SL<?+M8D#!]<@UYSXK2SM'U&VL888&TJV5DENM2EC9"P++Y*`G)S
MW/4\5T^CR-+XVFD=MSOHULS$]R7>CDTN'/K8ZW.>E4M+U.#5K!+RW#B-V=0'
M&#E6*G]0:YG6Q87GC'[+K5RT-C%8>?;J9S$K2;R&;((R5&WCWK#TBUBU+3/"
M5F]Q.UK//?;RDA0S("Y`8CGGC-"A=7!SLST_<*-PSCG\JX2:]M-)N_%MM-=+
M;JEI#Y"22D';Y)4;<G)Y&..]8.L74+PZ5;7C0R(=%A,:W6H&U5)&&/,!S\Y]
M>XX]:%3;!SL>LY!-+69H%FEAH5C:QRI*L4*CS4;<'..6!R>IR:TZSZE(****
M!A7-^,O^/#3_`/L)VW_H8KI*Y#XCACX5VH"7-S%@+USFCFY=29:(ZK[3!_SV
MC_[[%'VF#_GO'_WV*\FMX;T0()K&-Y,?,V[&:D\JX_Z!\?\`WU_]:O*_M&7\
MGXF/MGV/5?M,'_/>/_OL4?:8/^>\?_?8KRKRKC_H'Q_]]?\`UJ/*N/\`H'Q_
M]]?_`%J/[1E_)^(>V?8]5^TP?\]X_P#OL4?:8/\`GO'_`-]BO*O*N?\`H'1_
M]]?_`%J/*N?^@='_`-]?_6H_M&7\GXA[9]CU7[3!_P`]X_\`OL4?:8/^>\?_
M`'V*\J\JY_Z!T?\`WU_]:CR;G_H'Q?\`?7_UJ/[1E_)^(>V?8]5^TP?\]X_^
M^Q1]I@_Y[Q_]]BO*O)N?^@?%_P!]?_6H\FY_Z!\7_?7_`-:C^T9?R?B'MGV/
M5?M,'_/>/_OL5A>,IXG\&ZLJ2HS&V;`#`DUP_E7/_0/B_P"^O_K4>5<YS_9\
M7_?7_P!:FLQDG?D_$3K.UK'J%M<P"UA!FC^XO\8]*E^TP?\`/>/_`+[%>4^5
M<_\`0/C_`.^O_K4>5<_]`^/_`+ZI?VC+^3\1^V?8]6^TP?\`/>/_`+[%'VF#
M_GO'_P!]BO*?*N?^?"+_`+ZH\JZ_Y\(O^^J/[1E_)^(>V?8]6^TP?\]X_P#O
ML4?:8/\`GO'_`-]BO*?)NO\`GPB_[ZH\JZ_Y\(OSH_M&7\GXA[9]CU;[3!_S
MWC_[[%'VF#_GO'_WV*\I\JZ_Y\(OSH\J[_Y\(OSH_M&7\OXA[9]CU;[3!_SW
MC_[[%'VF#_GO'_WV*\I\JZ_Y\8OSI/)N_P#GQB_.C^T9?R_B'MGV/5_M,'_/
M>/\`[[%'VF#_`)[Q_P#?8KRCR;O_`)\8OSH\F\_Y\HOSH_M&7\OXA[9]CU66
MY@\I_P!]']T_QBL'P3-$G@G1E>5%86B`@L`1Q7$>3>?\^45)Y%[_`,^<6:?]
MI2M;D_$7MG>]CUC[3!_SWC_[[%'VF#_GO'_WV*\G\B]_Y](J/L][_P`^D-+^
MT9?R_B/VS['K'VF#_GO'_P!]BC[3!_SVC_[[%>3_`&>]_P"?2'\J/L][_P`^
ML/Y4?VC+^7\0]L^QZQ]I@_Y[1_\`?8H^TP?\]X_^^Q7DWD7W_/K#^5)]GOO^
M?:'\J/[1E_+^(>V?8]:^TP?\]X_^^Q1]I@_Y[1_]]BO)?LU]_P`^T/Y4?9K_
M`/Y]X?RH_M&7\OXA[9]CUK[3!_SVC_[[%<+\2KH);Z7)!-ATG8AHWY''J*Y_
M[+?_`//O#^55K^":.T9KJ.!8^G3G/;'O4SQTIQ<>6WS$ZK:M8T]!\4W>AQ>4
M\/VJUDD:4G.)`6.2<]#S7H&D^(--UA,VMP#(!EHG^5Q^%>*2:REBBP>5YK8R
M><;:;#J$UU*KPVC(X/RNKX(_&BCB:T?B5T$)R1]`Y%+7">%-=U0XAU&=)H\8
M4D?./J>AKN48.@([UZL)<RO:QT)W5QU%%%4,****`"BBB@`KG=!_Y&/Q/_U^
M1?\`HB.NBKG=!_Y&/Q/_`-?D7_HB.FMF+JCHA1112&%%%%`!1110`4444`%%
M%%`'SE\5_P#DH=__`+D7_H"T4?%?_DH=_P#[D7_H"T5ZM+X$>;4^)GH?QA_Y
M!FB?]A%/Y5Z2*\V^,/\`R#-$_P"PBG\J])%>?+^''YG='XY?(6CM1161H9$G
MAK1I=2_M&33+5KS.[S2G)/J>Q/OUK0N;6&\M)+:YC66&52KHW1@>QJ>BB["R
M,C4?#6CZM)%)?Z?#.\2>6C-G*KZ<=JQ];/A&U^S:/J-BK""/S(8(;223RU)Q
MD;`<9(/UKKZYDS10_$*X\R5(P=+CQN8#/[UJJ+9+2('719K31]3L,3:792XM
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M3VL%W:WYCCEGU-XC`BD;5\G&TJR^O7=247T8<R['H4FD:?*EY')9Q/'>G-RK
M+D2G`'/X`5G:EX9@NK/2M/MXH(M/L[I)WB8$\)D@+_P+&?;-8=QML?&*7EY*
MUW'<7BPV\MO?,&MF(QY3PYP5R#R,GGFN\J6VBE9@>E8T7A308;M[N/2+,3OG
M+>6".>O'09_K6U28I7:V'9%>QL;?3K2.UM(4A@C^Y&G1>_%6:**0PKF]-_Y'
MO7/^O:V_]GKI*YO3?^1[US_KVMO_`&>J6S$]T=)4<T,<\;131I)&XPR.,AAZ
M$5)14C*UII]GI\9BLK2"VC)R4@C"`GUP!3EM+=(9(5@B6*0DN@0!6)ZY'?/>
MIZ*`*\EE;2PI#);PO%&041D!52.F`>F*GQQ2T4`5+;3+&SEDEM;*V@DEYD>*
M)5+_`%('-0_V#HXN/M`TFQ$^_?YGV=-V[KG.,Y]ZT:*+L5BI)IEC+>)>2V5L
M]TGW)VB4NOT;&15NBB@84444`<Y>_P#)0](_[!]S_P"AQ5T=<Y>_\E#TC_L'
MW/\`Z'%71U<MEZ?JQ+J%%%%0,****`*=[I=AJ)7[;8VUSL^[Y\2OM^F1Q4S6
MT+K&C0QLL1#1@J"$(Z$>F*FHQ1<"G/I=A=S+/<V5M-,JE5DDB5F`/4`D=.34
MR6L,<IE2&-9"H3>%`.T=!GT]JFHHNP*US86EYY9NK6"<Q-O3S8PVUO49'!I5
ML[=&C*6\*F,LR$(/E+?>(],Y.:L4478%2XTZSNIXYY[.WEFC!"221*S(#UP2
M.*Q;_P`.7K:FU[I=];6OF0)`T4]H)E15SC9R-O7D<C@5TM%--H3290T;2XM%
MTBVTZ%F>.!-H9L9/.2>.!R>E7Z**76XPHHHH`*YOQESI^GC_`*B=M_Z&*Z2N
M;\9?\>&G_P#83MO_`$8*J'Q(4MA]_P"'$N[AI,GDU4_X1%?[QKJZ6HLAG)_\
M(BO]XT?\(BO]X_G764460')_\(BO]X_G1_PB*_WC^==9119`<G_PB*_WC^='
M_"(K_>/YUUE%%D!R?_"(K_>/YT?\(BO]X_G764460')_\(BO]X_G6/XJ\,+;
M^%-4F#D%+=B.:]$K!\:?\B7J_P#U[-512YD3+9F;!X24V\1WGE%[^U2?\(BO
M]X_G73VW_'I#_N+_`"J6DTAHY/\`X1%?[QH_X1%?[QKK**5D,Y/_`(1%?[Q_
M.C_A$5_O'\ZZRBBR`Y/_`(1%?[Q_.C_A$5_O'\ZZRBBR`Y/_`(1%?[Q_.C_A
M$5_O'\ZZRBBR`Y/_`(1%?[Q_.C_A$5_O'\ZZRBBR`Y%_"2B-SO/W3W]JR/"7
MAA;GPAI,Q<[GME)YKT*7_4O_`+IK!\#_`/(C:+_UZ)_*JLN4G[14_P"$17^\
M?SH_X1%?[Q_.NLHJ;(HY/_A$5_O'\Z/^$17^\?SKK**+(#D_^$17^\?SH_X1
M%?[Q_.NLHHL@.3_X1%?[Q_.C_A$5_O'\ZZRBBR`Y/_A$5_O'\ZY?QIH#V<%B
ML"M))+*P"@9Z"O5*BFA64<@9Z`^E14@IQY1-75CP?3=%2Z9I68RL)&5@!T8'
M!'X&NRTOPQ+*%Q'L3V%:_@W1X/L-W(RY87]P/_(AKL4C2-<*,41H0IO0F,4E
M<Q].T"&T`)4%JVE7:,"EHK0L****`"BBB@`HHHH`*YW0?^1C\3_]?D7_`*(C
MKHJYW0?^1C\3_P#7Y%_Z(CIK9BZHZ(44"BD,****`"BBB@`HHHH`****`/G+
MXK_\E#O_`/<B_P#0%HH^*_\`R4.__P!R+_T!:*]6E\"/-J?$ST/XP_\`(-T3
M_L(K_*O2?PKS3XQH'TO10<\WZC@X/(KJO^$/L/\`G\U;_P`&,O\`\57`[>SC
M?S.Y7YV=#GVHS[5SW_"'V'_/YJW_`(,9?_BJ/^$/L/\`G\U;_P`&,O\`\56?
MN=_P+NSH<^U&?:N>_P"$/L/^?S5O_!C+_P#%4?\`"'V'_/YJW_@QE_\`BJ/=
M[_@%V=#^%9]_H6DZI*LM_IEI=2*-JO/"KD#TY%9W_"'V'_/YJW_@QE_^*H_X
M0_3_`/G\U;_P8R__`!5'N]_P%KV-A["VDMUMWMHF@0@I&4&U2#D8'L:@FT32
M[BZ-U-IMI)<LNUIGA4N1Z9QFL[_A#[#_`)_-6_\`!C+_`/%4?\(?8?\`/YJW
M_@QE_P#BJ/=[O[@U[&C<Z+IMY+YMUIUI/)O#[I858[@,`Y(ZX`I]_I-AJB(F
MH6-M=HARHGB5]I]LUE_\(?8?\_FK?^#&7_XJC_A#[#_G\U;_`,&,O_Q5%X]V
M'R-2XTFPNX8H;BPMIHH6#1))$I"$="H[4R?1=-NKY+V?3K26Z3&V:2%6=<=,
M$C-9W_"'V'_/YJW_`(,9?_BJ/^$/T_\`Y_-6_P#!C+_\51[O=AKV--='TU=1
M.HC3[47IZW`A7S#V^]C-7OPKGO\`A#[#_G\U;_P8R_\`Q5'_``A]A_S^:M_X
M,9?_`(JCW>_X#U['0Y]J,^U<]_PA]A_S^:M_X,9?_BJ/^$/L/^?S5O\`P8R_
M_%4>[W_`+LZ'/M1GVKGO^$/L/^?S5O\`P8R__%4?\(?8?\_FK?\`@QE_^*H]
MSO\`@%V=#^%<YIO_`"/>N'_IVM?_`&>G?\(?8?\`/YJW_@QE_P#BJP['PQ9O
MXPU>W-UJ02*WMV!%](&.=^<G.3TII1L]1-NZT.]S[49]JY[_`(0^P_Y_-6_\
M&,O_`,51_P`(?8?\_FK?^#&7_P"*I>[W_`=V=#GVHS[5SW_"'V'_`#^:M_X,
M9?\`XJC_`(0^P_Y_-6_\&,O_`,51[G?\`NSH<^U&?:N>_P"$/L/^?S5O_!C+
M_P#%4?\`"'V'_/YJW_@QE_\`BJ/<[_@%V=#GVHS[5SW_``A]A_S^:M_X,9?_
M`(JC_A#[#_G\U;_P8R__`!5'N=_P"[.AS[49]JY[_A#[#_G\U;_P8R__`!5'
M_"'V'_/YJW_@QE_^*H]SO^`79T.?:C\*Y[_A#[#_`)_-6_\`!C+_`/%4?\(?
M8?\`/YJW_@QE_P#BJ/=[_@%V-O/^2AZ1_P!@^Z_]#BKH\^U<%=>&+-?&VF6P
MNM2*26-PY8WTA8$-'T.<@<]/IZ5N?\(?8?\`/YJW_@QE_P#BJJ7+97?]7)3>
MNAT.?:C/M7/?\(?8?\_FK?\`@QE_^*H_X0^P_P"?S5O_``8R_P#Q53[G?\"K
MLZ'/M1GVKGO^$/L/^?S5O_!C+_\`%4?\(?8?\_FK?^#&7_XJCW>_X!=G0Y]J
M,^U<]_PA]A_S^:M_X,9?_BJ/^$/L/^?S5O\`P8R__%4>YW_`+LZ'/M1GVKGO
M^$/L/^?S5O\`P8R__%4?\(?8?\_FK?\`@QE_^*H]SO\`@%V=#GVHS[5SW_"'
MV'_/YJW_`(,9?_BJ/^$/L/\`G\U;_P`&,O\`\51[O?\``+LZ'/M1GVKGO^$/
ML/\`G\U;_P`&,O\`\51_PA]A_P`_FK?^#&7_`.*H]SO^`79T.?:C/M7/?\(?
M8?\`/YJW_@QE_P#BJ/\`A#[#_G\U;_P8R_\`Q5'N=_P"[.AS[49]JY[_`(0^
MP_Y_-6_\&,O_`,51_P`(?8?\_FK?^#&7_P"*H]WO^`79T.?:N<\8\V&G#UU.
MV_\`1@IW_"'V'_/YJW_@QE_^*K#\4>&+.VL[)DNM28OJ%NAWWTC8!<#C)Z^]
M5#EYEJ*3=MCO?PHS[5SW_"'V'_/YJW_@QE_^*H_X0^P_Y_-6_P#!C+_\54^[
MW_`=V=#GVHS[5SW_``A]A_S^:M_X,9?_`(JC_A#[#_G\U;_P8R__`!5'N=_P
M"[.AS[49]JY[_A#[#_G\U;_P8R__`!5'_"'V'_/YJW_@QE_^*H]SO^`79T.?
M:C/M7/?\(?8?\_FK?^#&7_XJC_A#[#_G\U;_`,&,O_Q5'N=_P"[.AS[49]JY
M[_A#[#_G\U;_`,&,O_Q5'_"'V'_/YJW_`(,9?_BJ/<[_`(!=G0_A6#XT_P"1
M+U?_`*]FIG_"'V'_`#^:M_X,9?\`XJL?Q7X6LK7PIJDZ76ILR6[$"2^E93]0
M3@TX\O,M12;LSM;;_CUAX_@7^529]JYN#PA8-;Q-]KU490'C4)?3_>I__"'V
M'_/YJW_@QE_^*I>[W_`$V=#GVHS[5SW_``A]A_S^:M_X,9?_`(JC_A#[#_G\
MU;_P8R__`!5'N=_P'=G0Y]J,^U<]_P`(?8?\_FK?^#&7_P"*H_X0^P_Y_-6_
M\&,O_P`51[O?\`NSH<^U&?:N>_X0^P_Y_-6_\&,O_P`51_PA]A_S^:M_X,9?
M_BJ/=[_@%V=#GVHS[5SW_"'V'_/YJW_@QE_^*H_X0^P_Y_-6_P#!C+_\51[G
M?\`NSH<^U&?:N>_X0^P_Y_-6_P#!C+_\51_PA]A_S^:M_P"#&7_XJCW._P"`
M79OR_P"J?C^$U@^!_P#D1]%_Z]$_E3)/!]@(W/VO5N%/_,0E_P#BJQ_"/A>S
MN_".E7#W6I*\ELK$1WTBJ/H`<"J]WET9-WS;'=_A1GVKGO\`A#[#_G\U;_P8
MR_\`Q5'_``A]A_S^:M_X,9?_`(JI]WO^!5V=#GVHS[5SW_"'V'_/YJW_`(,9
M?_BJ/^$/L/\`G\U;_P`&,O\`\51[G?\``+LZ'/M1GVKGO^$/L/\`G\U;_P`&
M,O\`\51_PA]A_P`_FK?^#&7_`.*H]SO^`79T.?:C/M7/?\(?8?\`/YJW_@QE
M_P#BJ/\`A#[#_G\U;_P8R_\`Q5'N=_P"[.AS[45SW_"'V'_/YJW_`(,9?_BJ
M7_A#[#_G\U;_`,&,O_Q5'N]PNP\'_P#(,O/^PA<_^C#709]JX/PQX7L[G3[I
MWNM24K>W"`1WTBC`<CG!Z^];?_"'V'_/YJW_`(,9?_BJ<N6^XHMVV.AS[49]
MJY[_`(0^P_Y_-6_\&,O_`,51_P`(?8?\_FK?^#&7_P"*I>YW_`=V=#GVHS[5
MSW_"'V'_`#^:M_X,9?\`XJC_`(0^P_Y_-6_\&,O_`,51[G?\`NSH<^U&?:N>
M_P"$/L/^?S5O_!C+_P#%4?\`"'V'_/YJW_@QE_\`BJ/<[_@%V=#GVHS[5SW_
M``A]A_S^:M_X,9?_`(JC_A#[#_G\U;_P8R__`!5'N=_P"[.AS[5SV@_\C'XG
M_P"OR+_T1'1_PA]A_P`_FK?^#&7_`.*K$T;PQ9S:[X@B:ZU(+#=1JI6^D!.8
M4/)!YZ]Z:Y;/43;NM#O/PHS[5SW_``A]A_S^:M_X,9?_`(JC_A#[#_G\U;_P
M8R__`!5+W>_X#NSH<^U&?:N>_P"$/L/^?S5O_!C+_P#%4?\`"'V'_/YJW_@Q
ME_\`BJ/<[_@%V=#GVHS[5SW_``A]A_S^:M_X,9?_`(JC_A#[#_G\U;_P8R__
M`!5'N]_P"[.AS[49]JY[_A#[#_G\U;_P8R__`!5'_"'V'_/YJW_@QE_^*H]S
MO^`79T.?:C\*Y[_A#[#_`)_-6_\`!C+_`/%4?\(?8?\`/YJW_@QE_P#BJ3Y>
MX7?8\2^*[`?$._R0/DBZ_P"XM%0?$>SCT[QO>6T3R.BK'AIY#(W*#^)N:*]6
MG\"//G\3/3/C#_R#-$_["*?RKTD5YM\8?^09HG_813^5>DUYTOX<?F=L?CE\
MA:*2EK(T"BD!I:`&R.L:,[L%5022>P%<I877B'Q#`NJ6=W;:?8R$FV@EMO-:
M9,\,YW#;GL!VKI;ZW%Y93VS-A9HVC)'49&*Y_0$\16%K9Z5=:?9^1:(L7VQ+
MDD2(HP"$VY#$8ZG'6J6Q+W.F4$+SC/M7+:[XRM["VU);:UO)S:(R/<PP[HHI
ML?*A.<YR1G`(&>:Z#3I+V6RC?4((X+DYWQQOO4<G'/TQ7%_\(]XA;3GT1K>U
M6R;4//FN1-EYXFEWD;<<''7)YQQ3BE?4)7MH7;C6[C2A-+/+=W<FG:7')<P)
M$@5Y&S\Y;(.?E.0.,&L5=;\1?9]-LY/[:%YJ3>;+(+>`&%%&6$0SC&2O+9./
M>KVO6TD8U>WG>(7>MWL%O;Q!PS&`;03CTP')K4MI8]0\<3RVCQS1:=8>2I0Y
M42R-DKGIG"+^=6N5+8C6XVTU^*RMKB6>ZOM1>2]>VMH!`HD=D&&"!<`C(8EC
MC\.*LOK)N[_28Q]ML&D,TLMM-"H+)&,$.<G:,L"",YQ6/:Z#K>D+HEW;VD%Y
M/;031W-NUQLP\K!RZL00>1CZ&KVHZ3K%Y=7EX(85N&TDVL"K+\HE<DMR1T&%
MY[U+M<K432_$[QZ)8RW45W?ZA>J]PEO;1@NL1<[2>0`H!49)Y]ZZ'2=4MM9T
MV&_M"QAF!*[A@C!(((]0017&:AX0N$U2&9='MM5MQ90VT:R7;0&`IG/3[RG.
M?PKN+*!;:UBA2&.%40*(XEPB^RCTI2MT'&_4L444F?>H*%HHHH`*YO3?^1[U
MS_KVMO\`V>NDKF]-_P"1[US_`*]K;_V>J6S$]T=)12'I7'WNK:C+XPFTL:Q#
MI8C6-K6*6W#B\!&6^8D=#QA>:25P;L=C17':CXCU#2;W4M,EVRWLQ1M)^7`D
M#G;M/KL;D^U17/B#5-*\6QVMW<1S:7%!;QW+^6%999"P$F>R[E`([;JI0;$Y
MI';45B:!J-S?3ZPMS(&6VOW@BPH&$"J0/?J:HW-UK.K:_?Z?IFH1Z?#IZ1[G
M,`E:61P6`.>`H&.G/-+EUL/F1U-%</9>(=6\1'3;*TGBT^XDM7N+N98A)@K(
M8]J!N.6!.3VJ[9>)+J'1;[[?LGU&SO&L5$2[1<R<;,#MD,"?3FFX-"4DSJZ3
M=[&N3TJ_UVZ\,WYDF$^JV]W)`C0Q(`=K#C#$#'7G.<<]:K^')_$DGAN[>[67
M[2%_T;RU5LG<>A<@DYZ[L#&,4<@<QVM%<EX+FUZ6.Y_M@$*';R]O*9WMGDG=
MGVQC&W!-=;4R5G8:=U<YR]_Y*'I'_8/N?_0XJZ.N<O?^2AZ1_P!@^Y_]#BKH
MZJ6R]/U8+J%%%)4#%HK)\1:K)H^D27,,0EN&=(H$8X#2.P5<^V3D_2L:]G\0
M^'HH=1O-5BU"U\Y([F#[*L6Q78+N1@<\$C@YR/>FDV)NQU]%<^/%*2:E>64&
MFZA.;)REQ+%&I53M##'.6)SC`'UJO-XEDGLM4MVLKS3;^"QDN8UN`A)4`@,"
MI(X/8T^5BYD=116;I-TS^'+&[NI<LUI'++(W'\`))JAIWBN&_O+>%K"]MH[M
M2UI/.BA)P!GC!)!QR-P&11RL?,CH:*Y;3_&MM?O9,+"_AM;R3R8KJ5%$9EY^
M3KGL<'&/>K'_``DTJZVNER:-?QR.LCQR$QE75.IX8D`\`9`Y(HY9"YD=#16'
M#XEM+BSTFXB25_[4?;"@`W)P2Q;G@+@YK+C\?V<D%K='3=46SN6\J*X\D$-+
MS\@`.XDD$9QC/>CED^@W)(["BN>@\66ILM0GO+6[LI+`JL]O,H+_`##*;=I(
M;=GC!ZU8TK7AJ-Y+9S6-U8W<:"7R;D+ED)P&!4D$9XZY%+E8<R-FBBBD,*YO
MQE_QX:?_`-A.V_\`1@KI*Y+XA3O;>'8IX\>9%>PNN1QD-D4XNSN*6QUM%>:6
MOC:_N+=9#?11L>JM$.#4W_"7WW_03@_[]BN#^T*2TL_N,_:Q/1:*\Z_X2^^_
MZ"<'_?L4?\)???\`03@_[]BE_:-+L_N#VT3T6BO.O^$OOO\`H)P?]^Q1_P`)
M???]!.#_`+]BC^T:79_<'M8GHM%>=?\`"7WW_03@_P"_8H_X2^^_Z"<'_?L4
M?VC2[/[@]M$]%HKSK_A+[[_H)P?]^Q1_PE]]_P!!.#_OV*/[1I=G]P>VB>BU
M@^-/^1+U?_KV:N8_X2^^_P"@G!_W[%5[_P`03ZE83V5UJ,303H4<*@!(^M..
M8TDUH_N$ZT;6/2+;_CUA_P!Q?Y5+7G*^+;U$55U*#"C`_=BE_P"$OOO^@G!_
MW[%+^T:79_</VL3T6BO.O^$OOO\`H)P?]^Q1_P`)???]!.#_`+]BC^T:79_<
M'MHDD_CB\TSQ+J%E-`MS:Q2X4+\KJN!T['\:ZO2O$6FZRO\`HEP/,'6)_E<?
MA7D^I'S=6;41<),\S9D4<'/^%0RW%@LH87<<<J'@A\,I^M81QTE+:Z(55W/<
MZ6O+-'^(%S9%8+J1;^$<!E/[P#^1_&NHU?QE%8Z5::A;1[XYY?+(E!4IQUQ7
M=#$TY1<ET-5--7.KHKG=#\03ZK>/#(D"H(]X,;9/4?XU?UK49=,L/M$2HS;P
MO[PX'-5&O"4/:+8:FFKFG17)Z?XINKO4+>W>*V"R-M)5R3^%;^J7CV&F37,8
M5G0`@.<#KCFE#$4YP<XO1`IIJZ+4O^I?_=-8/@;'_"#:+@_\NB?RK/@\77<M
MQ%&T-IM=PIPYS@G%=8P6"!O+55"*2%`P*=+$PJQ?)T%&2D[HEHKC(?%]Y)+&
MABM,,P!Q(>YKL'8JA/7`S12KPJIN'0<9J6P^BN)_X3.[Q_JK/_OX:ZVSG-S9
M03M@&2-6.WIR.U*EB*=5M1Z"C.,MBS17&W'C"YAN)HA%:81V7)D.>#BNHL+A
MKNPM[AMH:6,,=IR.?2BEB*=5N,>@XSC)V1:HKC;KQA<V]Y/`([3$<C("SG/!
MQ73Z;=->Z=!<L%#2H&(4Y'X4Z>(IU).,7J@C-2=D6Z*XZ^\8W%I?7$`2TQ%(
MR#<YSP>]==&Q>-6/<`T4Z\*C:CT",U+8P?!W_(+O/^PA<_\`HPUT->=V7B)]
M$^U6D1MY%-U-*2[$$%G)(XKMM*O6U'2X+M@H:5<_(>.O:B&)IU9N,10DGHB]
M69K^H2:3HEU?Q(KO`NX*W0\BL'4?&,UCJ5Q:A+8B)]OSL<_C6/J_BM]6TFYL
M'^S1K.FTL&)QS6,\;25XWU)=6*T.AT?QQIFI!$G)LYVZ+*?E;Z-T_/%=,"&`
M(.0:\+LXU,+03;?EZ$GBM;3M>U'0V`M;Q)8!_P`L)6W+^'<5A2Q^O+47S)C6
MZ,]@HKE]'\<:=J3+!.3:W+<!'.58^S5TX.17HPG&:O%FR:>PM%%%4,*YW0?^
M1C\3_P#7Y%_Z(CKHJYW0?^1C\3_]?D7_`*(CIK9BZHZ(44"BD,****`"BBB@
M`HHHH`****`/G+XK_P#)0[__`'(O_0%HH^*__)0[_P#W(O\`T!:*]6E\"/-J
M?$ST/XP_\@S1/^PBG\J])KS;XP_\@S1/^PBO\J])KSY?PX_,[H_'+Y'-/XBM
M]+GUNXO;R:6WLYX8S&(`/)WJN`"#EP2<^U+)XQ@>PU*2"QOA=6</F_9Y8-KL
MISM<#/*\<^F*H:AX?U*X?7C'"I%Y>VDT/[P#*QE-Q/I]TUH:CI%Y<ZYJ-U'$
MIAGTDVJ$L!F3<QQCTY'-%H?U\@O(SM#\42V^CVKZ@FK:AJ%TOG"!;-0ZI@98
M!<#R\G@DY.:UY_%FGQVME+;I<WCWJEX(+:(M(RC[Q*G&`.ASCGBN=O\`PK=[
M]+NVTS^T#%IR6D]LEZ8&1EY#!@0&'4$'V(J['H^HZ/+IM_I>DPMY=L]M/8+=
M<H&?>&61OO'/7/KQ0U%[`G)%E?%TDOB.VTY-)U`P36XE\PP$,I+`<@GA1GD^
MM/M?$D%IICW%S<W%](]]-;0QQVX$CLK$;%4'D``_,>PR<4-;:TGB+3=4:QAF
M+VIMKI(I@H@)<-N&[[P`R..:S8M`UBQCM;Z"VBFNK/4+N;[,TH7S8I6/1N@;
M!!Y]Q1:(7D;'_"9:8FE7%_.MS`MK,D-Q#+$1+"S$`;E].0>,\5:TGQ!;:M<7
M%LD%U;7$`5FANHO+<HV=K`=P<'\JY^?0M7O[;4+V:VCAN[V[M'%L)0WE1PNI
MY;H6QN/'L*W8["X7QE/J10?9GL$@5MW.\.S$8^A%2U&V@TW<-9U'2]'NK2[O
M+;=<S,;>"2.#?(3@MM&.><=/6J%MXGT/3])N+M+22QC@N%BN+?[-Y<D<CD8+
M*.N<@Y&<TGB^2YCU'PZ]G$DUPM\Q6)WVA_W+Y&>QQFJ,NA:O?QWE]<6L<-U>
M7]I+]F$H;RXH67JW0L1D\>U-15M1-N^ALS>*K>&&`G3=3:XF#,MHEL3,$4X+
M,N>!TZGG-6+'Q'8:C=6]O;LY:YMS<1,RX#*&VL.>C`]16)XH\/37NNV^J1Z<
M=1C%N;>2W6[:W=?FW!@P(![@@^U1:AX>U"+P_IKZ'8PVFI6C/LMS<%E5900X
MWGJ>0WU%)*-D-N1K-XOL3;PRP6U[=/,\BQ0V\.YW5&VL^,XVY[D\YI9_&.F0
MV]A,B74_V_>((X82SEE^\A7J&[<^AK$U;P@T4NE2VNGG48+2S^R/;B[:W;J"
M'#`@'D'(/K5ZQT&>UN]`E@T]+.&U^TM/"+@R>69!Q\QY8D]:=H!>0:CXTCBT
MBVO[&PNIS)=K:RQ-#AX6W`,K#/#>G8FK::W&-8E>XN9K6!-.6ZDMKB`+Y0W'
M+LV2<X&-OM6;=:#JG]FZKY,$;SMK"W\$1D"B5%*'&?X2=IZTNI:!J.N7=_++
M"EHMYI*VXW.'\N7>6VG'4=.11:-A7D:NG>*[+4;R.U^S7MK),ADMS=0&,3J.
MI0_0@X.#@U#8>-],U&:U2&&]6*[8QPW$D!6)I!GY-W][@^W'6J]O::UJNK:9
M<:GIT-A%IP=_EG$IFD9-HVX'RKC)YYZ5%;:#J,?AKP[9/"OGV-Y%+.-XPJJ6
MR0>_44K1'=G89XKG--_Y'O7/^O:V_P#9ZZ.N<TW_`)'O7/\`KVMO_9ZF.S*?
M0Z,]*Y3Q+INLZY#<:6;#36LY2/*O9)CO@Z?,$V_?!S@AAVKJZ.*$[`U<PK_2
M)KC7-"O$V.E@9?,9S\WS)M&/QJ.;0/MFLZO)=JC6-_9Q6X4'YLKOSQV^\,5T
M/%'%',Q61Q_A_P`)/_9%W9^)8[:_>2\:=3R0PVA0QZ88@<_6I9-*U;1=5NKC
M0+6RFMKJ&.,PS2F/R6C&U6&`=R[<<<'CK75BCBFYMN[#E5K'&6_AS4]!;3;O
M2Q;7MQ#;/;74<TAB$NY_,WJV#C#$\8Z&IK;P@9[=9]0O;B#4&NI;QWL9=BJ[
MC;@$@Y`4`9^M=;Q1Q1SL%%'.^%O#]QHBZA]HO+B?S[EY$$LN\;2<AN@^8]ZZ
M';[TO%+4MW=V-)+83%+110,YR]_Y*'I'_8/N?_0XJZ.N;O?^2AZ1_P!@^Y_]
M#BKI*N>R]/U9*ZA1114%&5XATEM9T:6TCF$,VY9892,A'5@RDCTR.:Q[FR\0
M:\L%EJMO8V=DDJ2W#P7#2-/L(8*H*C:"0"<D\<5UM)^%-2L)JYS+:'J)L?$D
M,-PMO/J,[26TJL<J#&J\^G*GI6-IOA&^MYM0F73-/T];G3)+18K>=I,R$\,S
M$#K_`)S7?T4U-HEP3,NWTQO^$7ATJX;#?8EMI"AS@[-I(KF_#GA:32[ZT\_0
MM(C:U4C[?#*QDD(&`0A'RD]\D]Z[C\*.*7,QV1R-OX=OH_#>A6#&+SK&]CGF
MP^1M5V)P<<G!%2Z1::Y;^)+V\OK"T=;J3;]I6[):.%<[$";?Q//4DUU/%'%/
MG;#E1Q'AW3F'C#5L.CV&G2/':*O\$DV))!^'`_X%5BT\.7\/AO0+!_)\^PO8
MYYL/QM5F)P<<GD5UJ1QQ[MB*NYMS;5QD^I]Z=QZ4W-@HHY#6/"]QJTFO9:%4
MOEMC;[\D%HLG#@=B<#CM4_AG1#IUY+.^A:;IC-&$W6DS2L_.3DE1@>U=1QZ4
M<>E+F=K!RJ]Q:*2EJ2@KE_',"7.CVEO)GRY=0MT;!YP7P:ZBN;\9?\>&G_\`
M83MO_1@JHZR1,MC+OO#QMI/+LX$\M>`&7/%5/[&O?^?>+_OFO0B`3R*3:OI7
M-]7I=A>SAV//O[&O?^?>+_OFC^QKW_GWB_[YKT':OI1M7TI_5Z78/9P['GW]
MC7O_`#[Q?]\T?V->_P#/O%_WS7H.U?2C:OI1]7I=@]G#L>??V->_\^\7_?-'
M]C7O_/O%_P!\UZ#M7THVKZ4?5Z78/9P['GW]C7O_`#[Q?]\T?V->_P#/O%_W
MS7H.U?2C:OI1]7I=@]G#L>??V->_\^\7_?-4=:L[_3=%O+Y+>#=!$7&Y.,BO
M3]J^E87C11_PA>K\?\NS4XX:DW\(G"*6QS2:1>O&C?9XOF4'[OJ*7^QKW_GW
MB_[YKO+8+]EAX_@7^52[5]*7U>EV'R1['GW]C7O_`#[Q?]\TO]C7O_/O%_WS
M7H&U?2C:OI1]7I=@]G#L>#:]+<QZM<0%1YD1\M%48"^^*IV7A^24[YB>><=Z
M];U+PK:O=7%Y%$6N;A]S.YSCV`J73_#$<.&E&2*PAA%=MLE4]3C=*\-L2HBA
MQ[D5TUUX1%_8PQW,K!89/,V]=W'2NLAMHH%PB@?A4W&*Z?9PY>6VAI96L<CX
M9TU;'69MML$'DD;QWY'%:7BJW\_1MGD^:/-4[:V/)CSG;CZ4&&,C!&1[FA4H
M*/(M@Y5:QP.BZ<(]:M)!8B/;)G?GIP:[#Q!%YV@W4?E^9N4?)Z\BKHMX@<A`
M#2F%",$$CZT0I0A%Q6S$HI*R/.+/3`M];D:>H(E0Y].1S7H\PW0R#'\)_E3)
M((A$Y"#[IK%\%@S>"M'DD9G=K5"S,Q))]S13HPA'W022T1R=MIBK<P'^SE&)
M%.<].17I;C*-]#3/L\7]P4[RD]_SHA2A3ORH:BH['F)TL=]-7\Z]'TU-FF6B
M;=NV%1M].*E^SQ?W!3O*3T/'O2A1A!WB)12V/.+S3@U_<'^SPV97.<]>37?:
M3'Y>D6:;=FV)1M]..E3_`&>+^X*=Y*>A_.B%&$&W%;@HI.Z/.M0T[?J=TWV`
M-F9SNSUY-=UHL?E:-9ILV;8@-OI5G[/$>J"G>2@&`#^=$*,(-N/4%%)W1YYJ
MFG[]5O&^PARTS'=GKSUKT2(8B0>BC^5-^SQ9SL%*(EST/YTX4H0;<>HTDMCR
MR!1J,EW.--`VW<T1^;.=KD9Z=Z]%T"/RM#M4V>7A3\OIR:R_"$$;:9>$J#_Q
M,;GM_P!-#70B%`,`$#ZT*C3IR;BB812U1P6LV)?6;M_L0?=)G=GK61?VYL["
M:X^P*-BYRQX%>J&WB)R4!-4-8TB/5-)N+$,(O.7;OQG'(-93PM-W=M1.G%G@
MEP\]V!!'DY.7([GTJY8^'B2#-U_NCK7>MX12VN!!:QG:.KMU-=!IWAB*`!I1
MD^E94L(DO>%&FNIRFB:'+'(K00A,=R.:]&L8Y(H%$AR<5+#;Q0J`B@8]JEXK
MLC&,59&B26PM%%%4,*YW0?\`D8_$_P#U^1?^B(ZZ*N=T'_D8_$__`%^1?^B(
MZ:V8NJ.B%%)2TAA1110`4444`%%%%`!1124`?.?Q7_Y*'?\`^Y%_Z`M%)\5_
M^2AW_P#N1?\`H"T5ZU+X$>=4^)GH7QC;;IFBD@G%^IX&>@KJO^$NMO\`H%ZS
M_P""^3_"N7^,/_(,T3_L(K_*O217GNWLXW\SM5^=G/?\)=;?]`O6O_!?)_A1
M_P`)=;?]`O6O_!?)_A7145G>/8O4YW_A+K;_`*!>M?\`@OD_PH_X2ZV_Z!>M
M?^"^3_"NBHHO'L&ISO\`PEUM_P!`O6O_``7R?X4?\)=;?]`O6?\`P7R?X5T5
M8]_XIT/3+W['?:G!;W``)1VP0#TSZ4*W8->Y5_X2ZV_Z!>M?^"^3_"C_`(2Z
MV_Z!>M?^"^3_``KH%=74,K!E(R"#U%&X>M*\>P:]SFY/$VGS21O+HVK.\3;H
MV;37)0XQD<<'!(J3_A+K7_H%ZS_X+Y/\*W8YXIMWE2H^UBC;6!PPZ@^_M4F:
M=X]@U[G/?\)=;?\`0+UK_P`%\G^%'_"76W_0+UG_`,%\G^%=#FJM]J%MIMJ;
MBZ=EB#JF0I;EB`.![D47CV#7N9'_``EUM_T"]:_\%\G^%'_"76W_`$"]:_\`
M!?)_A70YI:+Q[!J<[_PEUM_T"]:_\%\G^%'_``EUM_T"]9_\%\G^%=%11>/8
M-3G?^$NMO^@7K7_@OD_PH_X2ZV_Z!>M?^"^3_"NBHHO'L&ISO_"76W_0+UG_
M`,%\G^%8=CXEMT\8:O<'3]5(DM[<!!9.67&_J.W7BN^KG--_Y'O7/^O:V_\`
M9Z:<;/03O=:B_P#"76W_`$"]:_\`!?)_A1_PEUM_T"]9_P#!?)_A7144KQ[#
MU.=_X2ZV_P"@7K7_`(+Y/\*/^$NMO^@7K7_@OD_PKHJ*+Q[!J<[_`,)=;?\`
M0+UK_P`%\G^%'_"76W_0+UK_`,%\G^%=%11>/8-3G?\`A+K;_H%ZU_X+Y/\`
M"C_A+K;_`*!>M?\`@OD_PKHJ*+Q[!J<[_P`)=;?]`O6?_!?)_A1_PEUM_P!`
MO6O_``7R?X5T5%%X]@U.=_X2ZV_Z!>M?^"^3_"C_`(2ZV_Z!>M?^"^3_``KH
MJ*+Q[!J<#=>)8&\;:;<C3]5"QV5PA0V3ASEH^0.I'')]Q6Y_PEUM_P!`O6O_
M``7R?X4E[_R4/2/^P?<_^AQ5T=5+ELM/ZNQ*^NISO_"76W_0+UK_`,%\G^%'
M_"76W_0+UK_P7R?X5T5%3>/8>ISO_"76W_0+UK_P7R?X4?\`"76W_0+UK_P7
MR?X5T54K'5K#4GN$LKN*=K:0Q3!&R8V]#1IV#7N97_"76W_0+UG_`,%\G^%'
M_"76W_0+UK_P7R?X5JQZK82ZG+IB7<;7T*"22`'YE4]"1^-7,T:=@U.>_P"$
MNMO^@7K7_@OD_P`*/^$NMO\`H%ZU_P""^3_"N@W#UI=P]:+Q[!J<]_PEUM_T
M"]:_\%\G^%'_``EUM_T"]9_\%\G^%=#D55MM1M;RXNH()"TEI((YAM(VL5#8
M]^".E&G8->YD?\)=;?\`0+UK_P`%\G^%'_"76W_0+UK_`,%\G^%=#N%)N%%X
M]@U[G/\`_"76W_0+UK_P7R?X4?\`"76W_0+UK_P7R?X5T&?>J^G:A;:I817M
MI)YD$N=C8(S@D'@^X-&G8->YC_\`"76W_0+UK_P7R?X4?\)=;?\`0+UK_P`%
M\G^%=%11>/8-3G?^$NMO^@7K/_@OD_PK#\4>);>YL[%1I^JILU"W<F2R=<X<
M'`SU/M7?5S?C'_CPT_\`["=M_P"C!50<>9:"E>VX[_A+K;_H%ZU_X+Y/\*/^
M$NMO^@7K7_@OD_PKHJ*F\>P]3G?^$NMO^@7K7_@OD_PH_P"$NMO^@7K7_@OD
M_P`*Z*BB\>P:G._\)=;?]`O6?_!?)_A1_P`)=;?]`O6O_!?)_A71447CV#4Y
MW_A+K;_H%ZU_X+Y/\*/^$NMO^@7K7_@OD_PKHJ*+Q[!J<[_PEUM_T"]9_P#!
M?)_A1_PEUM_T"]:_\%\G^%=%11>/8-3G?^$NMO\`H%ZU_P""^3_"L?Q7XGM[
MKPKJ<*Z?JJ%X&7=)9.JCZD]*[JL'QI_R)>K_`/7LU.+CS+04KV97@\6VRV\0
M_LO63A`.+"3T^E2?\)=;?]`O6O\`P7R?X5NVW_'K#_N+_*I:3<>PU<YW_A+K
M;_H%ZS_X+Y/\*/\`A+K;_H%ZU_X+Y/\`"NBHHO'L&ISO_"6VO_0+UG_P7R?X
M4?\`"76W_0+UG_P7R?X5T`=3G#`X.#@]*=1>/8-3G?\`A+K;_H%ZU_X+Y/\`
M"C_A+K;_`*!>M?\`@OD_PKHJ*+Q[!J<[_P`)=;?]`O6O_!?)_A1_PEUM_P!`
MO6?_``7R?X5T5%%X]@U.=_X2ZV_Z!>M?^"^3_"C_`(2ZV_Z!>M?^"^3_``KH
MJ*+Q[!J<V_BVV,;#^R]9^Z?^8?)_A6/X1\36]IX0TF!M.U61H[95W163LI]P
M1U%=S+_J7_W36#X'_P"1&T7_`*]$_E3O'E>A.O-N)_PEUM_T"]:_\%\G^%'_
M``EUM_T"]:_\%\G^%=%12O'L5J<[_P`)=;?]`O6O_!?)_A1_PEUM_P!`O6O_
M``7R?X5T5%%X]@U.=_X2ZV_Z!>M?^"^3_"C_`(2ZV_Z!>M?^"^3_``KHJ*+Q
M[!J<[_PEUM_T"]:_\%\G^%'_``EUM_T"]:_\%\G^%=%11>/8-3G?^$NMO^@7
MK7_@OD_PH_X2ZV_Z!>M?^"^3_"NBHHO'L&IP?ACQ+;VVGW2MI^JONOKAP8[)
MV'+DXX[^HK:_X2ZV_P"@7K7_`(+Y/\*7P=_R#+S_`+"%S_Z,-=#3DXWV%&]C
MG?\`A+K;_H%ZU_X+Y/\`"C_A+K;_`*!>M?\`@OD_PKHJ*5X]AZG.?\)7:9S_
M`&5K.?\`L'R?X4O_``EUM_T"]9_\%\G^%=%11>/8-3G?^$NMO^@7K/\`X+Y/
M\*/^$NMO^@7K7_@OD_PKHJ*+Q[!J<[_PEUM_T"]:_P#!?)_A1_PEUM_T"]:_
M\%\G^%=%11>/8-3G?^$NMO\`H%ZS_P""^3_"L31O$T$6N^(93I^JL)KJ-@$L
MG++B%!AAV/'Y8KO:YW0?^1C\3_\`7Y%_Z(CIKEL]!-.ZU#_A+K;_`*!>L_\`
M@OD_PH_X2ZV_Z!>L_P#@OD_PKHJ*5X]AZG._\)=;?]`O6O\`P7R?X4?\)=;?
M]`O6O_!?)_A71447CV#4YW_A+K;_`*!>M?\`@OD_PH_X2ZV_Z!>M?^"^3_"N
MBHHO'L&ISO\`PEUM_P!`O6?_``7R?X4?\)=;?]`O6O\`P7R?X5T5%%X]@U.=
M_P"$NMO^@7K7_@OD_P`*/^$NM?\`H%ZS_P""^3_"NBHI-Q[!J?-'Q(O%O_&]
MY<I'-$K+'\DZ&-QA`.5-%6OBM_R4._\`]R+_`-`6BO5IVY$>?/XF>A_&'_D&
M:)_V$4_E7I(KS;XP_P#(,T3_`+"*?RKTD5YTOX<?F=L?CE\A:**J#4;=M4DT
M]2QGCA$SX'"J20,GU.#Q[5D:%NBDW"J_V^V_M'[!YG^E>5YWEX/W,XSGIUH`
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MY684[WECXM%QJ-Q?FSFNEBM);:X'D+D`"*6+USGYN>HZ5VM9`\.:.-6_M7^S
MX?MI;?YV#G=TSCIGWZUK;A4-W&DT+129%5WU"VCOXK%Y,7,T;2)'@\JN`3Z=
MQ2*+-%5+O4K>REM4GWC[5,(8V"Y`<@D`GMG&/K5O-`!7-Z;_`,CWKG_7M;?^
MSUTE<WIO_(]ZY_U[6W_L]4MF)[HZ2JM_J%KIEH]W>SI!`GWG<_I[GVJU6-XC
MTQ=5LHH!>?9+B.=)K:;`;$J\CY3]X=>*2M?4'L/M?$NDWJV[6]ZCBXE,,659
M=S@9*\C@XYP:=>^(=*TX79N[V.(6:H]P6SB,.<+GZUSDDMUK^AZQ97PMXM2T
MJ4.MS:DF,RJH='&>0>Q';I5*2#?\.TO[G;)<ZI=6UU<G'!+RI\O^Z%POX5:@
MB')G</J=G&]HC7"9O#MM\<^8<;N/PYJ2YO(+*VDN;J:.&"-=SR.V%4>YKSY=
MVF>*M%\.S.2+2^>6S8_Q6[1O@?\``3E?IBM#Q)=:C-IL!U;38;.SBU&V,CBZ
M$H=/,YW#:,#[M#AJA\^ATNF^(=+U=)GL;V*40\R`@J4'J0P!Q[]*9IWB;1]7
MN6MK"_AGF4;M@R-P]5R/F'N,UR/C@F74]1-H09$T.7[1LZA3(I4'\`^/QK6U
M*2UEUSPD;%HB0\CIY9'$'DG)'^SG9^E'(K7#G=S4L_%NB:A?+9VM\)9V8JJB
M)\$CKSC'8]ZL-K*G39KV&VEE6)Y%9`5#?(2&/)`QQ7,QK?>%I=(@MM96_L;N
M[$"6LD*!@KDMN1EY.WKSGBMR/3;R**73T=#:SK</),5Y#2,2H`SVRV?PI-)#
M3;-33[MKZSCN6MY(!(`RK(5)((R#P2*LU!9P&ULH+<MN\J-4W>N!C-3U!1SE
M[_R4/2/^P?<_^AQ5T=<Y>_\`)0](_P"P?<_^AQ5T=7+9>GZL2ZA1114#"O+]
M(O(O#EP=;F.RRN;N\M;H]MRR.\3?7[R_B*]0/2LR30=,EL'L7L87M7E\YHF&
M5+[MV[ZYYJXR2T9,E<XBR^U:5JL^IR1[M1GT6>_D0C^,N"J?@`J_A5ZU^TZ<
MWAN_BUN[OI-4E5+B.67?'*K(6+(O1-I`Z=N#78M96S7OVQH4-R(_)\P]=F<[
M?IFJ5AX<T;2[QKNRTZ""X;/SJO3/7;V7/M3=1/<E0:./MWU&+1H-=.L7TDXU
M7R!"\G[KRC<&,J5[\'@GD<>E6+Q[F_MO$6K/K5W9S:9/+'!#%+MBB$:@J73^
M/=UY['BNL?3=+CLEM'@A2V,XE6-C@&3?O!'ONYK,U.U\*OJMQ=ZC;6[7UG`M
MS.[QD[8P3ACCAL8..IXIJ:;T0.+L9\+S^(=4NEOM3O-.2TM+>58K:?R<%TW,
M[>H!XP>.#5">\GM;C7([:[-N+O6;:V>Z7&8T>),L#T!/0'WKK[W0](UJ2WN[
MRQ@N7108W=><=0/<>QJ5]'TZ2*\CDLX7CO2&N%9<B0@`#(^@'Y4N=#Y7N<AJ
M<UWHAU_3[74[R>*/2&NT:>8R26\N2!A^N".0#Z<5<@%SHVN:>LVK7MS#>V,T
MUS]H?<%=`AW(,87[QX'%:TFE>']"T6ZB>SAM["<A)QM+>9N(4`GDGKC\:TVL
M;5[B"=H$,L"-'$QZJK8R!]<#\J.=6V#E=SA=!O[\>)=)96U(6.I12N#?7JS>
M<H7<K",?ZO\`#CG%='X#_P"1+T__`+:?^C&JU8^&-$TZZ6ZLM-MX9U+%9$!R
MN1@X]![=*T;*RM]/M([6TA6&"/.U%Z#)R?U)I2FFK((Q:U98HHHJ"PKF_&7_
M`!X:?G_H)VW_`*&*Z2N/^).?^$5&,Y^U18Q]::=G<F6QUGFI_?7_`+Z%+YJ?
MWU_[Z%>0V0O_`+)'YUD7?'4OM)'N/6I\7/\`SX'_`+^__6KR_P"T)?R?B9>V
M?8]7\U/[Z_\`?0H\U/[Z_P#?0KRC%S_SX'_O[_\`6HQ<_P#/@?\`O[_]:E_:
M$_Y/Q#VS['J_FI_?7_OH4>:G]]?^^A7E&+G_`)\#_P!_?_K48N?^?`_]_?\`
MZU']H3_D_$/;/L>K^:G]]?\`OH4>:G]]?^^A7E&+G_GP/_?W_P"M1BY_Y\#_
M`-_?_K4?VA/^3\0]L^QZOYJ?WU_[Z%'FI_?7_OH5Y1BY_P"?`_\`?W_ZU&+G
M_GP/_?W_`.M1_:$_Y/Q%[9]CU?S8_P"^O_?0K!\9R*W@W5@&4DVS<`UPV+G_
M`)\#_P!_?_K48N".=/R/>3_ZU-9C-._)^(.LVMCU*VE3[+#\Z_<7O[5+YJ?W
MU_[Z%>48N?\`GP/_`']_^M1BY_Y\#_W]_P#K4?VA/^3\0]L^QZOYJ?WU_P"^
MA1YL?]]?^^A7E&+G_GP/_?W_`.M1BY_Y\#_W]_\`K4O[0G_)^(_;/L1:CJE]
M8>-M4-C=O$QFR`#E6X'!'0UT^E?$",D0ZO!Y#?\`/>($H?J.H_6N'U(QB[C+
MP"&X')(DSQ[\5FR>(HG8JMH7YQN#]?TK".)JQDY1V[$<\KZ'OEO=0W<2RV\J
M2QMR'1L@U-7AFCZIJ=M/YNFK);;C\PWY1OJ,8KUK0]5EOK1/M7E?:,?-Y6=O
MZUZE&M[1;6-X2YC9HHHK<L****`&2_ZE_P#=-8/@?_D1M%_Z]$_E6]+_`*E_
M]TU@^!_^1&T7_KT3^55]A_UW)^T=#1114E!1110`4444`%%%%`!1110!SW@[
M_D%WG_80N?\`T8:Z&N>\'?\`(+O/^PA<_P#HPUT-5+<4=@HHHJ1A1110`444
M4`%%%%`!7.Z#_P`C'XG_`.OR+_T1'715SN@_\C'XG_Z_(O\`T1'36S%U1T0H
MH%%(84444`%%%%`!1110`4444`?.7Q7_`.2AW_\`N1?^@+11\5_^2AW_`/N1
M?^@+17JTO@1YM3XF>A_&'_D&:)_V$4_E7I(KS;XP?\@S1/\`L(K_`"KTD5Y\
MOX<?F=T?CE\A37$^7=W3^-&LYWBOEE1(70X*[(591]"2?S-=K63;:7+:^(K^
M^C=/LU[%'O7/S"5,C/I@KC\JSB[7*:N<JOBR<ZDNL&;_`(E!M/)\K^'S_*\[
M/U_AHM=+O[SQ#IUK=ZI>07!T4/<RQ.!*S&7.-V.`">WIBNH_X1?13IO]G'3X
MOLGG_:/*R<>9G.[KZU?^PVWV_P"W>6/M7E>3YF3G9G./3K5N:Z$J#ZG$V6H:
MCJ]MH&FS:C-`;D7/GW,)"RS>2VT`''!/WCCT-(VIZE")M$75)2O]KI8+J#8,
MJQM'O*YQ@N#\N<=_6NJG\-:/<:?'82V2-;12&2-=S`HQ))(8'())/0]Z</#V
MDC2&TH6,/V%N3"1D$YSNSUW9YSG-'-'>P<K.1U:\U'0X/$5A!JES.MM8QW4,
M\[;Y('9B""W&0<9`/O5N>2^TC5U@36+J]2]TZXGD$S*?+=`"KI@?*ISC'3I6
MGJ'A2U'A?4=*TB"*W>[3!:1F;<>/O,<D\"KMCX:TC3C<-:V,<37*;)2"3E?[
MHR>%YZ#`HYE8+.YS%B=0UFZT*T?5[VWAFT1;BX,#A7D?<@SNQP>>H^E57UC4
M)M'T>WGN]0D9Y;F.X:P*K<2K$Q56!.!Z9Q@G-=U;:186<L$MO;K&]O!]FB()
M^6+(.W]!7/ZWX3\^2R:PL=-N+:W,K-97Q;RV>0Y+@@-SG/!&/FIJ2N#B^AH^
M$K6^M]!C_M*>YEN)'>0_:91(ZJ3\H)'&=N,X[YK-B6XUG6M6EGUJ[LH].N5A
MBA@D5$`VJVYP1\VXGOVK4\,Z-+HFF203-"&DF:80P9\J$'^!,\X'X=>@J6[\
M-:1?ZBE_=6,4ETN/G)(W8Z;@#AL=L@XJ+J[*L[(Y*XNM1GT/5_$@UFY@N+*Y
ME6&U5@(%$;[0CICYBWKU^88K534[@W'BHRW+QK;6T4D2LV!"6A))'IS_`"K6
MF\+:+<:G_:,VGQ-=%@Y;)PS#HQ7.TD>I&>*=J'AK2-4O%N[VPBFG5-F]B?F7
MT(!PW7C/2GS1%RLXN^U+4KN+3[=;G57<Z1%-C3Y%1_/<<-(6QE3C^>:O2:5?
M2ZYX=L+C4KN*X739_M$\<@,C'='N`<CCGN.PJSJ_A*:;4TFMM.T>_M5M4MHH
M-0W?Z.%S]TA6R#D9S@\=:VM%T"+3++3UG?[1>6<!A6XR?NL02`">G`QG/`%4
MY)+0GE;=F<Q=W5S+\/KQKBX>>YT_4/*BG?[[>7<!5)]\<9KT`5A:AX?2>"WM
M+18H;1KX7=V"3E\-O('U?&?;-;M3)W+BFMQ:YO3?^1[US_KVMO\`V>NCKG-.
M_P"1[US_`*]K;_V>E'9C>Z.DJIJ&F6.JVWV?4+6*YAW!MDJY`([_`%JU14C*
MEII=C867V*TM8H+;!'E1KA>>M!TNP-C'8FUB-K%MV0[?E7:<K@>Q`JWQ11J(
MK3:=9W%Y;W<UM')<V^?)E9<M'GK@]LU+/;PW4$D$\2RPR*5='&0P/8BI*.*-
M1E#3M$TO289(=/L8+:.0Y=8T`W?7UING^'](TJ6673].MK:27AVBC`)'I]/:
MM'BBB[%9&98^'=&TV\>[LM,M8+A\YDCC`//7Z?A6GBCBBC48M%)10!SM[_R4
M/2/^P?<_^AQ5T=<W>_\`)0M(_P"P?=?^AQ5T=7+9>GZLE=1:*2BH*%HI**`.
M1\4W$TNI0:?9OJSW/DM,T-A/'`%3.-[.WOP!699WNIZY;>%(WU2XMC>VUPUT
M]N0&DV[<<]`?<>^*ZW4_#^EZS+%)J%HD[Q9",200#U'!&1['BI+?1=.M3:&"
MU2/[&C);A2<1JWW@/K5J22(<7<X6^AN+_1K>WN]1O6:RU\6B3+)M=UWC:6..
M6&>#ZU<\023P'Q%IQNII;>#0`RB5]Q+9D!8GN2`,FNLFT'2[BRN;.:S1[>YE
M,TR$GYI"0=V<Y!R!TI/[`TS9(GV12LEL+1\LQW1#.%//N??FFIH3AV.82:]T
M*^TMX]4N=12]LY9)8)6!7*1AU:,`?*,_+@>HJ*UFU"WL/#^MG6[FZFU*XA2>
MW9@8763J$4#Y2OK_`+)S75:?X=TG2KN6ZLK&*&:1=I8$G"]<#)PH]ABF6GA?
M1;"_-]:Z?%'<9)#`DA">I52<+GV`HYT/E9Q.IFZU+PQ<:U<:O<*[ZB(?L>\>
M2%6X"A`O][@'/6M;4]4U"SNM6T1;N3[9>7$1T^0GYD27AL?[FUS[<5O3>$]#
MN+V6\ETV%IY6#.V3@L,?-C.`W`Y'-)<:(;KQ;8ZM*L)BLK9TB/\`&9'(R3[`
M#\R:?.MA<K1LQKL0)DMM`&6.2?K3Z2BLC06BDHH`6N;\9`'3]/!&0=2MLC_@
M8KHZYSQC_P`>&G_]A.V_]&"JA\2)EL.U/P_]LG+JVT$]%XJA_P`(DW_/5OS-
M=A16?+'L.QQ__")M_P`]6_,T?\(FW_/5OS-=A11RQ[#L<?\`\(FW_/5OS-'_
M``B;?\]6_,UV%%'+'L%CC_\`A$V_YZM^9H_X1-O^>K?F:["BCECV"QQ__")M
M_P`]6_,T?\(FW_/5OS-=A11RQ[!8X_\`X1-O^>K?F:R?%'AI[7PMJ<ZS.&2!
MF!#$&O1JP?&G_(F:O_U[-51A&ZT)DE9F5#X49H(CYK<HIZGTI_\`PB;?\]6_
M,UU=M_QZP_[B_P`JEI.,>PSC_P#A$V_YZM^9H_X1)O\`GJWYFNPHI<L>P['A
M>LZ/=/KM_;1!BB2%7D[8X[U+IWAY%(VQEV]<<5Z[J&F)>)MPJ@G+8'4^]%GH
MUM:#A036$<-%2O+4A05[G)Z;X7DDP91A?2NOL-+BLE&T<U>"JHP!C%+Q73IL
MBQ:*2B@!:*2B@!LO^I?_`'36#X'_`.1&T7_KT3^5;TO^I?\`W36#X'X\#Z+_
M`->B?RJOLD_:.AHI**DH6BDHH`6BDHH`6BDHH`6BDH[T`<_X._Y!=Y_V$+G_
M`-&&NAKG?!Q_XE=Y_P!A"Y_]&&NAJI;BCL+1245(Q:*2B@!:*2B@!:*2B@!:
MYW0?^1C\3_\`7Y%_Z(CKH:Y[0?\`D8_$_P#U^1?^B(Z:V8GNCHJ*044ABT4E
M%`"T4E%`"T4E%`"T4E%`'SG\5_\`DH=__N1?^@+12?%<_P#%P[__`'(NW^PM
M%>K2?N(\Z:]YGH7QB4MI>BX8C-^HR.W'6NJ_X1[4O^AHU/\`[XB_^)KE_C#_
M`,@W1/\`L(K_`"KTFN"3:IQ^9V)7G+Y'/?\`"/:E_P!#1JG_`'Q%_P#$T?\`
M"/:E_P!#1JG_`'Q%_P#$UT.*,5GS,OE1SW_"/:E_T-&J?]\1?_$T?\(]J/\`
MT-&J?]\1?_$UT-<GJ7B.\B\2VMM9B,Z=%=1VM[(RY)DD!VJI[;>"?]X"FG)[
M`TD6_P#A'M2_Z&C4_P#OB+_XFC_A'M2_Z&C5/^^(O_B:L:EXDMM.O/L:6E[?
M72IYDD5G%O,:'H6R0!GL.I]*I3^([>QO=5O;FZN/L5DD$;P>0`$=^<@YR3AE
MR.V.]"YF*T42_P#"/:E_T-&J?]\1?_$T?\(]J7_0T:I_WQ%_\34UIXIL+EKT
M21W-G]CC$TGVJ/R\QG.''L<'K@^U01>+K2>6:$V&I12K`US''+`%:>,8R4!/
MN.#@\T>\'NB_\(]J7_0T:I_WQ%_\31_PCVI?]#1JG_?$7_Q-5M*\8K/X=BU+
M4K"ZMI)6"PQ+'DW!;)01`$EN,=<=^U+?^+86\-ZS=0QW%E>6$7SPW<85XV8?
M(V,D$'V)Z4[2O8/=+'_"/:E_T-&J?]\1?_$T?\(]J7_0T:I_WQ%_\31I7BBU
MF!MKD75O-#:BX:6ZB\M9HQPTB^V?4#KTHLO&%E>WUK:+9:C$UWDV\DUOM25`
MNXN#GICUP>1Q2]X/=#_A'M2_Z&C5/^^(O_B:/^$>U+_H:-4_[XB_^)I8O%EM
M=22?9=.U*XMP'*744'[J4J#D*21GH0#C!]:JZ-XP%WH"ZGJ-A=6S2.%A019-
MQN)V",`DL2`,]/RH]X/=+/\`PCVI?]#1JG_?$7_Q-'_"/:E_T-&J?]\1?_$T
MG_"9Z:FFWEY<Q7=K]CE2*XAFCQ(C/C;P"0<[@>#6QI][_:%KY_V6YMLL0$N4
MV,0.^,G@TFY+<$DS(_X1[4O^AHU3_OB+_P")H_X1[4O^AHU3_OB+_P")KH<4
M8I<S'RHY[_A'M2_Z&C5/^^(O_B:Q+'1;YO&&KQ#Q#?JZ6]N6E"1[GSOP#\N.
M/ZUWE<YIO_(]ZY_U[6W_`+/51D[,3BM!W_"/:E_T-&J?]\1?_$T?\(]J7_0T
M:I_WQ%_\370XHQ4\S'RHY[_A'M2_Z&C5/^^(O_B:/^$>U+_H:-4_[XB_^)KH
M:*.9ARHY[_A'M2_Z&C5/^^(O_B:/^$>U+_H:-4_[XB_^)KH:,4<S#E1SW_"/
M:E_T-&J?]\1?_$T?\(]J7_0T:I_WQ%_\370T4<S#E1SW_"/:E_T-&J?]\1?_
M`!-'_"/:E_T-&J?]\1?_`!-=#BC%',PY4<]_PCVI?]#1JG_?$7_Q-'_"/:E_
MT-&J?]\1?_$UT.*,4<S#E1P5UHM\OC;383X@U!G:QN&$Q6/<H#1\#Y<8.1^0
MK<_X1[4O^AHU3_OB+_XFFWO_`"4/2/\`L'W/_H<5='BKE)V7]=1**U.>_P"$
M>U+_`*&C5/\`OB+_`.)H_P"$>U+_`*&C5/\`OB+_`.)KH<48J.9CY4<]_P`(
M]J7_`$-&J?\`?$7_`,31_P`(]J7_`$-&I_\`?$7_`,370XXKC_"OB2_U#6+^
MRU+RL-)*UDT:;<I'(493ZD?*?QJDY-7$[)V+_P#PCVI?]#1J?_?$7_Q-'_"/
M:E_T-&J?]\1?_$U0TOQ-=WOBR]BE>%-'6WDD@8KACY;A&<M_=)W?E6A8>+["
M_N[:`6U];I=Y^R3W$.R.XP,_*<YY'(R!D4VIH2Y6)_PCVI?]#1JG_?$7_P`3
M1_PCVI?]#1JG_?$7_P`34<'C?3;BXC1;:^6%[@VOVIH,1+*&*A2V>Y'49'(Y
M%2WWC"PL;JXB-M?316A`NKF"'?%;G&?F.<\`Y.`<=Z7OC]T3_A'M2_Z&C4_^
M^(O_`(FC_A'M2_Z&C4_^^(O_`(FI;[Q1:6MW]E@M;V_E$2S2"RB\P1HWW2QR
M.O)`&3QTJC;>(A:7&OS:C.YMK6[CBMXU3+?-&A"*`,DEC1[P>Z6?^$>U+_H:
M-4_[XB_^)H_X1[4O^AHU3_OB+_XFEC\76)M;^6XMKVTEL8?M$UM<1!9/+Y^9
M>2".".M2:?XILM1O!;+;WL#/"9X#<0E!/&.K)W.,C@X/(H]X/=(O^$>U+_H:
M-4_[XB_^)H_X1[4O^AHU3_OB+_XFI;/Q-!>:E'8/8ZA9R3*S0-=0;%E"\G;R
M2#CG!`-+X2O;G4O#%G=W<GF3R;]SX`SAV`Z>PH]Y*[#W;V(?^$>U+_H:-4_[
MXB_^)H_X1[4O^AHU3_OB+_XFNAQ1BIYF/E1SW_"/:E_T-&J?]\1?_$UA^)]%
MOH+*Q,GB&_F#:A;J`Z1_*2XP1A>HKO<5SGC+_CPT_P#["=M_Z,%7"3YD*458
M=_PCVI?]#1J?_?$7_P`31_PCVI?]#1JG_?$7_P`370T<>M1S,?*CGO\`A'M2
M_P"AHU3_`+XB_P#B:/\`A'M2_P"AHU3_`+XB_P#B:Z'CUI#THYF'*CG_`/A'
MM2_Z&C4_^^(O_B:/^$>U+_H:-4_[XB_^)K-TGX@V5RQBU&(VKJY7S1\T9P>_
M<5U\,\5Q$LL,BR1L,AE;(/XU,:RELQ)1>QA?\(]J7_0T:I_WQ%_\31_PCVI?
M]#1JG_?$7_Q-=#1BJYF/E1SW_"/:E_T-&J?]\1?_`!-'_"/:E_T-&J?]\1?_
M`!-=#BC%',PY4<]_PCVI?]#1JG_?$7_Q-8_BK1+^#PIJ<LGB+4)E6W8F-UCP
MWL<+FNYK"\:?\B7J_P#U[-51D^9"E%697@\/ZB;>(CQ/J8!0<!(N./\`=J3_
M`(1[4O\`H:-4_P"^(O\`XFMVV'^BP_[B_P`JDQ2<F/E1SW_"/:E_T-&J?]\1
M?_$T?\(]J7_0T:I_WQ%_\370XHQ2YF'*CGO^$>U+_H:-4_[XB_\`B:/^$>U+
M_H:-4_[XB_\`B:Z'%&*.9ARHY[_A'M2_Z&C5/^^(O_B:/^$>U+_H:-4_[XB_
M^)KH<48HYF'*CGO^$>U+_H:-4_[XB_\`B:/^$>U+_H:-4_[XB_\`B:Z'%&*.
M9ARHY[_A'M2_Z&C5/^^(O_B:/^$>U+_H:-4_[XB_^)KH<48HYF'*CG'\/ZD(
MV/\`PD^I_=/\$7_Q-9'A'1+^?PAI,L?B'4($>V4B*-8]J>PRN:[B4?N7_P!T
MU@^!O^1&T7_KT3^55S/E8N5<PG_"/:E_T-&J?]\1?_$T?\(]J7_0T:I_WQ%_
M\370T8J>9CY4<]_PCVI?]#1JG_?$7_Q-'_"/:E_T-&J?]\1?_$UT.*,4<S#E
M1SW_``CVI?\`0T:I_P!\1?\`Q-'_``CVI?\`0T:I_P!\1?\`Q-=#BC%',PY4
M<]_PCVI?]#1JG_?$7_Q-'_"/:E_T-&J?]\1?_$UT.*,4<S#E1SW_``CVI?\`
M0T:I_P!\1?\`Q-'_``CVI?\`0T:G_P!\1?\`Q-=#BBCF8<J.$\,:)?SZ?=-'
MXAU"$"^N%(1(^2'//*]36U_PCVI?]#1JG_?$7_Q-+X._Y!=Y_P!A"Y_]&&N@
MQ52D[BC%6.>_X1[4O^AHU3_OB+_XFC_A'M2_Z&C5/^^(O_B:Z'%&*GF8^5'/
M?\(]J7_0T:I_WQ%_\31_PCVI?]#1JG_?$7_Q-=#BC%',PY4<]_PCVI?]#1JG
M_?$7_P`31_PCVI?]#1JG_?$7_P`370XHQ1S,.5'/?\(]J7_0T:I_WQ%_\31_
MPCVI?]#1JG_?$7_Q-=#BC%',PY4<]_PCVI?]#1JG_?$7_P`36+H^B7TFN>($
M7Q#J$;1W489U6/,A\E#DY7\..PKN\5SV@_\`(Q^)_P#K\B_]$1U2D[,7*KH/
M^$>U+_H:-4_[XB_^)H_X1[4O^AHU3_OB+_XFNAQ1BIYF/E1SW_"/:E_T-&J?
M]\1?_$T?\(]J7_0T:I_WQ%_\370XHQ1S,.5'/?\`"/:E_P!#1JG_`'Q%_P#$
MT?\`"/:E_P!#1JG_`'Q%_P#$UT.*,4<S#E1SW_"/:E_T-&J?]\1?_$T?\(]J
M7_0T:I_WQ%_\370XHQ1S,.5'/?\`"/:E_P!#1JG_`'Q%_P#$T?\`"/:E_P!#
M1JG_`'Q%_P#$UT.**.9ARH^:?B1!-9^-[R&6YDNW58\S3`!C\@]`!15GXK_\
ME#O_`/<B_P#0%HKU:;?(C@G\3/1/C#_R#-$_["*?RKTD5YM\8?\`D&:)_P!A
M%/Y5Z2*\Z7\./S.V/QR^0M%%%9&A4U%[N/3YVL(EENPA\E';:I;MD^E<=<^!
M)(-%4VEW>SZFDJ7+"2[8123!PSG;]T9P<5WE%4I-;"<4]SE8;;6]-\2ZE-#8
M0W5KJ$T<@N&N`AA"J%*E<9.,$C'K5=O#U_.Y\^*,K<:U]LGS(#^Y0?NQ[_=7
MCWKJKUS%93R!S&4C9@X7.W`ZX[_2N>A\6VMK8Z9%,;R_O+NS6XC\BU^>8<9.
MT'"GG.,\4TY;HFR6A4UKPW?ZG'XB.V+=>&W6W1WP)(XL,58C[NXEA^-.L-`F
M31=6CMM$M]*O+FW:*)FNC.[$J>K]AG'&?6HO$'BR26PTE]%^VA=0EV_:(;02
M,@`;*A6XWY&,$<8-:L7BRP2YCM)!>.H<6[WIMR(?-Z;2PX!SQZ9XS3O*PO=N
M9SZ=K*6GA^[@TJ+SM,#QO8-=#D%-@97QC(Q^M07GA_6KRQN[F2"U:^O[N"2:
MV,O[N.&+E8]V.2<<G'5O2MZ3Q19KJ;V,5M?7!CD$4LT%N7BC<_PLWKR/IFL1
M/&$U_P"']6N6@O-+>T=E6Y>TWJ`'V]">6]1VIJ4]P?*&H:#K.OV^JW=W#!9W
M<]F+2UMA+O"KN#MO<#'S$`<=`*F&EZ[JVJ_:KZWAT^"/3Y8+>*.;S&BE?`+$
M@`'@<8K2U#Q58Z9<O:M#>W4D*"2X^RVYD$"GH7QTX!..31=^+M-M9K:&-;F[
MENH/M%NEI"9#(F>HQ]<\U-Y;6':)1TNUUX>&9='FT^WLWAL3;0S+<;Q(^W:&
M``^4=^>>:S[WP]J-[H>@)+H\3_V:2DNG_;-N\;-@82#N.N/0FMZ3Q=IPL+*Z
M@CNKK[:"8(;>$M(P7[V5[;>ASWK9M;A+NVCG1759%#`.I5AGU!Y!HYF@Y4SE
ME\.RO8Z1;QZ7;V,*7RW5U$DOF8"@E=S'EV)VY-==2T5+;925@HHHI#"N;TW_
M`)'O7/\`KVMO_9ZZ2N;TW_D>]<_Z]K;_`-GJELQ/='2444AZU(SEK#6]5U37
MKV"WDTZ*WL;GR);64-]H9`!^\R#@`YXX(..M1-XHOUBGTXPP_P!NI>BUCC`.
MQE;YEEQG.W9DGGJ"*@U?3[_6-6MC'H)L[NVN5:/5O/3`B5LD#!WG<O&TC'-:
MDNE.WCRWU86RF%-/>$S<9#EP0/7IGFM+1ZD796L_$]TWC*[TB\BB2S\SR;6=
M,Y,H1796SQR&R/H:T_#>J3ZQHRWDZHLAFE3"`XPKLH_05D3>'KF\_P"$@W`0
MRRWD=U839!PZ1KM;V^8$'V)I-!\-27'ABS@UM+BVNXY9I7CMKMXP"[D\E&&1
M]:)<MM!1YKCKK7-=N9=4GTF*Q-GIDC1,EP&+W#JH9PI!PGH"0>:5-?U36[H0
MZ`MG$B6L5S++=JSY,@RJ`*1V')_2J\EIKFE'6K"PTO[7%J,KS6]SYZJL1=0&
M\P,<\$9X!S1:Z=J?A:^+:?IS:G;S6<$!"3*C))$I4$[B/E(/;GCI3M$-;DMS
MXJU-_!O]KV&G1M=!)3,LDG[J!HR0V3U;D'`'7VK6DOYW;07#[!=-F50.&S$S
M8_.L2?3-3T[P&^DPZ>]]>WD<WG>1(BK$\F6/WB,KEL<>E;VA^?/I=I]NTY[2
M>W4($F9'887&X%21SSWS2=K:`KWU-<4445F:'.7O_)0](_[!]S_Z'%71USE[
M_P`E#TC_`+!]S_Z'%71U<MEZ?JQ+J%%%%0,*X*?PQK2:(KV'E0ZM!J%Q-"6<
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M:YEAEATD7<5K-;`&)CNPQ.>3QC:>F*?O/?\`K8E\H1:9K.@ZA*=)M8;Z"Y@A
MB+33>687C78&/!W*1@X'.0:AN?#FJ/+J=U$L)N/[3AO[97;Y)=D:J5/]W.&Q
M^%:FD^*[+4)H;4K<Q320>;')/"8TG4`;F0GJ!GVHM/&.F7EW!"D=VD5RYCMK
MJ6`K#.PSPC'KG!QTSCBE>295HF5>Z-K.M1:Q>W-G%:7$^FM8VUJ)PY.26+,^
M,=<8'UK4N]*O9M8TFZAVH+:SGB>0D$J[*@4X[\@UG>(/&D4%I<1Z=]I$T=Q'
M`+O[.6@+^8H9`W3."1]1US6W)XCT^&QU*[D:58].E:.=2GS`C!X'?.1CUS0W
M.PK1.5T'PQJEKK^F7UUIZ1/;+*+NZ:^:9[EV3&\`]`3^/-=3X5T^YTKPU9V5
MVJK/%OW!6R!EV(Y^A%:T;^9&K;67(!PPY'UI]*4W+1E**04445!05RGC^X-I
MH%O<A0QAOH)`I[X;-=77*^/8!=:';6Q8J);^",L.V7Q35[Z$RV*%MXXNKJ!9
MHX+7:>Q<@@^E2_\`"87O_/"T_P"^S67=^&X-.80PV@E5>-QZFJG]F+_T#1^=
M>2X8R^_Y&-JIO_\`"87O_/"T_P"^S1_PF%[_`,\+3_OLU@?V8O\`T#1^=`TQ
M<_\`(-'YT<F,[_D%JISRVKVE](DNUHYB6#*<BK]G?7FCR^9I]YY63DQ[@4;Z
MK7-WMY(\DHB0*[DJJH.%%-L]!EF(:7Y1Z'K7-"G-RNGJ0D[Z'JVD_$"UF*PZ
MH@MI.GFH=T9_J*[**6.:-9(W5T89#*<@BO(M)\/[74PP;CZL,UZ5H]O<0PA9
M3VZ8Z5[%%5%']X=,;VU-:BBBMB@K!\:?\B7J_P#U[-6]6#XT_P"1+U?_`*]F
MJH_$A2V9LVW_`!ZP_P"XO\JEJ*V_X]8?]Q?Y5+4C04444`%%%%`!1110`444
M4`%%%%`#)?\`4O\`[IK!\#_\B-HO_7HG\JWI?]2_^Z:P?`__`"(VB_\`7HG\
MJK[#_KN3]HZ&BBBI*"BBB@`HHHH`****`"BBB@#GO!W_`""[S_L(7/\`Z,-=
M#7/>#O\`D%WG_80N?_1AKH:J6XH[!1114C"BBB@`HHHH`****`"N=T'_`)&/
MQ/\`]?D7_HB.NBKG=!_Y&/Q/_P!?D7_HB.FMF+JCHA1112&%%%%`!1110`44
M44`%%%%`'SE\5_\`DH=__N1?^@+11\5_^2AW_P#N1?\`H"T5ZM+X$>;4^)GH
M?QA_Y!FB?]A%/Y5Z2*\T^,;A-,T0GH-04]/05U8\:Z+_`,]+O_P"F_\`B:X'
M%NG&WF=J:4W\CH:*Y[_A-=%_OW?_`(!3?_$T?\)KHO\`?N__``"F_P#B:CV<
M^QIS(Z&BN>_X371?[]W_`.`4W_Q-'_":Z+_?N_\`P"F_^)H]G/L',C8OXGFT
M^YBC&7>%U4>I(.*YS0=%O[&_T:6XA"I;:.+24AP<2;D./?H>:M_\)KHO_/2[
M_P#`*;_XFC_A-=%_YZ7?_@%-_P#$TU&:5K";BW<S;/0-1AMM(1X%#6VK3W,H
MWCB-C(0??[PXK/MO",MKJ#V\^A/?0M=M,EY_:3)&%+[ANBW?>7V&#@5T7_":
MZ+_STN__``"F_P#B:/\`A-=%_P">EW_X!3?_`!-.U3L3:)6T^WUS2=0N;.'3
MXI[.>]>Y%XTX78CG<RLG4L#D#''2L^YT76GT#Q!HRV"D3SO/;7'GKMEWR!MN
M.JD#/7CBMG_A--%_OW?_`(!3?_$T?\)IHG]^[_\``*;_`.)HM.][#]W:Y2FM
M-<TO5=6DT_3(KZ'4RLBN;A8_(<($(<'JO`/'/7BGZ)X=NM(U33<XDM[72OLK
MR@@9DWAN!UQP:M?\)KHO]^[_`/`*;_XFC_A-=%_YZ7?_`(!3?_$T6J6M8/=,
M1M!OX=`M+:31&N[B.YN)4>"]6"6W+2,RLK>X/(S^!KK=%BOH-'M(M2E$UZD0
M$T@_B;^OUK-_X371?^>EW_X!3?\`Q-'_``FNB_\`/2[_`/`*;_XFAJ;W0+E1
MT-%<]_PFNB_W[O\`\`IO_B:/^$UT7^_=_P#@%-_\34^SGV*YD=#17/?\)KHO
M]^[_`/`*;_XFC_A-=%_OW?\`X!3?_$T>SGV#F1T-<WIO_(]ZY_U[6W_L]/\`
M^$UT7^_=_P#@%-_\36%8>*M*C\8ZO<L]SY<MO;JN+24G(WYXVY'7O34):Z$N
M2NCOJ*Y[_A-=%_OW?_@%-_\`$T?\)KHO]^[_`/`*;_XFE[.?8KF1T&!Z48'I
M7/\`_":Z+_?N_P#P"F_^)H_X371?[]W_`.`4W_Q-'LY=@YD=!@>@I:Y[_A-=
M%_OW?_@%-_\`$T?\)KHO]^[_`/`*;_XFCV<NP<R.@P/2C`]*Y_\`X371?[]W
M_P"`4W_Q-'_":Z+_`'[O_P``IO\`XFCV<NP<R.@P/2EP*Y[_`(371?[]W_X!
M3?\`Q-'_``FNB_W[O_P"F_\`B:/9S[!S(Z&BN>_X371?[]W_`.`4W_Q-'_":
MZ+_STN__``"F_P#B:7)+L',AM[_R4/2/^P?<_P#H<5='7`W7BO2G\;Z9=![G
MRH[*X1LVDH.2T9'&W)Z'FMW_`(371?[]W_X!3?\`Q-7*$FE9=/U9*DM3H:*Y
M[_A-=%_OW?\`X!3?_$T?\)KHO]^[_P#`*;_XFI]G/L5S(Z&BN>_X371?[]W_
M`.`4W_Q-'_":Z+_?N_\`P"F_^)H]G/L',BGXHTO4[_5+9X[26]T\1,IMH[TV
MVV7/$C$$%ACC`Z>AJ'0]`U&Q_P"$8%Q"@^P6UQ'<;9`0K/C;CUZ&M+_A-=%_
MOW?_`(!3?_$T?\)IHO\`STN__`*;_P")JK5+6L3[M[W,NXT+5%TR^,-LDEPN
MM_VA#"9`/-C#*<9Z`D9ZT[5-&U34I]8N!:"(WVC+;(C2J2)<N2I(]-PYZ5I?
M\)IHO_/2[_\``&;_`.)H_P"$UT7^_=_^`,W_`,30E470/=,Y=*UG5[^S74;*
M*Q@L;>6/S$F$GG.Z;,J!R%`R>><XJ*UTO7;BUT?1[S3X;>WTV:*22\6<,LPB
M^[L4<@GC.>G/6M;_`(331?[]W_X`S?\`Q-'_``FFB_W[O_P!F_\`B:+5.PK1
M[F!/HOB%=%GT"#3X9+<7GGI>&X`WQF828V]0_4<\<5/K.G2S^/+6TAV?8]05
M+J]3//[@_*<>C$J/^`UL?\)IHO\`?N__``!F_P#B:A_X2OP]]J^U8N/M!3R_
M-^P2[MN<XSLZ9[4_?[!:/<Z>BN>_X371?[]W_P"`4W_Q-'_":Z+_`'[O_P``
MIO\`XFH]G/L7S(Z&BN>_X371?[]W_P"`4W_Q-'_":Z+_`'[O_P``IO\`XFCV
M<^P<R.AKF_&/_'AI_P#V$[;_`-&"G_\`":Z+_?N__`*;_P")K"\4>*M*N[.Q
M6)[G*:A;R-NM)5X#@GJM.,)<RT)E)6.Z:&-SEE!IOV:'^X*Q/^$UT7^_=_\`
M@%-_\31_PFNB_P!^[_\``*;_`.)I*$[;%<R-O[-#_<%'V>(=$'Y5B?\`":Z+
M_?N__`*;_P")H_X371?^>EW_`.`,W_Q-')/L',CF9O!45@?W>9YV8EI",#GT
M%:VF^%@N'F_*KQ\8Z&3DM=_^`,W_`,33O^$TT3^_=_\`@#-_\34QH.*]U"3B
MC6MK"&V4!$'%6@*Y_P#X371?[]W_`.`4W_Q-'_":Z+_?N_\`P"F_^)JO9S[#
MYD=#17/?\)KHO]^[_P#`*;_XFC_A-=%_OW?_`(!3?_$T>SGV#F1T-8/C3_D2
M]7_Z]FIG_":Z+_STN_\`P"F_^)K&\5^+-)N_"NIV\3W1DD@95W6DJC/U*X%$
M82YEH3*2LSM;;_CUA_W%_E4M<U;^,]&6VB4O=Y"#_ERF]/\`=J3_`(371?[]
MW_X!3?\`Q-'LY]AJ2.AHKGO^$UT7^_=_^`4W_P`31_PFNB_W[O\`\`IO_B:/
M9S[#YD=#17/?\)KHO]^[_P#`*;_XFC_A-=%_OW?_`(!3?_$T>SGV#F1T-%<]
M_P`)KHO]^[_\`IO_`(FC_A-=%_OW?_@%-_\`$T>SGV#F1T-%<]_PFNB_W[O_
M`,`IO_B:/^$UT7^_=_\`@%-_\31[.?8.9'0T5SW_``FNB_W[O_P"F_\`B:/^
M$UT7^_=_^`4W_P`31[.?8.9&]+_J7_W36#X'_P"1&T7_`*]$_E39/&FBF)P'
MN^5/_+E-_P#$UC>$?%>DV?A#2;>9[GS(K95;;:2L,^Q"X-/DDH[$\RYCO**Y
M[_A-=%_OW?\`X!3?_$T?\)KHO]^[_P#`*;_XFIY)=BN9'0T5SW_":Z+_`'[O
M_P``IO\`XFC_`(371?[]W_X!3?\`Q-/V<^P<R.AHKGO^$UT7^_=_^`4W_P`3
M1_PFNB_W[O\`\`IO_B:/9S[!S(Z&BN>_X371?[]W_P"`4W_Q-'_":Z+_`'[O
M_P``IO\`XFCV<^P<R.AHKGO^$UT7^_=_^`4W_P`31_PFNB_\]+O_`,`IO_B:
M3A)=`YD'@[_D%WG_`&$+G_T8:Z&N#\+^*]*M=/NDE>YRU].XVVDK<%R1T6MO
M_A-=%_OW?_@%-_\`$U4H2OL3&2L=#17/?\)KHO\`?N__``"F_P#B:/\`A-=%
M_OW?_@%-_P#$TO9S[%<R.AHKGO\`A-=%_OW?_@%-_P#$T?\`":Z+_?N__`*;
M_P")H]G/L',CH:*Y[_A-=%_OW?\`X!3?_$T?\)KHO]^[_P#`*;_XFCV<^P<R
M.AHKGO\`A-=%_OW?_@%-_P#$T?\`":Z+_?N__`*;_P")H]G/L',CH:YW0?\`
MD8_$_P#U^1?^B(Z7_A-=%_OW?_@%-_\`$UAZ-XKTJ'7?$$KO<[)[J-DQ:2DX
M$*#D!>.0>M/DDD]!<RNCO117/?\`":Z+_P`]+O\`\`IO_B:/^$UT7^_=_P#@
M%-_\34^SEV'S(Z&BN>_X371?[]W_`.`4W_Q-'_":Z+_?N_\`P"F_^)I^SGV#
MF1T-%<]_PFNB_P!^[_\``*;_`.)H_P"$UT7^_=_^`4W_`,31[.?8.9'0T5SW
M_":Z+_?N_P#P"F_^)H_X371?[]W_`.`4W_Q-'LY]@YD=#17/?\)KHO\`?N__
M``"F_P#B:/\`A-=%_OW?_@%-_P#$TG"2Z!S(\3^*_P#R4.__`-R+_P!`6BJW
MQ(OH=2\;WEU;;S$ZQX+H4/"`=&P:*]2FGR(\Z?Q,],^,/_(-T3_L(K_*O2:\
MV^,/_(,T3_L(I_*O2:\Z7\./S.Z/QOY$<]Q#:PM-<3)%$OWGD8*H^I-/W`C(
M;K7'^,[RTGO=/T:]@N+BUDW7%U';V[RL4480$*"0"QSG_9JI8Z[=?\(;IICE
MEBN;?4(+"<RQ[7*^8%^96&1N0@\\\U*@VKCY]3N]P'5NE&X>O6N,\17%U<S^
M)=/6\DA@ATI)E"!<@GS-W4=PH!_2FQ'4K>S\/:-!JTX>_C:1[MXT+QQI&IV(
M-NW//4@\9ZT<CL'/J===7UM8QI)=7"0H\BQ*7.`78X4?4FI\^]<%=:KJ=LES
MIT]V+J2SU6SB6Y>)-SQR%3AAC&X9QD`=NE,U#4->,'B;4(-7,4>D7+>1;B%2
ML@"*Q5R1DCGC&#R>33]F[#YST#(]:,^]<E:W&K6&O0VUWJ9O([VQEN-IB5!"
MZ%?N8YVX;H<GCK6/97WB632O#NH'7`TFJNL$D;6R%(PR,0ZXP=_R]SC)Z4E3
M;ZASGHN?>C/O7"3ZMJVG:?K%J^HO<36-]:QQW3QJ':.1D)#`#&<,1D`5HZWJ
MM[::MJT,$Y6.#16NHU`'RRAF`;]![4N1W#G1U61ZT9]ZXNSO=8L+_2'O=2:^
MCU&UDDDA\E46-TC#C9@9P>002:I:!K7B/4+O3;UH=2EM[QLSI);Q+;1QL#@Q
ML#OXXZYSSP*?LWW#G/02P'5L49]ZY3QO:S3VVE>5?3VO_$QA7,04\EN#\P/(
M[?K5+Q'J%_92/:V.IZM-=6=J))%M;6%@#@X:9FP,-CHN.`:2C=!S6.XS[T9]
MZXV*]U;6-8TRWAU)K."?2H[V?R8U9BY8<*6!P.>?:L]=1U[5=:5+2_U./_B8
M-&Z0VB?91;JQ!82LIR>.><YR,=Z.1]PYST+/O1N!X#"O/+K7?$5UJ=_+IT.I
MNMI=F"&"&WB-NX4@-O9COR>>F,<=:U-&L;G_`(3O7)FU*YV*(&:W*IM8,C84
M_+G"]L'ZYHY/,%._0[#FN=T[/_"=ZY_U[6O_`+/71=JYS3?^1[US_KVMO_9Z
M([,;W1T?-'-+25(PHJD^KZ?'?K8/?6RWC_<MVE42-]%SFI!J%F;,WGVN#[*N
M29O,&P8.#STZT68719HYJ"*]MIIY8(KB)YH<>9&K@LF>F1U&:=!<PW,8D@E2
M5,D;D8,,@X/ZT687)>:*IW6K:=9W,5M=7]K!/+_JXI9E5G^@)R:+W5;#355K
M^]MK57.U#/*J;C[9-%F%T7.?6BJ%WK>EZ?Y?VW4K.V\Q=R>=.J;AZC)Y%$&M
M:?=>0;:[AN$GD,4;PL'4L%+$9''0468KHO\`-'-+10,YN\S_`,+"TC_L'W7_
M`*'%71\USM[_`,E#TC_L'W/_`*'%71U<]EZ?J)=1.:.:6BH&)S1S2T4`)1S5
M*^U?3M,V_P!H7]K:;\[//E5-V/3)HDU:PB@MIVNX?)N9%B@D5MRR,WW0"/6B
MS"Z+O-'XT9XS5>*^MIKNXM8Y5:>WV^:@ZIN&5S]10!8YHYI:9+(L4;2.0J*"
MS$]@*`'<T<U#9W<%_:0W=K();>9`\<B]&4]"*GH`3FCFEHH`3FCFEHH`3FN=
M\8DBPT[_`+"=K_Z,%='7-^,O^/#3_P#L)VW_`*,%5#XD*6QT=%1?:H`<&>,?
M\#%)]KM_^>\7_?8J.9=QW)J*A^UV_P#SWB_[[%'VJW_Y[Q?]]BES+N%R19$?
M=L=6VG#8.<'T-.KQW4-1NK3QKJCV-V\+-/E61N&X'!'0UT^E^/\`9B+6+<IC
MC[1",K^*]1^%<\<7!RY9:&:J*]F=W1S4%I>6U]`LUK/'-&>C(V15BNE:F@G-
M'-+13`3FL+QI_P`B7J__`%[-6]6#XT_Y$O5_^O9JJ/Q(4MF;-MG[+#_N+_*I
M.:CMO^/6'_<7^52U+&A.:.:6B@!.:.:6B@!.:.:6B@!.:.:6B@!.:.:6B@!D
MF?*?_=-8/@;_`)$;1?\`KT3^5;TO^I?_`'36#X'_`.1&T7_KT3^55]EB^T=!
MS1S2T5(Q.:.:6B@!.:.:6B@!.:.:6B@!.:*6B@#GO!^3IEYS_P`Q"Y_]&&N@
MYKG_``=_R"[S_L(7/_HPUT-.6XH["<T<TM%(8G-'-+10`G-'-+10`G-'-+10
M`G-<]H7_`",7B?\`Z_(O_1$==%7.Z#_R,?B?_K\B_P#1$=-;,3W1T/-'-+12
M&)S1S2T4`)S1S2T4`)S1S2T4`)S12T4@/G'XK_\`)0[_`/W(O_0%HI?BO_R4
M._\`]R+_`-`6BO6I?`CSIM\S/0_C#_R#-$_["*?RKTGL:\V^,/\`R#-$_P"P
MBG\J])%>?+^''YG;'XY?(J1:=!#J4^H*A^TSQI&[%B?E7.`!VZFJ=UX;TV\_
MM`30,RZ@4:<;R,LHPK#^ZPP.1Z"MBBL[LNR,2Q\,:78-=-'%+(]W$(;AYYFD
M:51G[Q8\GDBH_P#A$=,.EPZ>?M1CMY/,@D-RYEA.,?(^<J,<8!Z5OT4<S[AR
MHQ8_"^F1V*V8BD,8N%NF9I69WE4@AF8G+'@=:ED\/V#VNI6[(_EZDY>Y&\Y8
ME0IQZ<`=*U:0]*+L+(Q;T:-#J]A]KN8HKYHGM[:-YL,ZMC<`O?[HYJ2+0-/A
ML]-M4C<0Z<X>V&\DJ0"!GUX)ZURFL276E>+]7U<7KR"TTQ9Q`T2;2-S83=C(
M`/.<YK3AN-;TO5='2_U1;^+4BT<D?D+'Y+A"X*$<E>"/FSVJW%V6I">ILSZ!
MIUTNH+-"774=OVD%S\VT``CTP`.E4[?PMHUM)<Q@S//=6IMYFFN6>22(YZDG
M/?&>U1>#IM5U#28=4U'4/.%PAVP)"JJF&(!R!DD@<]J6Y`_X3Y.!_P`@B3_T
M8*5G=JX]+7L7H8-'N;NR,%S%-/IZ,L*QSABJE0IR`>>!WJI:Z#H>G:K&8)Y(
MI@QDBLS>-Y:DYR5BW8]>W<UP^DVTEKIGAK4YM%M+6UAN(RU_:N#.^[*C>-HP
MI)&>6K?ELD\/:]-=ZGI5M>V=W?K+%J0`,UL[D!5<'G:#@`J>,]*;5M+BNF=;
MJ>E6NL6+6EVC&(LK@HY1E93D,K#D$'N*SKOPAI=\Z-<"Y8B$028NG'G(.@DP
M?GZ]ZWQTYI:A2:V+:3,ZUT6SL[F&XA1A)#:BT0ER<1`@@?7CK7%1>$=42]PM
MA!!=?:S.=7BO&7Y2^XXA`QDK\N#QUKT:BFI-"<4S#N?"NF7.H27I%S%)*P:9
M(;EXTE(Z%U4X)X`_"K!T2U.MC5U\Y+O8$8QS,J2`9QN3.&QDXS6I12NQV0E<
MYIO_`"/>N?\`7M;?^SUT=<YIO_(]ZY_U[6W_`+/3CLP>Z.DI#2T5(SA[BVD\
M+ZK/>W-E;7VEWM\LIN-H^T6TCE57.?O*&Q@@@BHIM)D_X3'^P05_LBY?^U9(
M\_Q*<&/']TOM;\ZZ)?">CKJ/VXV\CRB0RA'G=HU?KN$9.T'//2M$Z=:MJ::B
M8R;I(C"K[CPA.2,=.HJ^8CE9P;JVF>*=9\10YQ:WZ0WH'\5NT4>3]4;#?3-:
M'AC49[+PM;M:Z9=:@LEU<DFV:,;!YK8)W,.N>U=5'I=G&UXPA!^VMNN`Q)#G
M:%Z'V`%)I>DV6C:=%86$7DVL6=B;B<9.>IYZFG*::!1:9R-K:65_I_C"?4H(
MGE-S,DC2@%DC6,;!GL`.1CZU'X3@34M4F?584GGCTJR5%G4-A60E^#ZMUKI+
M[PGHNHWK7=S:LTDF!*%E=4FQTWJ"`^/<&I-3\,Z5J\T<UU`_FHGEAX97B8I_
M=)4C*^QXHYU:PN5G.:)=VNF_#LWUU`D\5JTZVRNH8LHD98U&?7Y0*U-%\.S6
M-AI&\QBXBF>ZN\#&Z216W8QZ%@/H*UI=%T^:TM+1K91;VCI)#$I(52GW>!U`
M]#6ABE*5]44HB"EHHJ"CG+W_`)*'I'_8/N?_`$.*NCKG+W_DH>D?]@^Y_P#0
MXJZ.KELO3]6)=0HHHJ!A1110!QWB2.\E\8Z.MC;V4\PM;@[;PD)C*<\`\_A6
M1IT\^FZ;#8JHMKJ/Q"D5TD8!B_>'<1'QPI!'H1S79ZKX>T_69H9KQ9_-@#+&
M\-P\1`;&1E"/04D7AK2H+2"VCML1PW`NE^=BQE'.]F)RQ^N:T4E:Q#B[G*W%
M_JUQHVK>)(]8EMVL9Y5AL@J^3LC;;M?(W%FP><C&13;O5+JRU'Q'<VK+#<3M
MI\2/(,B$R+MW$=\9KIY_"6BW&HM?2VA,CN))$$KB.1QT9HP=K'@<D=JM3:%I
MMPU\9[59?MZJMR')(<*,#CMCVIJ<5T%RLYB[O-2\-7US:?VM+?1OILUTC7H7
M=#(A`!RH'RG/0]Q4&B-K,MW/=2W>M&SCL69UU&)(P9S_`'0%R5`_#IR:V[CP
MC:0:+J5MI8\J[NX/)^T7,CS-CLI+$G;R>/?-9FA>%KBVU5+AM,L])MD@>&6&
MTNGE-SN``W9```P<=3S0G&P-.Y!I=SJ6N1Z1I_\`:D]DO]D1WDLMLJ"29V.W
MN"`HQD@#N*FU*?4].U2":^U/4$TN-(5CN[5(VC9\X?SUP2`3CD<"MVX\)Z-<
MVEG;/;.J6<?E0-',Z.J8P5W*02#@9!-)+X1T2:XCF:U?$80")9G$1V?=R@.T
MXP.H["ES1O\`\`.5FV*6BBLS0****`"N;\9?\@^P_P"PE;?^ABNDKG/&/_'A
MI_\`V$[;_P!#%5#XD3+8\^LH;[;*9+19$,C&,N<'&35KRKG_`)\(O^^__K5Z
M'JFC)J!R>,>E9?\`PB4?]XUY3RZ[O?\`#_@F+H'(>5<_\^$7_??_`-:CRKC_
M`)\(O^^__K5U_P#PB4?]XT?\(E'_`'C^=+^S5W_#_@A[`\YU)HTNU#PI%.HR
MQ1LX'O68_B,2-M2SW^AW5HZQHES)KFH6\*-Y$<I5GQQ],U8T[PZ`5"1[V]2*
MRAA'*5DB53Z%72KW4HK@3V`>T8]6#\'ZCH:]8T'5I[RU1;MHVG_B:-2`:Q--
M\*LP5IA@>E=59Z;#9J`BC(KTJ%'V2W-XPY2]VHHHK<L*P?&G_(EZO_U[-6]6
M#XT_Y$O5_P#KV:JC\2%+9FS;?\>L/^XO\JEJ*V_X]8?]Q?Y5+4C04444`%%%
M%`!1110`4444`%%%%`#)?]2_^Z:P?`__`"(VB_\`7HG\JWI?]2_^Z:P?`_\`
MR(VB_P#7HG\JK[#_`*[D_:.AHHHJ2@HHHH`****`"BBB@`HHHH`Y[P=_R"[S
M_L(7/_HPUT-<]X._Y!=Y_P!A"Y_]&&NAJI;BCL%%%%2,****`"BBB@`HHHH`
M*YW0?^1C\3_]?D7_`*(CKHJYW0?^1C\3_P#7Y%_Z(CIK9BZHZ(44"BD,****
M`"BBB@`HHHH`****`/G+XK_\E#O_`/<B_P#0%HH^*_\`R4.__P!R+_T!:*]6
ME\"/-J?$ST/XP_\`(,T3_L(K_*O2:Y'QWX2NO%ME906MY':M;3^:6="<\8&,
M5A_\(-XV_P"AZF_[Y;_&N!<LH)7M8[=5)NQZ5FC->:_\(-XV_P"AZG_[Y;_&
MC_A!O&W_`$/4_P#WRW^-+V<?YE^(^>78]*S1FO-?^$&\;?\`0]3_`/?+?XT?
M\(-XV_Z'J?\`[Y;_`!H]G'^9?B'/+L>E9H/2O-?^$&\;?]#U/_WRW^-'_"#>
M-O\`H>I_^^6_QH]G'^9?B'/+L=U+H]G/>W%U+'YCW%N+:56.5:,$G&/Q-4M-
M\*Z?I=S'<1/=3/"AC@^TW#2B!3U"`].`!]!7)?\`"#>-O^AZG_[Y;_&C_A!O
M&W_0]3_]\M_C3Y%_/^8KO^4[_3-/M])TZ&QM0P@A&$#-D]<]?QIK:;;OJ8U!
M@WV@0&WR&XV$YZ>N:X+_`(0;QM_T/4__`'RW^-'_``@WC;_H>I_^^6_QHY(_
MS?F/F?\`*=-9^"M,LVMQY]_/#;,'AM[BZ9XD8<@A.G':IO\`A%+!KX74LMY,
MJR^<EM+=.\*OG(8(>.#R*Y/_`(0;QM_T/4__`'RW^-'_``@WC;_H>I_^^6_Q
MI\J_G_,5W_*>E#@<T9KS7_A!O&W_`$/4_P#WRW^-'_"#>-O^AZG_`.^6_P`:
MGV<?YE^(^>78]*S1FO-?^$&\;?\`0]3_`/?+?XT?\(-XV_Z'J?\`[Y;_`!H]
MG'^9?B'/+L>E9HS7FO\`P@WC;_H>I_\`OEO\:/\`A!O&W_0]3_\`?+?XT>SC
M_,OQ#GEV/2LUSNG?\CUKA_Z=K;_V>N7_`.$&\;?]#U-_WRW^-0K\/?&"74MR
MGC1UFE55>0(VY@.@//;)IJ$5?WOS!REV/4,T9KS7_A!O&W_0]3_]\M_C1_P@
MWC;_`*'J?_OEO\:7LX_S+\0YY=CTK-&:\U_X0;QM_P!#U/\`]\M_C1_P@WC;
M_H>I_P#OEO\`&CV<?YE^(<\NQZ5FC->:_P#"#>-O^AZG_P"^6_QH_P"$&\;?
M]#U/_P!\M_C1[./\R_$.>78]*S1FO-?^$&\;?]#U/_WRW^-'_"#>-O\`H>I_
M^^6_QH]G'^9?B'/+L>E9HS7FO_"#>-O^AZG_`.^6_P`:/^$&\;?]#U/_`-\M
M_C1[./\`,OQ#GEV/2LT9KS7_`(0;QM_T/4__`'RW^-'_``@WC;_H>I_^^6_Q
MH]G'^9?B'/+L=/>_\E"T@_\`4/N?_0XJZ/->7M\/?&#W<=TWC1S/&C(DI1MR
MJ<9`YZ'`_*IO^$&\;?\`0]3_`/?+?XU3A%I>\OQ$I2['I6:,UYK_`,(-XV_Z
M'J?_`+Y;_&C_`(0;QM_T/4__`'RW^-3[./\`,OQ'SR['I6:,UYK_`,(-XV_Z
M'J?_`+Y;_&C_`(0;QM_T/4__`'RW^-'LX_S+\0YY=CTK-&:\U_X0;QM_T/4_
M_?+?XT?\(-XV_P"AZG_[Y;_&CV<?YE^(<\NQZ5FC->:_\(-XV_Z'J?\`[Y;_
M`!H_X0;QM_T/4_\`WRW^-'LX_P`R_$.>78]*S1FO-?\`A!O&W_0]3_\`?+?X
MT?\`"#>-O^AZG_[Y;_&CV<?YE^(<\NQZ5FC->:_\(-XV_P"AZG_[Y;_&C_A!
MO&W_`$/4_P#WRW^-'LX_S+\0YY=CTK-&:\U_X0;QM_T/4_\`WRW^-'_"#>-O
M^AZG_P"^6_QH]G'^9?B'/+L>E9HS7FO_``@WC;_H>I_^^6_QH_X0;QM_T/4_
M_?+?XT>SC_,OQ#GEV/2LUSGC'FPT_P#["=M_Z,%<Q_P@WC;_`*'J?_OEO\:A
MN/A[XPND59_&CRJCK(H=&X8'(/7J*<813OS?F)RE;8]0S1FO-?\`A!O&_P#T
M/4W_`'RW^-'_``@WC;_H>I_^^6_QI>SC_,OQ'SR['I6:*\U_X0;QM_T/4_\`
MWRW^-'_"#>-O^AZG_P"^6_QH]G'^9?B'/+L=W?:='>+M(`!.3@=32VNEV]LH
M"H*X/_A!O&W_`$/4W_?+?XT?\(-XV_Z'J?\`[Y;_`!H]G'^9?B',^QZ4,`8`
MHS7FO_"#>-O^AZG_`.^6_P`:/^$&\;?]#U/_`-\M_C1[./\`,OQ#GEV/2LT9
MKS7_`(0;QM_T/4__`'RW^-'_``@WC;_H>I_^^6_QH]G'^9?B'/+L>E9%8/C3
M_D2]7_Z]FKD_^$&\;?\`0]3_`/?+?XU%<_#[QC=VTD$_C626*1=KQNC$,/0\
MTU"*:?-^8.4FMCTNV/\`HL/^XO\`*I,UYH/`OC55`'CF8`#``5N/UI?^$&\;
M?]#U/_WRW^-+V<?YE^(<TNQZ5FC->:_\(-XV_P"AZG_[Y;_&C_A!O&W_`$/4
M_P#WRW^-'LX_S+\0YY=CTK-&:\U_X0;QM_T/4_\`WRW^-'_"#>-O^AZG_P"^
M6_QH]G'^9?B'/+L>E9HS7FO_``@WC;_H>I_^^6_QH_X0;QM_T/4__?+?XT>S
MC_,OQ#GEV/2LT9KS7_A!O&W_`$/4_P#WRW^-'_"#>-O^AZG_`.^6_P`:/9Q_
MF7XASR['I6:,UYK_`,(-XV_Z'J?_`+Y;_&C_`(0;QM_T/4__`'RW^-'LX_S+
M\0YY=CTB4_N7_P!TU@^!_P#D1]%_Z]$_E7*'P+XV((/CF8@_[+?XU%;?#WQA
M9VT=O;^-'AAC7:D:(P"CT'-/DA:W-^8N:5[V/4,BC->:_P#"#>-O^AZG_P"^
M6_QH_P"$&\;?]#U/_P!\M_C2]G'^9?B/GEV/2LT9KS7_`(0;QM_T/4__`'RW
M^-'_``@WC;_H>I_^^6_QH]G'^9?B'/+L>E9HS7FO_"#>-O\`H>I_^^6_QH_X
M0;QM_P!#U/\`]\M_C1[./\R_$.>78]*S1FO-?^$&\;?]#U/_`-\M_C1_P@WC
M;_H>I_\`OEO\:/9Q_F7XASR['I6:,UYK_P`(-XV_Z'J?_OEO\:/^$&\;?]#U
M/_WRW^-'LX_S+\0YY=CJO!_&F7F?^@A<_P#HPUT&:\OM_A[XPM49(/&CQ*SL
MY"(W+$Y)Z]2:F_X0;QM_T/4__?+?XTY0@W\7YB4I);'I6:,UYK_P@WC;_H>I
M_P#OEO\`&C_A!O&W_0]3_P#?+?XTO9Q_F7XCYY=CTK-&:\U_X0;QM_T/4_\`
MWRW^-'_"#>-O^AZG_P"^6_QH]G'^9?B'/+L>E9HS7FO_``@WC;_H>I_^^6_Q
MH_X0;QM_T/4__?+?XT>SC_,OQ#GEV/2LT9KS7_A!O&W_`$/4_P#WRW^-'_"#
M>-O^AZG_`.^6_P`:/9Q_F7XASR['I6:Y[0?^1B\3_P#7Y%_Z(CKEO^$&\;?]
M#U/_`-\M_C4,7P]\80S3RQ^-'22=@TC*C9<@``GGK@`?A34(_P`WYAS2OL>H
M9HS7FO\`P@WC;_H>I_\`OEO\:/\`A!O&W_0]3_\`?+?XTO9Q_F7XASR['I6:
M,UYK_P`(-XV_Z'J?_OEO\:/^$&\;?]#U/_WRW^-'LX_S+\0YY=CTK-&:\U_X
M0;QM_P!#U/\`]\M_C1_P@WC;_H>I_P#OEO\`&CV<?YE^(<\NQZ5FC->:_P#"
M#>-O^AZG_P"^6_QH_P"$&\;?]#U/_P!\M_C1[./\R_$.>78]*S1FO-?^$&\;
M?]#U/_WRW^-'_"#>-O\`H>I_^^6_QH]G'^8.>7\IYY\5R/\`A8=__N1?^@+1
M757_`,'=:U.\:ZO?$$%S.X`:66)BQQP.]%=L*M.,4KG)*G-N]CV2BBN5\3ZG
MKUEJ-E'I=L)(78;B4ZMAOEZ\\#...@YYQ7G)7=CN;LKG544R)F9%+#DJ,\8I
M](845G:[J?\`8VBW5_Y?F-"F53.-S$@*/;)(K/MGUK2TDO=;U2TFLUA:2=4M
MS'Y!`S\IR=PZCGGI32NKBN=#17-VOC+3YUNC/'<6?V>`W!$ZKEXQP6&TGOC@
MX/(XJO:>)9[SQ(D1M+^T@33Y)VM[B`!G(=<,N,YXSQG/J*:@Q<R.LHKGH/%<
M,@O!<6%_92VML;HQ7,:AGB&<LN"1VQ@X-,_X2^(V4%RNF:DS74FRUA\M1).-
MN[<H+#`QZX-+E8<R.DHJ&VG^T6T<WER1[U#;)%VLOL1V-<IH&LZCJ-Q=276J
MVR21"03:7]GVRVQ!(4Y)RPP,YQ@YXH2N.YV-%<M%XMCBLM-7[-?ZA=7EF+I!
M;P*&=>,DC=A>O3-6W\31MIUI?66GZA?QW*&15MH@2@'7=N(`.>,9S3<6A<R-
MZBL.VUN*_P!2TS[+<.;>\M)+A$\H88`IR6SE2-W3'KZ4NH^(X['4/L,-C>WU
MPJ"25+2,-Y2DX!;)'7!X&3QTI6>P[HVZ*Y*?6[FWNM<,EU(D5O=VD<6V)7*B
M0)D8..I;DD\9]JL77C*SM+VZMWL[]X[258KFX2(&*$MC!)ST^8=`<=Z?*Q<R
M.EHK`G\00V%UK#74\K161A`B6$9RZ\*I!RY8D=ABG+X@F_L]KEM%U591((Q:
MF%?,;C.1AMNWWS[4N5CYD;M%<M/XB:]31IK(S6XEU/[+<PRH`ZD(^Y&'/<#D
M'\:FO/$5W;>+K71TTRXFMY8#(TT:KP=RC/+#Y1GGC/3%/E8N9'1T5RD_BV.X
MTK4KFUAOK>*T#J;QH%9-ZOM*J"PW']/?/%7M3\21Z5<;+BPOS;H5$MXD0\F/
M=@#))R>HS@'%'*PYD;M%<Q)X@;3]3UTW;2RPV\UO%;PQJ"Q9T'RCIU8]S6S;
M7S7>F&Y:WN+1]K9BG0!T(SU`)!_`XI.+0TTR]17+1^+8XK+34^SW^H7=Y9BY
MC%O;J&=>,DC=A3SZXK5&KQW?AI]6LF)5K9IH]ZX((!X(]B*.5A=&I17":9KN
MJK+9Q7&K6NH?;K![@K%"J/:LJ!@3@D$$G'/>M#PWXK&H6NFV]S!>K<7%H)$N
M)H0J7#*H+[<<^_09[53@TKB4D=716!;^*8);PVUS8ZA8DQ/-&UU"%$J)]XC!
M)&`0<$`\TD'BRUDTN?49[.]M;:-5>-YHQ^_5N%*8)SDXX.#R*GE8^9'04'BL
M?1O$%OK+W$*0SV]Q!M+PS[=P5LX.5)!!P>_:H[/593J6OI=2*+:P=-AVXVJ8
M@[9]>2:+,+HV\TM<AI6H:DDVA?:)6/\`:TEQ/*C\E$V;HT7TP,?K6MX;U&YU
M/PY:WMT0TT@<ML7`.&8#`^@IN+0)W-FBN$TCQ1=^9J%]J,>J'S+IK:TL1#'@
MD$@*F#DN`I+%C@5L-XQLH].FNYK:]AD@N$MYK5X@94=R-O`)!!R,$$T.+0E)
M-7.CHK)GUM;30UU2[M+J"/Y?,B=5\R,%MN6`.,#.3@]*2ZUZ.VNKFVCM;NZF
MMXT=UMXPQ)<D*HYZ\$\\`=Z5F.Z->BN</B^SCTN6]FM;V)H;E;66V:(&5)&Q
MM&`2#G<.A/6GKKP%^INC/91BP>ZDMYXE!C"O@LS`GGV&?K3Y6',CH**YZR\6
M6]U,(I;&_M&>%IX/M,043HHR2N"><8.#@\U:C\06LB:8^V55U&)I8B0/E4)O
M.[\/3-*S"Z->BL?1M=76E:2&RO((2H>*6=`%F0]&4@G\C@\]*IS^)8=..J2W
M3W$T=M=QVX2.`94NJD!<'+\M['M1RN]@YD=)17/)XMM/L-[<7%M>6LEFZI+;
M31CS26^X%`)!W9XYK*D\47+7&N2N+RPCL[*&0136ZL\3%GR0,X;(`_BQ34&Q
M<R.VHK#N?$D=OJ1L(;&^O)8PAN'MH@RP;NF[)';G`R<4D_B2.VU-+.:POXXG
MF%NMXT0$)D/09SNY/&<8]Z7*Q\R-VBN+3Q==SV.O2365U8K82.J7'DHX`&W@
MKOY?G/88Q6IJ/BJWTZ[F@%G?W0MD#W4MM$&6`$9^;)!SCG`R<4^20E),Z"BN
M;OO&%I9SO#%:7UXR6Z73-:Q!E$39^8DD>G3KZ`U/+XGMQ>V]M;6MY>&6))V>
MWC#+%&Y^5FR0<'GH#TI<K'=&[12#ZTM(84444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!2%<G-+65J?B#3M)N8H+NX$<DA&`>PP>?I\N.,]10E?83MU-2JNH:
M;::K:-:WT(F@8@E"2.1TZ54O_$>F:;<P6]S<A))>0".@()!/_?)'&><5JJ<@
M'UHM8=T95[H-K<^'I-&BS!;M'Y:;#DQD'*D9]#@UES:1K^KZ;=:;K%WIZ6\M
MNT):UC8M(Q&`Y#<+CK@9SGK72SS1P0/-+(L<<:EG=C@*!U)K%A\6Z//;R7"S
M3K%&R*SR6TB##G"L-P&5)_BZ52;Z$M(RK;PE<OIM]:7%IHED9[?R4FTZW(=F
MR"&;('&0#MY^M3_V+K]Y=RW=]>V4$S6$EG&;,/F-F((?+=>G3C%:]_X@TW3#
M="ZG9?LL`N)MJ%MB$X!X'4G/'6I5UG3W73V2<.FH'%LRJ2'^4M^'`/6GS2W%
M:)R6F^"KZU_M)G&G0-=Z<]F%MWE?+G^-F?GZX_6MK5]&O;O0[.P@@TVY\I%6
M5;S>!D*`&1EY4@C]>U;.H7]KIEG)=WDRPP1_>8C/7@`#N2>U4+;Q/I%S8W5X
M+HQ16G_'P)XVC>+TRK`'GMQS1S2>H<J6A#8>%[6-+&XOO],U2TB""\=FR2,X
M.,\]>_-5%T36+[6K:_U-]-0VD<J1-:J^^;>NWYRWW5[X&><>E:^E:]I^L-,E
MG))YL./,BFB:)U!Z':P!P?6GV&LV&I7U[:6L_FS6;!9P%("DYQ@]#T/3TI7D
MM1Z,S-&T"YTV?2WEFB9;33/L;A<_,V5.1[?*:R+GP;J,FG:7:F2RN$M4D22"
MX>18]S-D2#;@D@<8/J:[*]NX+"UDN;ARD28R0I8]<``#DG/85G6_B;2[NSGN
MHII`MNX29'A=9$8XV@H1NYR,<4U*6XG&.S*6B^'+G3)-$,DT+BPL9+63;D;F
M8H01GM\IZU)>:7K%OKMQJ.CRV1%Y$B3QW>[Y2F<,I7KP>AQTZU->>([.WTZ2
M>(2/,$E81&)MRE.NX8RH!P"?>MB"3S+>.1N"Z`D?44FWNQV6QS=[X<NKIM5*
MSPC[9=6LZ9S\HBV;@?<[3CZTZ\\/75QIVOVRS1!]2G$L1.<(-J#!_P"^3TKI
MN/SHXZ4<[#E1R^H^&KF\GU:>.YBBDN);:>V8J6"/"!]X>A([5'JNCZ_K6DQQ
M7;Z:)4N`[6T;RB&:,+C:[##=>>F.!UKK.`:,CO1SL.5'':7X3N["SL(#):C[
M/JC7Q6+=M"%6&U<Y.1N[^E:U_IM\_B.PU6R>W*Q1/!.DQ;.QF4Y3'\7R]#Q6
MW@>E0?:[?[6]J)5-PD8E:,=0I)`/Y@_E0Y-NX62.?;P[=-X-O=&$T/GSO,RO
MSM`>4N,]^AK,\1>#=0UG5;J=9;*2.7RS%)</)YEN%QE44?+@D9R>YZ&NSM;B
M.[MHYXUD".,@21E&'U4\C\:FXIJ<DP<4SF[S1+V2;6985L)UOWA(ANU8H55`
MK!L=#W!&:MZ%I-UIN@M97,ZR2,7*JK,R1*W1%+?,5'O6UQ1QBIYF'*CF]%T"
MYTZ?2Y)98G%IIGV-PN?F;*G(]OEJSI^CSV?A$Z2\L9G\F2/>,[<L6Q[]ZV^/
M2J6IZC#I5F;JX#F,.B809.68*/U(I\S8[)%'3/#]KI>A_8[:UM8)VMA%+)#$
M%\Q@N,D@9/-5H=`NHX]`7[1&K:;;/%(RY)+&,("OT//-=&/>EXI<S"R.#T7P
M;J6FZO#?ROIXFB@EB:9&E=YV8##ON..HR0/7K3AX+O;G3]1@N6T^T6Y\MX[6
MU5WMQ(C;MY5L8W<*5`Q@5W7%'`JN>1/(C"\.Z1/IHG:XL-(LVDP`FFQ%0<=V
M)`SUX&.*SM5T>\>;48%7?#K-Y")"@/[J%4`?<>V=I`_WJZZCCTJ5)WN5RJQE
M7NFR7&LZ3>1LBQ61EWH>I#)M&/I2^'M.ETC0K:PG='DAW99,X.6)XS]:T\#%
M+D4KO8$CE'\-W\=K'):W-L+ZWU&6\A\P$QLKE@4;'(^5CR.])_PC>HW"2W%W
M<6WV^>^MKB01!O+2.(C"J3R3@'DXY-=9Q1P:KG8N5%:^LXM0T^XLYAF*>)HV
M'L1BN4'A356\-36DU]!-J,UPDL[DNL<Z(`HC8CY@"JC..^:[3(QQ6;::U;7J
M1-$L^)9I(5_='`9"0V2,A1D'!/6A-I:`TF<WI_@^[L]/>#=91%]3AO0D!?8B
MIMRHW<D_*>?Y5K:MX??5M2N)'E5+>?39+(X^^"S`[AVP,5J7FH0V,EHDP?-U
M.((]HS\Q!//M\IJYQ3YI7N"BMCE[;1-8N[RWEUJXL]MI#)%$+,-F1G7:7;=T
MX_A'<]:KZ=X>UR"YTG[7=6!@TR*2&+RHWW2`IM5FSP#P,J/SKJK:[M[V(RVT
MJRQAV0LO]Y201^!!%3<>E',PY4<SX=T*_P!,U*ZN[H65O',@7[+8%_*9\Y,A
M#?=;M@4EQX=NYI[Z030J+C4X+Q<YR$C"`@^YVFNGXHX]*7,]PY4<SJ7ARZO+
MG5+B&XBCEGDMIK4L"0KP\_,/0GTJI<>'-9U&'6FO;BQ6?4+2.W180^R+:6/)
M(R?O=?TKI=3U"#2]/DO9PQBC(W;!D\D#^9JV,8Z"CF=A<JN<Z^EZS9ZW=7>E
MRV!M[UHWG2Y#[HV50I*;>N5`X..161<>#=0N/$0OWELI$6^2Y6XE>0S",$'R
M@OW0!T!_E7<\4''8<BA3:'RHY*[\-ZG+;^(+*.:T^R:DYFB9MV])"%!#<8V_
M+U'-2WVBZR+W4CI=S9+;:F`9C<*Q>%M@0LF.&R`.#CD5O:9J$&JZ=#?6X;R9
MAE=XP>N.1^%6^*?.PY4<[;^'7M9+Y(94\F73HK.(,3N!16&6_P"^A6;>>%]4
MN(M,MXI-/C^QP11B]&];B%EP&V8X93CH<#GG-=IQZ53AU&"?5+K3U#^=;(CO
MD?+A\XP?^`FDI,'%%Q>E+2<#\:,BI*%HI,\T9%`"T4F14,MY;P3P0RRJDMPQ
M6)3U<@$D#\`30!/15+4M1ATNS:[G#F-71#L&3EF"C]2*N9]:`%HHS29&<4`+
M12$^G6JMAJ,.HBX,(<?9YWMWW#'S+UQ[4`6Z*3-&:`%HJ"[N[>RMGN+F9(84
M^\[G`%44UZPDTJ#4HY7>WN&"PXC;<[$D8"XSG@T687-6BLVSU:.\U&[LUAG5
MK8)N=T(5MP!X]^:T>U`KBT4F11D4#%HI,C&<TN:`"BH+F\M[.'S;F58H]RIN
M;U8@`?B2!2+=(UZ]KB3>B!R3&0N#D<-C!/'3K18+EBBDR*,T`+129%&10`M%
M)D4A/'':@!U%9NGZU;:C#:2PK/MNHS)&6B.``<')'`/MGFIKK48;:^L[-]_F
MW9<1D#CY5W'/X46>P7+E%)GBH;6[M[VUCN;:5989!E'7HPH`GHI">,`\UC2^
M)M/M["2]E:86Z7)M5986<R.#CY0N21G(S[4)-[!<VJ*R;3Q%I=YI\UZEUY<,
M#;9O.0QM&?1E8`@\C'KFK>G:C;:II\=[:2%X)<E&92IX)!X/(Y%.S%=%NBLF
MT\06&H:9<ZA8RO<0VY=7V(=V5&2`#C/MZU>@O(;BPCO(GW021B56]5(SG\J+
M,=R>EK!TWQ;I&K3I#;3S"22,R1B:W>+S5'4H6`#8]JT].U"'4].M[Z#<(9T#
MIO&#CWH::W%=,MT4F11D4ABT4F16?=ZS964MU'/,RM:VWVJ7Y2=L>2,^_P!T
M\4!<T:*9&ZR1JZG*L`P^AI^:`"BDS1D4`+16=-K%K;ZA-9RNR-#:_:Y'(^18
M\D$Y]>#5Z*6.:))8V#1NH96'0@]#18+CZ***`"BBB@`HHHH`****`"LC5?#N
MG:Q<P3WD;.\+97#D=CQ[=<Y&#P.:UZ3O33:V$TGN9&H>&M-U2ZM[BZC=G@^[
M^\/3!`[\=<Y&#P.:O7ANHK*3[#'%)<`?NUF<JI/N0"1^1JS2T7861D3,TGAZ
MX_M^.")6B=;E89&=`AR#@X!Z>U<]H4T>IS7WAXZE'K6C_9`$NE`+1Y)7RF9?
ME9L<@]>.:[<@8Y[TR.**%<1QHB]<*H%-.R!K4\\A@9?AGJ5]<3&XO+IL2S..
M6$<@C0?@%'XDU)+%)I'C31M&$9^R->RW=DP'RJIB??'^#'(]F]J]`V1[-FQ=
MO]W'%.**2"5!(Z$CI5>T)Y#C->GU5+.RO-9M[2&VM=2@ED-K*TH$8R"S948`
M)4]ZR=:NH-2U/4-6L7%SIMM]A%Q-"-Z/LF+O@C[VU2,XS7I)52""`0>HQ34B
MCC38D:JH_A48%*,[`XW.&N[^;5]>OKWPN\5Y)'I@M_.CD`3S'D!`#]"P4,?;
M(]:3PS/-IOB'5H[G2_L%K;6,!D9KE9/+50Y!.!\Q;YB3['UKNDBCB7;'&J+Z
M*,"H;RR@OK66WGCW1RC;(`<;AZ$CM1SZ6L"CK>Y4U#6[#3M%?6+B?%DL8D#@
M?>!QMP/4Y'YUA^'Q8Z\NH73W]K+>W<D4LT-I.LGV=$(,:$C.3P<GN2<5U@BC
M,7ELBE.FTCC%"0PPY,<2)GKM4#-*Z2*:NS(N/#<$S3,EU<0M-YHE*;<LLA!9
M>1QR!@]:J>,W:R\)NL<K(H>*-SYOEY3<`P+_`,`(X+=LUTN16?K.DV^M62VU
MPTJ!9%E1XFPR.IR",Y'YBB+U5Q-:.QYTL9MO"VHWNF7-O!%=7T*3"*]>Z6U@
MX#!G5LXSDG:1@,>:G@@`T&2W@UR"XMY-3M43^SI)-L`+`,%=F8\_7BNXTC0+
M;2&GD62>YGN,"6:X8,S`9P.`!@9/;O6HL,2H$6)`H.0H48S5N?8E0[GG.J)/
MI%KX@T_39Y8K2*>T+>9)))Y,<G^L.<[MO&3@^N,57BB\OPQJ$5KKEM<V\EY:
M*G]G22%8"TJAMKNS')';/\Z]/V+DG:.>O'6FB*%$V+&BKG.T*,9^E+G#D/+_
M`!B;'2GFL+54@DL[/S8)+K4IHVW$L<PJ,[V!&3GV%:UM;::/'\%U>,$O+G38
M98"\S*99<L&P,X/&./QKNC'$[`M&C%>A*YQ2F*,LK%%)7[I(Z?2CGTL')K<\
MTM)K.?3?#L7B&\>+27L'</)<-&DDX;H[@@Y"Y(!/K4]G;MJW_"/6EW<7CV<D
MMYY>961YX%_U>XC!(QCWZ5Z&T$31B-HD*#HI48_*G;%)!*C*]#CI0YCY3G_"
M!9=%F@\QY%M[N>",R.68(LA"@D\G`XKDM/GMGDTVXAO9V\4R7P6[A,S%@N\^
M8K1YPJ!>AQV&#7IP55Z*!WX%-$<2R&0(HD;@L%Y/XTE+<;B>=LEI:Z-KNKW(
MN;B4ZA/;#-V\:)'YH&"0?E3NQQG&:S[.XW^'];@CE@-K#J%GY2V]R\\29>,G
M:[C)!//IUQ7JOEIM9=B[6ZC'!IHAB5=HC0+QP%&..E/G\A<AS?CJ:YAT&/R)
MA#$]U&ES*V[:D1)W%MI#!<XR01QFN9MX/^))':Q:W#<VLNK6Z*=.ED"P@_>5
M79F//7J<9->FE58$$`@C!!%-6&)4"+&@4'(`48!I1G96&XW=SSZ[;3-$L?$5
ME=!Y-/M[B#[-;RW+@"1T!`W[LA2W)R>.:5);3PSHND:Q:ZA]NM+;S;>[DBE,
MB.9.1CD])`JCT!Q7H#0Q."'C1@W)RH.:I:AI%MJ%M';2@I`LJ2F./"ARIR`>
M.F0,_2FI+J)Q9Q\&@_;-5T[3M5GNGSI;W%Q&L[H'E:0$YP<\%CCZ5!H,#0)X
M6U07=U+>WQDBN'EG9A*HC<A2IXX*KCBO10@SN*C=TSCFD\N,;<(HV]..E+G#
ME/,/"AGGUNRNI];LUU!Y'%W:`RFX<\Y1U+E0!V(4#@8ZUT_C&2%9M)BU&X>W
MT>6=A=N)#&I.W,:NPY"EO<<@5U`BC$AD"+O(P6V\G\:5D1U*NJLIZ@C(-#G=
MW&HV5CS;Q!<Z,MGIMG:-%-9F&62WFNM2EBA(#8PK+DN^>@YXJ?3+8>(9?#T.
MI3W$L<NC-+*JS,GFMN0`MM()QG->@F&(JJF)"$^Z-H^7Z4HC1<811@8&!THY
M[*R%RNYYM!<V]Q8^'H_$%]*FFF"?$KSM&))D?:@=P020N<<\GUJ;P]*1#X;6
MWFE>-KZ^VEV.9`!+C=GJ>AYKT$Q1%0AC0J#D*5&!3O+08PB\$D<=SUIN8<AY
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M?;8M=\F-O/;:D9F"E`N<8()SQ7HOE1;RWEIN.,G:,G'2CRX\8V+C.<8[^M/G
M#E9Y=K\FG2KK#WU[,NMI?K'%!YS`^2'38`G0H5Y)QU[T[5FN+CQ7J!NM:L].
MNH;I%M!.91*(\*5,:JX5@<G/RGJ<UZ>T41;<T:%B-N2O./2AHHF=79$++T8K
MR/I1[32PN1G+Z+817/BS7+Z9YGFMKL1PJ96V1@PIG"YQDY[U5\1OI[>)XH=;
MNY+:R6S\RUQ,T0:;=AB"I&7`VX'/4\5V@55)(4`GDX'6FLD;D;E5MIR,C.#Z
MU/-K<KETL>2%Y)-$\.6US?6UKIK63N)+YI$C>7?T)1EPVWID^M;$]]=^'['3
M=0%\VH?;+)[)9E#;7GSF$X/KDC/?`KT)H8G38T:,H_A*C%.*(0`44@=,CI5.
MI=BY#RG6;6:VU1M-N]9M;%+2TA%G+>/*"S8.^2,JX#/NZ@Y/3C%:VHSW4$GB
M"2*>1IA96'FSPJ0^PLPD=1U!V[C[5W[1Q2;2\:MM.5R,XIVU<EMHR>IQUH]H
M'(>9S2:?!:ZXGAN]DFTT:2[RM'<-*B3Y^4JQ)^8KG(!["G136`FNFT._GN(W
MTB>2_)G:3$@`V,V3\KYW<#!QVKOK[3+:^TVXL'7RX+A"C^4`IP>N/>K$=O%$
MFQ47!&&X'S?7UHYU8.5GG]GH%JVJ:+:27-\\-_IS37BM=O\`OW7R]I;GC&\]
M,=JS;N>YFT;0;:[U&&+3RMRKS7[R>6[I)M179&4YV@XR><=S7JFQ`0=J@@8!
MQTIIBB9/+,:%/[I7C\J/::BY#@K73UU&;PY87>IR7UNUM=%I+>5XUG4,NT$Y
MW$#USSBLZ6VT^:T\-W&L2L;:&^N;1IYIV4!%,@12P(YR`,]37J(1/E(5?E&!
MQT%(88F3:8T*YS@J,9H50;@<WXY*+X.N<LZ('ARR9W`>8O([YKG3>:=9+KDF
MDSW-[I"VD;3^5=N0)V?!Q(22I*G+8Z"O1RJD8*@CT(I%CC52JQJ%/)`7@TE*
MR&XW9Y;I=Q&VE^(;0:K9V5DOV<I)!>23VZ%B=P\PX8!L`'!X]:+J\$^@:;;V
M\D%EI?VR:&YFEN99K9B%RN)`RMY9.<9(&1BO41!"$*"*,*1@C:,8I?)B,?EF
M--F,;=HQ^5/VBO>Q/(>;J;:/3M'MM5UF.XT1YYP]Q#,\<.0,QQERV[:/FP2W
M)`&:Z'P&83I-_P#9I9)8/[1G\N24DLRY&"2>3^-=.88C'Y9C3RQT7:,?E2@*
MN<`#)R<#K2<[JPU&SN>90W%L[Q7"WLY\6MJ(22#SGW!?,P5,><"/R^^,=\U/
M/:*L.H:T+FZ^VV^N>5"WGMMC0RJI4+G&"&.>*]%\N/S/,\M?,(QNV\_G1Y<9
M7&Q<$YQCO3Y_(.4AOKFTL[9KB^FAAMXR"TDS`*ISQR>G-<GX4%CKW@J&QAO8
MG*%Q,L>R0KEV(!!!`R.>E=FR)(I1U5E/4,,BFQP119\N)$SUVJ!FH3T*MJ4K
M/2X]/N9)8II662..-D<@YV#`;.,YQUYKSS1E@U3Q9;O<7$"W<-[-)(\FI?O)
M@"P5/(!^7''X#OFO4CTXKG+7P5IUK<PN)[R2""7SH;6213$CY)!'&XX))Y)J
MHR23N3*+=K'(^'C<7'B&UN;G6[.'4S=.MS:DRFX=06&PJ7VA<8((4#@<U;TR
MT6WMM$U=+FZ:\GU1[>1GG8J8B\@V;<XQP.V<UZ+Y,8E\SRT\PC&[:,_G2^7&
M`!L7`.0,=#3]H"@>7:,;BX\20W-UK=G!J?VYUFMB9?M#(&(\O:7V[2N,$+CI
MS5D1VEGX8O\`5;D7$\UQ?RVS,]X\<:)Y[`!F'W(QCD@9KT?RH_,\SRT\S&-V
MWG'UH\J,H4*+M/5<<&CG#D/)-EO>>$]46X:*2SL=4@:/R+J26**,^7OVN<$K
M@L>>!DXK>O[AK9]6_L.>1H(]'MVMS`YDPAD?+*<G)VYY]A7>B&((4$2!2,%0
MHQ2K'&IRJ*"!C@=O2G[3R$H-'FXDTV(ZBOAJ^DGLO[(G>Z*W#RHL@'R-N).'
M(W9'MTK5T2R32_$&E+;SW+?;M->6Y\Z=I/,=?+PW)X/S$<8KLEAB12JQHJGJ
M`H`-+L7(.T9`P#CH*GFZ%<IR/BQ[,ZUID&M7!@T9XY2Q,S11O,-NT.P(QQN(
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M'4OT#D/+?#MU;ZAXEMH8/*2WO[6?[3!'J$LTK<#`F!X1QD]#GDU6MA;6W@O2
MH+&Z@MX9+DQ:J\LLA2-@K;5DVL"@R!W`Z9KUM88D8E8D4DY)"@<T>3%M9?*3
M#_>&T?-]:?M/(7)YG.>#D>/0Y$34K>_C$S^3);EC&@P/D4L22`<\Y/IVK`C\
MX_#_`,-BU>-+DWT.UIE)42;VSN`P>N:]""*B!44*!T`&!56PTRWT^&2*(,8W
MF:8*_(1F.2%]!G)_&I4NHW'H9=C9+HR7^JZY?VS37+H\\NWRH8PHP@&XGIZD
MYR:YW3M=A7X<O%IEQ#<7SR/;1Q12@L))96"Y].#GGTKT%T212KJK*>H(R#3%
MMX$^Y#&O.>%`YH4NXW'L<7X>:YTCQ,+&ZTO^SK:^M%6%#<+*&DA&#R.A*$?7
M;6IX6S_P@EO_`'?)EV?[FYMOZ8K=O+5+NVDA8LOF(4WI@,N1@D'L:=:VL5G9
MPVL*!884$:+Z*!@4.5T"C8XSPOI6HW6DZ'?ZA>V[6UG:![6&"(J<M'MR[$G)
M`/8`51\/64>G1>$[Z":X\^\#QW&Z9F5T\MF"[<X`!`Q@5Z,%55"A0%'0`4@C
M0;<(HV_=XZ?2G[1BY#RW0=2BE\66,MJZ6ZW(N/M""^DGGP%)'G(PVJP(R`.:
M2VO3:Z-K46DW0O+P6JRMJ-K<R3*X+@,70D[),%CA>W3&*]26&)7+K&@8G)(4
M9)H2*.//EQJN3D[1C)HYUV#E9Q/@B*.*\O/LNLZ?>6[1H?(LFD=4;)^8EW;!
M/<9'3I2>)R/[0\2?]B__`.S25V\<4<0(CC1`3DA5Q2F-#G**<C!R.HI<^MPY
M=+'.>))&3P!?NCLC+895E."#M'(-<_XGL$TR/2;"*[CMM,G,DES-?2RLCRX7
M;O96!&>2.0,]J]#**R[2H*],$<4/&DB[7164]0PR*%.P.-SS&_:WA\/:6;W7
M;._BA$SI"US+`MPN[CRWR2S*.%SG.?QK1O-<M;&ZU9KRXEM?M>D0O:Q3L=[M
MM?(4=W&1G'-=XT,3!0T2$)]T%1Q]*5HXW*ED5BO0D9Q3YT'*SSJ>V%_!-!(C
MRL_A:-MH8[F8$D=.>N*I7;:%#X;T=[74K1[:.%I7LWOI(Q/)A=Q1P?\`6*<@
M*<CGH*]2"(#D(HP,<#MZ4S[/!A1Y,>%.0-HX-'.'(QEC*)]/MI0DB!XE8++]
M]<CHWOZU8HHK,L****`"BBB@`HHHH`*PX;B=O&U[:F5S`EA#(L>?E#%W!./7
M`'Y5N5GII@CUZXU02DM-;I!Y>.!M9CG/_`OTIIB9?JM>ZC9:=$);V[@MHB=H
M>>0("?3)JS4<UO!<ILGACE4'.UU##/XTD,Q?%%[)%X8DNK.X*DO"4EB;JK2H
M.#Z$']:I:CXKOK.YU(1:0LMEILBBXG-QM)4J"=BXY(ST)`]ZV]7TI-5TIK#S
M/(0LA#*N<;6#`8_#%4[KPXMS:ZU";EE_M1@6(0'R\(%X]?NYJXN/4AJ70SX-
M8UH>*]8MW@MVTZU@CE7]]\R@JQ!`V\EB.1GC'>HV\:W%MX>M]6OM.AM1>,BV
M<;W.=VY<YD(7Y0,9XW'%:DF@2'6I[^&^:*.YMA!<0>6&#X#!6#=5QN/UILWA
MK?H>FV$5Y)#/IHC-O=*H)#HNW)4\$$$Y'O3O#J%I&;;>.DDT?^TY;5%M;>Y\
MB]ECD+)$I'$BG:"R\C/`QSZ5.OB?4[LV\-AHZ/=31&Y\N>X\M4@W80L=I^9N
MNW''<U;D\.W%]9PVVJZF][&)O-G0PJBS`#Y4('10<$CG)JHGA*ZM1;R6&M3V
MUQ`C0+(T*R9@+;E0@]2O9O2CW0]X/^$MN[I--33M)\VYO5FS%-,(Q"\1`8,<
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M`$IV%E-<2CY0-_F[LCVQN_2J>D>"O[*U"TG_`+1,L5FLB0Q?9HT.UQCYF'+$
M>IJFX;_UU%:13\,^(-0@TK1([VP(L[H>1'=M/OD,G)!9<<*<'!R3ZBK]MXLN
MYI+2[DTH)H]Y.((+D3YDRQPK,F.%)]R>1FETWPA+8O81SZM<7=E8G?!;/&J@
M/@C)8<D#)P.U+:^$7MYK>)]4GFTNTF\ZVLFC4;&!)4%^K*I/`^GI2;@V-<P0
M^)=3N(=1N8]*MUM;266%99KP1[V1]I)R,*F.22<\<`UDWOC'4;OP[>7&GQ6:
MWEI=PPRO#="6(J[+@HVWG.=I&!CGTK;N/"B7&AW.FF[8>=>->+)Y:G:YDW@%
M3PP!['K5>/P9C2]3M9=1=Y;YXY3,D"1B-TQM*J.,94<4TX7U$U(=+KKZ;J-S
M+J4,B/!IJ7$L4,YDCR79=J@@9;@?-[]*<GB74+:22+5M*CM93:274`BN/-5P
M@RR,=HVL,CU'O4TWA@7K3MJ%V]P]Q8K9RLJ"/.&+;QCH<GI[5'%X7N',TFIZ
MO-?S&V>UA=HEC$2.,,<#[S'`Y/I2O$=I!H_B6^OKZT@OM*6SCOK<W%JPG$A(
M&W(<`#:<,".35J\\7Z#I]W):7>I113QG#H5;(/Y5)#H:Q7>ES^>Q.GVS6ZC;
M]\$*,GT^[^M:U2[#5S)N?$-G%X?DUFW)N;8+NC\O@R$G:`,^I(%<\==O;'Q!
M>7FM6GV1+723*8H;CS4;]YU'`^;MR/TKJ]6TV+5]+GL9F94F7&]#AE(.01[@
M@'\*Q%\(O<274NK:I-?O<V9M'_=K$%7=D%=O0TXN/4'<HV'Q`%U!J#-91RR6
MML;E5LYC*&7.-K$JN&&<\9&,^E6_[=N+K3=-N9XXT,^HQ0JUC>^9&X/?<%&1
MZK@=*N6VC:Q%:SQS>(YYI&0)!(+:-?*P<[B/XCQ@YQWJO:^$1!&IEOFDN#?Q
MWTLBPK&K,@P`$'"Y'4]3UI^Z+WBO_P`)??2:M!;P:;;&UFOFLUDDN]LN5SN8
MQA3Q\IQSZ=,T^/Q=?/<J[Z0%T[[>;`W'VC+[]Y0,$Q]W.,\YYK"T?2==LO$?
MVA-+2.5[IVFF>VA*>2SDG$VXR,=N,`CKQT%=5_PC2?V>+3[4^T:A]NW;1G/F
M>9M^G;-.7*B4Y-&\":XN+X@V\^O+8QPPM;O<_90RS$S;L[=WE[<;<]]V<<XK
MI-*AOXQ=R7\NYI;AGBCR"(H^BKD=>F?QJA9^'KO3[XFUUB:/3C.TYLO)0\L=
MQ4.>0I)SCW/-0K*]RW?H4X?%M\]PDDFD*FG&^-B;C[1E]^\H&"8^[G`/.?:H
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M4#?*R[0HZ#YL]Z+Q':1GW>OSZ;<:K<3VSM/::=#</`EP6CW%G!51M'/'WN_'
M`J1?%=U;?;AJNE&V>WL_ML:13"4O'G&#P,,#]1SUJUJ7AM=1FU.0W+1_;K5+
M8@(#L"ECD>I.[]*K>)-"N+NVOKJS/FW4FGFT2`G:&^;=G.>OMT-"Y79`^8=H
M?B'4=2U>XLKRPM(5BMTF\RWN_.^^3M'W0.Q[^G6F>(_%<WA^?+6UFUNJ!V\V
M^6.609Y\N,CYB/<C-4_!EGJEE<SQ26"VNGE-V'M(;=S+GLL3,",=2:L:WX+_
M`+7OKRX74&MUO8EBG3[.DA^48&UFY7W`_2BT>;42YG$?J7BG4+:\U"*RTA;F
M&PA2XFE:X$?R,I)"C!RV`?;WHU+Q%>3BX@TK3OM21V8GGD:?RB@=25"C!RV!
MGDCZU>?P^KG53]H;_B86ZP-\OW-JE<CU^]52X\*3-(&L]6GLQ+:I:W0CC5O.
M500I!/W6P3R*/=#WB?2]02P\#6>HW3NZ0V"2R,<EFP@)^IJ"W\2:C'<QPZII
M*6GVB"2:V,=QYF=B[BC\#:V/3(Z\UI1Z+!_PCJ:).6EMQ;"V9NA90N,^QK,A
M\-7<1:>]U2;4I8+:2&T5XEC";EP2<?>8C`R?RI+EU&^8AL_%6I77V!I]&2"+
M4HBUFQN=Q,@3<%<!?E!`.",^XJCH^N:K<Z!H]UJB8>XOXXDDM[G!D!+`EQM`
MP,8V]_6KOAWPS>6T&DS:E?SS?8;<"&T=%`A<KALL.6P,@>GO5BT\)O;6EK:-
MJ4DMO:7JW5NAB4%%!8["1UY;J?2J;CL)*14F\9:A"99UT/S+**]-D9%N0'=]
MVU2JD=,X!R1C/?%+=^(;IM+U.._LWM+RRG@5UM;K(99&7:5?;GOR,=JT3X94
MV+VOVIL-J`OMVP<'S`^WZ9&,T7_AE;YM3)N63[>T#-A0=GE$$8]<XI7B/WAL
MNM:I#XH@TO\`LZV>WFW.)4N272-1R[)MP!G`'/-5+?Q;<S:[_94EI8B:42"%
M(K]975D&<2J!\F?49JW%X?OH?$5SJ:ZN3%<LOF6[6RD[`,!`^<@#D_4FJ>D>
M"?[*U&SN1J+2Q61D\B+[.B'#@@[G'+$9ZFE[H>\4=)UO5KGP]IMSJD>'FU&.
M%)+>YP7S(P.X;0,#&,=P.U:$WBV[C:>]32U?1;><P27/GXDR&V,XCQRH;WSP
M>*EMO"DEO:16AU%Y+:WOEN[=#$H,8#%MA(^\"3U--D\(.\TT(U2==)FG^T26
M`C7EBVXC?U"EN2/KS3;C<24K$5WXNOK:XOW71P]AI]RL%Q<?:,,0=O*KCG&X
M9R1[9K8UK5I-+@@$%M]JO+F40V\._8&8@GENP`!)/-5KCPTMQ8:M:FY91J-P
M)V8*/W>-O`]?N?K5K6M(.K6\(2Y>UN;>4303H`Q1P".AX(()!'O2?+<>MCF/
M$&NZK<>'=3M19K:ZC;R0Q3A+HX$<A&&1PN>>G0$<U?UR*73O`31JK6TL8B!5
M+AY"A,JY`<_,>O4U8'A0R:?>176HRW%Y>2QR371C5<^6054*.`./U-:FM:6-
M8TJ:Q:4Q"0J2X&2-K!OZ4[QT2"SU.:U3X@6^FZS/9)##)%;2".;,Q$I)QG8@
M4AL9[D=\5<U/Q;+I>M16DUO9_9WECB'^FK]H.\@!Q%C[N3ZYX/%6'\.WD>J7
M%UI^L36<%U*);BW$*/N;`!*L?NY`&>M4[KP3]HU2:Z746CAFNDNVB^SHS;U*
MG'F'YMOR].U"Y+A[Q3\2Z]J-SIFI+9V!6Q@N%MFNUN-L@<2*&(3'W0>,YSUX
MKIM;U4:/I_GK"9YI)%AAA!QOD8X49[#U-9%]X/ENFO(HM7N+>PNIA</:K&IQ
M)D$D,>=I(R5]>];.LZ2FL6!MFE>!U=98IH\;HW4Y5AGW[4FXZ#UU,^YUK5['
M2&N+S3[""X$NW]YJ`6`+_>+E0?;&WK5*+QE/=:9I\]GIJ7%S=W4EIY27`V!T
M#98/C!3Y<YQT/3M4UYX6OM0M+<7>M&:\MYS-'.]I&4&5V[?+Z'@GG.<U)I_A
M1;!+(?;7E-K>2W>3&J[V<,",#@`;NU-<MM1/FN1#Q5=MIZJ-,7^U6O6L1;>?
M^[\Q1N+;\?=V\YQGVK,@U.\5M4DO(KB"4ZO;0F&.YX3<(QPV.4.<XP,Y[5LW
M'A8R1S-!?R07;7QOH9UC!\IRH4K@\,I&>OK3(_"3"&<3ZE-/+/>PWKRNB@[H
M]OR@#@`[?PIIP%:1F>(]>U&ZTZ_%I8%;""Z2V-VMQMDWK*H8A,?=S\N<Y]L5
MH:KXLETG68[6:WL_LS2QQ_\`'ZOVAMY`#+%CE03ZYX)Q27G@^6Y:[BCU>>"P
MN;@736JQ*1YFX,?FZ[21G'KWJ.\\$?:]3N+E=2:.&>X2Z>+[.C-O4J<>8?FV
M_*.*5X#:D06_B;5+&\\1W&JP0?V=I\G!CFRZ_(I50-HSG.<D\$XI++Q^+FUU
M%VLXI);2`3@6DS2(RDXP6*C!!Y/!XYK4N?"JW5WJI>]D^Q:F@\ZV"#(D``#J
M_48VCCU%20:/K"6D\<WB*:69E"PRBVC7RL'.2/XB>AZ<9HO$/>+>AZA/J>G"
MXN(K9&).TVMR)XV'J&P/Y=JTZR-`T3^Q8+@-<>?-<RF:601K&I;`'"+P.`/J
M>:UZAVOH4M@HHHI#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`0USNJ>)KK3-0CM?[`O9Q/)Y4$L<L065MI;C+`C@'KZ5T=86OQ22ZIH#1Q
MNZQWY9RJY"CRI!D^@R1^=.-KZB=[&M:323VT<LL#V\C*"T3D%D/H2"1^53TE
M4M3M[^XMPNGWT=G-NR9)(/-!'IC(_.D,?J-U/:6AEMK*6]D!`$,3*K'WRQ`_
M6N>C\9SR:5=:C_85W%;VX8;Y98\,ZOL*_*Q.<YYQCBNGA61(8UFD$D@4!G"[
M0Q[G':N*>RN'^&^J6C6TQEDGN,1!#N8&=B,#KR#FKBEU)=^AV<%W;W/F>1<1
M2^6VU_+<-M;T..AIMM?6MXK-:W,,ZJ=K&*0,%/H<=ZXK6=!FBN-7M]$LO($V
MD*B^0FU7<2'Y<]"VWCGUJQX-L;:'4KBYMVU0L8%C<75@EJ@YR``J+N8<\\_6
MAQ5KW$I-NUCIH-42?6;O3!&PDMHHY&<_=(?=C'_?-1V.N6M[!/,S"W6*YEMR
M9G`R8R02.>G!-9%W<OH7BV\O[BSNY;.]MHD22V@:;:Z%LJP4$C(;.>G%946C
M27-KI`O]/<I<:S->26\J9\M&#E=X'']WKQSBA10<S1V,FIQB"VFM]ES%/*L:
MO'*F,'^($G!QZ#)]JL?:X#"LHGB,;':K[Q@G.,`^N>*XG^SI;<O#!9ND">(X
MIHT2,A5CPI+`=ESGGIUI]OIMY_PDC:.+9QIMM<OJ44S+^[)8?*@/JLC,V/84
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M/D0N9GH:S([NJNC,APX!R5/7GTXJ-;^T>[:T6Z@:Y09:$2*7`]USFLKPO!)_
M8IO95V7&H2-=OGJ-_P!T'Z+M'X5RFG66Y=*L$T>YAUNUO5EN[QK<J,!B7<S8
MPX8'&`3UZ#%3RHKF.KTCQ(NLZM?VUO'`;6T8QB=;E69V&,_(.B\G#9YQ5;_A
M*[[^U?[._P"$9U#S]GFX\Z''E[MN[[_KVZU)X7T^*R?5G%FD#OJ$VTB((63(
MQCCD=:CU&UNY?%5TULKJSZ,\44N#M$A<X&?7O3M&]A7=C<74K)S,%O+9C!_K
ML2J?+_WN>/QJ3[5`&`,T0RGF#YQ]W^]]/>O.?#6GVUI+'-<Q:N\]K9.ES;2:
M<B(<J`REE0>:21QRV:=IUCJ.DZ1JL5SI37EU+:(]JDJ&55MP>+<^I3)./XJ?
M(NX*3/08=0L[FW:XM[N"6!,[I8Y`RKCKD@XJ2WNH+N!9K::.:)ONO&X93^(K
MS73K(26WB#[7!>FRGAMB'MM*-N6(9LD0G.['&>.1VKJ_";W!T2XWV*0@3/Y)
M6V-MYZX&',9^X2<C\,TG!(%)LV5U.R<S*EY;,T`S,!*I\L#KNYX_&HM(UJQU
MVP2\L)UDC;J,C<OLP'0UP/AVVN;GQ-823:<((O(GCN(5TLV\<1(&(RY/[T<=
M>GYUTW@2*.V\/):&QDM;FW)CN`\!CW,">0<?.,=QFB44D"DVS0G\1VMOXCM]
M%:.0S3)N\T8V(V"54G^\0K$?2M)KJ%5E+31`1?ZS+CY._/IQZUY]=6'B2^LK
M_5X(;1"UW]MAAECD%SB(X1.N!E5/&/XSZT[5KJ?[/XEA72]0D?58(Y;;R[=F
M4CR@I#'&%*D'(//IFFX+H',^IWCWMJEPEN]S"L\@W)$T@#,/4#J:S8?%&GWE
MM=2V$B7+6TIB>)944\,%W`DXV^A[]JYZ[B\KQA#+:Z?-<W,LD(F2XL2T84`#
MS(Y_X,#.1GDCH,U4?3UAT;Q%I\.ER)>&_P#-5DM"!)$9D9=K`8(`SP.F*%!=
M0YF=\^H6D4JPR74"2LVQ4:0!BWH!GK5JN`UC0X[I?&%T^F^;=ML^RR&++G$2
MXV'V;T[UU][9W5[91I!J,]C(,,9851F/'0[@1^E3**74:;9H55:^LTNUM6NH
M%N7&5A,@#GZ+UJEIVE7UG<F6XUV\OH]N/*FCB50?7Y5!S7#^(HKVXU^=4TXQ
MR)>P/&8=,+M*@9"93<9^7N,#G`Z<T1BFP<K'HK:A:),L#75NLKML6,R`,6]`
M,YS[517Q'I\M_>V$,\;WEHNYXO,4%OE)PN3VQSZ=ZY;4]$2:T\578TW??->(
MUO+Y1,A"K&04/7KGI[U8N+.*W\2^(@=-8S7ED&MITMBRDB-@XW@<,3CC.35<
MJ%S,WAXB@6_2WN1';1M9I=&6690`6;&W/0_4'FM*XOK:SA$US<P01,<*\L@4
M$_4UP1AM[2]TNXU71+F\MX]#BA^6T,WER9Y4KC@D<=./:DMK(Z2FCR:[I-Q>
M6D>GM$D:P&Y^SR%RV&49YV;5S_LD4."%S,[^:]MK>)99[B&*-B`KR.%!)Z8)
MJGI.L1ZK;^9A8I/,E01%P6(1RF[Z''ZUQEO8G3H]%EU?2+B>Q2.X5+80&<VS
M.X,891G^#Y<]J9%'-H/A?3]:CT^:&73[NX3[*RX?R99&`7\S&?PHY%L'.ST5
M)8Y%+1NKA25.TYP1U'UJ)-1LY#)LN[=O+7>^V53M7U//`]ZJZ%I[:7H5K:R'
M,JINF;^](WS,?^^B:XH:!+'\-[9+:RDAN6F26]6*$>?(@D);AA\QQSM/7%2H
MJY3;._74;)[-KQ+NW:V7K,)5*#URV<4CZE91VJW4EW;I;-C;,TJA#GIALXK@
M8M+L!H5[)NUJ2*2ZA?<^E@!74'!\@(-R]`WR\\?40WMI>7-IHMU>6EQ9V48G
M1ELM/63:Q8;)#`RMMW#/&"035<B[D\S['HL^HV=K$DUS>6\,3_<>2155OH2>
M:6>^M;89N+F&)2,@R2!<CIGD^X_.O/;RT:TTO2+2"SGDM3%+MN;O2OM,H);(
MC\L8$8/7)Q@`#BK>BZ1]ID\*C4=/:1;;3)0XN(LB-\QX!!X!QG`-'(K7'S.Y
MVS7UK'=):O=0+<2#*PF0!V^BYR:IZ1KMOJD*Y:*&X9Y%6`R@N0CE=V.N.*Y_
M3TM+3Q#?0ZEH\\U_/J!E@NQ:&1?+.-A$F,*%`QC(Z>]4[/1$@T_3+M-.*7W]
MMM))+Y1\S897!)/4+MQ[8HY4',ST*BBBLRPHHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"DP*6B@`HHHH`3%&!2T4`)M%&!2T4`)BC:!
M2T4`)@48&*6B@!-HHVCWI:*`$VBH+NRM[^TEM+J/S()1M="2`P].*L44+0!%
M4*H51@`8`%&!2T4`)BC&:6B@!-H]Z`H'K2T4`)M'O1@4M%`"8HP*6B@!,"C`
MI:*+`)M%&!2T4`)M%+110`4F!2T4`)@4;12T4`)M'O\`G1M%+10`FT5!=V-M
M?1I'=1"1$D615).-RG(/X&K%%`"8HP*6B@!-HHQ2T4`)M%&T4M%`";11BEHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tpg27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg27.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`]P**`P$1``(1`0,1`?_$`1T```$#!0$!`0``````
M```````&!P@!`@,$!0D*"P$``@,!`0$!`0````````````$"`P0%!@<("1``
M``8!`P$#!`41#0X-#`T-`0(#!`4&!P`1"!(A$PDQ42(40176F!EAD:'1,E(C
M4Y/35187E]<86'&!0F+25-355I97"AJQP9(S))0UE7>W*#@Y6?#A<K)C-"6U
M)C8G-TE#1&2$=;;&1V=(>-F"HG.#H[.T9<5&AL>(N/'"P^-T1:5VAZ<I:!$`
M`0("!04+!@L%!@((!@(#`0`"$0,A,1($!4%189$3\'&!H=$B4A05!@>QX3*2
M4Q;!0F*BTN+451<(&'*"(S.3\4.#H],T8S6RPG,D1'0E-O*SP^-DA)2DQ-4F
M_]H`#`,!``(1`Q$`/P#U$Y,\H_$6DO$"Y58*X_\`+J&Q!C;#D#B::A(*RX(Q
MY>3"C=X=P+A)K(2\4234!-TP$>T1'8?-KSWC!X@83X=X-AMZ#!+O,\`S><7`
M\\51:^%!R%?)^]?>28V\D-=0V@9,VA(\F7/&#3[2^(QCX/+V_BE8Q'L[.S;V
MMU\4Q'\U_<?",4ER;Y=G3KJZ026M?,!M1H,6R'&&BI>+'?&^79NTD$N?5#^T
M%9/NP^,*/_2,T/\`]ZXD8P$WQAC?)H_6+X79<*G?U;Q]F3'B%BXILGB^BJAF
M#QA0';X1FB@/F6XCXO`/S@"-WWU3-_.-X8-A9PN=_5O'V5!\0L7/Q3Q?15?N
MP^,+_G&<?>](QC^UNJ?UE>&7W7._JS_LRC^(.+]$\7T4?=A\87_.,X^]Z1C'
M]K='ZRO#+[KG?U9_V9'X@XOT3Q?11]V'QA?\XSC[WI&,?VMT?K*\,ONN=_5G
M_9D?B#B_1/%]%'W8?&%_SC./O>D8Q_:W1^LKPR^ZYW]6?]F1^(.+]$\7T4?=
MA\87_.,X^]Z1C']K='ZRO#+[KG?U9_V9'X@XOT3Q?10.8?&%#;?Q&<>AU=I0
M'B1C`!,'G*`QO;^=H_65X9?=D[^K/^S(_$'%^B>+Z*K]V#QAO\XQC[WH^,?V
MMT?K*\,ONR=_5G_9D?B#B_1/%]%'W8?&&#R^(SC[WI&,?VMT?K*\,ONN=_5G
M_9D?B#B_1/%]%4^[#XPO^<9Q][TC&/[6Z/UE>&7W7._JS_LR/Q!Q?HGB^BC[
ML/C"_P"<9Q][TC&/[6Z/UE>&7W7._JS_`+,C\0<7Z)XOHJXN8/&%,8`'Q&:`
M(;[B!.)6+R&$`](0`YHW8HB`>75]V_.'X:7F<V2,+G1<?:S_`+,F/$'%P8V3
MQ?122KW(?Q=)RQ9&A6GB"4EDK0K#$UU99;BMBY8CE28K<=:"J"G[6;CL20V#
M;R:]MC/YIO#"[80V\C"IPF$1CM9^2BKJZ/Q"Q>H,/%]%*D<O^,.;8">(QCT3
M[[`'XI.,.T=_(`#&]HCKR+?S>^%HPH3IMQFR9NT`M&9>'9*H=7XU5.\0L8:V
M(::]'T5D)E/QE5NH$O$2H1N@-S]'$3&1^D/2[3=,9Z(>@;R_.CYM7R?S5>&\
MR7MA*>60C_?_`.@LWXBXR:VGB^@L098\8XOD\1G'QQ$`'8.)&+Q'8=]C;>UP
M^B/L>QKG7_\`.'X622UDN1,#\M,_[.C\1<9%33Q?05R66?&+6#?X1J@`&Q1`
M4N)6+!`0..Q1W&/`!ZAV`/..B1^;KPSGU29FN?\`9TQXC8R/BGB^@K%,L>,.
M*YVQ/$@H0N40**S8G$W%1G"/>@(I"L@5B*R0*%*(EZ@#J`!VWVUM?^;3PPD@
M;21-B:C&\4__`-='XC8R?BGB^BJ?=9\8U'T3>(S0NT?^K<2,7%,`@':4-X[]
M#MV^;7+G_G!\,6$ELF9#_'^SH_$7&>B>+Z"N^Z[XQHE`WPC&/.G<"@;\4K%V
MPB;<2%`?:WIW,`=GGUL'YQ_!61AS;SB.'7F;/IBYK[VT&FBAMV(H6N3XBXS8
M]$\7T%?]V#QB"@`*>(QCX#=HC_@D8P\@]I>WVM\VL>'?GQ_+UM=E/PJ]0'_%
MOOV13/B%C#C$M/%]%(/)?([Q@\>TU[;W'B`4B:2CI:I-`C4N*^+F_ML6U7JH
M5'NB#[6;H^H!9.\VW]+IU[ONM^:7POQR?-GW7"ISKLXO?+!G7@0:`323=P?1
M!KIX4'Q#Q8"EAXOH)?J9=\8-%11(GB-4`Q4S&(43\2L8&.)2F$"]9O:P`,8`
M[!'V=>6O'YMO#61BKI1PR?L1DVL^H1__`!TOQ`Q?HGB^BJ$RAXRBVZJ/B*4)
M0@`8XG3XB8R.4I0'83")(P2@4HCL(^0![-%Q_-YX&8E--^EX5>R&&G^+?:Q7
M_P"&SA'XD8L!9@>+Z"J&6_&$/NW#Q(:`9V5,C@S8O$W$XN2(&4%(JYVY6`KE
M0.H`E`XE`@F[`'?56+_G:\"W/%UN.$WN7/M0M&9?2`<]-T@891%#O$G%[)@#
M&&CZ"L6RUXPC9/OE_$AQ\@EU)IE4<<3\4(HBLJ;H11[Q1D4@J+G]$A0'J./8
M`".M-Q_-EX7SV1?=YI=H-X^"[K%^(^-0]$\7T%C^Z_XQI-C#XC./`#L'<>)6
M+@#8?(.XQVVQO8\^L%]_-WX829EG8S&LSQGG_P#QU.7XC8R'@V3#@^@KS9A\
M8L@'.Y\1O'C9!(AE%EE.)>+$2()IEZS**JJQQ4TDRA\T8P@`!KT6%?FG\([Z
MP6F3"\U0ZQ\$A:OQ)Q89/)]!9#Y7\8LR)54_$;HJJ9Q("9T^).*SD4ZB]8=V
M<L<)#]1!`P;".Y>WR:MG_FC\)[H'S&7>9>"&F#0Z\-@<\=@:LRKF^)&,%M#3
M7H^@L"66/&/.8>Z\16C*"(&'8W$;%YP$"[`<P=$88?0'R^P'LZY>!_FH[@7R
M=,>_"I[I()/\V?\`9UG/B-C1%+3Q?052Y@\8T.P/$9QWN(=6WXI6+A[/*`_V
M-WZ>D=]_)L.LC?S>>%LV_3[K>;E-NPE0A%]X=&/_`.N/A5LGQ'QAL8M,.#Z"
MN^[!XQX!O\(QCSLWWWXD8O[-MM]_]S>S;J#XX:JG?FY\*&$V6OA_C_Z"T?B1
MBW1/%]!4-EWQCM]C>(QCT!#<-AXDXO*/8'48!`8WR@`[_F=NL3/SE^#,D[*^
MW&\7F::0YKKVT`9H-NQ'"F/$?&'"(:8<'T%D)ECQBMQ[[Q&Z$@8@`<PFXHX>
M02!/81#J3>1H+F,(%$?1#I$`^(.NY=?S>>!5Y`)PJ]_U;[]E4OQ&QG(T\7T5
MS6^;?%TETO7(3Q),:23$3J(`[9\4L3.6YUT#"1P4B[./,W/W:@;#L([#V#VZ
MMQ3\W/A/=KK+[,PR>)1,!&;>8U_*NT5;+[XWV\-VLPV7FL4?12?MW(#Q=JHA
M4C/O$$I,@K:[_3Z*B='BOBY`C=2X2I(E-7H&-[.[,7??S_FZ]1<_S2>&,_"#
M>685.VUF).VGY!&KJZ;N],]WIN.;7P)5FRYXOXCZ/B*T$H;%]$W$W&"A@]$-
MP$X1H`8=_9UXMWYQ?#.6XL=A<Z(H_FWC[,@]Z+P:;6[4J#ESQ@2[;^(OC\N^
MVV_$K&(;[^3;>-[=]1_61X8_=<[^K>/LR/>B\5VMVI9ONP^,*'_2,X^#XGXI
M&,>S_P#ENL1_.3X91_Y7._JS_LRRGQ`Q8&`:8<'T4?=A\87_`#C./O>D8Q_:
MW2_65X9?=<[^K/\`LR7X@XOT3Q?11]V'QA?\XSC[WI&,?VMT?K*\,ONN=_5G
M_9D?B#B_1/%]%'W8?&%_SC./O>D8Q_:W1^LKPR^ZYW]6?]F1^(.+]$\7T4?=
MA\87_.,X^]Z1C']K='ZRO#+[KG?U9_V9'X@XOT3Q?15#9>\8579(/$8QX8RA
MBD(4W$;&)P.<3%$";!'`(";;R^QJ^Z_G&\,IEYEL[,G`%P'\V?\`9E5.\0<7
M#/1/%]%)!;D%XOS?(T)0E/$%I@/+)2[E="2JG%S%BK%DA6YNO1`Q1(XL6!BJ
M+FF.L#B/8!!#V=>YQ_\`,_X6W/"VWJZX5/;:`C_&O!K!SW=9CXB8RX<YIAP?
M12S-E[QA4^@@>(QC[J[L!,/XI&,1[=_^YNO$S?SA>&,F[RW'#)Q>8Q_BWC[,
MKI/B%BY)YIAP?15OW8?&&_SC./O>D8Q_:W67]97AE]USOZL_[,M'X@XOT3Q?
M15HYA\87_.,T3_WKB1B_8/\`5;QOEUU;G^;OPOO,@S'89/M`P_FWC[,I#Q"Q
M<?%/%]%4','C%!VD\1F@=/L]_P`2<6E-O[.W^YOS(!MK!>OSD>%MW)'94XP_
MXMX^RI_B)C'1/%]!7?=@\8@H!WOB,X]*(^3_``2,8;#^8/M;L(ZIE?G)\-)K
M+;<*G0/_`!9_V91/B%BYILGB^BJ_=@\8;<0^$8Q]N`;B'XH^,=P#SC_N9V!J
MS]8GAK]USOZL_P"S)?B#B_1/%]%4#,7C"CVAXC6/1#SAQ(Q@(?[VZ@?SD^&8
M,#A<[^K/^S(_$'%^B>+Z*K]V#QAMNKX1G'W3OMU?BD8QVW\V_M;MO\30/SD^
M&41_Z7._JS_LR/Q!Q?HGB^BLA<M>,<;H*'B+X\,)4G"X_P""3B_<X(I'6`F_
MM;V"8I=M=>[_`)M/#.\XFR[LPR=LW0HVMXRP_P#QU+\0\7-%DPX/HI$8QY!>
M,#D#&U`R&U\0:EP[6[U*L7,8Y_Q:Q;+*1QK#`A,C7@42C""!FX'`>OV.P->G
M[V_FD\+,"F,EG"9S9HF0?_&O!I!@0#U<C4@^(>+D>A1P?12R#,'C"A_TC&/_
M`'I&,OVMUY2=^<3PIA_#PJ</\6\?9DOQ"Q<_%\GT4!F'QAA#?X1G'VP[[#^*
M1C'8>GYK8?:WMV]GS:YS_P`XOAJ#$89.L?\`:S_LR7X@XOT3Q?11]V'QA?\`
M.,X^]Z1C']K=0_65X9?=<[^K/^S(_$'%^B>+Z*/NP^,+_G&<?>](QC^UNC]9
M7AE]USOZL_[,C\0<7Z)XOHH^[#XPO^<9Q][TC&/[6Z/UE>&7W7._JS_LR/Q!
MQ?HGB^BJCF'QA0#M\1G'WO2,8_M;K1(_.%X9SVNLX9.B/^+/^S(_$'%S\4\7
MT5<3+OC"*G3W\1:B'V,H()H\4,7(=]W39PX[DPC&#OWG<;`/L:W87^:_PYO4
M\-=ALXL)]K/^SJ0\0<8%%DP.]]%(S'_(WQ@;W28*Y)^(+0X49]2>5-'+<4L7
MNC(!%V26KY1!0L;V`?VH$VWQ==/'_P`V7A?A5XER.RIT3+!_FWC/_P"6*/Q"
MQ=WQ3Q?12O\`NP^,-_G&<?\`O2,8_M;KA?K&\+ONJ=_5O'V9+\0<7Z/D^BJA
MF'QAA_Z1C'W9Y?\`!(QB/Y_]C=9IGYR/#%KH#"YT/^UO'V9+\0<7Z)XOHH^[
M%XPH^3Q&L>C^9Q(Q@/\`]&ZA^LKPR^ZYW]6?]F1^(.+]$\7T4?=A\87_`#C.
M/O>D8Q_:W1^LKPR^ZYW]6?\`9D?B#B_1/%]%'W8?&%_SC./O>D8Q_:W1^LGP
MR^ZYW]6?]F1^(.+]$\7T53[L/C#?YQG'_O2,8_M;K7^L;PN^ZYW]6\?9D_Q!
MQ?H^3Z*R(9<\85=9%`?$:Q^`+*IHB(<2<8`(`J<""(",;L`@!O+[&K[M^;WP
MQO=X9=687.MS'!H_BWC+_P#K)_B#B_0/%]%(NA<BO&`OE9):&OB%4B/(:<LD
M.5H?BKBU07!*[+JPAWFWM7OTB=$3"7V==J_?F@\-L,$)^&3B1_Q9_P!G*?XA
MXP/BFG>^BEA]V'QA?\XSC_WI&,?VMUP7_G%\+@Z`PN=1_P`6\?9E'\0<7Z/D
M^B@<P>,,&V_B,X_#J#J+_@DXQ[2^P8/]S>TH^?R:C^L;PN^ZIW]6\?9D?B#B
M_1/%]%`9A\87_.,X^]Z3C']K=53?SC^&#6Q&%SH_]K>/LR#X@XOT3Q?15?NP
M^,+_`)QG'WO2,8_M;JC]97AE]USOZL_[,E^(.+]$\7T50<P^,+_G&<?>](QC
M^UNKI7YQ_#!T;6%SC_BWC[,G^(.+]$\7T53[L/C"CY/$9Q][TG&/[6ZN_6+X
M7?=4[^K>/LR/Q!Q;H^3Z*O+E;QAGHD1+XC&/]Q<-4C]'%'&#54Y7:AD0*18T
M:($[0\NW9KJ8#^9CN;WKQB7=<*NSI$ET`6N?,<2Z-<7R6F&BI:97?:^3VVY\
M6OJX.!J@'\*3XJ?Y9<#_`,]'W"/^8/%G]G/L[_8;^E_['Y-?I#M7!/8G_;[7
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MY$Y3B8G=(@Y5[[<RB*!RF.51PJILN@02$$>E0`V`HC[`ZY,S!_$EQL@7(N;6
M-O2-_F4([3N/LSJ/*KA(8#KIB`@=J.SH@E,!FP[(#LX*/:B.SE/YK;^F%^>#
M?/V/XD1A"Y1_\Q]1+M.Y>R.H\J`(8QSIAN*B:H(*)@!A.183@F")RAZ1514,
M!>D>WJ$`\ND["/$9KQ+=U$3"(@&\`$C0+$4=IW+V1U'E5$RBMT=S]%[P`,GW
M0"IWA1.1(#$Z-^L!45*4!#]$8`\HAH.$>(P=8/40[-U@1U6$=IW+V1U'E5-R
M]29.LH'5ZNZ(([&5Z#'(?NR[[GZ#IF*.V^PE$/8'4787XALF;%YN`FCXIO`!
MIJHL11VG<?9'4>54%RV:J-TG3ENV5D5FK6.2<+$15?N7PF38MF*:IRF=N'IT
MC%1(F!C*"40*`[#K2WN_XGN$6RKJ1HG'_31VG<O9'4>5)2JW6J7"4N<36;!&
MV-YC^>4K5Q912:ZCZK6)%DVDE8:25?;(@LDP=)+J%:";H34`1]G5D[NQXK7:
M6)MXD7>7)(M!SII`@<L3+A!2[1NGL7:G)>;&`BAC]`=R*A5S)]X*21T4RJKE
M$ZFQB]RF8#&ZMA*40$=M]8[MA7B+?7[*Y]1G3<S+P'G4UA*7:5S]D[4>5<>O
MV.NVN*:SU=L,);(%\<Z<?,UJ6CYZ)=G3,<BA&DC%N';)R=,4C%,!#F$!*(#Y
M!U?.[O\`B?=_]Q+NLO\`:G%OEEA':5RJV3O5=RK9V`W>"4=P3`QE-@$>[*3I
MZQ4V'T`)UAOOY-PW\NJNR/$<L,R%RV;1$GK`@!G)L0`1VE<_8NU%53**PF*C
MNL)#"0X)`*@D.4#B8A@)N)3E!,PB`]H`4?,.HRL*\1+Q+VLCJ+Y6=MX!&L,(
M1VE<_9.U'E5IRB!3@(=H%-V"!@$/1'6S#+EW_DWYCR_#A`Y;RWZ%".TKG[)V
MIR9+&91^Z1R5$`$=LET,3=@[!OBF#`.W?;7O>^<SO\SN_+=+F7`OL\[_`+RV
M`,:(&Q312=*.T[E'^48;Q3W@.W8!@*8_H)CW!G"@JG'9,J!"JHB1P8?F#]7H
M#VZ^/W+$L3EW:4WOY+N\_!C/:&ME3#-=M#Z/,:&&%=,>!5S,2N<*)1/`[E7E
MGR])D6=Y)M*)26.;9J:>\77LW3XC$>1WF/8JOW,^3E8ZOY,R$Y>RZ3-Y6*Z9
MZJ+\Q$G8KM5#I%2-UB)?Z!^'/=SP8O'=EMXQ&[-D6I?]ZRQ&T`#`OFC)FJK%
M*I[0NCC_`"#'><EF7/G(O'B?)!_:G=!L,1Q(QOC>0N4.E5WR=KO][LN-HM\Y
M7B;4UD4F\95D+&P7D$RF:%<*-@.B9(@*@;7F\5\.?!N?>]I=KGM93B0'-:YP
M$*_1FD:T'$KH!$R#J=RI.VKEEFG%$!?1L%HP=E^4C^/M"S73;'C.LHUZE5^?
MN60(JE!#V^.;S%A1?Q:+F=-(M@!TT7.W8FW*GW8[>HP/PR\&YA!.'N:W,9;_
M`"F:$CB=S)HDF&\Y(@<IY*Q3E#E/=U;GBC(5F@3\2:9)W>F5X[:EK0UEMAX!
M^Z".<V22<0]A;1\L\%PHL[4`J?0<03*8`'I]XO#GPBC(N@N;W2);'%K1+>0T
MO(+H0FY8",<R7:%R!+A),3H=RIY,@\K;RRN63:U1YW&9XL.1>",%8YODLQ2?
MU.J.LA5)6P6J7L)V<V:*LKMN\;.VRJ1G34J9CIIF4`P[:\9>O"_PG(+NS9T(
M>QF?ZB?:=S]@8[SENUFS9G#EW2JS/9HI-EIKK!3RR3\/6ZJWAZK:U8JSRS,T
M=5(PEDE56=W>`*2J2R2ZQ&35NHF)@W'3Q_`^Z^!]QVR<$PV2ZZ-MV;9F-?&,
M3%MHPT4K7+Q&Y[*WLH",(0,<^>I3^Z1*(E$`$Q1Z3'(*HI*"'E40!514Y&Y_
M*0.H=BZ_$\SO!(N^*N:["Y#6VC6Z8/*GVG<?9F&\>5,?R;Z?N'V#J`=OMSP3
MY`$1W^[WC7;LW^>^1K[AW"F=Z[U+F3[L;@,.<QY:QMX!<T6'6`6V21!T(Q,0
M*5%V)72%$HQWG)_7Q3"]=>B/^V%NW8WTPVOC&+WKQ`&/OEMF8<YUJD"]-)K,
M:`R*9Q*Y>R=J<O*SF\A>Y7-U9KU3>O450XJY9MS.)6SK/X.A(FPQ=N;>I68R
M44Z;QEPL:*9.IO&*F%LN7M4[1'7[\_+Q<<!Q7N?..-W"Y2K[9-$R:]CB>=2`
MYS28G,%QW8O=[1&P?7T7)&(\E']2:S67*_"UVQ69YQ'XM"3)-YA%X:U.)O(6
M0EJ>XG+F]CI<&33'L0[`9U-NDR3;*JF`3K`4^^MV']R>[.(S[W=L2N-V;<6B
M:0VV_P",UH)8"X6W.`@`*:!G3;BEWMC^"^T3`\UWE2ARMD;(,X_?XBR#<J!D
M=WC#DIPZFPRIBR`;5R&D6]PM;[UVG2D$N\G((L_"/&Z3E,"F,9(AR'$.D0$:
ML)\.O"/#?XG4YDF=9<V)EO:8/:6.'.F?&:X@[ZV=I7/V)U.Y4O8;E)F-Y9:I
M:5I3$DA2;=R;N&!SX(8Q)SY5C(")E;!"L+:K9'TF<PR+1I#D>':#')MDFZ@*
M"($$IM<R\^#W@_C-X%REW%P8^BULWP&6O:P4)N)71K21),=`<FAA.2F:\U4+
M-<C(JT.WXKK^!,PSUFJBN(IEG"(6:(EI.O5&G.+<[N#9UDJ$G8)`KR7>L039
MI;`GWI!.77H)/@#X:=W93,1D72;)F2G![)AE.`!:8@@F9"@U+(<7NY$#(?`_
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ML>3TYB`H3S'YHE@]AD:'7:[,>M$]:>.@(Y.D0AA)N!M7W'\N]WQ#&[_/[^W:
M7/NP+-@Z273FTQMDN;8`C1E.=53<4NS0"R2XC+`%*FZ\HN2,7FFSXRI5(K5D
MC\22>*XJ\QCZ,@(Q.P.[4SA$[8\G9^:NT)+40Z3J36%@P:LY5LOZH0/6C^CK
M+?OR_>#,EYE3I4MLS)&B@9(&:%5VI),O:"4Z`(!%ET8F,(#***3DB%VFO(SD
M`6U#,FD\<.<9L.8+WB]]K#RD.3WF6A9?J9Q]Q<3(3*D<=Y69("^N=P)>^9%`
MAPZC!J5R\./#[NO(-SP2[72;*>;9+WEKHU0`$PQ"UW3%;HZ62Z4X&/1=RI'T
M/+N8*[QVY16>P9&C[_<VF9;OA[$L0%>27LD+?9ZZ/:-65Y`Q)520+%R;V1*>
M+;`7J;-2J&VZ4SB%%YD85A[X,PR[F7")(=,,!")^-!:^T[D/[LQWCRKT`Q1C
MV+Q-C&@XXAT@;QU2K<?")%$ZBJJT@W2[V;6<.3K+@]>N9I=PLH<AC%$5`#V-
M?CSQ:Q'OC-[S3'X(RXW?"^998Z?9(H$:'-)%.<K-,ER;T\SV$-:<AH\J2F;R
M_0,2`('`?QB,']G281W^W!#IW#V-QU[#NU,[^S>[W\69A\-FZ$+RTFU`V1"S
M5&$3D"J-S;"AS:\XSIZG;V(C8I[*2TFPA(V**JM+2\L];1L7'I`<YA6D)!XH
MBT9)`3M$RARE`-?/1AWB)B%\F2[EU"=-#C%LN\AY!S$-82"GU-G2;K"1_P!U
M3&@52R6YAD2B3-2K3%:3MMJKU@C+)!5N.C$Q5.ZDWD*^GG;9PFD3J-W:12^R
M``&M@[I^+CG!C;I)MDPAM'_Z2!<V5VFZPE'%2T;.Q$38(E^A)0U@81\K#2B!
MCBVE(^600=1SQL=4J9SD>H.4S$`2@<>L`$`'LUQ)F#^(\J8Z5,%Q$QKB"#>!
M$$&!!YE8*V=HW-M!E.HT.6^82D,0ACE*=4I3)$,/2=0IA$"F3*(@8Y3"`@`A
MOOMJ`PKQ%)@.HQ_\P/H([2N?L7:G*I-E"B=,P*$!(%A,3<Q01,H9(JPF*(@"
M1E2B4#>03`(>74W8-XD-](7(;\_ZB7:=R]D=1Y5<1,RADRI@*AE2=XD4A3',
MHGL(]XF!=Q.38-]PW#;5DG`/$Z\.L2)=U>\BILXN-%=`EE':=R]D=1Y5C*)#
MCL0Y3CU&)L0>H>LH")B;%$?2*!1$0\H``ZA(P3Q*O5OJS;G,V?I69]JS^U!A
MAPP1VG<O9'4>59-A(<I3;E,)$E@(8!*8R2O:BJ`#L(IJ@`B4WD-MV:YMZN_B
M+=72+Q+-Q+>L-:2+P"`<Q-B$="@_$[F11))X'<J8^9_QC\<C[/W!\K[![&WV
M]8]W]GR[Z^W=X'=_'=U&/F3</$X-$!UEM4*8\V,:H;YS*GM*Z^P,/V7)[WSQ
MG')/I*1>LHV-CDC/)"1D9!M%L&#-%$#+.WCUZJBV;MD2]ISG,!2AVB(:^-8=
M<O$_&)AN]V;<YLP'FM9/M$QS!LLDJV7B=S'I22.!W*D_`W"GW)FZEZ=;ZI;X
MEJY,R=RE4M$+:(UJ]30.Z49N7T*^>MFKI-L0R@IG,4_=E$VVP".NK?NZGBUA
MD.T[M)N\:MK,=+CO6Y35;VG<O9'4>5*$R9R=0G(<H%V`PF(8H%$Q1.4#;^03
M$*(AOY0#?R:R/N'BU=(2Y4F1L'",1-=#7LX([3N1_NCJ/*N=-3\%6:Y/66P3
M",17Z_"R4E8)%P4CB-819$TQ.\E40:N7A6"?='$QVNZI0((B``&^NO<.[7B7
MBCH6;G;.3;T_]!':5RRRSJ/*D_6,DX_ND_)P-/M<38I./K-<N;Z-C2OUG+"I
MVIB#NLSS9:7;M&*45-MB"HW`=EQ)VCON76N\]T_$W#G;&:RZ,&2,^'EEIC$K
MD:I1/`5DN.0ZI1"UQQ=)Z)AV5OLK"IU=9V61.I.VY^D!XR`C%&)#^M(NFX`9
M3K]`%@,`=@:SLP+Q(?1+ZDXPC1/C0*ZF)]HW*%,IVHI7+E!)4"&`J(J*]TFD
M($)NL*??"BD5,>@Q@)N8`+N/1VZY+\"\3'37-:RYDQR3X_\`TU'M.Y>R.H\J
M3\M<ZM`R=*@YVR0\+-7ZQ.JA5$GH.G8SLZWBU9MLSCFK,IXYJ\&,0,EWRYBB
M)P'?M`=/W<\4[)>)-V@*8[4_Z:7:EQ]D=1Y5WR]0]_UIF1.(KB9(^W6D;U)7
MJ3/TCT]:8]@[=FX:T]T9OB'.QIHFON`@Z!_[R,D/D*7:=Q]F=1Y4R7%CI#CA
M@82@(E#$6/M@V'<2A3X3LVWWW$->E\8KQW\N]^EMD3+@VZ;6@NO+6P;:,+7,
MHHKB:%%N)W.`C*,89CRIV+/;JK4HTLY:;'7ZK$F<E9HN;+88FL-'KXY%%4HU
MM(S;MDS]>7(B<2$Z^K8HCML`[>5PCN_XKXNS:X=)N]YD]*5-,P:V2R.-2[2N
M?LG:BN2OD2C)2U/@372M2<OD)M8'%"3AE59./ML956J+^PV*$E(HSB(0;(-5
MR@;=3H<`43E$0[==R^]SO%J[7%]XGW:5+8T")=,<T")A23*`0<2N0I,HZBE1
MV>EZ0>BF14WZ5)0HG35-V]B:A"B)3>00#<->7.$>(XK%R_\`Y'U%'M.X^R.H
M\JO*F8YBD(`G.<=BD(4QC&'IZ]BE#<3#T=O9[';J(PKQ$<X-;U$N)@!U@1.]
MS$=IW'V1U'E5S<Q#']%0AMR$,'2.^Y5A/W)@V'M!7N3]/SW2.WD'4[U@WB1<
M0#?1<I(=5M)]B.]:8(H[3N7LCJ/*M%":AI1S*L(R7BY-]`/4H^>91\@T>NX.
M0<-BO&[&8;-EE5HQXNT,"I$ERIG,D(&`!*.^E>;AXH89)ESYC+HR[SHV7.GV
M6NA79<9<'0RP-"?:5R/]T=1Y5OIAZ"GGZ#^?Z6?XNO3=U)G?]]Y;:F8<*<MZ
M:/\`J([2N?LG0WG)C..`?\B='``$=E+MOV&W#?)=U'8=M=GQ#E=]AB,F9ML-
MV.P'.=>F`1RB-F'F0,2N</Y3M3DY%EO=&HR;52[7:F4Q-^*PL#V^XP-4!]ZN
M*)7`LPG9!CZV"!ETP.*?4!1.4!VW#?S]P[H>+^*7?K>&7.7>;J/CRGOF,]9D
MIS>-2&(W0F`E.)WBKD;C3W]P7Q\TL+->\MJ]&VY>N-#.SO2U:8.=.*L/M@D!
MHYS$2"B8E34`PDZ@Z=]]<^]]UO%B[QF7B[R)<O.Z8YHWHF4*E$XE<LLHZCRI
M2$#O")G(('(J0ATCE3*4BJ9P.*:B?=B*:B:@)F$IBB('`HB'LZP]B^)-FU9N
M=G/MZ/\`H)=IW'V1U'E52D$^P%W-OMMT@8V_5\SMMOOU>QY]19A'B-,,)8N3
MCHO`/D8CM.X^R.H\JJ5,YQ$I"F.8"IG$I"F,8"*@4R1]@W'I5*<!*/D,`AMY
M=0FX=X@R'!MX=A['$P@Z\AL8[[`CM.Y>R.H\JX;2UU1\,65C=:F[--OY6)A4
MVMCAW)Y:5@0$9V*BRHO3FD)*#`!]<02ZU6NWT4I==N\=VO%:YLMWN[W>4R$8
MOF.8",\72P(*7:-S]D[45WD=N_1[/^JI^?V#A\74L#NO?YN,78M?AQ<)S:.M
M-S_LH[2N?LG>JY,?QW`1QJB4I3F,-XR,!2I[]X(_;G/@`$#M'K'V/BZ]1W\O
MGB-.O9NTDW!TPF%D7D%VH,BD<3N1/\LZCRIRE[[1F,V-5=7FCLK:8$@0JLC=
M:RA;5G#M(QXY%O6'<FG*N%'QP`$R%1$5"[B4!UQ[IW'\9I^'NOO40644QF0U
M[&".TKC[,ZCRK)7[E5[<K:FU<G8J9/1[-(T>SEC`>F]I[-$A'*+0QU'Y2E!!
M%20.7Z`(E[XO3Y]<V\]V_%:YB-[D7>4/ES7-_P"E+".T[E[-VH\J[@F(4`,)
MBE*)@3`PB(`903@F"8"(["<5#`4`\NX[:Q3\%\2A($YS+F),?2,^#==B".T[
ME[(ZCRK("9S**HE*8RR`F*ND!3"H@)2G.8%DP])(2D2,(]0!L!1'V!UG9@OB
M3-$93;FX#-/CY&)=IW+V1U'E6%R[9QK-[)2+Z.C8Z.256D)"5>-X]@Q10*!U
MU7;QVJBW;)H$](YCF*!2]H[!IW7#?$*;,=)DFX/G@TM%Y!<-\!A/$GVG<O9G
M4>5<Q6X5!HF\5=VVHH)1\8QFWZAK)#E380LF821LP_.+T"M(J1.`@W<*"5%8
M0$"&'78=W4\6V2]J^ZR1*SE[P->R@CM.Y>S.H\J5+<Q%!*=,Q3D.FBH0Y#`8
MATU%4C)G*8-P,10H[@(#L(=H:7<6Y=X!XFW.5C3I0FV6_P`MX>V%K*8"!T+D
M7]S+U.$R2TM:&PRCRKYS?_6%;:_L%V5(Z;/^2=(5ZUBZN[YJ]Q<A_P"5Y\1;
M_P#H'C)_O#,:_)WYSO\`D&#_`+'_`-0+V_?_`/W[OVT[K^#BK(W)"SD1%3T0
M^<MB2$1-,F\C&/6Q%05.FY:.B*(J%*!.H!$!Z1#<-?CWNACMZ[O=^)-_N<=J
M;D]M$:BX1J(\J\Y*_P!BW?"\987'[)MQ`IRL+`!4;/*<UFD*O:*W5VT9<X^(
M;9QFE8MRS,BR%YZI7HYV1R@<"'*DD(*@&Q=]?M'!/$/`K_<1(Q^:T$MIBYM4
M*?2<<E>I4Q2BRA<LYT>K92H->R-DN3H=)Y20U4L>6;I/6ES:JKB*9QO$VYB$
MK>:Q3IZ]DK[ZWNE$%'<5&.%&Z:G=]ZB&YPZF`83X18E/G3`9`?,8UP_D\X%S
MF@CFF(+@1O@HT+NXYE,MWF;XIU*8SOD2Q5N>4Y*.YJQ8NF<@UZ1MT+29"N6&
MCM;)8\@5&%L,D\32,JW9RSDRDF[;N`3(X.D)TPT-[K>$S;T27R(-<`3_``:"
M:@>970=2,J8^KY[S))(9TFX:_9`B&4AQ@RY>6\),W')$S8L2WVK6L`@&\D]M
MM7BH*MS<*P[PQHVO=[&F!R538B@>EU6]Q/"'$<9D3R^[Q9)LT;&GG1IYAII4
MWOMAH@T66PHRTFDZ:81S`)=-\J9H^UG-4W@O(V<,KQD9QBQS:K5*Y$3G)22I
MF99"X5QM98^DQDA#QBJ71C&87?E28E7<,EFQ'"('..P/%?#_`,().*RW.F2`
M/\&FL>S4:A$Y5FJF3LK0F(I^[)YZL=^Q[6N06!925GJO*YHMDS4Z"^</%K]$
MV6WW&M56X7.#,HH4KUCZO*-6QC"19)`G2)N#CG<CPCE]ZILUCKLYSI3&B.Q,
M"6B!',KR`Z4PXB,0*1#>T[ZY>2IQ;)Z+_)$E=<TQ>+Z?XAM4+#2,+-7>H'J6
M'+738$K2XQL0G74W<=7ZRJB*L4[:)'69*O5B-$SIJ*B7HS+IX6W-@DR'R3,J
M#0942=ZR@`5D@`9TN+'D:]QLW=F$]D',%>P=^.`G6;U>*[*6%O8JUC"'PW7Y
M3'[2'L;2!EW%=@9FTB0LF="/<(N!6,0RFXB`<+O#>.Y^*8/U:26/:9/,!L$%
MI!`(&:N&D*^T2T1-0`WE)CD%>7-=XF1+/%DE=KQ:,J0E3Q3BF8L!7\==K)*W
M-)`5)Y^JI'QSF!M"-0=+.'D@]:MTP,1,YB%\@?&O###>Z&&=YYLQQE-`>28%
MD!2<L*N%/(H6EF<D8*Q?RHPG#5VV8">0[[#N2<!,86P1UL=5ZO6ZUU^MV9.O
MV>FM7D=,O'4NQ7>&2Z>HK==8P@';K[;CX\+L6(!?)>VD5RH1`B<AJ%*(I4<D
MY7,^-,E,<?P>>;U2J=7L75V7QI?+W;\JN1O>2K-8Y>1GO;M]CZJ7^3R"KZ_(
M-VZL5*D:%1CB!VE*&X:,*[K^$%XPR?)FON]F9*<"!L:B*?B5)B'QC0JW/,^4
MHWEK3XIA<,@1)(C*F.:18*=+SUPE:Q:*W,5HOMU=8_&JM`94*)I`3,@=M'/%
M9()-FY$HCN<NO-8WW8\*<#[G/[!F2-J&&%DR<WR6!!BO8)R7Z,XV#T0!0"CY
M0[!'V1[1[-?@USKY.[QF7=XFX&88FF$(G-0H/H:4QV,.S(7)TINP1R50A#?V
M=L5P8CM^<&O<]ZG!N"ME9PLZ<JQVRM4.(>V>Y6B$I5>BE6:4E9+'*(P\5%G>
MF3.T]8>+CT@JZ+L"9``3'Z@`/+KSG=ON!?>]5T:VZ-)?*>)M`-3=YIW95;*K
M.\N)4SXVOSIIEZDA3+FLY@'].C,@U5HP=NG%*0FU';RJK3K)RX<G;DDW9Q4:
MJ))AWQ"";80#?K]\L3[]2)3,`NTJ<1+@(0F9OVA1P*X&(B*DH$Z+6DY&P6!G
M4H)B_N8II6J<0@&+21NK6/:C&1Z4X_*UG5WZC5H86:I%6Q?H8_-`&MMVQ#Q&
MP[#)#+DR;:,;0`FZ,S@JIM0WTT<M6,`8*I<T[=8[HE)H=ODX:!L;*`QVV7A+
M#(VJ2"$B("7CZ_`22LVQ?/Y4R1.\.B1-1P8QBD+UB7U>$]X/%=Q`L3HPC3M1
M4(Y7UYAEJ"IC#?5^-\><=[>QO-8H6)Z@A"#+N\.7B$3QNQC6LL-17`J-4<(2
MD,52SUR&77,DFY./M<V.;K:.E!*;:O'N\OBW(Q*2&LG$.E6J-J<IK@^@T4@T
MU'*F2YQ),25@QQ5...5,?SKG'F-\?R]$M\D[K=@9)8V)#,IIY1)5S6G*4M'2
M$&F_=.JV^CCM6*KTBI70E,JF0Q#`<SQ'O1XO29-BQ.)L@\TS7"!$:P^$1416
M#0:4@:(BA+!#&^(4I^MQ\?2\=L[-BJ)*XJ[!K78Y28QC595T9@L%/;&&'0I,
M8\<**]+I!!0BZW>[)ATCKR-XQGQGQ6[]7?*O'53')/X?C$(3G.&[A)8J:J;H
MIUA5!`KSN@<*E1W$P'4(!$EEB$#<PAL8WEVUX:\X7B=QF&=WA8YKC7:!_P"L
MA,'R;$#X/GA)V@:Z8*`OQ1+GO&@F+L/;N`:^K>$^Q:R]S94-DX3",T+!6D^C
MJ4B'BJ17+HQE"E*55<QC"(;`4@J*'-OOY"IIF-^8`Z^37+#W8CWXFF6(FV:M
M]T,A4C6HH#.\->0EN)%J/./.:[G%Q3Q+VI6&N6V>8L5C+.WT>U:/VK,QF!GC
M82N2IF/TJ@(#N(;Z^S729XHX*S:B5/V7Q21-J%4*1D64QRI]'.+*2Y6D576/
M*X^-8ZI&5&7</JZD8):A11UFE:HRKM5N?OH",.BJGW)FO=^B(>37)Q#Q!\6)
M,]LQK)Y##&J=D_Q$`N!BTP(7*BL,XHB:\TK,/B>BL:DWGF%U:P,93:Z:-&ZP
M91+%61O'NX]R@BO6&S3^HUF[5,Z:B0=!@$`UFG=__%_%G;6Q>(;T[_4*1C&)
M-*Q+XIQ4RM\U>U*+2H.[O4),LQD2/KT5!W/UR08&0G';BPLXUO*-S#&!N"G=
M-P(*>_?#L(#Z'NSX@^*3L3DX4YLX/>:OXN2GI_`FH7<;..W&Y:T34G3<S0?(
M%"!KL]0)VMQ3#%\BDZA++(D(X9Y0E*Y&P[W),L]29K)(O)IJ55$I-TP,H0IM
M>^\0O%WQ4FX*W!Y;)X?9$!_&I&0_S/@3<]SH`DV14,E--"FT.),6.;3`6A3%
M5$6ME%;,V=5GGE0C#66G)PY%6$4WK\R1E&R3!K$MDS(H'5!QW2@#W8=FOBUQ
M[Y>+M_PPX/,EWB`-N'\;((=,^1*E*UE58:)L,U:T:\$=8[.QC(BR3S5J:)L$
MHU@4'*K6#F7S=53V^723=CU"[!!$$E!`0WVVX-U[R^+6$X@)S94^`.:=],(B
MH=Y<X*T7(DDDXBY(N*H4U7D:I-5F`QY5)*LMH6?DB6B7>U()]C)N:9:'Y@ZG
M$Y$G[X1$""`!K]']WO'SQ-NN$S;G?6SP"T`1VOPS4P>;9TQCEWMY2"^X%BE9
M2CR\UC&I6&9IT36VM.M%KAV%FM+)M#-$_::4+;I8@OPF&R1`<MY`C58Z.R6R
M9MPV^.XUXD=_<0Q)TVS.#7&!_F4B(,/3-"4352NV3&>-EFZYAH56,W4NB=W<
MKJ5J-/U7<JY`:Y&736ADBER(^=K=;J4#9=4"`8R(>34?>[OP^:V<UDV#6PJF
M;_216D=8N.^*YF[0=X6JI*I9F.0FN5I="OL(EBC=<@0;-]'0TADMVK`E>62)
MC'=B<O6_JR";A)\!1/N7IUU)O?KOP^[NDB6]Q<V$2)D6T@Q;SZS"&\2E`E+Z
M+R%7)N\W>A1T@JM;J(WK<K:(<\2]CUV<3:$ECQ2Z=@DHZ,9.G"[5MNJBB@7H
M.`AN(COKQO>?!L3Q#!Y6-XFUPO4QQM1C'FF`C&)UE$4WV;2%3+BC8W40.1^$
MN@PD.GZ/VYHB`&!3TA.4.P1\AA[0[->D[J@=B[.B,$9$G.8:"CKBWR#(V1%X
MX6QX_8,BHMCNP)(OGK<4C'8)%.=^=!LF<!#I$=C:[W@I>L!N'>B^.O):)IO#
MH^B*8Z40R+SUE92GS;Q&_P#%6&F*PRHW##,T-F>]4JJ2],A'EHDX*%^T-BN*
M,3!FL&1(*Q,E19@V3=&3:FW5.<-Q']C77&NZ?:)N]Y<UEX`%!+`1&KS(:011
M2G#B\EY';YQP^S;W._Y#F+)C>@0R^,X>3M-.)3)MSA\9=Q+Y<KSR%-C')=-G
MKFY046L2;UM+L7'T,J?9KQ4_`?"]QFOG&[DOG&+SLK5J)+A&SEC$K9%L("-H
MUQXH?"DS`Y,M!^/S^=9YNY*O\ANK#0&G*]NX;V>6=84AG=Y0:7R2QK"S-=;,
M:P^4:JF,W3@SO1;L2G7`/0T2N[GA:V=(+M@T.A9_E<X6B(^C32"(Z()&@1*Z
M*60<E5*H6C+E0O\`F7)^`L)<B:86J/+@^G)*SY5Q%;*TXC<EQ1'+F%8S>3&-
M0L#IN\C',L@V,U[I4[4%#!MK5B>!^%1G!@?),R,(?P:\WHK)I2!R=<.0D=4,
M'N;CE:V8ZKN6ZOE/+D]<IB?R2QC(S(LS93O*)433>.*O-VN'8UVJ2*"*,"_9
M@R<J-E0-U`40'I7&Y^'&'W<WO"G2G7QK3`-V<8&AQH`,`#$THB!`N,!%/Q58
M/,67LF7NFV?-^5H5[#\6L+2\4[H<W::=5G&7+/6;>R>7<B"C6N/)(H`#-RDS
M6:M4/6%$U%60!]$+XY^%=R>Y^-LPJY&268J>>061YUD9`T933`FD@F"G:#06
M@`QRFO)R<92TX99!R=F^;M]^O3ZQ1L1C.MUO!OVL.Y1<(F:S!37:S7,=X=L&
MLI(-'L\K)%;MU!7Z2-^]'NB@81U\A\>.[/=ON9>;K@N!%A,Z>V:;-G]GXK6^
M3A4I5?`I#S7^,?CC^X/EC_O[QYKPG>4#L!G[(\BN7.Y@-1><7.1B`$55[S$M
MH`$D"*K*&,+9J!3>JH%.NY3*80Z@(`G*7M*`CK5X+8OAV"]Y)5[OY`@\6:JX
MU4D<2JFU+S[E<29-Q5B2PYLCK+"8KM>0X/BE1HB(X]LK/%G@HA&RU5C*7:4?
MSK`9F4NDO&30D<HD8@F5'OB]1BF'7ZW\4.\?=+OM.D<Z7,,II)!+3Z(B:B2(
M0KC0J":-"S<@I?.=!SH;'4%G.RX]K]4@,:H8@L%RMV5)=/)CN0GI-:1E7@T"
MBV..R=,/7Z?J;I"549ILF12@/H&$=:<-PWN/?.[K6OF2B]C85LH`'[.=,U)2
MWFY/Y>9Y9P>2,E9LALI1<=G&$QCA1@G.-<42.)&&*I1*$LYJX%69UE9:1;N7
M"_>@Y4<^N])!#<I0UYW#KGW.PR]B9+,NQ;@'<RDYHPU(,`8:$BIRXY:B:G;&
M-8N.2(!I&8V\.2,A'4">4,]AD[>V8L,@A`-'2#%!%PE%E%5V)P<)-VY"F$IR
M_0M>UQ23X;WVZMO>)NE"<ZT.<95;39="(-1KTK6P&PUU0,:<\$Y$A,94I-ZF
M*$QOV3K56J?SMP)"QDQ:)F1GY2RTNY4EO8+G6;3-*-DUI6DM)46RYDU5G#-K
MWZB8.``O0'*P[#?"J4]CK<A@F-,#&4+;8EI/HTB(+:**$S4!#SI'L<N3L9B7
M,TO/Y&Y(R/(X7TI&90QVWG[;3Z7AN)D+^I&0T_!#$5$&53J$17DTQ"3@?6)=
MRV$"F+T@0Z=7=7`.X^)8U-8YLD7+K+RQ\&<\`@$1@06C,!E5%NP^,`8.C3EA
MD.C0N;A^SY$O,EQI3M5FL5\"J<Z+Q#52;E75QG`7J+W",C.1G^[USA(:\K5]
M0[T21OKC8J!P``[P3:R>*%W[H=V;G,?A[Y9:V7$P+/C<T5!N4P51--.4KV++
MT"*XICNF(N13$0V$2>I*]`[=NWH^QK\(=UBUV/VA49A.LHR)D>+(`/&_`P".
MP#B+'P"(>4-ZA"!N'YFNYXV,ES)P9-_EEY!WHF*<NL;R8WG/"R$]"<=8J-BZ
MY/3!>3^+UVC"U-WKFH*-BC-M`<60L;%S3Q.*!T\13<G3:N%`(IL5,YA`H_H_
MP![U=V.[/==LI[V-YN=HH@-(6H"+@"8`G@4>X_C=/4/)_%[&LY;Y:FR-NMW+
M7*$Q,8)]8I<10B76&824IC_'$DY8OYNI5>N/B$9HFVB9$Y3&*F!2&,77UJ\=
M^.Y7>2Y3KG>YDLW1T+42R%=$8DY="4TQ!I)\WF3)Y)S=G!+!&'TR7_+-3O!L
M69,D6MJ6M]_B&=GMN/<@3E<@(M]`XZIEF>7;(J<>1NL]]MWS-@M'G-U!L;6#
M#^[7A1?'1,R[EL,IDY?W"J`&!T'$P&92$:94R$XY)QS&.NM]R(^M%$A7%?QC
M7I.UU2N8\?DQ7]L3MSD7&<C6WF.;S3+'D%ZLJ6;:OB/FCM<&Q0W1,4-6-=Q?
M"^Y7.3>L--W,[K+(D;*(`B:"&"O+H48UZ53A1?,Q67(2BE[S$[L[A>B/SY0Q
MO8'F1Y>2I5U)/12'2T)::16:S1G,6#M1IZC&NG2#\J@*(>BBH.OEOC+A?=#$
M+G=BRR2+-D\RR0T$.R&)!@-:=$*8VN+=%22X\M`:YYYWF*T5:H/,Y8]5:**(
M'1!\DUQ+&LW#@JAB%*Y%%TF9,YBB8"G`0WWU\P\6L4PB]]U<"P_#'-+KL)UH
M"%%JS"K>S!62ZCOJ7R?Z(?8[L_;_`.P-KY!W?`ZRW?Y%8F2XU"4,*TP1$`W5
MN8@/9V[9)NP#MY^T=6^)C!>FRKF!SBP%"B]RVJ%CNW)3C)$5:LXWM,F;&/)P
M$&V7B3)J`V%>MU=HLLX<UQF\F&<NFV<G6;%*445UD2%5$A0ZM?L3P*\0)/=7
MP^F8=-?9BVS",*Z>D,V92:XM>'`D'16H_3V%;1BB9N]/J^6LJPTK@;P_ZW)5
MBXTE_(5]]=;?5YBVV2%CK$Z382KE^QC7:INF+$WT=J5,?9[/;CO!W#Q[NK=;
MOBDR6[$YDYX+29=HESX-`!B8F,-*SS"089%I90S?EP^9L>*P4_D>MOD$^+3V
M0K1K9:FM=RE$WUG%O;`_A:5#464J3:!9KF=(/E9-ZDN$@=1,I2[](=.Z=UO"
M>=@A>]]W!A33)^A6H"JE=M3*^<&DORQC<<7+(F:+O%TVXVVJRK<+!]HM5<1V
M0HENQQ]+XENM$C$\>7B#K3QVI&.H)P[:+I,SJN]E!3`<ES[H>$UQE-G%]W%I
ML1_)I!R^@B#81!IRJ27`J9N$TO<R3N96&6*TU7I+NN*NW>2K3+UN1>C/#947
MUBRQ0*[)*J/5(]J*S=)(Y(\7!"E[-M?&?$+!O#,7Y@C*$QKVD1V6<$'T<J0<
M'&A1VP4Q42E.$_?0AVID.6_/I=8JD>X(#,KIL[.DHL<S5($$URFW(H<"%4#M
M+YM>A\5<2N&(84&W=P<QLEHC$0`L@#R+7'(O7=#^G(_^ZI_Z\-?D#!7B3WHN
MK!2#>6#C2-28C`(`.+P`1V`;IDH!'<`V#[<9_P!D1*`?GB&O5]XWBY]]Q.-0
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M)4_69&E.Z,68/*TN^N*8KF.H49_:(LZ<D`QRRD2X5*T0.9-4=^-@>#>%C73;
MM,ZO+G`!MD"4*0(4BS6ZLYR4BYKJ6^A5_;ISZ5*B'=W2P^'[E+[<+BQRM*_:
M'D5G`7-@SM!U96K.4W1JU%J.+G7*_=K/*-TE.A9\\;@=40(&W;KXQ>\)[@X/
MWL?/PUTH.,SG0V<8@T1@T94@:%'#),8["L<A`",<F%[PCXP-FI48YR<7:R$E
M(F4:H@5`>_<(%0.)DR[G(!1W`-?8\7[T=U9O=T26O9!P+6F+:7`1(%-8B([X
M0081/HKV0K@@,/7SAOT+U6JND1$HE[QLX8M3H+%*8`$"*D#<-P`=?D7">S_Q
M2N[L-(,DM!,(5VM"87SP_P#K"=?T\_\`].I?17N/D78GB[^(J<QB](T'C)V@
M8IMO]PI@/2`HB)1W\^VOS#^<]CV]W\&+A064?U`O4^(;'2\0<'B!MIYN\*)1
M`JABFV$0%,H"N7;MW;B82@FN'Z$_Z$>W7X2;/GR.\,J9=VVW]4<(4=(9UYB3
MSKBT-KB%D`5R&,4CU=`5$CD.L04W`ID42/L9JL1-`4%S*@45MB[G']%[.NA>
MI.)X@;+YCY+3F<1_T7*%A]4%:90Z?J:B;DP`P(JVCO6%%A%BR%RLH5JR2W,:
M/:]T"0]R4YCBH0#=8`'3J%UPO%<&#IMQOTV9,F-`(MS.:&DD`1=0(DU9:4B+
M-="M5=]YWQEGCYZ0XD7$7KIRN87*&XH`9J8Y7+DB8G$4^M<"I=H[#OK"UW?#
MK!<9\ZP3$\]U.GTU&(K7#NM:A<@U>Q4RS^L3-8M4,O%6!DJ^<(G>M9-,K=TR
MZ&P(&.FFF7J$!.`!MMZ6O4X9B?>.[7UDR9>9HEAM=MV?]I2`+J12NA$,$HJ,
MB8IF4$F,-&,XF&0<+&*K$L8Y(K5F5B^1+ZZT=IH)%V,)U"].WLZY>/XGWPO.
M)-G72?.?)!K#W0RYWCR)ECUM*N%1'9P[>NUBE,J@HJ]='<).4^TBH/U3F`JR
MW9NH*9P-L'8&VD^\=Y[QB'69MXG`$-IMNR#]O(HDV3!U:N2>G`I7"ZZRCM-,
M7+<IEG*WJSL1^B$.Y*=)UWJIA$VZ(IICOZ0;[ZU7N1BL]@+;Y,$S.'O!UVDH
MC+4@[Y4RH+`HL51/8&RG>"JX(@8`.HBDKL5NQ1%4QA[KNU!'R]>XCJC`;QW@
MNYF7>^SIHDMYK"7DQ:*H<XD"M:FP(B$"<2N%'C$R[=R\V*\4#N$EU1[L44UA
MD%$USE138B*`)D(0P`.W5MK+<6XU<\4=>&/>)3C7:.GY2:MW,V`"LP<-DFYR
MMVC!F]7(BJ@H0`<%>.EQ55%F@CMZJ0.Q-?<0``[=#KCB\2YMZFUDPMOR_O(W
MU>DL[3*8!55(10I@4*@[<-.@H@(=+?U+N]@.4=C^3?6"<WO8QID7>\3A+<($
MA[A`']\%!H$34K$G2R)@4(\4,8K<&RJ7>&(BLT,'2FW*LJ55=4K,!WZ3"`#M
ML`ZZK)>.7?!NJ]9F39UGT;3OA=!0,UF=!UTN@_IE["F_,^9'^;J7=>[7YA,J
M^RBV:XT$EIRZ"4B]CJ`:2F1Q:JFKDOD>9$[9<5LDT@R6ZI#)E%'%T$F=54"&
M,8GJRA@,(&`!';R:]/WOPK$QA\MXE'9"LQ;GWU78=F3,<LX";2N7%_([BCV'
M)6-,6Y:?3>0JO7X`]PL;91Y3WL3#73[36I7!K1&0<VH15%L1-15,X`?I#IWU
M]-\),4N^&7!_5`V9B#I1;8HC`[XAQJ;?X=+J`HB\M;-8<@,*C)X@QQF2DUY_
M1LAV:N3T#C_+<3+RF28JQKF<QZE'Q\:KI1]DL:($DO;FSLU1%LF*)4!'M#]!
M]P+CW+GWZ;>>_+Y5VGU#:-+ZJAS&OJR*6TEYUO7VE96LR7(B^J+9X87NEUSB
MA8<5M861R-$PSB^/*PQ4M<^VJ#9(4+8LK]&2E""4[5,1'K1*IL.M.,WGNE=L
M2?V4),ZX?%(:(?.8#Q!0F/80`"(KDYOKUML5]R>:]5'D5,Y#=9^Q)/XS8UN$
MO4GA@O']%[57A#R]=(JM49:4"T,GKJ2:>JC)((&34Z4RD..NC<,>[MR6A\R5
M)#8P]%N2'R-*JB"E-/QF32KQ@9/8\A7>$B<T,[$OT?CEWD%6[R44[9Q1\3HP
MLDP40MB&+YF:<K)LE&1U8DJA!*;J*03!T+UC'<Z=>9<Z<V0&E@(-@51-/H9P
M5)W-A:RB(WE'VP5[+[+C3BFE(4;-L<_3D>5$PTG4&^6G%Z4L#G)TPE2ZT_J6
M.O4%C6<\(JDY93LF'J#5)$?1,J8^^F\XWW%F2+#>KDPZ`_TTK385TI^XZBY"
M:9LG<C-JWEISFG(O!;',MC:SHI6Y&M!G2!J3V*O3"\'>B^K%>D8\S),K2+F4
M3-Q?+F53*3O%.I89C/=F7),MUWD"YTP?893G^)'B4F6'/#7.LM)`CFB:^!./
MP-K]\AI:WR5AN>0G\=(8[@QL%-O6-LLUYE"9%;NPD'TJA9,HS4K#R]K4!06Y
MAA"%BS].Z7002E#\V>.N#=W<:NW_`*.^7M'`D!HLQ$89FU$%1+F1(!C`J77)
MTQON)3BJHFW4O>#%A$Z8IG,+G/F,$B@*0;CU@X7`A@+N`#V_,]NOE?AE@]]N
METFW,,)F"5,`I&1CM*T5LYN5/;*"&TGL4YN[;R:YQ(F=0`2!C)(B<IB`)3`"
MBI0[!'RZ\UW)PJ?AW?1UYQ=FRD;2,70(K.8DJ9*\<\0P$Q<L:<4L-U_$N0H;
M*F)\]_;_`'.[6;&\U2H/']4AK38)>RR+>]3,?#N+8POL&Z2:-6Z`O$RJCU`'
M1L;7[SQKO3W=F765)E2Y1&S$.:W,*?06,O:28%*2O4^^TG"..<PO8S/<M98[
ME)#6;+\0[?9%G;,GC2+R'=&@%:XR6<"_"$5BWC5V?NFZ@=T(;D$=RAY>3?>Z
MT]KA>)4D/<#19;7ZBDUTL$VP2(&&2G(=X)JLO77(KJ+D&Z$+EQXED'E?FR98
MXV>2&0JG='E09X_K4A4'R):>C+WHM5KLG)'<H-HMNFR$0$JY2%ZMOJ_=3N7=
M,9P=UYPFX2YX#8Q`E#-T@$%[8@C(./.I?N:%,7?PZ"T3"UF?9+FI;$K%HSN!
MY6<<RES=Q=E+,VVJ.K981"345E%WDE';*"DY2$B::H$#7YMFX@>[7C#<KKBE
MS9=[L'S`8B60.8Z'H@Y="5IA,7).Y$N<+><1Q33$V)\W49.JR>)J_G`D7A^R
M8BNZN$U)-PI>ZE3Y6-:L).SR<8_.F50(@[I51LL91-01`0UVY=\ZUWKV^*71
MK<)<8M>=F6EM0@`"0*Z()%PCI39,:GD.Q1M;@*PGR-A\*63F/CY/&BD^^OL9
MD=GAM2@/HW(J-O>2*OVXP%,D;>]W;*S"R*Q2`<P"GZ)A^B7Z_=R+A>S-NS)!
M@TAW,%%-/Q$6@*%LXWQI?JO8<5S,0ZSJ^"$YCW[$4=&6*8R%9:^CQF%C<%(B
M)D$7H*JJUN.=`FZ3G7`KN!%4Z95P`2E-G![KXI3=I$E[S\EOPM"+384ION.C
M_(%KF,#RV-I7D#,Y/1F^0;?*MGNKJSK8KD*`0+Y'X^)"/;$^<5!"1CKG'LSH
M$3`79E#G(<@(@`ZD<&[JW8'MYDJZL?\`RR6@VL_H--6E$0E#BZJY0G!B6=%8
M\D(;)DU@/.;'E0OET]OB:5+Y=?5=V7'KVA&LA&4*VL!K<B99DM7B]RFV`I3"
M;J*`<#$\%\/V-#I$R0XN$1S#&'J94K33E6G*6W*E\I;EW5Z]R#B9.I>'_.4)
MR[EZMD*MR<CG"+EZVB,7#L'#AS'RMR"11?&3D"-U';E!0JJ912`3!/#KCW*E
M8;,;>W2&S=K0"SY,0*&FB&12#P1"(A&M*6XX\S;CZ`SC7L/&SC-1\UQBPI<Y
M%&9D[3:9J1MTM>G3#*?VK6N?*JZC+<VHJ*P':L>Z>)'!+NDDU/3-5=+EW*9-
M$R:Z2)5J@V:\O1R1"0>T.H*?#B%`1C#-G)>:I\%F6,QI+U;$Y*1+9N;68MED
MV,?&ND%4C3%N.M,/`:"4"@F]74?%'?O``!+KP/B\.[%ZPOJN"S)3YT2;+6EM
M,::VM"L,9A+AE,<U:DMG15+HQ,D90B:@\A\*+@FN8$#F22MR"ASE*L*9C`!!
M`0`-Q$/)OKXAW;N5[9=C(>PA^^.5%AV9/<V7(0Z9CJ]UWQSE!P4ZS@R*`"*B
M)R`V.V.T`QA\FZ@Z\EAN"'"L5OMZ?-,J>^<X@1.?08*LD`P*RK/%U3^LJRCU
MTN0>LJZCA5-YWOTL'!P.].V`0#8"J%[/8#7(=?.]K,6=/:^<Z430XO)WJWQ0
M"W)4KO6>\;BW5?JJ$.(J@@85TFZBAQZC`]Z#^K+E`1[.\3.8?9'?6IUVQAWI
M7J;28PMOK.7TJ]*OVC,A5/6U5/5Q<23L3(`(`(.%5^Z$.TH-C;)"R*!OUMW9
M?.`AV:DR[XP'M)O<Z#:N>^@1C1SJ*:8#*8HVC,ZL46`5#N%'[A9X8HE$Y3.4
MB@4VX"L#I!5$%'A=]RF!,H]0>4-9[_=<<FS+<N]32<]M_P!-41:`L*#A9#O#
M%<.1ZBF(.T@JDY<IJ>@JFJLFD)]E$C"`]Z*@#KJ89+Q60/XU\FM@T_'?284"
MAV4HBV%-2.\2.9)FZ.LZ9MUTDT1%TX!'U),@D;E2`QNMNJR:&.B!QZP'JV``
MWW#E=V;_`-[,1Q&=B'>C:R)EW)ZO:?&U"D0LO="D"N"(C.D30,>TW&<(:MTJ
M-"*CGE@G+._,XD#+.9&R6*1%Q,/EA4V*HI**=*H=O5Z/G[-7XSB&.=XI\K$\
M;+^MLG!C6DQYE<?2(KX59)<+1&A-[+J%4Y'XVZ0/Z>!\M@3J3.3<4KWCWK#T
MRE[2[?G^QKZ'C.$8CB'=]IN<HS`&BHM&320M"?A44Q.<_5T"8HAWZ9$U%S,S
MI`1ZS0[XIT2^V*8`F83%$`#7RF7AE[V;PQSI=]E&(`,#'?!R;ZIFD``%9$EP
M*N9=-==DZ723!1<IT'1T"D,3U<"/%T3`J*9DDC'3[L"E[@.D=;<*./L8[KDR
M:UU,.>8GA#C7QJF(5C5P=JB*+=95H54JB`J-5P;!ZD<YU5$EFO=*]T55T8QQ
M3(8.L5-^HODU!^,=]KM-,BZ;8W4Y0^`_Z:(A;:#\QT42G>.442(*@LV!50%"
M;N$`63B0-WIXYS(L4SHK'%0Y3)&`-M7B_=Z9@C,?-!KA;-?K(B%47QU=EEG[
MDC@HOE#`1143%*\5$#-H]P(_U(55DFDFZ`2B#GNPZ>[V[8WKWCO<B#KS.M4T
M6W41KASX4UF%>57MF-#0TFKB6L9<Q4&Z!%TP!(0(1=$SHCANP./>*1;<#*#Z
MO%'5,)E6NYC*J")P4*`[:P7*Z]Y);QMKS.LM$!%[J!&-'/H$23`924]HS.@C
MM=!1(4GITRE6542.B9\95B8Y=N\:E%\0B2*X!TF0."A$OF@[==AF-]\<'=;P
MQTZ88FI]%-9`+Q".7.J7.!='(JG>K&(85ESF261%JJW!=P\6[@5_63QQ53&1
M,BP%X'K`.R&]:Z@[KYC5[\1[Q=XV.;C\R9*!%1<3&%53BHQ"P`(F,X$Q^\,8
MSD1.(`43B+)81.)=QV$P]NWL:CW0P?$3BHG,E$R`ZN+80COQ5EA\*DQG%I9,
MO&_`_P#5""1ON.8\6*HJJD0A2GJL,W2/NH<I#&%P02@3?J$0VVUV?%W#YV)7
MQMWDM+OXL'0($!:,<H28TB#C4$^9A1ZQ.)"*D50.D_0.)`0D3'+L<#MU$S@W
M!7?81((&#V!#7DAA5]N&$&[7":_:PA9#B#5O@*TS99RK:4>]X15+OUC$!4%P
M46*GUO'YTP(Y?+$3`%FZ724A2I)*%!3H`QO)JC";EC<O#ILF\S9DN<XT"V::
M8Y'?"DZ8PB@TK`DZ<)E2[I9X9TB@+;UI:04,N5+ORO'!DA,0Z:_K#],BQ4]B
M>D0.H1UJEL[Q78QDWF:?WW?35$6K(90QD#M5C.!245,N!3/^^3.X<=CA](.5
MD3.%SG`.UH79(/T(AKI2,6[UL!;,FS7-LF`+S7ZZ(A"KE15))JO)O7B#1-P1
M`C@ASH%$[5=,J+)OUE;LV:@J=(^B90!$!`>P=47>;CF(N+<7F3&L$;-IQ(%.
M06C!$1G6`QB"1`A`.)4VK1,H**D,#+NT.E2/0Z$B'=($4]+OU3&4W]'R:Y<^
MYXD9CQ,M/DCT8FC3")5TH@@YU<F)=CEZR%,)1``,<A-Q,`D*`=1@W$3F`/S]
M=GN[AE^=>`6RR1$91HTJU,7QP,3[B5&V.F8>NZB/0JF<2@?)5T4+U@0PB03$
M,`[#L.PZW][\(O\`[P2'3Y9%VZN*8B$8[ZB7M;0XI\/H!DEP6[Y0.@I1;@HD
M5%PW.8!=($.*9EV[@_200$A@*KT@4W8&O/8E>^\=VA=\)8]UVRP<`-1<%':2
M\ZVTW`=1%U'RX+HO4WB*C<AFZZSSJ;E]LU%4C@5G(IMBG3*H`'(F`_,#OK#>
M+EWBO;)4W;S94T.C9#W"R0:Z'PCEB%6]S2ZNA6'46`3*(N52G,JJH95N)C.5
MEW!A4?KJNEA%3J5,85"*%Z=W9CJ`4O5KUEYO&-2\#ZK=;W,-YA5;?&._:AQJ
M$0LKAV?H315,9<43E!(OKBRZ+<-@$KM!=P3UXKHH#N=-,Y""IN/L[ZY+)W>>
M9<Y<N=>9HF-8`1;=1H]-%H9T'=BN8@K2+F0`P',JL\.\;+]2'8W$6ZJSILH8
M^WL_GZY-XP/%K],VUZO4USQ2(O>:JA2XHB(J[UTBO?>M++""I"%`HB=<P%+M
MW'K'09`CHYU-P=@0$^M$`+N;;6QV-]]+XS87J3-V0$/2;`@5?'6C:RZXK21,
M`+)#N78%"=NX%*`=0;CVB.Q=:>[F'8A,[S7&;-ED`7EA-(S[Z1FRX5IC^//2
M?&8&**"I$KOD3O`$4UR;*W*>`FZ8'^C$'?M`.SS[:]9XEW"_2<?-[8P[.U7$
M<L51::4^!03(3U9#UA='T2)'?/.ERHD<0,N#ERV33<MA3VV3$ISCT>CV`.OG
M6+S>]6(2FRKE+F&[1$7!P`'S@46AG6TKV'4$DD]!,.A(JIB*$,JQW#>*,V*J
M)$X8INT4@'OA\O>;ZZ\Z^=YKOAC)=U=-=>&BJWRN@B(60T@Y5(D59ZX.9H?I
M*)W(.$A0`?ZF;I%50[QVQ;_H"',"C?V#&UW,)[Q][<1PIV$XU,FR)+6Q;%Y,
M70@!S7'X$6AG6-R\]8/WQ7+D[@P`0RRJ[@H]@@/<;N#N54X\>G<0`1+U`7T=
M<?"I6.2+W,FS[W-`<:R]Y_ZQ1$9%B76.JH1X9R7UU+NB=(+/%5NE,^X"E(`=
M-))-+YH$NY$JH^B/9JJ1<,3EWV\7B9/>XO@6DN<<\:W(#@%E.\$QA,FH1`R;
M@SQF``MW:3S8H*RQ"F4,#)^J&P=SL=!3;?8NW;7/'>&9"5M9ID@Q'.,(FL@6
MJS!%H92J,B[**$*<%3&43.)A467<KKN%R***JK.%#J+'5.41Z2E*1/YD`UT>
MX=XD87X@761?YL)[@UP!B3"U#2I`&S;^*OG/ZP^=4_R@7K/])5_I'TSYCR?$
M\NOZP]K8=[5O_)HU'D4=K+S_`!5ZW\FLO2.-?%?Y[JPV$,Y9E4L-/X]L5&.%
M:JC9G,">%@I$[I_.-3.&9DD7(N2%1$ZR951ZND3=`AKS?YB_"3$>^7=_!+S+
M,93V"%56T'RAF7M>]URO6)X@\@'TM]8$^5MP`W4/!OGB`%`=S&PTS`H=GLB-
MMU\$Q?\`)Y/Q^^W>[F\-D0NY<7@M-1J_GM%.^N5*P.]R;J!9,8YEE2Y:6I58
MC<.$'.XBRA5#I$6PRU2[PB1#*'4()[8!3$`I=M]^T1`/9UC_`$&S?O0?,^TI
M=E7L5M.I83<L[8KZ*?!OGBH8"E4,4,,--R)*&5(@J8`MHB5-UW)C)"/8H0HF
M#LT?H-F_>@^9]J47X->Y@]$T:%9^-9<?R%N>7WF&ONKT?H-G?>@^9]J5?8-[
MS%94^5]N()2CP;YX%.H)^DGW&6HGZ4R@8RAB_;9Z*7I``&'L$W9H_0=-^]!\
MS[4K&8->Y8A9)X%F#EA;A(4X<&^>8@<#"`!A=KU%Z3"78Y1MH"4VY=]A]CMT
MOT&SOO0?,^TJ795[%;3J6!3E;<3&W#@OSS'L#M'"[4!_[[!T?H-G?>@^9]J5
M;L$O;S:@5C_&LN/Y"W/+[S#7W5Z?Z#9WWH/F?:E'L&]YBJ_C67+\A;GE]YAK
M[K-+]!LW[U'S/M2M&$7MHLV30ML.5MQ#U<@\&>>76N*!$T_N,L^KZ.JJW3,8
M/MN]!,543>D.P`&P^0='Z#IOWH/F?:4^RKWT3J6'\;:U=[W(<'N>(J`8"&*&
M&&@]!QW$I%!"V^B<W2.P>SH_0=-^]!\S[2GV5>^B=2SGY6W$A1,/!KGD)?1`
MIRX99F(KU'%/Z$8+</>`0P>GM\R':.C]!TW[T'S/M*79-[<(633H6E^-9<?R
M%N>7WF&ONKT_T&SOO0?,^U*GL&]YB@>5UR(`G#@OSS`Q?2+MAMNF(F+VE`%"
M6HQRB8P`&X`(]NIR_P`B<V0\33B@@#\C[2I-P.],-JR3!-EC[E);65TS@NWX
M=<SII:PWBMV!_'P.)>]D:VN6APD<2.L#52Q)^K++B@91(B@E%1/I4+N40'7J
M^\?Y'7S\"8WM40`H]#[2I]DWJNR4["7+.\]727@YST3!0ATSF)AUNV4[LX;'
M[IRE9UE6ZFWD.4HF#V->0PG\BE_NV&[6Y8J&SBX>SJAIO*3L'O<P6;)5OXU=
M]2.*R'!_GL+HPD,Z<%Q$S057,CZ+-1%T2<]9770*;Z*=P`"HGU%[1-K7^B3O
M+EQ<?Y7VA0[!O?1*Q&Y473=(P\%.=20("L5-$,+1JI4P<&[UZ5B\]O1>,VSU
MT`*@'8<HAT]A1T?HD[S?>X_ROM"785ZZ)5R?*^ZHIE21X,<\42B=0"F1PZS2
M.0JP=*P*%+."5!-5/<AUD!]9.01(/HF-I_HD[R_>X_ROM".PKUT2@O*>X',"
MI>"/.8I@;DCU@^XJQ;'6BDA$S*/:+MYT5(YM$K#UM4D_02`3=NYATOT2=YLN
M+C_*^T)]A7H_%*S!RKNHE%-;@WSV53,H"RA@PQ%=8JI`4$.[,2PM5S`*A>\4
M.=7J.)A`2^<_1)WE^]Q_E?:$=@WOHE8#<KKN("1SP6YUJIJ+B^=-4\,1P-%G
MX;`@Z!O[<ID<`4"AWB2XB3<.P1U/]&7>IK>K#%^9_A9?_P!A'8-ZZ)BJ*\L+
MPJKZRMP=YYNW>WT-9QAF,.5'<!`Q0*XEW"39(H_TLJ*>R9-@#R:PS?R%X_?O
MYF+B)_[+[2$=@WKHE-)G3DO9YS&<G&2/#CF=4DU[1B,S6QVG%201<<\B\OT*
M;2*H]<V5@DNO.OXMNR;D[HACN7":10ZC%W]SX?\`Y)9^$SIKGXJTSF-F,/\`
M+ASF.8?_`!)%`<2IG![U9L63`)Y#\L+JL=9PSX)\Z&G6?ODTT\.!ZNJ5<XF<
MH%3-;>I)$!$>D#!Y->-O'Y'W#&GCM41B8>AI_P#R4^RKWT3#>5B_+.[F)W0<
M'>>IFR*I2M6Y<,QI3IHF[5A,J[GGW4F!A]$GF]C2/Y'>\4:,7HC1_*^TJHX#
M>XQLG4L(<KKD4Q3!P5YUB5N`F:G+AEB1R`E;E<E(L`30F$QY(3%`W?F`N_5T
MB'9H'Y'.\<:<7H_POM".P;WT2FZR-E"&RXRC(_*GAP\T[\C!.G3Z,-+8523.
MS>/@`J[R*>15HK\Z5^Y0,"+PZKU))<B6W=B`@&O;X/\`EL[Y]UY'4KKB_,-%
M4G_6<CL*]=$PWDK8'D?,U2NQ-7J_`#F[7H&$:EC8F"@\$U^*AXR.:&%9J2);
M(R"GM0==4PBN0G?^LF])541[=>7Q?\CW>'O#B7O+>,8!OC27?W0I=0:.L@9>
MB@8#>A\4KL%Y6WKK14'@WSO<*D$!(=7"[!%5N/DW34^V!R!Q`H_-%!(0\H=N
MP:S?HD[S?>X_ROM"?85ZZ)60_*RZ@LNY/P6YX"JJ4".%`PU&&._2,'IMGSM2
M94=R+17R'37*`"'DU5-_(]WDGML'%Q",?[K[0EV#>ZK)6D;E1>CD-W?!CGD<
MIFRJ)D5<1,!452,<@@U6*251;(MB%#H222-W?08>OM`-62OR7=Z</_E8O1_A
M?:"CL&]=$QWERJQGN4IE<:5"H>'YS>KE8:/)5RVB&^%(HK!NL\EY"1%RK&$E
M7#-V9UZ^8P[B4Q##OOOK1??R>][<<(ZWB],L0%$D40`R3QD`1V!>A0&F"4/X
MU-V4[@''!7G@J5J<JJ"!\,1#ENBLGOW:K<[Z>=*AOOV`)4^XV^A[[CMA_0[W
MCA3BX_ROM*.P;WT3J67\;.]D[L#\'.>0J=:I@7<XB:2ADN^W$RC8[F6148.R
M_,E=)`+A,OH$]`1T?H=[Q_>XA_A?:$=@WOHG4M0G*>WBCW?XC?._T3&4[I?"
M$2#<ZHB.ZG]2SHJ)+F]EP7Z,?]$&C]#G>.KM>C_"^T([!OF8K)^-5;S=SU\%
MN>2A.A4PIJX9B7B"#@FW<F,S>RBJ*Y3CY%=Q5']$`"`:V'\C]Z%T`O>*@WC+
M_+^"\JQN$7I@LEI3591Y1VMV7&AG?#OF57BP.:,8V9'V_P`2D:IS+UE8FW5!
MQ`)3:2'MD[ZRE0;D+UK+*%(0!,8-='`/R1S)<V(Q40((^)41`_\`B4^R;T:V
MG4G2-RLN@CNIP6YZ`<P%,<#8;04$#F*!CAUJ6DAS`!A'81`.S7)O_P"1";,O
MLUXQ40+R?B?:E6<"O9,;)"M_&LN/Y"W/+[S#7W5ZR?H-G?>@^9]J2[!O>8H_
M&LN/Y"W/+[S#7W5Z/T&SOO0?,^U([!O>8H_&LN/Y"W/+[S#7W5Z/T&SOO0?,
M^U([!O>8H_&LN/Y"W/+[S#7W5Z/T&SOO0?,^U([!O>8H_&LN/Y"W/+[S#7W5
MZ/T&SOO0?,^U([!O>8H_&LN/Y"W/+[S#7W5Z/T&SOO0?,^U([!O>8J\G*VX$
M!14>"_/`!03,L4QL)M%S$.F("!T4?MKW47+OZ(!V[^36.^?D,FN:R.*#TQT/
MM2FS!+W+,;)U)J)+DO;U<]TN94X:\S4'$;BG)5?1K0XC34M4O[862C2:\^T2
M/;O5UH2.*F1%R=/?NEUTRCVCKZ?<?R2NE8*;J<5$2![/(#_^3ISJ79-ZC&R4
M[2G*JY@"8CP7YY]A0*/_`",M/*'_`-K-?,F?D-F&^3G#%!21T/M2B[!;W,`Y
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MK`/R,ON->*",8_$^TJWLN]0]$ZDTV"N3EK@L&X<A6G#3F9:F$;CBBQ9;/4L9
M%E*G8TV,1%D.]C%EK%W:[/O3?0EDQ[M7;<HZ?>?\CLS%\1??>TP'/F%Q'\.B
M)C6+R!Q!)N#WH-#+)JA4G3_&LN/Y"W/+[S#7W5ZXOZ#9WWJ/F?:E7V#>\Q1^
M-9<?R%N>7WF&ONKT?H-G?>@^9]J1V#>\Q5Y.5MP`P"/!?GF`=O:&%VHCY!]C
M[;`T?H-G?>@^9]J1V#>\QU+(IROMXEV#@QST$=P\N%VH?^%HZ/T'3OO0?,^T
MI]@WO,=2P?C67'\A;GE]YAK[J]'Z#9WWH/F?:DNP;WF*J'*RY?D+<\OO,-?9
M_P#M9JJ;^0N8YL3B@H_8^U*;<%O<L5&E9V_*VYD6;B/!CG60BKI%`5E\2)MB
M-NT7!G1R(6=4RI$$FYA'?;8=@\HZWX#^1@R;P#VH*#\C[2I=E7OHE,Y@KDY<
M(G%54C`X8<UK'ZH-CZIN`Q$B]8O#.KE9'P)BX/9TR'69INBIG`F_0H!BFV,4
M0UW.]'Y%YE[O<J8W%11*`^)G_P#,J+\#O3S$`ZD[?XUEQ_(6YY?>8:^ZO7F?
MT&SOO0?,^U*'8-[S%'XUEQ_(6YY?>8:^ZO1^@V=]Z#YGVI'8-[S%9R<K[>!0
M`>#'/0![>P,+-1#RC[/VVAH_0=.^]!\S[2GV#>\QU+$?E9<!,(AP7YYB`^R.
M&&H?(^VS1^@V=]Z#YGVI+L&]YCJ5OXUEQ_(6YY?>8:^ZO1^@V=]Z#YGVI'8-
M[S%'XUEQ_(6YY?>8:^ZO1^@V=]Z#YGVI'8-[S%9$N5]R2535_$5YXCW:A%-C
M88;=(]!@-L;IM8FZ1V[=NW;6["_R)S9&)2)QQ00;-:?B9#_YI'8-[S%-/A?D
M[<(:B$BV?#7FU94C6^\O4):N8S(]C4U9"T3CV1ACJ)V/N%58Y$XD.43!TJ!T
M#L.NMWS_`",.Q*:9C<4'S/M*.P;WT3!.N7E9<0,`CP7YY@`#V_\`(PU'_P`+
M`UY6Z?D1F,E&4,4`/[GVI'8-[S'4LA^5]O$H@'!CGH(]G8.%FH!Y0]G[;1U=
M^@Z=]Z#YGVE/L&]YCJ6#\:RX_D+<\OO,-?=7H_0;.^]!\S[4EV#>\Q1^-9<?
MR%N>7WF&ONKT?H-G?>@^9]J1V#>\Q1^-9<?R%N>7WF&ONKT?H-G?>@^9]J1V
M#>\Q1^-9<?R%N>7WF&ONKT?H-G?>@^9]J1V#>\Q61+E?;$E2*+\$N=JZ15$%
M%$S8A9MER(MU>M==,0E9)94B)%`$2$,4QO8*/EUZ'N;^4N[]SN]4@7J<+R[F
MOMT"`C51/<$I^%7J3=C0=2\6_MSE?X*LI_XV7VX?\5F7S?[A/]M?\?O^P_Z;
M\37[[_#*X9A_L-GP>NO+=6O.8YE]@_#9(0\:#Q6-SG/W>)>'Z'8;NR=+>-NQ
MNONP`0%9<51`YMPW`@?G<;OAB.(7[NYA,JZAHE26.$"XCXP<Z%!HA'-F7ZEP
MP7&;>YMW`=MVBDPH-66.>"]-^3V;YK`>/(.S5NB(Y*M%OR;CS%E6JS^YI4")
M7G\C6!&O1KN:N*]?M)8&(8++=XLN5@Y.````7<=P\;+MWZ9_"<62FL))'I$B
MG31#A77O;;C*`9-:81`H&4QA61FKR)BJISRQF7'DK:<P-Y;%EFALJWG!<G1*
MXWM6<Y5[D3'RR2%J-0"XZJ#^TY"KT(DJ#AY(H0K8D>B`F=IH;AK3,PZ8RR1/
MF%I;$U1$<XLT1J$:RL6TPTT69E!A4*2*X4D&&@^5=J*YJ8W9W#,19,S]_C&@
M8\XV7^K7FB5:[Y(E[Q$<AF^2'D%[5TK'M9L=K>,8]K24C-C-F:QS)NE#'*0"
M[Z@[#YE@.;.FVH.B**($455F/D5DN9AAB&M?`0K&J%-0IWEW)_Q`.)M:KU(M
M$IDYR>(R+33Y#J0P]`RA8I%]1F\BO$R=J?0T!3I.7@(6O/VQDY5:00:A%#TB
M[[D#%$3LR\VBW:S8C>S1S*TOPP",';N%8,@\UL)Q*&2X>G7-E8+QCS$UQR>J
MN6"R*[Q2Q3K%`/D5%K;,RU6J3F/(L4:\HVD'D:E(N)OVM7(LBR5!1(#IMQ+7
M@39TZR36(51@?BUQJXTO_3G&+0^(T<.=9:USFX[O;G5L23&16OW6IW[GS%]"
M0M7R/*5>'G<FTJO7BC,)2]J5!*I5Y&\1%B0&#/*/60RK@PM$`,]35;$BZY.C
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M05`2!;+N)+F[2=.#,L($[P$$;7"HPLS-^`Y:O.D!->)CA>GDS"A8Z]E8TS@P
MV)&EP3KV),PV&,E765VM=6;/*O(,*`<)E@P?6,$V_HIN7R!"';I*@<H#LEX*
MZ898%XF`/#C\7(2`#16<V^HB?A(YUF;$'H^?($Y#7G/B2)D+4O?+,E7ZFR>X
MPC:4*=0RT?)5JFLGU!2<A:M+8M4QTC:X>[3*[<Y8R#:H.Y=RJ06ZC9)WNWUF
MF8<X2@YLV<3`DQ@!#)`P$:*ZJ:E8'X7:L67DQS#X#PI0V/Q!N)M4H56R9,Y(
MDSU&X1$E8(ES7L;97N\LR@H>16AI69M=:H]+L=DH<7'S3=1BLXG&D<DF^3.V
M,8%TU$RTNPV\,A_%FF.8#D6QC</?0&F.[2I9L9IG-QS%]'`X,TF&"3V-7<MW
MD<JJFX1!=(JC"100DF;@B)@4,1=!,2E^:V'66;<W3)=C;S:=[D5K[M<[)-DP
MANRJ(G'(KA;DQSR*N8-D,HX602.B?H[Q%'`--Z#*)`4"@<PJ^D'D$0`=;+Y(
M$RZRI+9T[:;.DFS$&-0HJX*UE;(N3&FP'`$B-&6GE*FHMTMTQ,;J$NY2EV./
M68YC`4A`[.G<PCMV[!K"V295V$D39I<#71'>5LJ[W-SJ`;6FI:0R#,$3+]:I
MDB*I('.F5RL4BBPD`O4***@%3**@=:@_0R``B8P``B%6S?[:?J;R*_JMUZ(6
MRDJ5155+NG)#)"'4)NH4S`;M(8BI0,D)3AV^7<H;=0!N&\7!S*YT_4U'5;KT
M0K3.D"`(J`LF(&!,`4W)U+#U;(@8P@7J$"]@B/0;<-C".H6O^->-02ZM=.B-
MW"@[@I``>X=G';<2IE.<P"`E`Q-R`<@F*!M^P1#8!`!$>S2M?\:\:FHZM=<C
M1NX50'+?8QA.)2%ZOHAE3`F?I4.E]#5Z>[.)C)B.P#U`':(!HM?\:\:F\B75
MKKT0J>N(%.*9@/UE*0XE`XG4,F<Y2$6(D7=4Z(F-\V!1+L`COL`[;)32Y@.U
MF\,$^KW3*VG=I6=)4BJ`..[633$`_IFY1ZA4,F)`\H'V,7<#%$2&*("4P@.^
MF93O;3.+D2ZO=.CNUJ"'B7(`3B18#F2.L4V:N(Q00.N*0>L+\P,#H-5!.4@F
M!-H[$BVP?-@3I'L$=6X9*9=)KC>9TY\MY)^+$1&2C@WHJOJEU)B00-'GWOA4
M]CH"*AS@)OFC;`!]@\H^QT]@:YCL.>Z]&\]8G".068#BJ3-WD&L5K+ZN;S?_
M``AOU.MVQ=[:;Q*?5[IT=VM4%`P`(](CL`CL501,.P;[``@`"(^QI.DO@83I
ML8:$&[W3H[M:Y@OD.PW0L4ICD3*8Q%A`QSB(&V!(IQ!-(X"4ZAMDP']%MVZ4
MIKFCGS)Q,,PY%6&7'*T[N%8TI-HLKW`%=%6Z3B8ATE2@0Q`#K(JH(=VV.7J`
M0!42=X`[DZ@[=8YLN]":'MG3M@*ZH\`@FR3<WNLM;NUK:(LDL3J2!8P#V%ZN
MM(X[*&3'8B@%4Z0,0>W;80\@CJ43[:\:@M'4;MT1'A6)-TD8@J="G04JAC&%
M=(Q2D3.*8G,8JAB@!A#<.W?;XNI-?`Q,Z>>!J#<;L*PV'"J"^0$%.@JPG2[3
M)B59,PE](`.F)R%3.D(E'TP'H^+JULY@K?.U!+J=UC"`W<*#.@(F=0Z*P`0Y
MDQ+W@]8J!OW:92CMU'7'8"A\4!-TAVZ'3I;A1,G#@"BZZ709`K!?H@!1,18F
MY^E3O5.Y%`A2G.HNL"W=[-TBD'J.7J#S;ZKVK?:S]01U6ZYA4MQH8KLJADRG
M+W2IDCE4.;L,780$IP**9R'((&`2B(;&#?8=PU<QIF"+9TX;X"CU:Z"MN[6M
MOU<WF#ZH;]3J>Q=[:;Q(ZO=.CNUK&=#V#"(;`'S)Q'^:&J9UU>^6?X\X#1#D
M4.J75SH-!CNTJ#_-HZR$#Q]*GN9)?F?Q.25`0.H8C=OEVN.U7!3))&.F8RX)
M$Z1`0-T@`]AM9[ALI;RPS;TYQJYK2(Z:*LY5-XNMRD@3)HA3OTY]V9381ZS)
M$,)1*)@$PE55.*A>H1'8?B!['Q-M;'6;1C.FMIJYM"M8RX/:'AKR#H\ZR])O
M,3ZH?4>9[>;\U2V5QZ+M7G1TF\Q/JA]',]O-^:C97'HNU>='2;S$^J'T<SV\
MWYJ-E<>B[5YT=)O,3ZH?1S/;S?FHV5QZ+M7G1TF\Q/JA]',]O-^:C97'HNU>
M='2;S$^J'T<SV\WYJ-E<>B[5YUC5W*F)A```.T3%4.(D#8?3^9-\SIB4)U#9
M\V(I^*HNDW(U-?'>\ZA1;RJF\0C`/6`CT<5.1H@3U@"E2[S(F!@`YB`.ZAW`
M)@.^VQ>GXNM]A@N]G:S3,M#(V$(5QA&,5#J]SM!P:^U9S9,N53:`I@\P_FK"
M/^M`-872=F2YT^;3O*3)-S'I-?J\ZKTF\Q/JA]1YGMYOS5/97'HNU>='2;S$
M^J'T<SV\WYJ-E<>B[5YT=)O,3ZH?1S/;S?FHV5QZ+M7G1TF\Q/JA]',]O-^:
MC97'HNU>='2;S$^J'T<SV\WYJ-E<>B[5YT=)O,3ZH?1S/;S?FHV5QZ+M7G1T
MF\Q/JA]',]O-^:C97'HNU>=<B;*/M)->4/\`<>5[06\S!QM[&_RM,EKJ!-F_
M-5>PNT>:UV7=6H7^'"(?!^\'!0`P@IQ:P4<@D6V355#',"J9!8.DQNI03F.8
MP]IC!Y].,N/\Z=9WFQ_M46W6XB',?`#-IC"O/2IS])O,3ZH?4>9[>;\U7;*X
M]%VKSHZ3>8GU0^CF>WF_-1LKCT7:O.CI-YB?5#Z.9[>;\U&RN/1=J\Z.DWF)
M]4/HYGMYOS4;*X]%VKSHZ3>8GU0^CF>WF_-1LKCT7:O.J"&WE`/SE#?_`*6D
M9DM@AMII)_94'2+DX<UK]7G6NOU%(J#<O?.>X6420$P;*B0"@!=Q["@8YP#\
M_1=Y`,P.,^=8C3Z-5&A0ZO=,K7PWO.H=>'T9-3B7CA1!QZVD>PYD.591PJHH
M!S9PR.*[<YS%*8?4E^I$`]@J8!K;?=D9T63IUF%9#03OJ<N1<6,#0Q\-[3OJ
M9W2;S$^J'UCYGMYOS5/97'HNU>=,QR!SYC3C!B*\9SS'*NZ_C7',6RF[?-L8
MR3G5XR(>3<7`C(%BHE!U)/$6CV72,L5%)14$@,8I#;;#IDW29>"!*FSC$P%6
M_F.92-WN#6;0B`T_VJF$>1&#^2=)9Y'P'E&DY;I+Y)!1&?H]@:S;=%5PD14L
M=)-FZGK\+,IE4`%6+U)N[1-N4Z93`(:LFX?>)+09LR>TF-!`!HKR)296&SC9
M81K\Z=PCU%03`GNH4@`)U2=\9$NX]($[W;H.H!PZ1*43&*/E`-<B;>Y<EUE[
M[U779;!2;=[@YQ:VD@PW4K<$IP`!Z`V'].IO^>&W8.M=V`O3+<N=.`TAH*KG
M2[A(]-KCO#SK*""H]NQ.W_9%/E:LV)]M-^;R*P7>Y$1LG=PJXJ"@&*(@38!`
M1^B''R#YA#8=,2B#';33HYO(CJ]S%+6FT-V=0?X#-ER\?@3((@4,M9J(<17,
M)NLF4[.L=4#&()A[\`Z!+[!?)JV^2VR'D&=.,0*8-C5'-D3%VN(YK&D-Y:U-
MX&Z@]NQ?JA]O];OK(R5;-ML^=#]WD0;M<NB=W"CU=7S$^J*?*U;L3[:;\WD2
MZM<NB=W"CU=7S$^J*?*T;$^VF_-Y$=6N71.[A1ZNKYB?5%/E:-B?;3?F\B.K
M7+HG=PH]75\Q/JBGRM&Q/MIOS>1'5KET3NX4>KJ^8GU13Y6C8GVTWYO(CJUR
MZ)W<*UUFQA$AC[`"?:4I#F](3CTGZA,&XE!/V//JR1-V<_86G/);&+H?`L-_
MNEV,FTT&`^%?!ETOOL@/^6N]6_I)O]J_3/F_Z?\`$\FOOG6;[G'^TSE?*>I7
M'H_WT*E]"G#;_+0^*Y_<KXC_`.]ETU\PQ?\`]OW']_R+WV"_\XO.[*%Z3\K.
M.L/R;H5,Q]9&M;EJQ"YAQ9DFS5FX5]O:*S<X'']F1GI*GS4&]36CGS*?12[D
MP.DU6Y1$!.0P!MKR&%O$MI<:HD:P%V[^+<VP*Z#JCRJ"5O\`#4<)P%.KM'M%
M*;U_$&1\L2."<>VV"LP4ZGXIS)&0Q)C&)EJC.0<R9C0K'$-W,&NCWY$6`*L5
MRG(Y!9OUQ>&B-J)<6@&K)HJ6$W<G>B3N-:W[+X>5F7BK8QH62*[4_;BM\/ZZ
MO5H>MV*HX[L[+C$3)P3-=L,-6K:C:VE,OKW(8.%&+>9>+B9F3O5'`'4`T!/9
M:BZ.6%6CD3V18VR*B1\/*FEA>'^=L2VW&&&\992H$=ZMQ>S+5[+?+1C=5_#3
M#J[Y3:S$^$-5G-V<3I)B!9V))<[85'OK&S5%V[1[Y,X7F]!PM&UZ0->4*NP0
MZ&A+Q]P+D&MJM=,H>7J74JR?C-:L#$IM=93S2Y7:O6/#P8=Q[(9^@6E[4IMG
M6IS]@XDV=A+")RCWK-&$,BFD85*C>&F$1%T<M($3&(W:5,--/"**\U.C^Q.4
MOP^3AZ]8JT^R/!&F[IF_AWG"ML@9LXZ94:\1:1@*(E*W"M52]Y(O+".$G*Z2
MA45RL4)+Z(4X(F`81=\6J!&LQ'&F2#0='$(;N-0VX-\<\EHY(RE3LKXHN4K0
M\B1M\C,KN,BTO)6.!Q^W5O\`-9&KE2P]D2?R]<*KE:O6>T/_`%N95IT!38PZ
MY22"J2RBHIA:]S86H@OB(91FIHHRPK19<&_)@>7AR%3EN'!.!MM*Y08NB;4C
M4JGR'H^.:A6U$(-=U+T1KCRI-85D=ZLM)1[^R(JKLT5U&PN4FXE`3'#K6,4\
M-H!`P@YL=ZFBA1A7304DL3\*WU.MF-7DI9,/QMRIN8%LWV"IXR@K''*6.%1I
M\EC]H+DEOMEBL`@564.?UH"HLR%3!B7K[1TWSFEA:(B(A%-MVBX/(!6:8X#R
MTSC:G4@^1HU)W7Z/R.J9Y!*M/B-W[O-KM!PTG31S)XWV5K39!$#@IMWH_1$0
M3(`)Z!/8.>`8DC@A4EU4U9`M^9X8Y&DB<@8!KE>"2K^::#@9K#NWU*?O+%3,
MA\?(NO,HN7D7K689-[%CRU/ZL@LI$;M7:'?+@@L!5!VH%XF!P+:VDPX^5-UW
M<10:(`&,<WDHH74)Q?L*&78W)V0,L4M*W2F4\.95?5Z&C73)"47Q'07-9MS>
MOQ<C+/9)RQE4GR;MH4AUA8)!N8O>".[ZU.,O9BH@C76FV[&7,$PFH@F$:@O-
MWE3Q,S-1\D4EK0X"^7Z*AJYD&SPT)4L77Z_TC)=]O.89K(###F9RXURKB1K3
M*DZ(Z9G=/[.C:*Z"2JK@L<"K5QW^B9>Z.9&!`!CH`%"ONPSU\N=?1#64UTH^
M(([8-(I^X:M?;./C3M3L&D@VBFCA\DS6CT&Q%6C5UU-"B83%,1(O8(=FN8)@
MVEC4NDZF6[>48../^,SSV_NJ8:_O`4C6F=\3]CX5B^(=\?"I09'JLE=J?+5>
M(OMQQC(2Y6[=O>*`>KDM\$8'"9Q7A?MTJUUK)W)RE$G2[C'28E,/H@.PAF;"
M-.8J!+AZ-<1NT[R\8.+6<^3J<9QG8OKY.\D+7RDI&>+?89K-%JH],J.)JQQR
MN\!69A[18;&&'64O.V*WP^0T$U2O'3A(L@W(()M&XJ"7=,E26N,"+(`H%9)&
M]5%4-G7DBHQ,:XP\JWZSSESG6<903JBX<B<L(U+CU#Y[O$KD_-*<5<)JO2V2
M+!3'E(K#Y&EIQ4E<U4FZ*C)U*%8PQB)=VX<)'(3K;[K*F.LMA$N@*-$8FCR4
MK1=I\R!,W-\*<6T>(3DO'$=9Z]><4U9AF-?(N.*)C%E&V>U6C'TK7<H8LDLO
M1%POSZNT5Q=8!2L0$*^8S3:-C9$OKC(IF`K)*`86RX2G$U%G.%$(\V`S93'@
MK6@SP.+C7=C.<659AQQN7E<*QV+H+*Q;"RN5PRM8;S6HR.N\/=WM/@:'CZ3^
MY_)(J35U:MTYV'2MA:^FZAG12IG]>V0U"9<VL)#;)<,P^+"@FC/02$Q.$(Y$
MWT7S&Y*TGCW;,@9$8<=Y2]O>1>7\7XX@(JVYB086..QC9[XPE(IO'53%<G87
M"U<;UDR315C'N4G+%N#M^LB(G*1]4EESFRQ4&U@?&AHW^!&W``)J,4\\!5+M
MRLI>+N36/+'<:"[R/C&@612';9>R(PAF-JAI1>;?,'-8B)Q*IKQ3N9CV[-XH
MDU(J]CN^34#Z)L&2?+$J<Z6(0!R*QK@]H<,JF'@2D7RCP4\SR#8CSUAL%MDK
MI)KC)2,C$1TA9&"#J;AJL,H(NHZJL;(JX&*8B)BL8WND`$1)JE23">)8;IX@
MS(")C"7-W#3J,/E,(\S,!E$?*/LAO^9H0I]CY1_U1ODB(Z$+8T(6)<P%06,/
MD*DH8?2$G8!!$?3*(&+V>R':&FWTAOI.J.\O-#)DSE7,G*MQQKK.:[Q@FGUC
M!U3S*XGL71U$D\H6Z3M5ZMU.09O7>1JI>JY%T*MI5KZ.0T.H[>O5Q*18I$0.
M.TL8)-LCG1.B@<%9Y5C%<$R&%>9^:I9.C4A]!X^O$U#P/+BTY)S5;K7(42M-
M:AQ4Y#&P=+6II`Q\-8EEI2ZHJI+G(@HA&H.RJE2*FS*!M3=)E$BR8RS"B%/D
MA4HN>]C"\4.`W5)#5+G=DO-3:IQ"C.,H,I7.4O'*#<6#&\U>'U-O.-LM0<].
MI,F3W)]2J=G?N1!F"+GI9`Q5(8#H**$$HZO-QD-B**C"($8C>$(+$;_/-,85
M5$PXRI-<ON;-KX_96KF)<;XM<90L9\=O\LV>&20O2KD*?&V!E6QKM.94NF61
MJ[M<RN_.H@>5,UB^I($E7"2JJ0#1)NDN8P.@+),,FO>"C>;[/EQ!)M#?U5Y4
MTV5>;^>HQKR9J]:QYC_%D_CK"%SRIBJ%RI.W=ID"V15;1K*J]V<U^.QV_HLI
M5%4)M<$V\=,.'S.021:R#9$JPJ%8N4JTVT`6FB@#3H69U_GD&S&(TGE2@N?)
M7DXC$95I,WC?&$=)4#A_-9UR=?<=Y9L<0=%>;JM\%M!XE1D,>NY=&U-?:"/4
M1DY-LBR1[U93TE$$DU$^ZR1!P`LF99R+7=[S>)D1'G!D<N7)O[HY52,YK7]B
M\AIR$QG7)'!-.O?&3#F4;?+Y!D&.875\S97\6F1FJ_7&]:&O6V`K4E?6"$HX
ME7<7)R0H.RL&BI%&QUEU-GHD-$PM<0(9CO915O+1MYY$0#9!:.+?(K%,=2EQ
MP/NELOW&^"LEVF'MAL;C(O(*.>3+[NN^<-:YR*RS5H9H(H&,@(1,#!-6Q0+V
M`FD7R>36:\2V2YA:R`;1Y!3PK9=G/=*!F1M4^53$U0M"US&`5#%'S!J1`L0-
M169LVS>2TZ%Y'^,IFN3XV\0UN0D1!QL_*X0S3@_)D-79*1>1[&RR%7OL(_"-
MDW;0B@M6BADTA*`AU&%(=@\F_J^ZF$7+$;Z;M/$&.EF)$`12`(&!IKXECQF\
M[*2'-(M`[J%X",?XT7R<<-VYT.(N)5DEFQ'*2WV]Y`(50BA0/L!35<Q@$@F$
MOE$.SL[-M?3_`,);E/\`XS9ILNI$2/H+YM,\0G728;M8B&&SDR?O+:+_`!H7
ME"8H&_%!Q*&X`.PWV_;AO[`_\%M'X0W/VN[^FJ_Q*?[,\7TE=_*@^4/Y(6)?
MW^W_`-RVC\(;G[7=_31^);_9GB^DC^5!\H?R0L2_O]O_`+EM'X0W/VN[^FC\
M2W^S/%])'\J#Y0_DA8E_?[?_`'+:/PAN?M=W]-'XEO\`9GB^DC^5!\H?R0L2
M_O\`;_[EM'X0W/VN[^FC\2W^S/%])'\J#Y0_DA8E_?[?_<MH_"&Y^UW?TT?B
M6_V9XOI(_E07*`=M^(6)MM]]_N@7Y-,-BF[5S?:F<>X^>V`3>3;3_"2Y2P29
MQJS_`/VT?B4\_P!V>+Z29^3_`(Q+R+E<XTO/2G%+'R4I1<=W_&,?!%NE[&,<
M160YND3[A\_?*5<%U)*-=44A$BE+W?=+B.^_9H/A5<2VSMG5@QC3_P!""!XD
MN]F8<'TD[_\`*A^3QAV+Q!Q1V>437V^[?F=E6\ND/"6Y3*IQX3]1'XE/]F>+
MZ2K_`"H/E#^2%B7]_M_]RVC\(;G[7=_31^);_9GB^DC^5!\H?R0L2_O]O_N6
MT?A#<_:[OZ:/Q+?[,\7TD?RH/E#^2%B7]_M_]RVC\(;G[7=_31^);_9GB^DC
M^5!\H?R0L2_O]O\`[EM'X0W/VN[^FC\2W^S/%])'\J#Y0_DA8E_?[?\`W+:/
MPAN?M=W]-'XEO]F>+Z2/Y4'RA_)"Q+^_V_\`N6T?A#<_:[OZ:/Q+?[,\7TD?
MRH/E#^2%B7]_M_\`<MH_"&Y^UW?TT?B6_P!F>+Z2UGG\9_Y..V;QH;B!BK9T
MU<-!$E]O@FV<HG0$Z8#50`3$Z]PW]D-'X073VIW?N)_B6[V?D^DFJP%_&(.1
MN!,+8JP?%\6,?6-CA_&E0QPSG9FZW>)D)EK28UC#-9&419U11%!TBS:CW@)"
M8I^H!W[1VE^$-SI(FUF.]_EI?B4[V9XOI)WOY4'RA_)"Q)^_V_\`N6U'\(+G
M[7=_31^);_9GB^DC^5!\H?R0L2_O]O\`[EM'X0W/VN[^FC\2W^S/%])'\J#Y
M0_DA8E_?[?\`W+:/PAN?M=W]-'XEO]F>+Z2/Y4'RA_)"Q+^_V_\`N6T?A#<_
M:[OZ:/Q+?[,\7TD?RH/E#^2%B7]_M_\`<MH_"&Y^UW?TT?B6_P!F>+Z2J'\:
M$Y/_`*+B%B7\Z^W[^?5=43_"6YRX?Q(QW=!'XE/]F>+Z2L5_C0')90HBXXAX
MI%%(2+J)$ON0"J'(BH10RS=0E3$2KLP+WW2.Q3$(;?V-:KOX1W)Q!VKAPC_3
M@C\2GY99XOI)JL)?QBGDE@S&T'B^-XI8QE&T"]M$EZ](7>]H.UW%PM\_='IU
M")584^[]>L*@)B`[B0`W[=6WGPAN1F6A--.2-7S*$?B4^'\LPX/I)U_Y4'RA
M_)"Q+^_V_P#N6UG_``AN?M=W]-'XEO\`9GB^DHS\O/'IS[S%XY9?XTV7B_CV
MK167JZVK\E:(2\7EV_@D6$G'3C=XQ9K0\44TB@[C$SIJ"N0I``-P-J=Q[@X7
MA^(-ES'N<^48CT8&(A3S(P5%^[WXA?+J9TH%LMPTY#H=!?/_`(*Y$9@XMW)G
MD7"N9K9AK(+!8I7DK498T8WL!$E.M5:PU]-N:!L(21PZE"/FCA)8INHY!5$3
MCW<5[KX1-D\]K"80J%$<W-7(PSO%B;9U#G#A/TE]8'`#^,Y.;)-US&W-;&\K
M+S,RX0AVF8<$P<O8/;5918S5F6PX8C2.Y>/.9=9,R[V%%T"8`8ZQ$4P``^/=
MX>ZUTN<HNNS@Z6&U.@3'?LC)GRKZA@-^O5ZG6IHI=OU;T8+[$JO9(FU0L?-0
MC\LE'OFC9TDX%,R*@IN$"+$%P@?I.@MT&#J((`)1[![0UX9DMDLEC*"O;S);
M+/\`$&M*P/('Y@:BJ%70A0DX#_\`,`?^Z]FW^^9:=/%?3U>1,5J;)?)K/=_0
MX4&M7:O21H0C0A&A"-"%K./)\;^?K/+_`-__`(?PK/?/]J=\+X*O_77Z_0?V
M-?)_M"^@[AMV>-!XK@_^2SB-\F+N>OE^*NM8%<FYK?D7N<%_YS>=[X0O;MR<
M2)`<I!.8A!4#8`$2B0>KJV'L'YG7D;DW^":?C?`N]>76;X/V2O&?G;D[D'6\
MD\DY/'6:K9C*L\>O#WC.35;@H:J0<E`V;+##(V:4TV]CFY6$DY=W#.X>CM&,
MG$,U4Q6;*D4[#]V(:@W)EC#X4[8A&%$/,DM8,]YFP'=\@5[(.?)JVXTQSE[@
MK?<AY=O=4J\,QIV*,^J9:CLP1=CFX2)B:[5\6PC^CLE4GZ_2,&+TR2S@$03$
MLF,C$#,>)5S0)H`J@X:LJC5EB_VSDM)25GA;5<'\G]ROQD:[B>UT6(7A[27'
MU*ROQ>84.+A4O:]O,B92)0*T$QT`6>I',MNH1)(YKQ()A%P!HXZ\N3C65T@5
M-)A3J2GM&?PJ4<G;L5<BHV3JD;@?BHI$<CX:(K62I9.&M^6[?6KG.RMF+`NF
M%E@JJU*HU`JXJH1I&*BJZ:)"+":UDIMDL>:`X\0H6:<Y\AT/2,!H@K)O-V77
MD_`Y"Q+9W_*!SB66YHK\7\FO(!(JV<6$-@VJR3`WKM;KZ$/D&OUW([J0A64Q
M$D7)*MV:+HGK*:ICC8&2[$*@6MCO;M:K=>7A\0TQ!._$9:N+(ID^&CE[*^8X
MW,$ED',>,,MUR'>TYU4EJ%F*%S3<JE/RT(^>WN+OJ]>Q=BLE5]8F!2<,:\]C
MQ<1I4SHI[$$"AGF66S(2_1R[LE"UR@9DH.=03H^'*HOV7ECF&GV7E/'-,[?;
M>M4KLP:25PQ(:H91QIQKP1+YDAZK9YZVU&,JR%MQEFO"6-[$N_=1$V6893[.
M+4E3F5%L=!!E["X.+:!17JT;H*0E.A"UQ)%Y>RU;Z)><AYCXYY>5Y`RD=P1K
MK*N9YFWE>38$IDIS()'6*SHW:(J5B@)VB52)>NW)K&T92B+)%`[I0YRLED]*
M7,NKC&80T@Z3D^&I;6NLL`K@*4\F`<M<G,M2F`:B^Y&5<\);[%GN65M.%\AT
MK.:EYI6,(VJRE=JZ^7!Q]0::M,MK%+N6KYW'Q)3$BR=R=8Q]U2R>;DUAV;HN
M%0@16:=5:8F1,()%T3E'G"?D%7L)REAWF19/%O*65Y`TRY5*K-L>\,++1EUT
M\/SMM2+%-YS&[!JX70;ILK"<I;4@B+UJ59,IQ5B'2A%I:2,\3$YRHEX(C!<V
ME\C[?=ZMB*SP>78UM:8R@\O&*6?LE/:)D_'E7M%<JU6F)"ZT7+],C(IM<\4@
MO.J))R8LD0:@@H@N@3U4P&(R2""RB`A2HNF40`@[R+TGX`Y6?YDP8WLTU=)G
M(3^"O]QJCBWOYRKW2!EGL0[8HJ.\?9)K4+68;(U&*JM_N1-E8-5I!N*H'`PI
MAK/-;F-!"KDQ8*:2%/8&@D.40.44BE_I?=@0$Q3ZCIF1!+H*4>\-N;<!`VL<
MN0631,M1T06MLT3/X=4<JAIQQ#_"9Y[?W5,-_P!X"D?+UKG3*&T5-1L:"V.7
M,II+H]Z3IW*4Q3D434$A5!24(.Y%"%.`E[P@^3<!#6!LXS'V6T45I!K9///.
M&:I,/4>,N':*M07-5J3.'<XP@<B5BD+MS+'&%@LLS=?L&16*22ZBB'_"B3K#
M)1<_2!BBB'0)=6D3.EQ)B?+!]"C?2:C>&_'N*@92LL\?1B,)*X[-B1VQ*XD3
M$7QL-@=VH*NLJH[.N+4T^^5<&,4Q3[FV`0#LU;+>^68DQ,8K//(F@!G-SZ=Q
M5URX@8/O?VQ'L-3(LZM!J$>4?-).:C9-NYQBDV;4.7@9:/D&TG7IVM-6:94'
M355,YP+TJ]:9CE-:)[FB`W168R23$N*3ZO!W`3EQ3%7]>E99"B$1+#1TS;+9
M+Q<@LUF5+*PD+9&2,TY8W"6869RK()N9`BQQ7.7?T$TRE?6'@0"6PSN6";X)
M\=K*SL;.:IZZI+9D*QY9F/4[):6(-LD7%F_C[?9:V9O,$5JYK8PF7Z,B@R,D
M@Y3?+`)0$^X`O#@@R#D<I(8VQ]5\4T:LXXI,2T@:?3HIK!5F#8@L9G#PS),J
M;2.;&>*N7(H-@W`G6<QNG;<1'<1I>ZVZT:RMDI^S8&5P2W,4I^Q0`,4.TH``
M%$!\O;MV#VZC!6;<9E`KQ,``_$:>`/1`,X\-BA[/]+YEX#-\3R[ZC$YE>($1
M4^1[1'\T?D"(:471JH3@,ZN[SXGR?]+4EGVXS*TY@.0Y-MNLIB[]@[=0"&^P
MAL.V^B"1G`B$%&[+G%C#^<'$'*9!KZ[BQU^.DH9A:J[-SM2LHP,P;O):N.YJ
MOOV+U]77RQ"*BT6,HFDL!E$N@YC"*A,JM<2JB$,N+6((QI!QD;4X9E%06)['
M@MI'I,OZG+B6VRL5,V6H'3,H(.T;`^@F9GKA83N5C)G4ZP55.<6PS&NC:0"*
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M"S$O-R[^;Q:8)P0JLE(/9!1R9(#65Z7O4Q(?N5"D\A`T]LXF)SQX5INXE7>,
M&QBM%;A+QX<9&8Y46H$8>W1?VD+M%#.Y<T(\E,:0\9"X[G9VL&D!@)J>I#*(
M:DC7JK<7#8K-N)3=20&TA.<!`5+1MY<?0X_,GVQ;C2JX@J+:DTM@$97FDE99
MA%B55=8H2EOMD_=K(_,LZ46<'7F++97;M4!,)2J+"!`*0"E"IQM)&>W(V"<7
MO?B?)_TM*"6W&9:Y]Q4ZO.`=FJW3X?PH4YU$70S9G6`Z`.2'G7GUXCV/JCE/
M$^(\<Y`@8^UT>]<L.,53ME:E2*'C9F"G,KP;%^T=%0516,!VYS`&Q@#?;?R:
MZ^&8A.P\F?)_FV3`YJEBO^&]9`8Y\&1&11)L_@D\9I:;</ZY4(>!A3F'U");
ME<F09M3$+T-T!4?=X5-,=P#JW'7<?WSQH.(;,(:-Y<Z7W4PETL&:T.F0I--)
M2>^`XP*'8$%&B`=@#LKVA[`_[>U'WTQOVI5GNE@O0"K\!Q@;[!1OQE?V=H]]
M,;]J=2/=+!>@$?`<8&^P4;\97]G:/?3&_:G4CW2P7H!'P'&!OL%&_&5_9VCW
MTQOVIU(]TL%Z`1\!Q@;[!1OQE?V=H]],;]J=2/=+!>@$?`<8&^P4;\97]G:/
M?3&_:G4CW2P7H!6*>!Q@0R2J9X2,*54H$,(E6'T>LIC`&S[L$P%VW]C5,[OG
MCCF@"::U)G<_!7&%@#6H\6#PA<-QO+O$&*BMVBM5M>!L_7*18""A4?;VJ7G$
M,7`N`(+GJ,9JPL[A,!WV#J'5H[R8WLMJ;R0(P]'/3G69W=C!Q,V8E1X5(9/P
M.,!AU$+"1IQ`PB)@*J`;#Y`V]=U3*[XXY+<YIFDK4[N?@H:'6!3OK)\!Q@;[
M!1OQE?V=J_WTQOVIU*'NE@O0"/@.,#?8*-^,K^SM'OIC?M3J1[I8+T`CX#C`
MWV"C?C*_L[1[Z8W[4ZD>Z6"]`(^`XP-]@HWXRO[.T>^F-^U.I'NE@O0"/@.,
M#?8*-^,K^SM'OIC?M3J1[I8+T`CX#C`WV"C?C*_L[1[Z8W[4ZD>Z6"]`(^`X
MP-]@HWXRO[.T>^F-^U*/=+!>@%K./!%X]LBK+GB(_:/CY)T8027V44(S762*
M']7#T]*A0[>W5WO?C0;:VQAO)>Z6#>S\JCSP[\(##N6^)7&/)MC:M)2Q9#X^
MXRN5B=N>\.+F:MU(CI*74`2NB=JSIP`@/D]'XND>^&-@?SCJ3]TL&RRQ#A4C
M_@.,#?8*-_\`A?V=JKWTQOVIU(]TL%Z`1\!Q@;[!1OQE?V=H]],;]J=2/=+!
M>@$?`<8&^P4;\97]G:/?3&_:G4CW2P7H!'P'&!OL%&_&5_9VCWTQOVIU(]TL
M%Z`1\!Q@;[!1OQE?V=H]],;]J=2/=+!>@%0?`YP(`=L'&AO\17^<^U5,[X8Y
M,(A--&A39W/P1T8M`AOJXG@><>TU$CN8=D1(OK)#@F57TTG#)RU<`/\`5AMA
M%%8P!\4=;)'?+'&TF=5H5;^Z6#,JE@J/'$_P?,-96X]8]OD_',W\_+N,@,Y-
MRJ"G4<D!D^Z0,84-GA0'NHF.1)_['4KUWSQMLVQM22!FX5%G=3!GMCLP`I#?
M`<8&^P4;\97]G:S>^F-^U.I3]TL%Z`4./$*\(C'.'N$_(R^XMI\A-90A:&U^
MTF(JT:]EIZ3LDA;ZQ'H-(>/:O#K.WZT8LL0J>P;[B._9KM8=WN<+,R\O+IY/
M.R0T^049UCO?=BZ%NRDD-E@441^%?-IQP\$GD+DV>AG6;X:7QVU*2.4)3!*#
M^X$2<))J$:V%LB<1@'O=&`3$4,L8F^P[#V:Z]Y[W7>\,L[2&L_`L%U[J2;L^
MU;:?W?.OK7X1^#90L%-HYRQKS2IJ)ME5W4\0Z2]ODW+T2BN+JP%!)VS0.F7I
M,1J"`F#L,(Z^?8MB\V]O=*:38!@#GTKVEQNDBZ-!;",,T%[S4FC1%%@D8"$*
M8C-,"%#J.=3T2$`A2@8YSG,7I#RB(B.N!*!EDEQM*^],=>*GV>!+<#@4`*`=
MA0``[?-V>;4JU7MH405P*;B`;>4=O+H@F)P)`A6H4<".S`"G]U[-O]\VT_*T
M[\-NXFJ@>16RW!](J4U"J^QT^<?+_I:R2G63LX1I5DP6&E^97=[\3Y/^EK5!
M9=N,R.]^)\G_`$M$$;<9D=[\3Y/^EH@C;C,CO?B?)_TM$$;<9D=[\3Y/^EH@
MC;C,L"Y]R[[>;5$H1O\`_A_"J;W-C=285E?!3U_$_P"FNW\NOOFT/1_\)G7R
MJV/\^*]J\/YLBL'^,9XH,M-43+%V;S^->)S9J3%-`D\@+M3-HFVF-[8HQ*A3
MLQ,*O9U;=@:^;XA)<[`KJ\0YEHF)@:<PRKW&"/CC4\"MU`S5C*O3@_/JCG)T
M_<`YBAZ(EW_%NN'9Z0#Y.^^)KR5S!=)+F4BUO<J]!?++;[9?$/LFB$1KB/(N
M>ISIHBCI9W]P;F0158A2=X3C9;.^*0HJ"5$5#',55J0%!$J1RF(!C&-MN/9I
ML/S#6H19G.KSJOX]./"()I$X]\P`[KO#$ZN-=R43[U03&,8Z9W(B9,!,(%)U
M=)2[%#T0`-0=;8*<NE`+,D=7G6@?F]C_`'$Z.!>8J!S&*8Q$^-=R3:JBF8%$
MS+MD'2`*F*J';Z0%4(/0<IB@7:)F$[X3%D93J\Z1M_Y/83R3$1\)9..?,LS&
M*ML#>(\K#CO>(U1.S5R1+)1SYPJP=-U'B152@0S=03-U$P`JA#@`:;9Q;J54
MR4R;63J'*EQ^/%CP3)F^X!S$+W+A9P@8G&BTD5;G76465!`X#LD"I5!(<2@!
ME$Q$#"._8;4Y!QJ'5V&LG5YUG)SGQZ5,2#Q^YAF,(;BJ'&RXI'.H*8I'55*@
MNDF<RQ>TX`4I3CON';J30]W.`KTJYH8QH;$P&CSK`?G!C\ZJBH8`Y@D!7I(H
MF7C/;>@R`*BJHD(&7'<JQC#U@/H&`I`$HE+TC(,>(T5Z4XLSG4.58U.<%#.!
MB%P1S'13,*>YD.--L0<&`K8Z"IE%D%DDU5%#&ZR@9/NBCN'=COV/L"9._C?P
MQ:I],"M2#F9"=2V1YSX]Z.@O'WF`0A@,54A>,]J*FH0R229BBD50J6QSH$,8
M1*)AV$`$`'1[N3(Q_A^N$%S3E.KSJI^<]`4.*Q^/_,+OS"<5%B\:[DF93O-@
M.4X$<E*<IBB("!@'?LW^9#2,MX,"!`45J,69SJ'*L'X[^/0'T<!\QP(90#J(
MFXVV\Z(I@J9P9J4@K`(-57`]1R&$Y>G<I>DH[:5B9"`%&^BTS.=0Y5M-N=&/
MFB@*-^/W,)$.L3BBCQFLR*(AL8$DQ!("'Z&X''N_2W+U#OOOIV'P@1QI$L.4
MZO.ND;Q`*,4IS'P#S#*0J9S&,/&ZX]A2$,8?(J(B(@&P!MVCILDO<X`0CI*;
M7,8;43J\ZBE@KFM28;.W,:RCAOE%(M;ID/$<BQ8Q.!K2_E(U-MA"J,#-YMF@
MJ8\:[,9D8X$/L;H$!UHGW28T-JC9IIRZ%,7IIC$J5X\_Z/M_B_\`,3;_`-&Z
MX_7M<TR=FXN-:1G,F<V)CO>=6_C_`-'_`(`.8GO;KC]>T*,&9SJ\Z/Q_Z/\`
MP`<Q/>W7'Z]H1!F<ZO.C\?\`H_\``!S$][=<?KVA$&9SJ\Z/Q_Z/_`!S$][=
M<?KVA$&9SJ\Z/Q_Z/_`!S$][=<?KVA$&9SJ\Z/Q_Z/\`P`<Q/>W7'Z]H1!F<
MZO.C\?\`H_\``!S$][=<?KVA$&9SJ\ZAGSYYJ5*[<:YFLLL+<GX=TOF#BK*$
M>6/!=EB(LJ4#REP[:'2*TDNOZJ@_<LH-1%NU-]'5=*))@&Z@:T-N[W0H%*EU
MAH$`IGFY_P!%`QP#`7,,X`<X`8O&ZY@4WI#V@!SD/L/Q0`?B:.K3,PUI]99G
M.KSJS\?^C_P`<Q/>W7'Z]JBI0YF<ZO.C\?\`H_\``!S$][=<?KVDB#,YU>='
MX_\`1_X`.8GO;KC]>T(@S.=7G1^/_1_X`.8GO;KC]>T(@S.=7G1^/_1_X`.8
MGO;KC]>T(@S.=7G1^/\`T?\`@`YB>]NN/U[0B#,YU>='X_\`1_X`.8GO;KC]
M>T(@S.=7G1^/_1_X`.8GO;KC]>T(@S.=7G1^/_1_X`.8GO;KC]>T(@S.=7G1
M^/\`T?\`@`YB>]NN/U[0B#,YU>='X_\`1_X`.8GO;KC]>T(@S.=7G5WX_P!1
M_+^+_P`Q/)^3=<?KNFV07OM"M:F36LE@1H43^6/-FD6^*PE'ML-<IHES!<J>
M,5K6]OL!VB+3>,XC+,0Z581QG*Q?795P"'2FB3J,)CD#]%KI2+I,<US>;Z.?
M+17F7-O%Z8UP,3".92K1Y_4/NB`3C_S#4(4.D#AQNN.Q^@1+U`/>AN`B'9KG
MS:)CK4(QSK1+O,NP*35F\ZS_``@-(_)]YA^]MN'U[5:GUF7GXO.CX0&D?D^\
MP_>VW#Z]H1UF7GXO.CX0&D?D^\P_>VW#Z]H1UF7GXO.CX0&D?D^\P_>VW#Z]
MH1UF7GXO.CX0&D?D^\P_>VW#Z]H1UF7GXO.CX0&D?D^\P_>VW#Z]H1UF7GXO
M.L+CQ!**FD8Y^/?,=0A=MR)<:;HJ<WQ`(FJ)A_F:@^%&^K95X:2;)I@HC6SF
ME2G7.+!]O2PMRF,VB>.O(6#/$A@"U#.N%IJ]80?B[0B^^!T:.8EBS)K*B7I(
MJH0H_-:Z[9<PW6B$;0->8+D/O<L7R+B84Y,NM2^#G_1B_,\?>88;[?\`FVW#
MZ[KD_P!XX&M==]X:&`DT%5^$!I'Y/O,/WMMP^O:DJNLR\_%YT?"`TC\GWF'[
MVVX?7M".LR\_%YT?"`TC\GWF'[VVX?7M".LR\_%YT?"`TC\GWF'[VVX?7M".
MLR\_%YT?"`TC\GWF'[VVX?7M".LR\_%YT?"`TC\GWF'[VVX?7M".LR\_%YT?
M"`TC\GWF'[VVX?7M".LR\_%YUS)GGW2%HB72+Q_Y@D,I%2).\/QNN`%)U,UP
MZC&%78"EWW'?LVUHV;^#?3ZTS/Q>=1.X%<XJ'3>$O$>GJX5Y1S*U>XY86KRL
M[6,"V>P5F1<L:!!H^MQ5C8K&CG[%42#L<H[=7H[[ZD]KXDDT;_P)=9%F)4Q/
MA`:1^3[S#][;</KVLJ.LR\_%YT?"`TC\GWF'[VVX?7M".LR\_%YT?"`TC\GW
MF'[VVX?7M".LR\_%YT?"`TC\GWF'[VVX?7M".LR\_%YT?"`TC\GWF'[VVX?7
MM".LR\_%YT?"`4<?_-^YAA_^&VX_SE=*,"K9<]KHV2K%>?M$43`AL"<ODA55
M3;D!3C?<0'J<B*0*_P!,'9)$3;G-V=(:TRI;W50UK-/O4L5DQWH_"HM<*.;%
M/IO&7'<"XPCRNF#MI/)ZH/8;CM;G;$Y7.7[\L4I52+"7O$^O8P;CL(:G?!"<
M79#R04+M>6B7!QI&CAKC2I4?"`TC\GWF'[VVX?7M9%?UF7GXO.M%SSSH;HJQ
M5,`\QB`L0I-T^-UN*8HD$#$4`3*'`54SE`2&VW*(=FKFX4Z\MVP+`#G<!Q)&
M8QU()U>=(V&Y:X:@I!Y+,.-/+5"2?N5G3Q\CQEMI'3M=90RAUW:YUU5'#@YC
M;G.(AU&[=@\FGV"[.SUPH?P].KSI=EY]T4H`'XOO,,=@V'?C;<!$?S=E0#Y&
MJ3+V1V?1HKBI]8EBB/%YUD_'_H_L<?N8@>;;C=<=@_\`AM)/K,O/Q*S\?^C_
M`,`',3WMUQ^O::AS,YU>=7I\_J.8Y`^X#S"+N8H=1^.%P(0NX@'4<XK;%*'E
M$1\@:DQI>X,;6:$K3&<\DP%-7G44N&W-FDT["HQ3O#/*:55/DC+$N1>#P#:Y
M)J9*8R58SH-P605,07*'?;*%`?1V[=="\W28'D\V$`*U1=KTPL`),8G(I6?C
M_P!'#M_%_P"8G:&W^+=<?KOL:YSI!:ZT:%TG30^61&A6_C_T?^`#F)[VZX_7
MM)98,SG5YT?C_P!'_@`YB>]NN/U[0B#,YU>='X_]'_@`YB>]NN/U[0B#,YU>
M='X_]'_@`YB>]NN/U[0B#,YU>='X_P#1_P"`#F)[VZX_7M"(,SG5YU0W/RD'
M$A!P!S"(0X](JGXXVTI"#N`;J;N.\*0.KM-TB`!Y1U9=)#IU\#60MEL*3`5Y
MRJ+XZ6VZDN)LQR")\J^,S[J<3^Y#*G^5L^Z+_P`W4Y_8W[!_,?\`&K_L'^F?
M%U^@>I:1_M8;N5?+8_\`S=W"OI5XB+E:^,OXL3PP()@SQ)Q/6ZRD]6+T^U%P
M$YW2C<@J*E("`"8PE.<"[[`/DU\GQ-H["N.<EU>@9-_D7OL$:.V;P,GG"G1B
M_F8XR8N^N)<06NJ<<T&=ZD8[DC:+118VCNX.A$=B\N$G"N+0E:("A652*=C$
M2J[<P+IHE.LB@FH537EKM+_@<VEQ=EIU+OWR#+]9,0T,.C7NK2KC.</&F<I$
M]D"'S#47D!79:#@'Y$73\)LT[;&(2=,BV59?(1UAD'5XCOZJA`1;&3E6BA5V
MQU$@$PVB3.J+1'>4#-DBMQUI*R?B*\1XVJT:Y*YOIB4!DB-G9NE/WKN5C2V:
M!K=B0JD[8(1N^8(.GL'7+`X*UDW0D(@R'=14Y$P$0!(<[^8"W>H^!9Y]YL0V
M)B=/F*YUXY\8YQA<7M8OB*!&CO*V/L3U68H\J_OYG#^^8A89<2G+E'Q$0A]J
M3!K%/>E!%!:45>-C(.B"5-?9-BZL(B'.U^:M9C?9X@"!'AY:DO*7R\Q_*$R$
MVN]FHE7E\<-,KVJ:91-P=6$2XLP])(0UMR'(;1#!.(4C9)42/XDJCM>-`Z?4
MLJ)A`J==FB!BZR<L<IJ!H6V[3YDQAM0M`[JRE)7N6>"+1D*&Q5`Y2J\U?YUN
MS?,J_'N7AU12EJ^E<8R'4>])XM*S?::X)**,#KD>BR#O>X*0Q1UG=*AE*OVI
MC"A);E7S/Q%Q-J=AGK]:H%O8(K&V0<D0M)DY92)D)^,HL,X=]X[DB)2)*K"2
MDZ1"+3E'S<K'UUVDEU]X8I3("=#F!I;I%*BZ=*'IN(=OI2-.56*CTEO<I6V1
M$,F:SU^BR4>X?E%W"7R;B&4^K4I%-==F1-VQA7Q71UC'(D#,AG)N@@;`X7GH
MMCO*.VD0I<=:CKE#Q(<;0\!A][A).'S+.YGS75</5MD[GYZDP"`62+=V$MJ=
MSJ%0MSWVL<5]L5S%@1B9*7*L4R*P$`3:H-WO+B71<(G3!:&F[EH-HU9U*(_)
M?$255@+<[O\`6X^(L-:N5J8/UI%R:(6B:"H@E;7@22K9HHBVA#*_11503.`>
M4I1#;4>K7F/I.3'5\KCK2-A^;O&2?J5ROT/FZB/:9CYU7F%NFAD7;0L>]N((
MJTE%HT<$+*RREV2<$+"%:ME@F%3E(U.<P@773V$P-!LQX/,L\3&NC?322?B1
MX+>6"W4^@2"MFLU6Q*EEQJZG#.J?C^P1JQ;BW<P3F^R22Q:7*UJ1ICDDN,C'
M]+/L3V,IWG=!N\T-C9&BA`<"0"3#?3V(<P,%#?:QBAUDBGH9/LL96W:510L)
M'8-I.VP`62NUUS.)$]IV=ALD.V>NH>.<JH/Y=HR56;HBF0QBY87C*UNI7PD9
M'G6%N8NY88$SA;)>@XPRM4;M:8A"8?/X.MS9CRR,3`3B5<GI))-<6QG*-7L#
ME!A+=R)SQ[]0&ZI0443`[!G-<"]K;.\HO;),LV7.M;X3=\<$=N3'/4O>'`"Y
M6P^(=V!4=^\P/3EMC]T4O>=`+=`;[[@4!'M[=7OO3YC6M<&\UL!Q+()(`<X.
M<(D9=]39/LF43=2AC"(%(0%0**AS#L4A1,8A>HWL=NJ'/)%`$5;(EBU6ZK.M
M8KGO-NY4[T`$Y>\!<P)G43`W>HATG4,B*(@'48P"7?L\HAJN+]"U;-N=RO:K
M>LE*H!C=T<IC$Z%5S@;8P%ZA4,1(""`[AT"&X^7R:(OT(V;<[EO%2`V_IJ]G
M^RG^7HB_0C9C.Y!D@+MZ:O;_`+*?Y>B+]"-F,[EC,78-RBJ81["E[TP;C_JA
M'I#1%^A&S;G<N>LY5)U%(14IBIJ*&,93O4OH1P*HGW@+I)D4(0>L=S!Z(>?4
MHI&6,Y6=JMZTW(L`G3[TYRMU#."'2<IE.().4A175#NG28=9`$>H"B&X`/9H
MBC9C.5`WQ+T$E>(TZK]&`3YPX<$W%0Y%``G,_`9MMRF\G67\\!V'L';5@FN!
M!`%')!5]79$DDF/+%3[%,!,8>M7M.8=@.(!\T/D#V`TA,($(#4DZ[-+BZTZD
MQK6;N0^?5^JF^7J$=Y6[,9RJ"B4`$>\5[`$?Z8<?('F`=QT13V8SE:!ER)F(
M"RO1W@`*9.]5[]0N^PJ`@`&.!`W_`/S:C%^A&S;G<JJ*[`KW2H""90#O.^.K
M]&'M!$R!#%4`Y@\@;Z(OT(V8SN6,[H"`<QE4TBD(@L/?.SD4*BH03*"JF!3"
MF<HAL4-QWT1?F"-F,[EE05[_`&,0QA1,'619-8ZR*Z8]A135+T@0P#Y0$-$7
M:$;,9W+:Z`^>5^JGT1?\E&S;G<M1VKZN5(P&4V.J!!W.<_4(E,)42%`Y3]\L
M(;$$`-V^4-$7Z$;,9W+1%ZL<`,D<H)F*<`.`N'($63!3J`PD%+J(3I'K\@E[
ML?+U%T1?F"-FW.Y;S!PC($4505%1$A@3[Q)R<X"L7<%DQ*($.7NQVV$0#J*(
M"'8.I`G+!&S&<K?[D/GU?JIOEZ(I;,9RL9R@7LZU1VV_ZH;4K1:PN`$=Y3;(
M#A2YVM0:YO?0J]Q\$57"?>\T>+"20G*BX`RRN4J\4ADC+*F,@DD<H']$H?12
M=H"`COIN-XF.M1:VR6P(JHY5Q<5D[$-+"8QRY%-=%1/N4N\6,!Q3(8X"N`[&
M.4#"`"8XCL`CV=H]FN=>;P^7/>QK8M#B*BMMVNK9UW9-<]X<YH-9S+/N0>T#
M*"`^004*("'G`>OR:IZU.Z'EY5=U%G3?K/(C<GSRO]&7]7HZU.Z'EY4=19TW
MZSR(W)\\K_1E_5Z.M3NAY>5'46=-^L\B-R?/*_T9?U>CK4[H>7E1U%G3?K/(
MC<GSRO\`1E_5Z.M3NAY>5'46=-^L\B-R?/*_T9?U>CK4[H>7E1U%G3?K/(L2
MW0).K=3<A@4*83%$$S$`1!3;KV'I^+N&H/O4RBTPUY/[5)MT,N)EO)=I)4(K
M@!"^(9Q_2Z^D0XJ<D%T4Q53*<2J9%P'WRI$RJ`)BG$I=S&`=A]D-QUV&SB;O
MZ)](9.)8>S7[7;6H$`BC3'1I4X"FWW`QE.SR;*`/_P"L$-<DWJ8)K@UAW<*V
M"ZO>T-FN@!FBKMR?/*_T9?U>GUJ=T/+RHZBSIOUGD1N3YY7^C+^KT=:G=#R\
MJ.HLZ;]9Y$;D^>5_HR_J]'6IW0\O*CJ+.F_6>1&Y/GE?Z,OZO1UJ=T/+RHZB
MSIOUGD1N3YY7^C+^KT=:G=#R\J.HLZ;]9Y$;D^>5_HR_J]'6IW0\O*CJ+.F_
M6>1&Y/GE?Z,OZO0+U.Z'EY4=0;TWZSR+D3FX0DUZ1^R(E!_IA?88N!^?UK$]
MYKEG4JA<YH/I44Y3O*&7AN]!N`'"(Z*HBH/%+"*X!WI5E#MW-`@51*BKU@W4
M$ARAN8P"(E#R[]NHNO#X%U@QWO.@7&=!K;0@!`UYXYE.3<GSRO\`1E_5ZS=:
MG=#R\JMZBSIOUE&Y/GE?Z,OZO1UJ=T/+RHZBSIOUGD1N3YY7^C+^KT=:G=#R
M\J.HLZ;]9Y$;D^>5_HR_J]'6IW0\O*CJ+.F_6>1&Y/GE?Z,OZO1UJ=T/+RHZ
MBSIOUGD5#'`H=AS!O\\MT_&Z3#J)O<P$%[##=I3%U=+'\-Q,<Y/(M1?90BO2
MX$@@V<;B!R'V*!2F$=S[[!Z/;V?&UNE3B\#FG4J7W.:XQ+A2(5G*H>^'V*!.
M)&,!*L44U)3*JA#)+@9$PGS)D$3BF<RBAC``CV[F';4;Y>I@FQ#*2-V5$C#A
M+EB6][HC,?,IF=ZA].'ZL7Y>LO6YO0/'RJ[J$OIOUJ+7,WD\QX=\:\N<E)2K
MR-[A,0U^.M$K5(.2;LYV7B5K!#PD@2+6=]349!L24%5(A^E)3HZ3*$WWUHNV
M'7S$9PL.F-MF``C7".8YE5/G7.YRSM'FTT1,7"J/!G4?N%GBR<+>=\>DVPIE
M9DED8K%)_*88N(J5G*L0D)"=^<*L^`'%C8(K&$HOH8TBR`>PRA3`)0UW[N[B
M%R#B]UX#6PI,84Z;.XK)=,3N%YJ?08PI&3A7HZ994A%#'Z_H>QS'#J,3I/\`
M,)&*FHJN0X;AU'$G2`=NWL:YDQ]\D,`LAPA732NBZZ27FV'S('2MI,JADTSF
M'8YB%,<J:QU$RF$`$0(H)$Q4*`CV#TEW\VM<B:)K(NH=E$5#J;`?3?K6YW(?
M/J_5#?+TXJ[9C.4=R'SZOYZAA#\\![!T[6\D98(A$J$G`I'KP"(BJL`DR[FP
M/05,0IMLEV</2*40`2]GS/D#V`UHQ&]/E3"X-:20T4B.19Y5Q9*:&,<^R"37
MGX%-@I`'LZU>W_9#?%UCE3C-9:(`.@+0)<,KH;ZO[D/GU?JIOEZG%&S&<H[D
M/GU?JIOEZ(HV8SE'<A\^K]5-\O1%&S&<H[D/GU?JIOEZ(HV8SE'<A\^K]5-\
MO1%&S&<K4<H`._T10`Z!)V&V4#J'<1*MMWI?)Y`';XFHRI[A>Q+@VS9C2(K/
M?)?_`'8F+A3D--.E?!][8OOUR?\`RT7J7D#YG]<?_O?^R>77Z'ZV[HM_V>GE
M7RFSI/\`/@O?'B8D5QXR'BTMC$.<CC$?$M`_=E`RI2K1=T2,HGU`8`41*?K*
M.P](EWV';7R?%:<!N`.=WD7N\%_YU>!NK">..XG9[1P](<-9#*N*XKC:?'UH
MJ&*)9M$V4,]EBF2QY2AURW1S^09U&0A:$DS03>2D>LJ_G&K0.^0;"Y5.3S=P
M>R4`]XB`1#-'RU<"[6,-?-O!;*H<08YX4&BF%8!C7I4>.4G''DT5E"9NRU+0
MJU\F+[A_'5E6XNU>^O:G0<24.F9K7A[_`"<8:0B,EN;'*W^_((F&$(<60JLV
M9P<1P.S:Z-WO4IL`^%%K?,31J`7)GW2<3%A,*,\*J:SE*>+#/&?(.3\<(6>6
MK5?P^E-<.>3_`!6@*Q+PD^6?D'N5\H-)*G9ALT=+.W4Q&NKE`UY.9FXQR[<O
MEGDL8!5,)#@&.\S022T@Q=&J@"H!:[K(</3;4V&F-<=V2`2M8<*\OT=U*VG'
MMVQ7)7EMESC?EFE(V:*L"%.51P9Q7KG&&YLK2>(&0G"C8&#"0>QJ\6D7U<56
MJ2H&Z%C'S":0-V5:'7>T^)%`AQ"'P),WG@9:KC&,HF#RQ4H>73Y#Y-ME_D6$
M8^D#2F`,PR\)8+GAY\T8N4Y&#MRR,>F+-02^HD.H=44C*JB8NJ5.)817F`A0
M<^\FV5LFPHC6NEBSP_VM+Y5S.;HT^-;-CA+,=]RM`/)'(^=$L@XWNMOCI>NV
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MBXEHT%)J<J:B1"0=>)3FED*2V$8"N-=&X^7<RZSFD/R`Q@":AD!B33Q)*I\&
ML[2:"U!-E3"JV.,>4ODEC?&[IA6[,ZMHQ><9;UYHYR"FJ)JVVD*H@@E'JM&O
M>A(>DX,*?4!=2%ZDQ+K-)(.K)\*!<Y]%-`W^-.3D#A7DF9L#2]T.]4&!N>/6
MO&FQ8WAI^"F5JD_N^!JY:*D];7YC""G)/:#9X:X.T6R[(!>Q[E)NL4#=P"9J
MS?I5@MRQ=35Z1C1R5+7#/50B_P#%;D3D&5R)-6"]89%SG7CB_P`*9:*A#7F(
M^U&P1L[=9VDN\7E:G=*3-<),VTS.17D3-I%XR8(N1)ZPIW28R_R0&MI(:^--
M.2&;5D"1:7`@0B1"A)YIPNRTK9);'/W1L5FP#8\P8SY%W\R$=8%\[L;_`$Q.
MJS(U5D]7.:J?:78;50V*R#YVI[:,XI19J1$2KBH60O$JT:*;,-%)XJ#DX5GZ
MK/L5TQCECY:M_@RI\L+\3[+C.P\;I1]9JL]+A.#S5#V5.)92;<T^ZRQ,N):)
M/#%=&`C-I&`L`NRN"E567(!T^KM$2=>)<R66M`!-6B'*B7=ILM]IQBT#33$?
M`EAQR_QF>>W]U7#?]X"D:PJ\>@=\?"I37^O3EJJDG`5NX2U!F9$$$6=M@V4=
M(2<.8%R'.NV:RJ:K%03IE$@]91V`VX=H:DT#+D"&NLG?,%X\\:.1_)@\'Q^9
M6F5DLW6SDY4\WW"0E+&ZJE!K^(*U@"Z5^J3\I%,H5H^?VN3L\7;&JJ;9$HF1
M=IE4-Z'4&M1D`5T5<:B+R3E6]7/$+R94<?0CFJX4MN;&]?P(7D'?+#;,CU>#
MN9JPID:6IR]681ZD9'M)NVK]TDLP<!W,<DU3,1=0JIB[IUV,851,!J3;>:(U
MPI/D2_NWB;RV+:G9$\F8IC*GE`M]QU3J7`-K%.W*K2<9E;'C_*-:M$^]I%3G
M[5%^T%9A)1"4CT8UPX.]CP[@P(.4E@3;M:X^*OC3-YA#.MRF^)/8;LMQP50P
MV-7ALVM;(M,V#)$U.XZ@HB5@KHM1$*M6I.VTR)]8F9I=N$Q'I3:4,O)1BZ:3
M4BKH>C1U<`6HT`)=9,;)KBDNESZSS0./MARQF&H8:2G&?)/*V*X*-9V:W-O7
MZK1K;=(Q`6E5K=2NMWLEB;H5Y&.`D:Q5*8Z@RCH6T>DN)1TB#K+08^1-MY)$
M214G()'Y`Y(U?'G(["J%AI;/)>+J9=B0SG(<M#OX^V,7DE-.:.\ARKA7U$UG
MC9"+>/R-B]ZB90X@`;`&>:TL>6FL+3*>'L#A45,'`E8RA7*[,_=/DCS%DL%K
MD+*Z,>7+*L8-Q+,DG[Z"@P*DB"$#"SZR[5DEN/0T33*)C;=0UJQ,)XEICAQ!
MF>L0%0,V\,A4$`V`5#<S,!@J(!N.P";?8-^S0A3]'RC^:/R1$="%GT(5BANA
M,Y^ST2&-V@(AZ)1'M`H"80[/8[=,4F"1,`2O.G*EOS-D_D^?CGC_`">.%*U3
ML'5[,MEL\#7H^P6B[3=OO-AJ,76D74^=!O6ZU6"UGUA54A5U9%9THV.#?N2'
M4U"50'$5T:EBZQDB!!-%AOG/F>;/0<>RN.ZG?;@Q@>4<IEG*3BX0N,:D6!XE
MYX7P3*6L(QZD^0C9K(CH[5Z+,'!F$,8ZX'7.D@.X9``CD-65,7DF-5'`FN@/
M$-LN?4:JC62*8[F*[RFP)2+4YJ#V9E(>V57*5<EYKVK(I<:A5I,K=$K,&QGB
M;51B\Z!=LE5FYB:GU:BBF@J)O)!@:"G_`.8WB)QO$C)]8QPG0G=S?2E+DLGV
M)LQ97MXY95UA,,8$T!`MZ'0[RH^N<XNNHO&D?$8L%B-52&7*J9$#0;(+FVA"
M%29O-DP*2F1/$!RJM!\HV6/,85NG6S$^&;-D7&S3+$U(P=IL(P<)`3C>S/**
M\BV2<O3)6)L!':!X^16<L1(1O*),UEBD!B[B`TF&C>WT&\D59EM7#EYG1:NW
MZFS>+8R(FZ7P]F<_Y/R)0,D,&_VBA*52YJ1;/'Z,E%.G$S89`81%XR=+H%:-
M"]YWG48A2F-@V((-$8<*?6'U981X%N1_.6[ME8!9EB$9W"]0M?'C$^3LFR&0
M(9K<FUJS'`41VM.0-;]29-+!7*=+WF-:RBW>HK2!Q<J,4EB$3[QB[$T@5U)=
M:A7DK@I/\%[C:L@<=(:VW:;>62QO<E<A(E:9D4FJ#Y>'JO(G*U6JS!=)FW;(
M)D@JS#M&*10*)@1;%ZC&-N(YIK;#[.ZI:I3[;`Y2^U6K%@6_FA_/TX\V"MEK
MQK\<;+UWP1P1MN7\:K-(_(F.,I83M-'D'L6QE&[:SQ>08%Y`.UH]X<`DTBR"
M`I'1`2=8&``'L$=>E[M7)E]O9NSA&+/A$?@7#Q\D20YM:^4J-\;?Q=',;'K+
M9=@6*CAFV$J(XVJ"@!LD0H'ZA<%$>^`.OM[0ZMM?59?<CNF]@?/>X3S2X6LI
MK^*OCMY[Q]Z),]\J[V]@TP;O"KXRVQ\:WQ<P$0'--=$0'81^YK4@W$/*.WKH
M;:N'<KN=#TSK^HJ/>;O=\O=^^J?#7>+E_#17?O:U+]FZ/<KN=TSK^HCWE[W?
M+W?OH^&N\7+^&BN_>UJ7[-T>Y7<[IG7]1'O+WN^7N_?1\-=XN7\-%=^]K4OV
M;H]RNYW3.OZB/>7O=\O=^^CX:[Q<OX:*[][6I?LW1[E=SNF=?U$>\O>[Y>[]
M]'PUWBY?PT5W[VM2_9NCW*[G=,Z_J(]Y>]WR]W[ZJ7QK?%S`Q#_=F@%"IG*H
MHBGC2H"HX3+OUH$ZGP`!C@/E\H:@_N5W0HLO->?ZBME=Z>]<MQ<\.(AE_P#B
M2'E/%I\4EUD*NY46RG`C=*I6+338656HE)2[FLW:1KTQ-QQVBD@;UD?7JJS,
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M1H%%`136(9)4-Q?[D$2F'8=MRZT^X?<SIG7]1;/>_O/59.[]Y)S&_BU>*1B7
M'U,Q=1<GP<12\=5*MTVHPA,?4U\9C"U%@A!QL4,B61#UQ12OM45A6``*HH!C
M@`;[:E,[C=S23,+S:@<M%<>AP#10D>]W>8M+`TT[NDE=\-;XN7\--=^]K4OV
M;K'[E=SNF=?U%D]Y>]WR]W[Z/AKO%R_AHKOWM:E^S='N5W.Z9U_41[R][OE[
MOWT?#7>+E_#17?O:U+]FZ/<KN=TSK^HCWE[W?+W?OH^&N\7+^&BN_>UJ7[-T
M>Y7<[IG7]1'O+WN^7N_?1\-=XN7\-%=^]K4OV;H]RNYW3.OZB/>7O=\O=^^J
MAXUWBZ;#MFJNA_\`VTJ`C_[9X.H/[D]SS`![O6^HKY/>KO5+C;#C'=TE7X:W
MQ=S=V4F8H!VH+A(Z:)<9TT2KE0$7+EHJ`OB;E=LDE"%\QQ`?8VUNN_<#N83:
M+W5=+ZG&M`[W]YLK3N_>2,Q_XMOBEXJI\+1*9EBOQ5=B`DGL<U-CZG/]@L<U
M)V9\870/3%5,$Q,.B#L!>DI0+^AWU/$NY'<Y\^W;(+A$P,*:/D:%EF=Z>]3B
M#+#@(0W<Y*\?&P\7,![<V5P/B#CFBI_^U6>@8?S?)KGCN-W-]H[UC]!5^\_>
M[Y>[]],]G+Q/?$CY&8NO&&\PY8K\OC7(40>&O+8M0IL<'M&T,WF"[NF"RSIH
MF=[')D-L(D4W$#%-OK9AG=WN[<;\UUVB[9QLDF(BZLGFTD5`Y!$*Z\7K';]<
M=M>2ZVZNN-%7QJEXB,+:A5%H-RW?2<;,P;M%[!S-5<S;2=@C-S`HV?,92+<1
M[VNR9#@'0Y8K-U03`"`($`":]'BUUPJ9=RR8QA:<X'(L&$=JRYP<QSH#)$PU
M17TR^%?XX?B-QUHKF)K)09KFOC@KEFP*M:7+"B91H\4<PHJ2),INS&@9Z+8M
M]CG)/)HJJ@'T-94^OA_>;#</9,F3KL++G40$`W5"'#6OK6'8G,V+)$TTM;`Q
MC&C3Q+[OL=W:*OM5B+#&%]7*^CV2ZK$SHKT6;APV35.T!\0"IO00.82=Z4.E
M3;J#L'7S5MWF"82PD-BO627B8P."<`/(&_EV#?6Q25="%"3@/_S`*?W7LV_W
MS+3IXMZ>KR)BM38*`>7V=9[O0SA05?J])&A"-"$:$(T(6LX\GQOY^L\O_?\`
M^'\*SWS_`&IWPO@J_P#77Z_0?V-?)_M"^@CAZ4#>,WXKXB05!)BOB,H!0VW,
M9*-N:I0#?<-Q.0-O-KY=BKW-P2Y0R!_D7N<%_P"=7C=E"DESHN\[C>V\>+/3
MDHL+#"1?,2>BYE>J,+([AY>J\1,M6MF_C7+Q@^-6U5;,R1!P+8H#(D'U54%$
MU!(/!N[&=6+GQ+>83PNY(KNWZWUP;&`<6NAJHXX+B<*<J9UE\B)8_P`RY4=9
M?:VWAYQTY6-9V6H=4H1ZA9LKRMP@+#3JRWI4-"(*4Q-Q34WR))8'TTW?+JE,
MX.@5)-.<WJCH&4TMYQ%9,1GIJWED;U\4N=&CHMKW?V)BC9*YB6[)L<,=R0?U
M"G6WEWE#C$K4H_#F.G"=)H]<K8R[.^Q5AFZQ+R4AD]%P`'1>2`N:N=J)BKQZ
MRPE$-+1AL'VI=H-EQ'.<(NUU)--^,`7P)?30VAJ34+S=R[C_`!J#[+V8(>*E
MW?%+.#NO661QU'Q[>X9IQ-D60IS.<C6:$(BT<VHT*YAG#N`0018J&>@LB04!
M!-.SJV%F`LT[1M1=Z)$2*3DSUJ%K$(F!$('($UEAGKR_O1[8IG2\X)6F^</$
ME')%QJL704ROU;E@!H55G:0LU7M]=]HUYM$`2=I)M(HKESTJIF%-(2)YN4J4
M626TD.K)Z4!Q*MS[XV8TS7<W>$:N5*=3D7?ZA-#0&W(RL\7Z?;\Q^*99GUXB
M<:8Y]L++8,,\A:,:@QA%;K692L)6R7BK!)JSL@Z8J*2Z9GJQ#B[%)VUS_P#=
MA2YMHP;E(&E0$Z\.%#[+::P#3"C6=6=(":Y-YV@IG*^1VCY;&]US76O#+B\E
MWMK]J\`EC]6\8=RM.3U@KA\JPEJQ_7FSZ79BS%S88]=FS*N1!9`5U$5B1,FX
M$FT*HY74YJB*HPTJYLS$'M#FD0(&09*,N>M>HN/<LYC<<*['D2V9`PVWS57:
M7DM:.R9,3;"9Q2B>I2LY&UNXWY]2VD7%)I^K,$%9HL2S*P;.U#I-2*HAZ5#Y
M5R$WF-_AT93FW\ZL:;^6Q<[G;S5`^M\JK]-TG&-2N'*K).#V3ZZY\89&Y(W2
MF\:9>7&Y8LA:M-)XUK%@A*']P6:I#J+G#N4I-*O-Y6:8H&9D492#99/6UUWP
MQC+;&6G<T`6G#?-<1&JF,%!M\OH?9F.@!$>B.0U5IOKKG?.F.%KA3L07=GC-
MAD#D]RKLBN6W$QC6$/,V^GI4!Q6**TELS5F8H3)M>&4A(S3\4&)WP1L8NW8K
M-SB=PC9U3"K5N$&!@HBXTQIJ,:J*U`7^_5%T8T5-X,B?:P<A.6A4N4>11RA`
MA&8-Q1Q7"-H5!I,#/4)*RYZQW49K*V975@7A9"^RE6Q,C*R%HB6+5^BBLR;'
M26,J42CK`+OAMJ&S):7.,;3A1&BB->3RA6%M\(M!\#11`&)RFJC/PT&A(&W<
ME\_5JHY=AJ3RV89*Q]3;%C.9C^2Z$9@"EY7OBUGHMTMN1\1XH>3=,0XY6C(F
M/(FLPLP=-S"IJ+PTYZEZ[Z^F5P$Y-UPUTT.+"`<A<ZN.<&-(WLZ&]=:X$NB`
MZ)H'"M"[9_R6S<<D+;B_*,1B968L/#:R2=QE('"U`S1>Z1,\427NQ1M;>Y@K
M;_%UHRP,DLR<`RFD4XYHQ,Y:(/&/0D?3G2</E$@L(,'?&)@0Z@4$Y**\D335
MTG7A\*Z-[0O;_#UU-?\`'=`NGK#]VC<J=6[,V7E8'VAEA2F(8DB8L_#D45)"
M3`&4Z3M1,(-SAT%.H(".N0U\HW@-EQ@=_C3;,?,YK_1*87CB'^$SSW_NJ8;'
M_P#P!1PUKF-+0+-9"GLY=4*-]39V\@[^0P"`_F></-K)*FS-H1,]&"6RE1C9
MJTJ.5*XGX,QZOC)S5:J]9+8>J^5J;CTSBRV21""KF;)BM3^2(\2OY1P5^6=E
M:BP5(=QWJC3N1*@*93G`VUUZ+C$FFC)FJ5;;K(;4W/E.6O*DY$\(^-T'!2M;
MC*0^;Q$UB]IAR0;C;;8LHIC]E8'-H;0Z3E:8.X;KDFGBBHNB&*Y,`]`G$@``
M3-^F$@EPB#F2%TNX!%BO2>5=&[</,#WU*R#-0%@92UE5Q^\4M58O%QJES@);
M%\:2(I$_3+97IJ/GJ;88>,**`O8Y=NX<)*'*J8Y3F`8];=8L!W-IR9ZT^JW>
MU:L\[?.3A7'E>%&%+"3'+6T/\O6Z)QHX;/V%>MF<<KV.MW"8CY[[9HJP94@I
M:V.HW*EAA9TI'#)[/)OG#4Z*0)F*"9`!]<=G&K/10CJMWZ/&>5<J8X%<>IA"
MP-P1RC"DL&5[-FP%*OFK*M8<5O(=XC;%%WR5I#J$M;)Q26%[;VV3/,L(PS9E
M(KO555DC'-U:77'4TBFNC@1U61D;5I/*I&8WQ?2,1T&J8PQ_$>T-)I$.TK]7
MARNWKWVJAV(;-6*;U^X<OE4DB]FZBAS"`CN([ZK?.;,<7O/.*O8UDM@8T<T:
M4O.[+L``(AL4A`V$VX%3,)B!OOOV"/;Y]1MR]T5*+<W&H'>)@4!XBSV_;_RY
M<-@\W8',O`A@^,.HD$F@T)$C,I[>R/\`JC?ZX=*#HUT(B,RKUF^>#^AU.W+3
MBW-QJ@F,(;"8-A_2Z+<M!LD0(HWU&C,?$O#V;YZ#N%G)?:Q?J[#O:U%Y'Q1E
M#(&(LA$JDD^"3DJDZN./+#7IQ_5Y"2*5PLP66.W.L0I^GJ#?5O6G62RUS3H6
M;JMW!B&4[YY5>RXB<>(UA&0\?CF.9P41AFZ8`9U]![*E@@Q9D*;A+%;X%Q%B
M^%H\>3$S7FRYWZI3ORG!02JAWJG4S>W$Q+J8QXH(%UNX$+&2%9SQW94@J-P"
MXUT!*."+A;W,O(FRT&U,)BZ99R5=IU"1Q>S4C:&T"9LUFDI`T'7(HX-$6`J"
MT%JFFF9,2D*`,7QX%D.`;3DSUI&Z2'&+FQ.^>5./E3B]BW+MBK-OGW.1*U;*
MK&K0+"RXPRID+%DV^JKF2:S#NFV&1H5A@G%DI[R28I*JQKTR[0YB!N32ZV;)
M;$0)C5E4NK2`X.#:0,YY4FW?"S`,M<[==[+!VJYO;A4K517%?NN1+U;*+7:I
M>1C!N<-1:-.3[RL49O:#0C,7HQ;9L9<6J74(]`:EUZ9TN+S*/4[MT*-\\JSU
M[AO@^O5FSU06=YLK&Z8F6PC;9&\9.O\`=;'8\=J)V%NC%RUELEAD)MW(1[&T
M.VS5^9?UULV%-)-4I$DP+'KCJ.=48U936F;K=R8EM,(5G)1G7.4X/<=%+_"9
M%+6K*A)0SK'4LO6VN0KTVQU:++B&*@(7%URO&.$I\M,N=SH,;4XI.+E)%FX>
M-?:UL8I^I$@@NM.A9C1`BK/6GU:1&-FBC*<G$G[QGC2G8@J#2B4"-4AZRREK
M7.(,EWS^46"4NUMG;S972CZ3<NWJHR%GLCQQTF.)4^]Z"`4A2E"MTUCS%QI5
MK&,EMLM%&^E]UF^>#^ATK<M3BW-QJPPF,.PCN&P>P`?%UG<YQF\ST5:V`$0H
M1<YV+1_4L!L7J#=RRD.8W%%B^9NT$G+208KYC@.^9NVRY%$7"*@%^9.`AY?/
MKKW*]WNZATR[O+'EA!(K@81@<ATBE8+W+DWB#)HB(A<FW<`,)7"<?3DI78GU
ME\X]9,5&.BTDTS"FF3H(`(E'H*!```'R!V>36J;CMZ?,+YDPEY-)SG4JY=QN
M398`EBH94EC>&G@<YA/[21X=0[[>UT:.V_L;]SV[:K[;G](\:EU*Y>S:J?!H
MX'^PL?\`VNCOK.CMN?TCQHZE<O9M1\&C@?["Q_\`:Z.^LZ.VY_2/&CJ5R]FU
M'P:.!_L+'_VNCOK.CMN?TCQHZE<O9M1\&C@?["Q_]KH[ZSH[;G](\:.I7+V;
M4?!HX'^PL?\`VNCOK.CMN?TCQHZE<O9M65#PUL"HJ%4-!1I]NKI`\;&B!3B0
MP%-L*.P](CJF=C%[>`)+R'10<.P^8TB9*%F&=1.LO`7"$;SCPQ4F\0F6.D^+
MF>Y)=L@SCR-EY.(R!AM"+>+-S)"FJX:I3#@I3B&^R@AOKLR\<Q%MT_F&%J%0
MS+B/N-S%XL-8+$%*X_ALX*7[OK@FI1!(!4%6.BND51'M$H$1[!$-<=N+WUDU
MYFS"031N"[,O#L.8P%DL1-=)^%6_!HX'^PL?_:Z.^LZM[;G](\:EU*Y>S:CX
M-'`_V%C_`.UT=]9T=MS^D>-'4KE[-J/@T<#_`&%C_P"UT=]9T=MS^D>-'4KE
M[-J/@T<#_86/_M='?6=';<_I'C1U*Y>S:CX-'`_V%C_[71WUG1VW/Z1XT=2N
M7LVH^#1P/]A8_P#M='?6=';<_I'C1U*Y>S:CX-'`_P!A8_\`M='?6=';<_I'
MC1U*Y>S:KW7AR8&8LI%P,$B!$8F2.H(1\5Z1@8K]V)![D3$Z3;#V:L[?O>1Y
MW<"H[)PWV0UE13X(<`,*7?A)Q`M\I%Q[V6LG&S"TN_?.XIJJ]>R3G'L6Z=/W
M+@Y>M5VX7>*&.<>TV^P]@!I=OWHB%MT-VA/LG#@ZWLA&.<J5/P:.!_L+'_VN
MCOK.H=MS^D>-7=2N7LVH^#1P/]A8_P#M='?6=';<_I'C1U*Y>S:CX-'`_P!A
M8_\`M='?6=';<_I'C1U*Y>S:CX-'`_V%C_[71WUG1VW/Z1XT=2N7LVH^#1P/
M]A8_^UT=]9T=MS^D>-'4KE[-JJ'AIX'(']@8]3?_`.;XX-MO9[$0UEO&-7\E
MNPF$9\OE4VX9A<T?QI0HJI/P+*CX;F!FRA5C5R-V1`5P,,=&G$AD0$Y3%W1$
M0'?;\[L'L'6J[XWBK&\Z:=066;A&%M]"6(;Y44N$WAZ80MG%W%\T^C6SQZJX
MR2V7>.F<>NNN5GER^MVP'6,D8R@(-B%3+N/84H![&KI^.7RU"<\EPHS>1%WN
M%Q:R(EB!*E0'AIX)+V%B&)0\P1\<`;^?^DZH[;G](J_J5R]FU0X\0'PQ8"T<
M..1-(P312V;,MGQZC%4&+!U"5IA(/U[/"*.4UK"^!%C&*-H_UD_4JLU$Q`$`
M,.P:ZV"]Z+[+O@DNF?P8Y@>.$?*N?>L'E3W&#1LX5;BOG7XO?Q>Z79VM%/.H
MM+W8VI&*4I6JL9XPIC)\!$SKH3<ZKZL[DE69QZ?ZC.+=42[D$Y!`1]/WA[SS
MY=UM2'@/AF!\H627W?E276I;8.W_`#KZJN-'AE8SQ7"1C%]$QK.)8IMUFL'$
M19(B-351`>[%1DCW9G(I"`;"OUCOV^SKY]-QF=>Y8-X-HD4T0\@71E8-A["'
MF6=K63:->]%>H,#5X:MQK:+B6Q6[5L!.@"]0&,<A0+UF'??M`/)Y-8Q>`*J`
M5UY1$EMF6(!*/K-\\']#JNW+2BW-QJH&,(AZ7LA^AT6I9H%:(C-QJ%7`C_F!
M4V_A>S=\C)MJU.]M,UQMTF`\BIE3`X`G.II`<^^V^P>7R!K%+)EOLGT%J+6P
MBKNLWSP?T.M5N6JXMS<:.LWSP?T.BW+1%N;C1UF^>#^AT6Y:(MS<:.LWSP?T
M.BW+1%N;C1UF^>#^AT6Y:(MS<:UUSFZ1[=_)[&WE,`?S]42@'8A%OHB7\*PX
MB\MNYLT4A?!QT%^=_P"FOV\H_'\NOT#9=_\`TU\HB?\`.7L]AG/F/L'>,9XH
M$C?#W$C6?QMQ3:QZ%3QC?<BR9EV\3:Q4%PGCFO6Q1HW`3F$@NO5NP1\H[!KY
MEBTIQP*ZNYL&-,>',,J]Q@KHXU.#8\[/P&G4O2Q[SNXL28H#)Q.9)`$`<]T#
M[B;R%<@F+Q)5N\!,%<7'`"/&ZYTUB_,JIG$IP$H[:\[)DS)MUBUS0R(H+H'4
MO07Z<V[7T;2DV353ESK(WYX<6&:H+M(O,S5<&J#$'#?BCR(2<%9-14%JT*X)
MB\%BMVW>F[L@&`J?4/2`;CNNIOZ3-85/:,G3J\ZM+SMXI$,4R<'EU,Y)%:8(
M=/B1R`3.27<$Z%Y4AR8K*8LFL0=C.`'OA#]%I&[/:/2;P%':,G3J\ZP+<X^)
M+E-HDYK>5W24>JLNQ3=<1,^N2LUG._K*S4%\5*=RJX$=U#%V$XCN;<>W4=B_
M.-:.T9.G4M=QS9XBNV[MHYK66G+.05:KOV;CB/R"<LWRS`B2;`[UJMBU1NZ]
M1(B0$`.4Q4ND.@`U-MW>16WA*F',O8MMJ&A-I/\`)3A?.9&IV1I*&R^*U$I>
M2ZPVBWG%OD)]KCJ-R58*!:;5)34`IA]VG+S)Y['$2+1<3=]WBS@X[CN8+!<W
MNRMKR%(W<1!@*$Y[CG1Q.E4I9&3A,N2J,R1)E--Y'B1R&?)RK9D;=FTFTGV*
MCI2P,Q'J2[TJA$P/L3;MU$W-_2;K"1O<N[G9.C$+<:\[N*S*+1@V41F-E"MV
M81R$0SXG\AFL8DP*B#<K(C%#%R;8K8C<`(4G3TE(&P=FH]3?G9K"7:,G3J\Z
MY0<S^'P0["O$J64DZ[%J-5HN`1X@9\1@XY5BY!ZQ581*6*B1[-5F[#O$C)IE
M,F<1$HAN.ZV3FT1;K4]FR;_$`$'4U+,_YK\195J[8RE6RI)L7[U"3?,I'B!G
MMZS>R35;UEM(NVKG%*K=R^0<`!RK'*90#@`[[@&RV;CE&M&P8#&`U+I%YY<6
M2&=G+%9D*=^5$CXQ>)W(4!=D;MQ:-R.1#%WT9-!H842%-N!4A$@!TB(:EU-_
M29K"AVC)%%.KSKD&YI<.5(9K6STS)*E=9*)+,J^IPXSLI!LED7(O$5F<0?$Q
MHYJLF\'O0,FF4P*>EON`"!U1XIM-UIC$)3C9$8G1YU65YK<09LSD9JJ95EC/
M7#)V]]LN(&?'P/'D:W.TC7CH'.*E"KO8UHJ9)NL;=1!(PD(8I1$-5F[NF"$6
MPWU.T(98;R[7P@/&MJW.#5+.+<J)55RE)Q7Y')I@;9158_2AC#J,LMU&$1`.
MHYS;CN(Z4C#;,\/!9'?"'3`!&FC0HL8&YQ8,A\Z\QK.\+FI&/N.1L3248B7C
M?G=_()-T,*UMF9*19Q>/7:\>X[Q#T2.2IF[DI>S?72O-S<QK02V(;`F,*53U
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M@^5^%[#(O/;*4QVSA$DO::(<"DF98'*CDI"E((F`!M;=7B`%DD9C'(@7IM-)
M@IM*^(9QU3553'[N>Y%5">AQ:Y%*$]$Y@W*<,8B!RCMV"`[#J'5GB@EL=]!O
M328B,-Y6?"&\=?/G7WK'(O\`!AI=F$TVI?K!'6VZ=2/A#>.OGSK[UCD7^##2
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M:>:17&G2N5>+U2#2('AX%+)/Q">.@$`J@9Q$Y=P-T\5^1IB[@80V`RN,!.(%
M\G;O\;6*9AI<\NM2Z3T@M4N]@,`IJS+)\(7QR\V<_>K<B?P8:K[+^5+]92ZV
M-.I'PA?'+S9S]ZMR)_!AH[+^5+]9'6QIU(^$+XY>;.?O5N1/X,-'9?RI?K(Z
MV-.I'PA?'+S9S]ZMR)_!AH[+^5+]9'6QIU(^$+XY>;.?O5N1/X,-'9?RI?K(
MZV-.I'PA?'+S9S]ZMR)_!AH[+^5+]9'6QIU+&KXAO'0J9C`GG(Q2@)E1_%9Y
M$D,1$"FZU$Q^YB43*%W["AN8?8`=2;AYEN#@6$Z"GUH%IKJS*(4_S@P@[YL8
M0NG_`"P&B(WCKG^OO5#<<,\(.COY*\85?QHL8=UCK[9%6P-H]8%E^X]6*?I`
MQ@,8H#V^HN=<39+!%X/I#(*:<\<B\\^]M;?:8U')G4Q#>(7QTZ0`P9OWWW'H
MXN\B5=QV]D/N7AM^;KB/N#ICH.+*-*]`V]C9BO4K/A"^.7FSG[U;D3^##4>R
M_E2_61UL:=2/A"^.7FSG[U;D3^##1V7\J7ZR.MC3J1\(7QR\V<_>K<B?P8:.
MR_E2_61UL:=2/A"^.7FSG[U;D3^##1V7\J7ZR.MC3J1\(7QR\V<_>K<B?P8:
M.R_E2_61UL:=2/A"^.7FSG[U;D3^##1V7\J7ZR.MC3J1\(7QR\V<_>K<B?P8
M:.R_E2_61UL:=2TY?Q!^.JT1+I!]VS=6)DDPZ^,?(@@;F8KE+UB.+P`H`(]N
MX[![/9J0PHBHRZ?E!/KC8TQ43^!/.7!E.X5\1ZG+AF1S*5SCAAN#?!#<=,\3
MD>D\;42&3.[82\/CU>!DXH4"@4JK158`\@CV:'82YM!<VC.0HB]B%9J4O/A"
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M>=5M'<:.0,JU20>Y<OKMGW;IKC=PD(':*D,(=6Y3B8!\FP2O>'F;-+XL`R1,
M*E7=KT!*`,8[T=6CX8J5OPA?'+S9S]ZMR)_!AK+V7\J7ZRT=;&G4K#^(-QI5
MZ>^3S<H)#=0`KQ<Y$ATFZ1+U%(;%X@&Y1$/BZ;,,F2W;1A83^TMDJ_2FL`,8
MKF,^=?%2.5,LPBLRM3FW$3-^*7(<0$1-U";J^Y?TB<3=N^V^_LZLFW:?>19F
M.9PN\RD<0ENJ)@NL'B&<<P+TE'.W2'D`>+7(P1[1W\HXQ$P]H^?50PL@0M2_
M6"R/OC;1A&&\KOA#>.OGSK[UCD7^##1V7\J7ZP4.MMTZD?"&\=?/G7WK'(O\
M&&CLOY4OU@CK;=.I7I^(9QV,HF4OW=3&,<I2E'BWR)(!A,8``HG/C(I";B.V
MXB`!Y1';4FX80:'2X_M!(WQH$::-"B/PXYS8+J&$PC9%7,"BX9/RO***1?&O
MD#)H&;2^2K$=!!-2*QX\0%VCWNRQ1-L40$1VUNO-U-LNBVEH%8K`62[7H%H`
MC6<BEP/B'<=-AV^[MO[(_BK\B_P8:YG52]]@EL3I75,\;(NI5GPAO'7SYU]Z
MQR+_``8:GV7\J7ZP6;K;=.I'PAO'7SYU]ZQR+_!AH[+^5+]8(ZVW3J1\(;QU
M\^=?>L<B_P`&&CLOY4OU@CK;=.I'PAO'7SYU]ZQR+_!AH[+^5+]8(ZVW3J1\
M(;QU\^=?>L<B_P`&&CLOY4OU@CK;=.I8C^(=QR%1%$YLX)^LF[DBSCBYR32;
M@J82@0AE6^*7/='$1W`QR@0`\I@T2+EL[Y8#F6BVN/-KRE4WR<'W0NIA'A7Q
MO?=7Q[^O;G_E:OM__P"(5O\`[!_/_P!@O[.?]@?V1_[%U^C.JM^3_L]W`OF.
MO^=NX5])?#8YA\:'Q6@ZAV+BOB/TAOV!O%W,!V#R;[!KXMB__M^X_O>1>^P8
M#MB\[WPA>XQ!$3DW$1]`1[1'R[AVZ\9=7%TDEQB;7P+T<W_=!OQ;!HX5GV#5
MRL@%C4[`#;L[?/IA4SJ`()%7FUQ5)K4Q:K#+MX*N5^(E9N?F7VZ<?%1,2S4?
MR$C(//6$/4F;1D@H83[@(FZ0`=Q`IFJ`3`UJ+^`N3]OSTLG*MN/>9<?8KF(&
M)MV.<PY%?4"%C+_#339)Y'.4<<-;@GE:II2#=8IVC6P1#!XH@;O%4R]F\72)
MDUP+"0I6B!`1UIPLW\B\38"8Q#_+V0Z_CYG:G2L36%K1*>H+V"P!&NW/M+"!
MWK0R,@"1#',JD<Z*28%*J=(ZR0FU7>Z/>XAMIU-=8W9$[3JXFI0EOGBC8^QI
MCDN2+7&&CF<A1,06NFUPM^J#JR6V?SD1Y8:95)2*7;)2%+*6@-AFCNI$K<KE
MBW<)MBJ.TA*I:;E,VFS:02#`PJ$*\F3B53KY+EN+)A@0,N5;N(_$RJF9<ADH
M]*@X*391UVK>+IRTGRK6(Z/5N4M2IJ_VM6I14J+:7N5:H\34)I!1R@5-\X4B
M7IDT!02]8--UQ<P<Z,3$\`X%2V_L=Z(!`KW13Y(<VL-V)6$:XGR52LD]_E9O
MBBXR;.\M6D927;:I6>T3,BR-,,F"EX>12==#JCXP7#IPW5[X%$R$,8<1N<UU
M(M51X%N%^DMYILYENT'F_A>RL\#M[9?8''&2N0M/J]JI>'K!-L75M1>VI@N\
MB8-R#551DO*2B0@D@V*L3J=)`"7?=8;KJ<V!,70!K\NI/KTDF%$2-VM3B2,5
M1--0O4)3D(<HG`2G$#%`0$Q1`HE-L/:&P;#JND4*Z`-*OVT(@%70FK%0W3/_
M`*D?D!OJ3?2&^HO]`[RA#QQ.<>3'/4!.80+E/#8%`3"(%`<`TDP@4!'8`$P[
MCM[.M4\DA@-09\*R-`:UQ;021\*FR`B._:/QQ\^L1$30K9+C:I,57<WG-\<=
M%DYRM$1H1N;SF^..BR<Y1$:$;CYQ^..BR<Y1$:%01'SF#\P1T6VRZ'5IQ&A'
MI?/'^/HVTO,G'0%3<WG-\<=2!#A$5+)-<ZW10-".HWG'XXZ%7;?G*@;XEYC%
MXCSIBG.4PYNX=$$2F,41(IS(P(FH41`0]$Z9Q*(>R41#R#H:YS3%I(*TV&O;
MSP#$95/3<=Q[1^:-[(_/#I*Q9]"4$;?Z-]":P;F\X_''2LG.41&A&X^<?CCH
MLG.41&A&X^<?CCHLG.41&A&XC[(]GQ1U5-#PR+28Q1$:$=OSQOCCK-&;G<BT
M-"!W^>-\?6B3,+`=I$[Z8<-"MW'YX_Q]7;>7HXN5%H9@K@ZMO*;\\1T[;7TM
M2-*R$[0[1'R^<?B:$H*P^_5V&$.SM`!'58O$H3-B?34A12H4\W!,6M\=Q*<P
M=7-+B:!MC&#J`V8:^4Q3;"'4!B@`"'D$-7BVV+FN(!$"`81&90=U=U#VM+HT
M1`KT*:0'V``W-V`'\P/BZAL8TVG:_,IV`:6D!JKU_%-_H_/T;#Y3M?F1LSG&
MM'7\4W^C\_1L/E.U^9&S.<:T=?Q3?Z/S]&P^4[7YD;,YQK1U_%-_H_/T;#Y3
MM?F1LSG&M'7\4W^C\_1L/E.U^9&S.<:T=?Q3?Z/S]&P^4[7YD;,YQK5ICB(=
M@G\OG^(/Q=`D4^D[7YD&7G(UJ#MQ-OXAW'TP[]0\4^26X[CV[9&P&/;V]H]F
MNH6$7!QB;.V`AD]$4P4.JRMIM8-VD(1RP.GA4Y.L=@$1-_H_/US#)BXFT[7Y
ME/9TP!XT=?Q3?Z/S]+8?*=K\R-F<XUIFLQYRQKA!G6Y3)US8TJ(LT\UK4=)2
MX."1JLNYW<(-EW;4O4Q%1)$VRBABH[;@8=<?$\8NV$ELF<X!SQ$$D>98KS/;
M=YK6O=!IRQH3D5^:C)V,0E(:7;S$<\W.TD&4@UDFCA,NR8';O&1U&ZI#=&_8
M.X"([]NHX3B4N^NM!UIIJIC\*TRY\IS0[XI79W$2@`J'*/G`PAO\GMUU+Y=I
MMX`$EY80<AAY`K3+MNML/,*N$>S;K/MM\UU#O\??4C)<Z09`<=K"N-._&"@+
MNZ,;1UE6"<4B"85#&W\GI"/9MY>T0U*7*VLH2+3K;1`D&F(TJ-VNTW;.+R2V
M-`)*Q]1UB=1%#E$!\@'$.S\X1USKS=9]SC,$V8YASF/P!67N0^`#"0=$5SYL
MPD@YD.\.80B)01,)A'M!BX'L'?V!#6VXW:;=Y`9.>Y\PFLF)I.E&P=62=>>A
M0[\-H0'P]N$1S&.8Q^*>##'$3"(F,.-Z^H81'?M,93M$?*(ZOO#)C9CY4QYV
MCB6Q)IM9U6VZ!KFMR"CCC\*FQZ1R@8JAP\X=0[_(WU3):+DRQ/<7G.:3QP55
M\N\YS_X3G-&@D*[KZ!*43G,(^78V_P#/TC=9DR>+PU[A+'Q8T'@@M,J0_867
M$V\Y)BJ%^:$05.;]+UB/R-]4W>YWB3/,V;,<Z4:@22!P02,AT*R.$JX3"&QN
MH_E`!+N.W:/EVWU9/>+O,$][CLG<T#)$Y8*J9*>P`@DTYRL9C'!4``Q]NSLZ
MAV_FZU"0'#:6G`YHT:H+<T2S+M4163J,8Q@`Q@Z0#V1WUE;.9.FF2TP<RM<U
MP>YYLD@&I:B^X%.;O#"<"*%`>KTB@*8F$`_-,0/C:V2I+FUEQIC70D;E/<;3
MG&$,YY%#WP_#F'B5C$3G4$QY7+`F4,<QCB;[LN0MA,<PB81[?9U;?93W/>P.
M-N(ICH"OD7<"[V&4.%%'"ICI%4(8QC+G.';L`G,(>SML`[=FN5=KK>9<R,V8
MYS8Y253)D3Q,B\NLZ24C[I>JI0(HT]>+0PJ<&9VTB_;>9>%CX]%[+"+9DEZT
M8>[[]5<OH]X(``^00U;/FLES"XN@T9%LF,%JBI*B)DFLM'-)*/>)OF+U/UAF
M]0<M7:#IJ<PBBNW<L3J-ED%4]A((&$>GYKTM]5&\RYOH.U*.S.=;OI]0^D?R
M]@=0_&U?>)+YLH;-[FNAD,%=_#@!1%5W-M\T;?L]D=1N@<QEF<;3M*++<RV@
M\@?F:O5!"KH1!0EX$"(X!4$3&$?NO9M[1,81'_E,M/8(B/:&IXJ]PF1!,8#R
M*+)<M@LL`#8F@4*;(>36:0261-)4RJZN48(T(@C0B"-"((T(@M9QOMMN/L>0
M1#SZIEN=UX,CS;%62M47NB[$BN*^#+UMU^N%O\M=M_3#>3S>7R:_0NVG=-W^
MRA7D7R>C_/7T#<-?\M#XKG]ROB-_O9=-?+<7_P#;]Q_?\B]S@W_.+SO?"%[B
MIG)WR:?67O!1.<$^H.L2%,4HG`F_4)0,8`$?(`CKQ=T_D']KX%Z*;_NQ^P?*
MLZJR2*9E5E4TDB``G45.5-,H"(%`3',(%*`B.W:/EU>K5100V#M#S_G;>73"
MHGU!1UY58=><@./F7<,,IHM>6R;CZV4@LRJU*\;1:EBB%V*4C(->M-5[&L%%
M`56;$,4SGI*3J*`[@U0(IN*$_P"6'<0"MVA<!QBZMKKS2PM:?)7AV8N/VT6[
M:VBTP;F1=K,DK%(2"#4D?'^F*+9,PJJK")1)6^>V4X,=EW9E*-4:`H]\N>-.
M?\M9"R%/8>MF-8-/*/%E?CJM+Y*AIN7>XC4?VZQ3EAGZC%QSL\9/'RBQF63*
M5;*@0[96OLEE.M,2E+TKI>VM`:8V6NM;YR5C)!(T)B+?1(?$O(6+:RS&YN:G
M3<J5CDE;YRJXSR;;(ZD80P/B%MC/CO5Y29AX27"YV9Q9IB83+$5H)B433,@J
MX9))_1M3-[8YMEXYX:1$41M&)H5#[H][]JPT$@P/R:O*:%UXSB=FG-W':E2K
MZS/\-V&XT#F!E1]%V%FK]N="SIRHGCRM3D7K2,57%`M2I]QL49(-2%#NT90"
M"4!()0?7FM!:T9&@1`,(;X5+<-(<'.,1&D1(\A3HW[C/G+-5'J$78F>$\52]
M1PGGO%5>J>.7,TZJ==<97H4!BRG.F;YU&MBIM<?5I!X=B!$4P*<R*10*0PZR
M"^MEN(:321Y8G)`1-:W=0+FVG0,(Y\T*XQ,,BY.-^"TS7.2$QD6WMZ3D3'2U
MSJF28*>>3]S:VB+L>/<?4^LXY9?<Y:/HF@.Y'&=IJH.8J7<IKIJ,G('[@'IA
M=&'XB7MLF$#HW5I-PYK71$8C=Q+UZ1`2HHE,8#&!,A1,`"4#"!0`1`H[B`"(
M>3V-9S28K950K^LG7W?67O`*!Q)U!U@01Z0-T[]72(]F_DWTDU=H0K%/F#_Z
MDW\S4F^D-]1?Z)WE!_CC_C,\]O[JF&O[P%(UJG?$_8^%9/B'?'PJ9C\3%;B8
MJH(]*B1C*&ZA3!/O"@MWH%,03)=T)MPZBA\76=@B[@*K<^P(KQEALY\NGS_D
M76);(7VN\B::A*Y)HW%VTXBAH*L2N,:-;V;I^3"F=6_?)Y0A,D4LY(]W-.E%
MY2M24@U458MQZ2+;!);01`L,*8Y<QW;ZAMR*#$.S0R9]6?@BD9<^:?)Q_5,'
M9ZQ<$*KA?,&4,GWRN8SFZ>Y97.V<0<08L<6.9.I8'"(SM7OUJ<-).>C5R-G!
M31B#-L4.\=B8);$%YEFAXAO1*!.B`X1L$G4*5*?"G-&MR]8R!:<A7N)71G.0
M&4J-@9DPC';=2W52HFC7E*CGPQK5TLA,OHAPV26=.4T2H]YNMTJ";0Z[/;"C
M)3H/#D4>M-<:31DWN#*H=V;FQREPUC?#F9[1>JCDZ,YC897R#C"GM<>MJA%8
M#MEF6QZZIB#R=BWSB0R3#QD!DYJA(-W:@NW+^+,*1D4E3=*;<=O%P^*89-,8
MTT5:DS>8`4BG?Y*>4:WDE^2N9N,\_EW!F:<MUK-&34H;#KO!E^EJC7\/P\W;
M,]OLH5E")OL1779*_#U;&TCBR:G'DD0Z)UH,0*;OW*(=X,PT3);9M`:X$[P&
M7R!-UYL/+3208<*1?W1O$"SIQGXVW[CED:E6S((V.]P^8K8P2J477[&[IMEO
M53;OT8#N'Q8ES+FA6#D$2=4<U.ND+IF[2W+K->)/5YSI71*M:\O8'Y2/A7M3
M6%WCF`B5I#?VP,Q;!(;J)*B+\J)"O1[Q!-%L<!=`?84B@B/Z`.G;5*"H3>)H
M(AQ&G=AV_P"6_AG\GF;@3?45M9Z(4^A\H_FC_-T*2-Q\X_''0A,#R'RNOA'!
M^5,LI12<R_HE)F)IE"**./5'<B0K=*):2AVYRN",4I!\F9T=(2J>K@82COMJ
M;&VGAHK)47FRPNS!0$L^8>47&.4QM=<U91A,]T[+<'?P?46#HE?QR7'5QJN,
MI'*,>GCNT0@OI:PX\F4*](Q:SJQD,NCTLE!5(98_>=!EW#W.`$+)`W:<JY9O
M4&@QK7,NGB76W&,)C>Z9-P"QIU=NK>!MSJMN>0T!,9:A,76Z2K4)6KB7&L-C
MIVZ?SGMC8DV\G%&>MV3-;8$I-R<?1&W5YB&D6AH\Z1O3#`TPW_,I&8JY"3,7
MBKEOE?+LPZ<5S`6?.5+-2119`1Y&8KQ-,JO(A@Q8M$%3RI8V#05*"G0*JJJ/
M3N(CJELL%S0?C`:RK7SK,0(Q#B.`048ZSXGTW::4J_;<;K9)WLV:,+8MIM2K
M^3HE[$3ZF>7DTG5)17(TU4*]!P4U5E8-4MA@NZD/:YFJDHV=O]QVD^[.EM)?
MZ--.XJ(O#7.%DFT84:]"<9[SRRBI6L92]2XU)2T]9L]3_%C(=&>9X@Z_8:;F
M*KV]>K6S[GQ%L?R:.8ZO6(^-?S2\D@6+[J!C7#HS8IBG3)4)335OU9$&\%L3
M"@$BO,MZR>(@SJT"[D'&'K0[M=3_`!BG63Z:A;8E2P8^A,&/F:<=+R3I]'LF
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M?%'R0&(,!4G*?J`3`X[Y(\>+PI#=Z*!Y5K5LEPDFLP15]+NUS](F`VV^P;:Y
MO>?&.QKDV<!$QUKR>(7TW=X=22'5:`H[1/BN.Y:+C9-C6\?(M7[%HZ10D+5(
M(/D"K($,*#I$K0X)K('$2"&X^3?7YFOOCWU.]S+HYI)EO+=7[JX'OBR5_">V
M+FT$Q(70^%,E?W/XR_?A(_L+6;]0@Z)X_HH]]970.L\B/A3)7]S^,OWX2/["
MT?J$'1/']%'OK*Z!UGD1\*9*_N?QE^_"1_86C]0@Z)X_HH]]970.L\B/A3)7
M]S^,OWX2/["T?J$'1/']%'OK*Z!UGD1\*9*_N?QE^_"1_86C]0@Z)X_HH]]9
M70.L\B/A3)7]S^,OWX2/["T?J$'1/']%'OK*Z!UGD50\4F3.(%-`8U`HB'4<
MEODA[LH>D90^S'L2(`>D/FU7,_,(8"RTQB,_T4G=])9$`PZSR)F9+G4M+9ZH
MF>#IXY))T?&&1L;$KB-KD5(UZQR-9*38B3979F/4"[8U(*F!/)TJCYM=Z7^8
M&,F-CFPJTY_1R!5^^3!,MAIL0(A$Y>0)YOA3)7R_:_C+XG_"^2_86N&?S"QF
MN!881W?%5OOK*Z!UGD5/A3)7]S^,OWX2/["U+]0@Z)X_HH]]970.L\BA7SLY
M1R/+'#*-(WQS`+P%K@[D0R5F7<A()U\R[E:,,5TBB'2]3W(8OI%.4=A`?)KQ
MO>?Q8O&/O9>I-IK9;89:]07'Q/O,Z_/8V4+(;$Y5#S%G*BY\<1C93&V=(W'#
MMVUC)&8QK8IQC-4%XZ?-TG"H+UZ3V38M'*!RE`S`Z"P&#<#)_-#E[N^+U\P^
M?`.)R98:H%77/&;Q+]$FD5&D+VSXL>+#CO-\A#8ZR##%JF1Y=RE%1<M5TY>Z
M8[L+GO@/WJ:\,1W+5?OREV(1XJND0PALY4+OM^IO#OQ#9WDES'S8M+6Q!W@?
MDKV]PQQCKLT.!:=-/P1\J<ZB>(_1\D976Q?`4N23<IY:E<3/W[VX0K19M*QT
MLUB@>FBTV;E1PS<&>%41334[SNA#JV-N`>:P3Q/-[\1S@4#8+R!$T5@='3G6
MP8W*(#&M.TC7'S*3_(SD*SX_TZ$L3V$7L034J$2FW)+,JXHF?NS'`P.9-($0
M$`+L'HAOY=>T[^=]F=Q[=[F",MSB8<&\Y2OF,-NLELX@FT-[X%@XU<@6W(.&
ML$JV@35P*_+)L3MU;)'61PJ+AD)^OUV**FT0V$-@*("(#VZI[A>(-W[_`$I[
MI3;+9=,-?R6J&'XV+^#`0`S_`-BCA8O$"A8^YS..W&.>_5;V5:DN''W2JFD*
MYW3U.-,OW9FO?)"HFL)A*(]11';RZ\)BWC,+MWVE8)+!V>TLY,A`Z*3L;8(@
M@QCGT[R>69DZ=P?XRTFMU6#D)6C8E@Z-CFDP;ZSLDI0L)$M(ZOP$:ZL,R+=L
MNX;-$1$QS`)CE+Y!U]'\4^]GNW@LK&VCT7"8Z&_&B@Y("K)4G,QG9L=-<V(;
M7N@E3QFY$,N1M8M$TSA5JV-;FRU]9LM.Q]D%THI$Q\P1XFZC$R(@7NWX%`-M
M]@[=9.X'>]O?S#.T0++<T=[0,ZON.*LO<K:`6=\Q^!1ZO_B"PE#R+/T-U1S/
M5X.QIP!G_P!T2OMSKKNE$$"G;QJD85PUV[W<"JF[.WMUXWO'XNLP+O-*[MP)
M=,?".]^Z?*L<W'I4J\"39)KR^92@S9F^.PICHN09*)3?M';V(8^J'F6\4*9Y
M=1%)(JDD_*HS,8JBP!U%+L/L;:^B]_.]PP3NCVNV,7M;`41$:\BN=C0#1$4;
MM&9([C+R5CN1C>XR$=!*0!:;)1;=RD:QQ%J(["8C5G*!D%X1!,K4A`8F]%01
M'J'?R:XOA]WG/?/NZ;PZ-J40ZDTT-W@K[O?Q?'NL@V`([J`F8GO$`KD'EN<Q
M:>JG5<PM\5HBD@-RB&I/6&<J:/.Z-&+IB\3'J+N(".P^3V=>8OWC%+P[&NP7
M,B\.LQXNCHSKF3<4;*O/5RUU!A71J@I`<E>0<3QUID'<)2-/-MIB44BDT26-
MC!&(NJW.^(8D@]:N&Y_02$`#8.SV=>C[S=Y!W;%QOCPXF^6JCF`.8QK3Q;$V
M8:^[B:UQVA<*#4:#F*[V%,R,,T8KC<I,H].)82[B?;(-5)EO,]T,5,R$*=8T
MFT;MFIRIG:B/840[?B;Z[S._,M]P$\"L;OBKO/OL;AMA0TBC=OKS:X>\PZWC
M>#QOQH<Q#22E6UOO=<"::VR..11>9R%;[%WGJIB"J)TTY0"^7XFO'W+Q/ZUB
MC;NYIC5OT[R\CA7>=MX.Q+3:#H1C7Q:5//D]RH@.,495Y6PPYYMK:I!:*:)%
MFF<0**Z*7?"=15TQ<@<`*<.T!*'Q-=KOEWZ&#X9UAH-(C0=&>"]->\19=9>T
M>(Z`?,O'7G-S;KO)KCG>,45R"CH:PS;FNR,,]<76&FTA-"S/KZQ#-D(CI[Q-
M-(Q?G@ZMM]?G?%?&R8<+VS0X/B8&,:B?DKP^(=[Y9G.8QKFN$(1.O)E4->/?
M)7.F!H6%GL8Y)3C8=T1%Y.8KOTJC+4N8]$0<^I-9-9A)P)E3"8R?M3W28`8!
M,ION0/-]V_&^]S[P6.<8$Z3\"Y[>]\QL1&@KV:XY>*IAO*LA%T[)[DF(<ARC
M@6L>DXEDINBV!R80(9**LZB+).,4,([)LY$J)P$?H:BHB`C^H.Z_B/*Q>6R4
M\670&GX(ZUZS#\5EWMH?2TN`TC@\Z]9&+A-RT:N452K)+HI*I+%$XE434)UE
M4+U['V,40'M[=?0W7FVVVW*O52B7,B5U@\@?F:ZPJ5:KIH4).`__`#`'_NO9
MM_OF6G3Q7T]7D3%:FR7R:SW?T.%!K5VKTD:$(T(1H0C0A:SCR?&_GZSR_P#?
M_P"'\*SWS_:G?"^"K_UU^OT']C7R?[0OH(X=B`^,[XL)0$.HN*N(HB4#](A_
MN7=#%`_2!C%*;;M[.TNODV,_\CNG[+E[G!O^<7C=E:G`YU9HO^"LJS]@QJ>G
MH7:'X-Y,M-5LMJB3SDQ"SA^2'&VA,VQDTW$>9_2!+:C/W[#O4SN9!NW$%2@&
MN1AKFMN;;;06VX:?1)^!=O$*;RZ#B"&1A^\!7HC5PJ.O(UMEC)=E_%EREEF%
MN4#COF_AK'DAZ_B^N#$Y6@KUQDL>?(ZN7/'R\R^A+&Q@;$R[J.CBF+WW0FLK
MUJI$#71E7EA=:#0(L)I)H,::=(@L3FN82(TM=#)NR))XOY_<Q[-C[,V59E+'
ME?K*6-X&6C$)>S86FI#`]EF<L0]14<V#'E#R5.Y'+4J/49Q;VX3ML;%.?;5D
M4R96Z2JC=*M^Q,R`%D-JKIHC0<AWJU'GD6B8ZJ*84A/^O<;>WY$8&C4^:Z&4
M*%*X*Y:)(.V\74X;'V5[11YK'S7VB=^HSDC&VZWQK"PKMT7#-0ZJ<>@J=$HB
M9421BP,#RPQ)%$31EW:5*R;1`=0`:=V>I,+1N7>9(3"N)E*KDS&&*FV,^-?!
MB:HG'$U,CY20Y$I9GJ\(E:U*XY4ED;>I48YDH=A%_:ZV?NVJC473P`3V(-,X
M#:9R37F5TD'9QS<:E3B7/W(-UFRBO+5D2K3&+\B\Z.6O$]IB].CM(R5JT+A^
M&S/+U&?;7Q"9<NK#;B.L4J-GK@&S),[-]TF3.H@9RK11"K)%70IX=U*<_FGG
MFX8VRSBBD07(/'''*HV_&F6[=*WF_5)K8VQYS'+2/>Q[%FYE+#5VC4SLIC)N
M$165</$2F313,<0$NF4&NE6B+7.ANAF66;Z<`8"$=0W!187Y?<M)O%.>\Z][
M!1?W#N/.(;L.`TJ8W]M3W[)V,D['9)VR6-U+MG;6`K2DFD_:,BD9)@@"@.G9
MT0Z0M>UH<`:'$T&NJK6J@20<RUJ]SBY!XGQ2GG'/"U>L^&:KDF7HED6KUHPY
MDBQ6=G<L=.9ZER<P_P`$VNZT^NN8G(M?4A6Z"3_OY?V_8I'9)'#K/E-ES^;&
M&KRK8T.#1'=%98+E-SA+R:QGA.;^T--Y77W'JNY(CIVWX9I!,@1^1*C7+KDJ
MYP]=LEY@\INWC,EC<P->0JL/((MGT*L#TZXG%-O6;$-!XE8`[+DAPQ2#0Y)\
MM;%B"(E)7,K664Y(<=_$5F*VVI.-8V&L^+I_C-:'\5CF3J4E&V(ZDK9Y2'DA
MCGR@)D(L^206;IHJB)5.@)C+0`$;)$::P8>2NE<EUW<1SLH)$,D"1HKSA=IS
MR-MN,RQ]LK^6\=9%LLQQ7X_L9GDY9*W&S):4RR)G5>HOK]:4*E;#1KVA8J1<
MN%IA`TD7JDVY16<H;'2-9%DQAEPLMBX`#>T\.M)DDMFM=O&*=>*Y&<A+K?&>
M"Z#GFD3T,?/\]C6.Y,QM`A+*%XI;3$*N1)9E$,8.RHU5]::!92EA9%X@LBW.
MHHF86X`0R1\<VRYML"`S9BNK3&$5Z'\1<BVG+.`\7WN]NXEW>9.-D(^Z.(DI
MT63VSUA\_KDM(QK8>Z)%(2#Z$.JJT(`IE$_HB("`CA^.!I5DH\\124XX_P",
MQSU'Y[*>&Q*/SP?<!I`;AYPW`0_.U.=+(@#1%JU;05Q4QIA`Z[$Y$U!2,"B2
MG6!#JE`$C=9@43*!@43$H>D4Q3E$.P0]D,,J6YLV)S*J:ZTR&E1/Q[Q)H5+N
MLED)24R-=K0ZJ]AI-8D\F9"GKJYH%(N4HRE+C5::>8>/#1Q)YY%MEG+H_4^5
M0:LVJKA9)F@5+72L\,HK2KK/&K&E-B./L?#-9(B/&5A-0.,EWDBX7!E$SM36
MIS]E+(;=,LU<5Y8B)0$/H9B@8-A#1M]B"#E^"HJQDC;4='X<^A:V#>,N*./E
M/D*!BJO.H^HRM^NM^?14B]>SC-I8;T\=.[2@U,Y7(J$.JZ>*IILC=XD0#E.7
M^EAJ3[\7D.,;02;A[`"(B!SII*]X?_'B#@[=%&B;C9(:R5:4Q^Q@+;=K=*P.
M-*+,SJ=D?U?%<)[=-6.-TV,R5-TQ<1XI/X\$4$D'!4T")Z8Q!P-H1M&OSC>1
MV?+A`PANJRI=T#A_A*BQ4\P>5V3R(XM$LRL=HG<Q2CO*=HD7\%!?:U7HY:0L
MJSILA$0=?='(P9,$FS-JL=1QT'<N%U5`X@Z,08;V_%`PUB>;!^'*!@?'47C7
M&<(A`U.)DK')-&J94A77?6.PR4_+/GKA)-,SMXYDI%3=0X=?04I=]BAK#>73
M+Q-,W.KI;6R&"6VH)V^D`[`#8/8`.P`_,#5&R?F4]II4!/$P,!>)4^)S%*'W
M<>'/:80*';S+P$!>T=O*([!YQUN9*`8!#(LKJ7.(W4A3Z,'I#^:/\W4MF#2H
MO)M'?5.WXNG!*E)&VU.`N=9GZC;HQO.5FRP;RO3L,\3,9C*QTFU4;/$0(@8B
MZ:BC=4Q2F(8IRB("4Q3``@PXL-L9*5(-MFP:B(*&E.X%89JH*)K.LFVE%O0K
M1BVL,\CY6O5\;8]QI<8YO#6&JTAI9G3ENR(]C8UOT/W9'TNB*!4".2MO1U8,
M1A0**4SAS*SNXUDR3P$P!E=>$?6=AD&,*SHM$Q],-("^6"OIVRL42:9V"IP^
M0VT6K[7VDE9E>\5;E4`4SF=N.L!#;9=HNRUG1G$/(CLYG!NTI_X;!N.:_3,H
MT<($Z]9S';,EW6_1,BX7=H2C[*KD[B]H"NB`J-F[TSP_=E((=(?,B&VX0%]`
M<"*P`-2FZXM<""1").NO+H30U[A7B>KQM?CSR64[#'5;(N,<H5M"XY)L5I4K
M4SA\KI+'D,R%XJH5S!PB+]0KI1?OY2:5$AW[UX9),Y).OY<(N]*$.#=E2%P8
M#1"N.3=P+0><',3N;E%7J'L>5:E8HC(66LCM'=5N'M4'VPYOML;;LA)N$W<>
M_(JPEI-HF1(4R)JMF`J-B'Z55.IB_P`&6!Z,()'#VN=;)YQB=U*3+#A34K%F
M'F#>K\S;J17)VO8]HJ4=!.I-I*1U5J,4*=BEW@JL&L?'66_3*+,T@#?K!9K"
M,A,(F#8$+^19S-,0()]09!PCZ0A&.04Y]Y/):>+.);,-V&483@GR(CBY*P':
M34HV0,OAA9HZH)V_J0HG;&:.HM'U@P;]^&R?D.;0V_D68'T8\=:1N##'@XN%
M:5!XKXTQU?9')554R%%*SS^P3+NCM[A:$\?HSEM<)/IV<2QZ#DL3'.Y"4(=<
MQ.HY$C',)?FS;IT]T_G.K%"B9`D<QM5:E.S2!%(X%$PE477<!N7H$/65!7Z>
M@`#IZ!4V[>WLU$J)CDJ6]L.WD'R!['YN@FB"V2_Y07G]X@]4@KOC_#5+MC%M
M,5:V\M.-,#.PKPAA0E(R1R97T'4>J8FPD0.B)S"(B`=0@&_;KDWBY&<0,D5S
M[R`Z@U1346;@A.R$\Y>52>C*_"N1.LU9-JY"N$63=0H&(T15<P3E=0J&XE`3
M',([>7;7S^]^$^%7Z\OODTM$R:ZT1#*?WPN,[!3-.THYU.1)3X/N_F](MU8&
M*;M*8U8K@&,`]H"("T1$!'_4%_,#6<^#N$"BT-7UTNPCHXN5'P?.0?W9Q_[V
M:W]9T?@]A/2&KZZ781T<7*CX/G(/[LX_][-;^LZ/P>PGI#5]='81T<7*CX/G
M(/[LX_\`>S6_K.C\'L)Z0U?71V$='%RH^#YR#^[./_>S6_K.C\'L)Z0U?71V
M$='%RH^#YR#^[./_`'LUOZSH_![">D-7UT=A'1Q<JN#P_L@(@HK]NT>0Q$5>
MC_@_7T.HYR"F4@J)Q[PVQNOR=&P^R(:1\','<0"YL(YOKK3=L"%HVH0LZ.5,
M'8^*6467*S%N'DLA,0JUIP1FJZ+L$Z?6A2&<HMKQ)!L7(/@AF:A]V]I6`"B;
M8=Q';L[/0,\(>[[;H'EPLD@5&LB(^/0N5-[NQO<`-VM/Z;P^\BF!/>[QQDP3
M#I+]K5<W*;XOT'RB&N`[P=P7:.+'"O-]==:=@31+8&PT[HJSX/G(/[LX_P#>
MS6_K.C\'L)Z0U?767L(Z.+E4(^?'#W,&/<+QBE;?/;<^LU[KM9=0%?K;$CF2
MCGZ<@H=)XXC4.[91S==`JAUE1*4H[`)@WUY'O-X6R[L-C<@',<R-67UBN;?,
M!C-$<V[*O+G%/A^VVZVAQ*W&/DK/8W;TZDC'`AW;1FNL8JZ;582=2:RK1!0I
M!,4=NDH>;7G>ZWAO>+K?]H]@A'-'/I6Z[8#1"B&[2O?'B_X="E-/#3DW_P`'
M&S)TU?%BXX#-%CN&9!(S_JM+Z(4#%..X`&P:_1,ON9A4W#F"\.#9YK`!^!P7
M?N^$-9)`.[C3[L>`="H65:1<<:03&-;1F28_(5F>S1%9>3>2[N>4F)$[1^?H
M6[SUEOV";Y@#`'DU3A_<'!KH\W@$%XB:H$P_>5[<,:'!T1NX4^7*W!<OG&H5
MR`AF\.LZBK0I,&&?CADFP[-Q1*/JAS`0A1`?)OI]X.YF%XG=-F\@/:-)K%/Q
ME9,PT.$'$&GRPTK7XG8)EL%U^UQ<ZV@".IVQLGH%K$.+!,>Z9`!Q.F!N@O2(
M[!MN!?)K!W;[B87ALMYEEI<0<L/^LB7AS6`@$`F!R9%%:V<(+<^RI.7GU/'_
M`+2K7@UI5D%JJF=XDU0DV[Y0ZOI=:BJ:!!$Q@#M,`CKBX)X983+O#YTQPC;)
MCPD]-5=FL)C$1-.ZE2;R?$5SEMQIJ\WBR4A+35LAM*%D:FRTA&JO(:6K*KMG
M+14V=L]*DJ556)6*'0;8PC^9KT^)=R<-O%SF7:8>:6D4TTPR<[@BK9F'VY18
M30=ZO^Q;7$C!<S@>IVR#L)8+UR>L"=B;E@(L\,S(U;QC"'*11!'K*"G2PW\X
MEU'N[W)PO"KF);3$$P,(B%'[>A8I.%NEM+6D5QW4J,63N#EFNV5K)=6[2GBQ
MG+62>*O(P8.UDP8JM%B&,\$071,?NNPP`([ZYT_N!ALO')>)2"#-;$B(SC2X
M^10EX,!-M$BO=E4R^1N(9'+.)'-,BR1;I^$A!R@A.QWMC%D&(4055*V8J"`'
M*)4C=V`]I3;#J_%>[3[RRR><-V2,%O?AP<T!Q!(*0?$3CS*\?6U_C9<D)W-F
MFX19B2!9GCT_5XIE(M%#*(I@).G94!`-^T-9>Z_=)ETO<\W@0E.ED`54U9"I
MR[@UK#+!'.,8\$,^E1^GN$ULE\YV3(Y6]25A9O));RV%U7B'DR(OIL7ZA57X
MF[U10F_:40\O;[&G>_#G"9N*&\$B),?+\M5.PUCWEQ(M$[LJE9RJPI(YPH$7
M6X-*&,[B+2VF2)3D89RP5]52.S`#)F$1#_;(_FE_,UU,:[D8;B+;LQ\&MDQ-
M9/I`?*T*N]X<)@:*"(QR+L\>L6/,28>@Z#--XYO*1SVV&`D2U%M%@K-6.2E4
MO5D0.!?5A%P7O"CMU;[``[[:VL[G85+NXN["'`-KCGKHM;WF5;+@6M`C0`1K
MI7F)PUXVWO(;3$V?Y]''ADU[Y?IMZ:(JI(]0#0F0;E64`0`!Z^_*A%!WAC``
MB8=PUSY?AU@]VOFTM"+:<NKTT[OA+`V(A7NRKT(Y;8$FLYQ%-90"4.*]>G'#
M[IG8WUI(>^2!(3$ZC;$2V#\T=M0[R=QL,Q7#W2WP!`SDU_O!:IF&B922#".Z
MM>07-#BOD/"7'R[7A!A31D$EX^LIIU>N]=C79V=V5F[2KG=%.8KU0J>Y]@$1
M#R:^*XIX:['#.JW<1EM)R9S^T5X_$^[AFWMTUOHF&ZM>,-6X=9"RW<6T_?F4
MHV*^5191E>1(L@L1JH4HMBO6I!ZVSHZ(%,L`@&R@FW#?7G>[?AO/N]YM.9ES
M>=<_W9=N_M7N5Q1\,>1@EH^>6B4ZBU0.@J*P%%5^;NQ'I4.5<#=:NQ=P$`U]
M\PONL;E+8^%(`R>=>PNTC8W=DKHM`7O71JN6HUYI7_;!P_!H!-G:^_?+])"A
MWIQ'?8RO3N(:]S=[PR2P,>*A!:FQJ"6_;I&628JR*H0!ZB^7RZ3);@X$I,)M
M#?4)^`8]7'TP@.^V8LW=H=NVV3;3OY/S==*>PB80<RU;05Q4VQ`=A^*&N6^2
MZW'(H/?%I$5C`!W]GY.F)3HU+,"8J[8=/9N4XHV'1LW(BC8=&S<B*-AT;-R(
MJTX@!=A$-Q\@"/:(`/;L'E';3N\LMO5H]#X5&>?^ZG?7P3])_,/^6M\VOO\`
ML=!_VFE?-J/\Y>U&(<[XUPCXQ?BD2V19&S-&DWC'B$VCBU^AY`OCE-9K#VXY
ME%V]'K$VNS23,3<"+D`3B'2`]NP_,<7DS'X!=WM:2T-,3DS+U&"D'&IT(T^;
M=45Z&S?-OB!8)`\M,'NTB[3BU(`5I+C#FQXLJQ<R:,L$2HLZQ.X47A).1B&K
MI5$1,@DX:(F.7J`HZ\U<GMZE"(B",N_2-/P%=[$`1?`QH-JP:*\U?EJK"$^<
MW$-P[>/G3B^JR"TDUEU7YN-.</7TY>'8*1C&35DU<3&?/9B/CU`;HO2'%4K<
M>Z1$J8"`6VQH64LFFIKH[WPYUI1W,+@Q'O++,1<%-1<C;VZB5VE8_B3E]E*V
MY%1,>]"R/D,3H2-F16,.RR3P'`J@(^C[.IM=&)C5G/DTH:R::"TT9F^4Y>%:
M`<N.#!8>LQ3&MRS*&JRQEZ7'->).8VC"FOW*+EN]>TZ.)B5-*HN'D8NND99$
MC42=8@8P@?5I>T@<X&.6-,/E<*(/:3$$9Z/(K77,3A$96L/2P5@0EZ%'H1]"
MD%.*68T'=.8I,FJ36-J#\F)G\K5(%\W222%LR4;&(B02"38=PHFS&-/.<(PS
M[J5=(,6FSG793YM\-TR1Z[;[<&GJ%AE;,&_&#-Z"I;58$9%&P3S557%H+M9V
M9]M'0.7*`E=/&[U4A^H3CO#:RA3:;#?"M(.2*0=ZY(<%\BWZJ9`OILDV5_1Z
M[.56'@;#QDSE.TX`EI%B^&1>UJ3Q4]*M-0ZC`@,G1DB*)["<#;&U?*FL;*B'
M"R71H=3J\JJF,>Y\0TF`AZ,1KSC(G//SOXDIJ/E4G&1N^ERMFLRLGQESHHK,
MQS!!5JU0ES'QJD#TA&CGNRE5,J!4PZ0(4`Z0FV8R)YS*/E0KS*K93<C70WDF
MXWEMP4@*\[IE=K\[`U4'32:>5Z"XCY<BJ^K(MGR#EH_5K\=B-)J[D4)5LB[(
MZ!H<Y7*20@J!@)JIT22\")CG6IK'@`0(HS+K2',WA;)3\':YB+L<W:ZT18L#
M;GG%;,DC/UX-@=JA`3+_`!<]G&))`[D0/ZLZ2V,`[;"`Z5AW!RJ08_*#J5&G
M-_AM$^TZ;,MW9)UX9AK'$9\8,U-2L#SS@'4DBR!CB4YXUE)N`%1QZH84G"@]
M;@1.`#JNV0=XJ9D@KB1?+;@[78A6!@:_,P\,[)),7<-&\3LRL8QQ$3#X):>9
M/8QCA[VJ=-I"4?.WQF@D%LJ[5$X@)Q$=2$PQ$84:4;("D5[R[D)S3X8UUK%1
M-:8VJ%BJZ#H\!%0G$_,<2PKY7R2A)%>$:(XL91L0FNFH8%"-2`NX`=C@??I&
M;BVJ-,*::\V^?(H$.(J,-[=!=]GS^XH0;;VOBWN08ILW5%9)I%\;\]IM6@K"
M958S1)MB-)!0[TPB*@=FQC=HZJEMMS`VLE1<'-:7`*,>"N<7'2N9XYE3CZPY
M"1C[-E+%;J*2:8)SK(ORII84KB9VLJQ0QFJYB0[LA52E5`HB!@\_;T+TS^&P
MD@NLP.@B%.^LPFNB19="-%&^I;%\17BV;L4L64.G_P!'3D&';['_`(K@U@LE
MU#*3H5C9G3H&E7?"(\5!_P#K#E$?_P`.O(,?_NPT]E-Z+M2EM9><:T#XB7%8
M/)8,H;CY^.O(/^?C#SZB;N]WI-.I3;>`P<RG>5/A%.*WZ*?R@;S?X.G(,=OC
M8PTA="?BG4F;X_(TH^$3XKC\S/90#_\`#IR#_.\N,-!NL*V\277B/2$$?")\
M60\M@R>'_P"'7D%^##2ZL,W$EU\*T?$5XNA\S8<H;;=G^#IR"'_[KAU(,#!9
M-"@Z;,FFVUKB-"I\(MQ>_=#E#WNG(+\%FCFYPHQF]!VHJ&O/7G!@"^<;IFO5
MV<O:DHKE[BK(E]OL#YOA8M*/A.5.&[!(*.)F3QRVC43*1<8L1HW4,#A>0,@D
M0.]43`;Y;(N`HA#@J\OP*X$0B8ARF@IXB/%7O%-[!E$1!0X#MQSY"AV@<0'L
M-B\I@[0]D`'5%AR9<"8Z5;\(KQ;]BQY/V]C_``=.07D^];J$40.8JH>(IQ=$
M0`+%D\1$=@`..G(+<=^S8/\`DM\HZ*#1G3%IIM0-&A6!XBO%C<VUAR<(IJF1
M,`<=>00]*Y"]9D1_Y+QV4*4-Q#R[:6P;F"?69G1=J5WPB_%SJ,49[*.Y2%.<
MH<<^0?44A]P(<0#%H"!3CY!]G1L&"DP@EUN9T':E3X1?BP/8$]E(/BCQTY"@
M'9V^SB_;2V4K.U'6YI^([4J#XBW%E,.K[8<GAN(%#?CKR"[1-Y`_YKQ[1T"3
M+-5E/K4SHNU*T/$:XKG*(C8LG=!2E.)OQ=>072!3&Z2F$?N7``%,8=@^+I[!
MN8(ZU,/Q7:E>'B)<61*4P6#*`D-U=)@XZ\@A*;I'I/TC]S#8>D>P?BZ-@S0C
MK,SHN5IO$5XKDZ.NPY.+WB@))]7';D$'6J8IC%3)OC#TCB4@B`!V[`.C8,T(
MZU,Z+E<'B)<53EW&PY/$.HQ0$O'7D$(;EVZ@[,8=@@.BRV70$B]\RDM*K\(?
MQ8'M+8LH`'Q>.O(,.W[V&G$(@[,5E+XA_%G8/^$F3_>[<@OP7ZJM$S",BTL]
M`*)/+;G%QTM<3@E*(L.0%%(?EIQJF5_;/!><X=NHR;9,AES,6ZCS&B8/GJ[E
MF7NT2[J&,8H![&NK<[MM0;8@+)AOC^U<^]>0J52'B*\512)TV/*JA0Z@*<W'
M+D&03%*<Q2B!0Q>`=``'HB`;"78=<Z9=9UL\YPT;@I2[T&L#0"0-'G67X13B
MO^Z'*?O=.0GX,-0ZK.Z;MW`I=;^2=2I\(KQ5_=#E+WNG(3\&&CJL[INW<".M
M_).I'PBO%7]T64O>Z\A/P8:.JSNF[=P(ZW\DZD?"*\5?W192][KR$_!AHZK.
MZ;MW`CK?R3J1\(KQ5'_ZPY2][IR$_!AH%TGF@/=NX$=;^257X1/BO^Z#*?O=
M.0GX,-2ZE>>D_=P(ZY\DJT_B)\5=BB:PY5`0.`I]/''D.<>\V-T[E)BXPB7S
M[AMY]5S+G/$"7.KW9%;*O8)-&11*M?.CCFXYP8-NI+!D+VACN./(*N',;!N;
MTI$\E(7G"CP@H5LN,_;91F5&..!W0$[DANDIAW,&NP+G.ZC;)C%PHRU5D07-
M??V];AD`ANI4N1\1'BP`;C8LHCOYN.O((=OC8OUR!=)[ICH.=NX%TWWH!@(!
MI5OPB?%?]T&4_>Z<A/P8:GU*\])^[@5/7/DE<B7\0#BA+-7#!W-Y46:O&YVK
MA/\`%UY"@0Z:GS13;8O$!`?B]FM$JXN<PB8PO.D16&]3)LQX>QC[(%8!@D14
M>7O"6C&.:"#(+4ZBQUS*AQPY`&6%50"E,<!+BT1`-BAJ1P]DD1;++3O*Z[WQ
M]4"2G,+XB?%H=A^V+*.P!MM^+GR"+MM[&WW+@'L\^N>^[3#>#,<\AN0+<;S,
MA`L='>*L/XB7%P1':Q91][KR"\P>S]RT?-HG78O9!LPAV^%'K$V,;#H;Q5GP
MB'%WR#8\I>]UY!_@MUD.'S'B$R:3PCD1UF;DENU%'PB'%WV+%E+WNO(/\%NA
MN'.E_P`N:0-\<B.LSLLMVHK6E/$-XMJ1$LD6Q9/ZU8J23*)^/'($A>H[)<H=
M1QQ?TD+N/:(]@!Y>S6BZW!MV$6N)<:ZN1!OCC6TJ)/`KF_QUI7";B/3[)+9%
M;3=*XZ8A@94L9A'-]B9>OP]*A2*&93\/C1:#GHN41.55!=`PIJD[2";MVNOF
M&.?/#!.!:,H<"(9JDA?7N(!:[5EUYE,,/$2XM_NBRG[W7D%_/Q;JEMSV=#)C
MH<"T&:[HE5#Q$N+(&W&PY2$/_1TY!?SL6AJ4NZ-EOVQ>2X;R3I[PV(:8JIO$
M2XK"`],_E(#=FP_BZ<@P'RA[/W+QUK;"N*IZS.Z!U%8_A$>+G[HLI>]UY!_@
MMU&8RVV#763H2ZS/Z#M11\(AQ<_=%E+V?_-TY!>SY?\`Q6^SK(;BPFT9CK7`
MCK,[H.U%6F\1+BZ'DL64NWL';CIR#\GWK?)JT74.%E\QQ'`JYEYO(A98[45J
M*^(=QA$2'"P94.)Q!JA_@ZY_.`NU3%5:D,B?%@B'6=OV*^1,?*(;AJ5UPZ8'
MQVAL1&492-"I=?)X])CP8'(HP\)^=7&RF<9L>UR4G\BD>,Y3*#DX1^"\[SK,
MQ)/+]^D"'2DV.,56Z^XKB!B@.Z9BB4>T-;<5P\2;V6-FQ`%;2"#0,JLD7R:^
M7&R3P%2J^$1XN;?\8LI?G<=.07X+=<UUS$P69DQW$KA>9V1CM17,EN>G$J<:
M@A*R61Y!J0Q5$T'O&[/3E-)R3?NY)`BN*S&2>LM_H8AL(^QJ4NY7=K-D:6@9
M4&=,-):Z.\>5-?5.2O`^I2[Z;:CDE[*O'"KI9X^XWY_57[U8XJG<`J3%NPJ*
M";JV\H;[:&W*[2S%@%I1VCZ[+M2>)/Q#^*J9"IISV403('20/Q<N0A>DH>0`
M+]RWT0#5@>#S($#B4K)--DZEG^$0XJ"`;S^4M]@$?\'3D'Y?O8:3I$MU<*TP
M'YBKOA%>+GL6+*&WL?X.?(+R>Q_XK=6P&<)679BKT_$4XO&.0I;#E`3&,4I0
M#CIR!`1$P@```CBT``=Q\H]FI-;:(:(1)00YM,#0HC<-.>/'.LX4!A-V'(/K
M2F2LKR)AB\#9SEFA6[W)%@,R*+F(QDJU&0W$OK">_4F._7Y]="_!FU)YL``*
M,\*8Z!D6-LQ]D4&.\I:!XBW%[?ML.4/>Z<@OP6:YT65!PCOJUCW.="!5WPBW
M%S]T64/>Y\@OP6:*,X5]EV8H^$6XN?NBRA[W/D%^"S11G"++LQ1\(MQ<_=%E
M#WN?(+\%FBC.$679BCX1;BY^Z+*'O<^07X+-%&<(LNS%'PBW%S]T64/>Y\@O
MP6:*,X19=F*UG/B'<7%!;G^V;*:9SJ>JI?X/'(D$CKKB4$DU$T<8)%#K,(!U
MF,4`U9=FQO(@"XD0HW](/D5=Z(;=#:,*ZU\;_P!W&E?9&>_RLWV[?\3[5_8/
M^U/^W_\`YO\`[)?['K]#6KOTF?[6%8W17S6VW./YJ^DWAVHLIXSOBLH^D=!+
M%G$@2)*F3%,BHQESZE$R=`G`#![._EU\>Q?_`-OW&FGG^1>PP80QF\0'FJ7M
MZD0_638I4_H9O23(4#>4/.GMVZ\3<_Y!_:^!>DG4WT$UV#Y5M=VI]-6^,G]:
MUH5JL.4P"`F,H?R]AB)FV[/+V):>1,5%<U\4ZIFZ)`,7K535$P$(02E17;F,
M;J$$_0$!Z3`&XB!M`@LMX@H*T#GACJSW>+IT]0[_`(_@+)-9<KM.R9>(^):8
MWM4KA":LT'D($+$636/'A&)4]X\ZG*:*16C=10Q@`HCK3+NC;Q)=-$"]N2LP
MB!%9+O,L-A"`)K*?!'E'QV6JK2]-LW8J<5*1FC56,L"=PA31DC8TF*\J-;1>
M;];A^,0F+Q%JF!G"Z!BJ)@<BA!,QA[[9E&6=H,D!'5IB-"NV[13$07*Q+R]X
M\Y=<6>,I&281=_5,K/\`#<@R>E)"KNK^T%3NXB+0<D,>1&2!LMZH<-CNR-U#
ME+TD$VJ9MV=)=9++-$89EIESFN;04NYSD+@NMJPR%@RKCZ+7L-OF*%#)R,_'
MHKO[?7IQ6LS\&1,VQR.8*QI"P>&.!$FKSI15,50Q2FALG9E+;-SIO;SRBQ?!
M-KV>J6&K9!LN.IFIP-PI4/<JW&O(3[:;G!TMN_DGTV\3BF2+"4F@$Q1(/4X0
M%N!^_$":M:"69M/P9T]JT494[%<S!BNV66X4NM7RG3MKQXHFVNT%'RC5U(UM
M<RIFQTY1),!!([=X045^D3`@O]#4Z#B!=)Q>,\"F)S344Z12G,4IBJJ@42@)
M=BD``*(`(``"D`E#;V![0U2FJ=T/TE'ZF'ZC0A4[H?I*'U,/U&A"Q+)G*D<2
M-D#F`.P@D``-VAN&X)]G9J<N-L0,#G4)GH%0GXYB8_)7GBCW6Y6F6L2%2[[<
MY025P'2C]2&Y>PHF-Y`[-:9SG&R366!9H"DY`5-4>E/TC]PB`B!0./0EZ1AV
M*4#'3VW,([`'E'6-TS9TA29+;-YIJ5@+(J`7I.17J,8I0,&X=28B4X#_`%.7
MI,0Q1`0';4.M$51BK>HRZR*.!!E")I]Z'=)DVWZR@&QB[;]@@B;J`0[0V\NH
MOOI`IB5%]W9*'-H!6`SQ`"G,=5`2IF.4W>AMTB3HZQ`#(D$2EZPZC!N4-P[=
M5]?(JB%79`IC0KP<-P`/2:[FZQ`"B0=P3-T',`%((F`APV,/D*(;#MJQM[F/
MI!*M;=I<T1<(D+(15$YBD(HD!CB<"%()?3$G5U]/T$0-T]`[B'9V:EUB8:T^
MI2L@HX%4[EJ0"B=5H;J*82"82*&.!!$I@3`B>ZG08!`0*`B`]FI!Q<(FM6-8
M)8L-J"S$$B@=1$T#`!C%$02\AB")3E[4_*4P;#IJ42H&>)08R7$RQJ='<%3S
M;P]%([0QTU53J<P,#$$A^DG:F8X@4P=NX:O83$`Y<^18WB)=G\ZGF=,1.?9)
M$0$YNT2`(CVCVCZ`[B/LZB'.A64$"V=]9NY4^>`/B`)-@^('T#52U@F"L,F(
M%,/<(=@"/:GV=@;]NR>_QNW3%:1,`2H4XQYMX@R:WY&OT%+/3F'&"R6"`R._
MN;%G%))PU9A'<_*WJK%$53RE3!-HLV!YL)>^1.F.QR&`-3I#V.#75G=#X5C%
MY:6DC=I6UC[G'@:X8=QWFZ[VN+PI!Y)D;/%5R"S+(QE-LB4K4[!)5F?C5XY\
MN4YA8.8PZJIPZDT$S`90Y2B`Z3Y#F@MA2*^5`O#3E`3OO>1F!8^\M<9/<NXR
M;Y!>KQ39M3CV>(-/JN)^$^V.OH^H$5.J12Q06[J.`VWKZ13"W[P2F`*=E$1`
MH3,^!@2(YEDC.0&#K';+%CR!RQC>5N]78/9&PUN,M4.K+0[",(@M*NWI4728
M((12"Y3.C=Y_4Q3`*O3J39<#$CFI;<5`M+M&Z'&FF9<Q\.6:_P"-Z9CNV0>1
MFN0YJ\P2UJIL^Q?0=-=T2KM;<=G9%Q74!!60A7:;I,PD`%6JA5BB9(Q3&NV+
MPVT:(9]W`EU@1@""EW7.3O'BQUZQ72'S-BU_6*X[A&5GFT;7#'BX"2G4S^U)
M'SPRQ4T&=@,F(QSD=F\ATB+<ZG;J+I4P$,@;5.I/K`KB(+5G^4O'.)I,%D60
MS;C*.HEE=/F$1:E+4P2A7ZL2Z(2>3360627(YA"H*$<F,*8,C^BN)!.4!&RG
MVBT@VADW<"#/%<6P7;QOFF&R!E+,>,(^)<"ZQ/'XKFE;0+J)?U^UQ65Z_,S\
M$ZKRD<HX7[EFSA3%6,L)@5$Y3IF,0=]4/`$"*BM,MQ<*:T^O0'TE#ZD'UO4%
M8J=`;C]!0]C_`*G_`/L]1LP=:3,8*$O-U8[>`XZB!3IB/-+BJD<&Y#=)FJV6
MJVF=1<I4_P"EE75*7?SCK9*O6S:YI,;38+FW@B,<D5-%-/NTDB=VW#H22+MT
M!["90]E/6">+Y,G.>QT&$Q%:W2)+#):2*;(R*_;_`&-O_0A];U58OW3\JMV#
M,W$%7<?-\8B>WYWT/R:6SOO3\O*EL69AQ(W'S#]33^MZ-G?>GQGE1L69AQ(W
M'S#]33^MZ-G?>GQGE1L69AQ(W\X`(>8Q"=/Y_P!#\FI,EWRT(O\`*C8L-$!Q
M*G47Z6W_`*`OZC6FS>^GY4^KMS(WW["E2(8=P*<B91$IMAZ1[4_(`^75%XE7
MQ[`&OJ.E,2&B-`J4)K?TCXA&`0#I^B<5N1IE`#J*BH=/(N!RB<4A2*`G((CZ
M0[#L8=M=(,O;;K;>>:'`9:X1&7,N4^[2>MU"HT0W]"FSN`"("FW^)Z(?6]<V
M6R^B8YSGT$Z5U=@TM``J1U%^EM_Z`OZC5]F]]/RI=7;F21MU_I-!2B'%WLU:
MJ32>E4("(>6%\UBF+^:=D44:QB3UX"30'C@J1N[(8Y1.(;!N/9JJ=-O4EL;4
M=:D6!C+-02F:N$EB]XBLV!(Q>LITQ*4AB#N!5`,*0E%,_2/2;?I-MV".L\J^
M7F\T`B&>GE6"0)6TBTTK?*4_=@<R@`7M#<QB%`.T?.AV:VV7-H<8N6Y\0Y7`
M3J`!`B*@#Y#B4IA-_P"R!,`';0H1*.Z'Z0A]3#]1H3B4=T/TA#ZF'ZC0E$KB
MSA-H6:'ND@_W(E.T"``_[1<?I`\NIT+((6CPJ'GAO&,/A^\)G!RJ*'/Q:P6N
M)QW577,KC>!*(O#'3`QA`HZ5$$-H+5-WN1^D(?4P_4:BM:.Z'Z0A]3#ZWH0C
MNA^D(?4P_4:$XE'=#](0^IA^HT(B4=T/TA#ZF'ZC0B)1W0_24?J8?6](UA$2
MM5T0Q4U.E)$#=RMTCT;`4>Z$=P$J>X*!['Y^KF%U0C"*S3CE.8J'7A[%45XD
MXQ/WJR@^V64@,LX'Z*H8N8\A`/4)TC"($'L#XFK;Y_/(W5!0N7\JC.IH"D;]
M$1-3XIRE,(?$W!(O9K*M<2J=T/TA#ZF'UO0A'=#](0^IA^HT(B4=T/TA#ZF'
MZC0B)1W0_2$/J8?6]"$=T/TA#ZF'UO0A5*EVANBB`;]H@F`"`>R(#T!L(:`8
M&(01$04*.!BG?8`,?;O-LM9J;@+@HB82(9*LI2#_`$OM'T/-MK1/))(-4%B`
M`%K2IGD((FV[I'V?^IA^HUSFPVG"K9=FTL_=#](0^IA];UI6A'=#](0^IA];
MT(1W0_2$/J8?6]"$=T/TA#ZF'UO0A'=#](0^IA];T(6LX34#<`("28D*/6ET
M!N<%`]#NC)[#N7RF]@-6R?37/Q'^0O@Z[U'Z>?\`RUVWD>_T?D\OZ3YC7V/[
M.OE?^LOH+X:_Y:'Q7/[EG$;_`'LNFO"8O_[?N/[_`)%[W!O^<7G>^$+W$!0B
M1DS',!0$H$#RB)CG.!2E*`;B)C#[`:\7<Z9!_:^!>CF`F^"'0/E6`LQ&G4>(
ME=I"M'G`CY(!$56@F(15,SA/;K13614!0AC`!3ICU%$2]NK7.:T1=4K0TFI7
MK2+%,G>*.D2$!4J/4<X%*94XF(0A!'8#F,<H@&V^X@(>QJ(G2W5'B*D&F&^N
M<XE&O=-G:*R:K83`;ODP4.4X&,4"]P8`!`3'(!O2,8`*7<V^P".F)C%0^2]Q
M#FCC"\D%_#6C)7".::[)*Q$?G?),EG5:IY0C+1:WS*H1.2LJS60XMM`1CI5H
MO4E;%!*L8N=<0W=+N"]\9-3M#?;=K\V0($\P.C57HBN4;E>Z0UD7$=(4;H0X
M4F,-<!;;2)7"MQN%4K$6]IG)YWFK)S&U\B,F\BBS4-"\9K]A>KS,99<ETJ!7
M9R4=/SS$[:&4;`SCHQH4Q7SARU0ZK1?Y086VC&D1@8TF-=>]F3==;]:#@QM3
M3"+<U(UUYTO9GC!R"8*7=>@P&%7Z,#S0K/+3#X2E^DZ\I?VJ]0+7I_&-[]0Q
MA/IX^<0_KKQ>-F69[*1VF)$U&:/I&TW7N[3YAF3'&);"H\4.12;*O,I@86\\
M.SC<0FZ_$EY/E+CN981^'X3-#/,_(^[SN8Z_D>QLH:C5C/.=G647L.WP[8L8
M6N'SK47,0[1[ZN3$A`^H2[,%F\F98J+M.KK%W@8N)%$*#3N*=F=00!Q:H*Z1
MX89]?+\BH>(3P[C7&E^NN,;75*BUR!8,CH/YVJ\I*3F2UVWUV=QG"O\`$;"9
MH]9>)+T]B^GHQ>?<*R`KI=X80J-XE&$35HT0J5HDWF$6MKTBBGR0R4T\"DAQ
MIX\Y2Q%G7-%D=0%+IN%;O)66:@J5#9)F\HOIR[W*^2-NG,C$=VJ@U>;P_#SR
M"BZKNGH/+!%C)/N\1<IF35.NC>)-F!-.\CJ][M1#1"NL;J%Z1E=H!L45!`0+
MVF.0Y2@8!*42F.8H%!3<X>COON.LVU97'B*WA:RTS&-S@DJ\2*H*IT!('48R
M:J;<KI0JI2@(I=VV.!S";8`*.XZ8F-<0T5E.JE4;3<2[67;MI!JJX;*().$"
M*E%9`[I`KIJ"J6_6GZTU,"B6X!WB8]1=P[=6EI%:AM&9UO'.42'`![>DWL#Y
MA^)J+'M+P`:8J+IC"T@&E0BXX_XS//;^ZIAK^\!2-;)WQ/V/A6?XAWQ\*EA=
MG4LRJ=@=P,6UFIMM$23B(BW[PL<P?2C=BX6CFSZ2,4XQK-9ZF0JC@"F%$HB?
M;LW#/+:U[X/]&"K=,=*;:;6O':A\P<Y1N(++EFX6!C9IG#UNQ[-<J,"GP5-8
MSRSBC$]FC9-C<E8QC(6*5"VPU8179V:*FF*KT):#CG@).'JRB*9-IN<L.@!0
M8@'37G58OTV$3DW9D+<UN15)RKQJDLGQ==3PQDRB3N6LNP'VO!%6O%E*R%F2
MEXIP9)"]%\N5,*.C:63BT(`51R9Q(JD2)TH@.H3+FSG!HI!(WX"/PJ3;T7@;
M4B!Y8;M"6'PBU"JG%L<B97OF.G7(9?#^7\JUC!L79"UVWY!K6.W=U8MW-9B"
M/EY,T:+BG'$[TB*@)'07*4.OM+4;FT3!+AD&H\*D)K+%HFB,*CR07(N_)'E;
MAS(E<X]W"Q8DNF3,W1F)3XGR?$46>@Z-CRQ9-MTG2[S&VBC(7,JENK]75C%5
MZ^0L@E(F`Q1?N'9@$-:)%VD-9M)A(:TF(`K@(UQHC1NI1UIS7"7+IM?"89E@
MNW)7EW&GM=`K1'DU8,!YQG,;Y=RCC'##>^KOJ3*8&KN::#928Z>3B2$5*;7"
M-CYE1FL*+M\W6.U;-R*D0)KZO<A68@@$5BLF.6F`W4JOKTXT`;M2=Y?+TU?L
M:93E("[6ZPI9!PU177&JX4.KV&M2-DR(?$ELLMFD*[%,(X)JM/3W!DC[8Q;P
MR:L8Y.#58"+#T:Y$YH9,+0("-6;,-4%TI;[;`XUY=_+QKT.QK#N86A5./=O;
M!(O20<<O(.[5+OYNP'D';5)T_))2,HNX>K+I.U3EZ3'$$P`"!L!0`*E-0_\`
M$Q`0XC3P#Y1SCPX__+*P'JQK@"(YO@6<L<2XPKY0I[^R/^J-_KATHB""QUJ,
M*(K/J"T*T^_2;;??I';IVZO)^AW[.KS;]FB(%)J471+2!7!>*Y/#IR_]N]=G
MC6FCP]6NF7,H*\F(N/EK"H]NV`7V4&^<L652M&7C@:,Y9AD%@HTG6ZX`T>P4
MP_:@H8IR`'6%^N;B;)B;(+:#0Z!'"N$;M?6MI;EIYPJH7%2X,9XJK':#KV!<
MES-JH?*3%=FB<FS\[&0>/(/D/GRV93A,E4XX4>WHV.=2KDJ5I,UD&D0D[=$3
M[N8*@W*FM*\3[N]I-HAH=6!6(;]7*HRF7@.LV09A%1(W1R\"4/P>]W8PV58I
MA(8^L<I8<O\`AZ6JFW>9*Z3LA:GQ&:X)C;X+AR2,>NJS8YUOCJ9/`LFCMRV1
M%Z0JZR)5%AUB-YNL?2,(&B!A$U;ZN%WO=FS8YT6TDM)@!`P-8C1`;CQDN"&7
M;&@AC*:<87IE,H2W*A_5<T560DIG*F5%N1C>\MF$9D.B.*_5RUUA7T[T0\\)
M;)*J3PL1*D2/!9,R5K+[<V':`DU1$##3#=2H"[7PBP6"`C3$1WBNM;.''(++
M5+IE5MD)@K!H4^C96Q*DMAZRSL^X!G9L.Q&*8&_E>.*'0'CUXK(,$5W,8/=K
M13!)-HB_>F+UJ6,OUR8TDN<9I--!JC5FJS*4RZWPO`:T6`(4$#)7GWUJ2'"7
M->3BNY_)5)XV8OD65;X\XQ;8^QK+S4UCBST[#606%YE;38E)*EUY9@_<*Q::
M-8A3-9((2.`Z*LBY$YA+;)O5W>"UI+@(Q,,]0&;6J9LF]2[)<*2,XK6GG/@9
MGZZQ>0JO0)BEMJ-?,UYHR"M1*QDNTX*E6$3D^MP[.)FE<FTRBV.Q"@PL320>
MSM79H-XZQA*I]^[3]63$S,ZZAH:XNH`%1I@03ECO1JXE(2KXXES&"DQK;IT0
M\@4M>#G&7(_'WVZ7O;JIKDDN/_#C%C1"LOWSHJ4_Q_Q))42ZN2H.XJ.(A7Y&
M9=%6B3]1EUVIA,LD@8`3URY[VO=%M43QF(XEV+LQ[&0>(&`HHR``U:5Z!=!O
M-\D/EZI6A6B(%$0'L'8/YGQ-3`M"`K4X$M!"\V_$UR+%XJPWCG)<VD_<0^->
M3/'"\R36-**CEVPA,F1CUXD"90,<Q44FO>;``B/3L&XZ\SC-_;A4L3[VZQ+B
M*81\@)R+A7V]W>32]T"",AY-"34;XEE-DVC9[#8XLDA&O6Y'S!X2=J2I'+-R
M'?)+`H>4`W:4^PE'8Q!#I$`$-M?"K_X_8=<;[-N;7$MEO+0;#J8?X17!=WMN
M$IQEVCS?VOHK9#Q):T(;_<PLG;YYNG@/QAEMPUD_41<,_P`P_P"DH^^.'YS\
M[Z*/A):U_!A9/[=T_P#;;4/U&8=TOF._TD>^%PSGYWT4?"2UK^#"R?V[I_[;
M:/U&8=TOF._TD>^%PSGYWT4?"2UK^#"R?V[I_P"VVC]1F'=+YCO])'OA<,Y^
M=]%'PDM:_@PLG]NZ?^VVI,_,9AEKG.,/V'?Z2/?"X9S\[Z*K\)-6OX+[)_;R
MG_MMJ_\`4;@_3/J/_P!)'O?<.D?G?11\)#7U@,FABZQ&5,4W2F:?J*0K>B.Z
M*2H2HE15.'S)C;$#;M$-47C\QN%618<8QZ#_`/24F]\</;'G&,,SOHI@9WF)
M$R/);'.<D*C)^TE&Q'E#&3J%/.5I:9DW=^L>.+!&2R2OMB#=!C'%I;E%4AS`
MJ<ZI1`.GMUUI7YB,*ZO`N)97"PZO/_*7'=WJE]:$VDL@1EUU)_0\2>L^3[F%
MD$0_^>Z>'_TKKDR_S&X6)SP]QA'H._TEU_?&X%@!)#A^U]%5^$FK7\%]D_MY
M3_VVU?\`J-P?IGU'_P"DE[WW#I'YWT5`+Q&^0WXU6!V%-JE#?Q\I5[U7;LHE
M,RM;>-WT?$@](_;M(QG(KFF7P)J@(-S%2V`>LJH&#;7F.\?CG?<3E"9@C;<D
M-()@&T_O,!66]][;M,E;.0XVZ<AIUA1@P=RVY"8+C8^0H%X;VZBG1(JKBS)D
MRO)1,6S*95)Q'UN<7>?;/5%2F,<0!-1TF0P])@4(4"!YWNMXT=XKO?AUR7"1
M'Y)\C"5RKACEZ9.BZF7'1E7M?QL\2O`><'#"FSKY7$F1'RZ:;:I7%=!Y#S!P
M'Z,A7+0S*$2^(8P_0N^]2<J#_P!;@/E_4W=CQ#P3O!=9=N<1B#XQ;8?Y;`:O
MI>&7CKET9.%;H\2]+$%2'*8"J=?28^P]'1L3K'H```.D2@78`'V0[=?0#0P3
M#Z)"W+8T@0X1%10C30N#/?V$F_\`N1*?_(G&AKFS!%E(682WVC1G4.O#:[?#
MXX1;?HN*F!=OB[8W@!'Y&B8X2^:^@Q@F);Q`P4X]"T(T(1H0C0A&A"H(@'ET
MC6$UI/!`43;?.J?_`!*FKI>7>^$++>*E#KP]/\4;&/\`W6RM_?DR#JV^?[AW
M!Y`E<_Y`X?*5-/65:D:$(T(1H0C0A&A"-"%!W@,0P<?C!MVAF#-PCVA_";:=
M77MS93S;HH^!9=D^S"%,2IM$(8#`(AV?FA\O7/E@N?;'HQ4V,<UT2%L:U*]&
MA"-"$:$(T(6LY[2;>SOJ4J8P3=G'GPC!8K^USI$14"O@CZ#>;_IKO.&OM>PF
M9O\`PT>!?*8'_.@OH5X:_P"6A\5S^Y9Q&_WLNFOG^+_^W[C^_P"1>\P;_G%Y
MWOA"]N7IC%1*)2B(AL.Y5")&)TF`P&*=0!*4=PV[?/KQ%W);=R1TPNW?9CI=
MX#FUV3Y5XDH<B+?@XF=^3<\O#(TPO/K.&'<ZS4A#=Z]B\9X_J$A1<#/J\X]?
M(C%EC+1"PD$H7NC^V2TP!Q`OS0]FZ787A]@0M0!I,`::03DH6=]ZG-$<MHC5
M"$-::FX<DN369,2R=!ML[2*QDW#R^%JKG,E?BWK.,A.1EOSR@UHCJ'1:SGKH
M4W[E=<<3#R'.J!G`OV1#KID.IOT+SAUWN\&@AP=$M=&ES;(-(J$"8#*5$WN?
M",#"(C0GG=<C^3ZUCC^/4EFG$V-[Y'97SQ5+%RLG,;(#2I*(Q)!TZYP$`EC.
M9O#"MQ%^OC*Y'662&6411BJY*.4.KH$J>#JTLRP\5V08;]>I,WJ<)A;6`XB/
MDUILG7/#DS:*?(6]KD[`V*Y+"^$XC+TA5INL.)8O+N57NMXI,.AA]_,3]?=5
MC&MU/362L5(L4IIRJZM,>D4AB'3%2?5941"D6H1S"&_YJ*2EUN=`QH,*H;H;
MJ$X9N8V<Y7(ZDDM><0,8-IR*@<&N>+)J@8F7I"$N5'83D[=QMKRP(3D/8L9,
MY60E5VZ<.#9S#0[KK63.4PE!=)+JLT?-7EXN%(WR>!PPW;O(F@H?)7DU7\.0
M;G$]OQ1`4?#W';'F:IFKRM#F)YQ>65LRS9*[.5!"PSN0%I6ILI"#(+EO(*JO
M797J(`0AD%=B)UUE!X8#6XC>$(K1+F.F,MNKA\*>?#?+O/.;.<$QBZ`R53(;
M&=5N&4(Z[8M4H5/]O0I-+BG<7775;R"]R,TR3.6=_:E&KF3:#5&K-BW<',U=
M.FI"KJQ==Y;66X\XP@-_=E4@XU*0^;,XY"<<H:WA*NYQQ5@"NP=,K.3+!)7V
MJQ5LGLMH6'([>D&QI65YFP5^.K)>M/N47K)21DAE'*919]V4O>HW=@:'&FF!
M`R9C_;0J3>9K2Y@R"C3NT1*ADTYM\DTZFQRS&9#Q!>&F9<?YYL$-@F!Q^12V
M\89/#4),6%-/(EA9V!_.WAA#R\<-;M`2L=#^I6=XF1%38Q"&EU:47'(V(&_&
ML\'D4#>YP:*[5=6K)K^%=S//B)6RL-\@_:+?,;R,/!1?%Y@VO4'$UR[/Z7,9
MWIMBMEEFG,=(6RK4J>D"-:NDY8,Y:7AFID50`SGK,B120NTMS"8P=%W%5K64
MWN:V8&"EG-S981U'<$BXF_\`+.TR>`,@M,]X\:Y+2X;\SLMS%C1QW"3]>LM`
MIN9\"2=-A&]#JF2)2A1=U<0)&K*3?IS,@,0L\=`F)U>HNHNDR6TBF#@-VZE.
M3>)[YH::*-_X->;?"F[QMO3NU<J36YK&MH)CR)X)<;N1=PA&CLSA!I?)*7F:
MDP(D\<&!9XBRJZ1&@*'#K5]7`P^D/9E?_+(R@E=-PICD(&\O3'Y[_4F_F#K#
M)_GC?24*N./^,SSV_NJ8:_O`4C73G?$_8^%'Q#OCX5,*>BQFX26B`7=M?;..
M>QXNF#L[!^U!XV4;>M,'Z93J,7K;O>M)8I3"FH4#;#MMK.PP=3F2#+="A1&<
M$J42I9EK%TO67<O2N=<;(87O>1,HWV,E;^?$K9M.)LZ7`R=<IE4A85DP=VZ6
M<IJ&C7+I5R[.HLN?T"DN$TP`)H;2*,J9N])@*ZZ4ZEDXOT"W67[;K%'.9F6^
MX3/\;UFLC($7AGV++/.0LS.-'K))NT44GI!:O-MW9%$RIE$>A,IP*8#:D&C*
M8G?1U<D0(J$`N9CCB)C#&O'-EQ98-I:RXC94Z6Q^K%76;=6*9F*9)$?(%@96
MT)$AI<Z;9J\!--1/H.4A!ZC*',900S7.?;)IW9*D"[`4`4)H8_P[,7$A;5&6
M.ZYOO4_8&=+:PV3;ADQN]R5CM#&RI7F/6N.;)'5^+2KZ51D>IPB+AH^5>.3"
MH_6>`(@,MNZJ,&TY,]:.KTVH4T9<R43W@]#HX\5IU7S7R+I\Y+6FQ6V^Y$K6
M0JBWR)E61M()-;`G>YB6QQ+5]VE)1S=!)#U.,CS1Z;1%)J=NF42F1G&`T549
MN'(F+N(DPH.E27H&**SC&CT['M.BV\?6Z!!-:Y4FZJSJ3<Q46R[H@]4K+.74
MR\D)5%+^JG2BYEUEC&44,81UGF.+WEQK*T2F6&!N9.HU3!%`B8`!"EZ@(F``
M`)$ZA$B0=/8()E[-_*.V^H*Q0,\3/_%(G?[N/#?_`/++P%H0IY^R/^J-_KAT
M(6QH0@?(.HO]`[Q0M%R8"MUS&.1,I6ZIC**'!--,`3$1.=0P@"9"AVB(B&P:
MRW?TPHS:BO`-UX@^;BY$STC7[C5;90U,>\BIS%2-FQ[6*VYI=JP;D!I0EXX4
M(*Z3%PN5<D91%]UN9IE!KBF!#(%.H8J>N[+E-F0!)`)$5QKS.=*=$`%P%'#N
MRJ_+^8>8C*GW*GS7)*@U.Q53*O"F[-<N0^((Z-915.SO;JM`RM.L5=G[E[1O
MXVLR\JFH63]:1<2;(AV[A%!54K@EC;K*+7.C$`NRYC1K69]\GAS13&#2:,X!
MW9\J2ENN>05>1L<QKV9,:86MK;GAR5QZVS5:XQW)5`YE>`F$9M6Q2%*F[^G4
MK%9Y"0=J&CH\[Z-CD6Z94DR@N"JSBC92PTG+9!AE$3#^U:1>)I>#&BVX$T0(
M&;)EHIAF.97/N?6?Y_&B-ZB<CX0Q/+XRXMU[DE;(&TU;V\:<CI20MV1:XK"5
M!%[9HR6H]+LGV@]\5]')2\H@M)@FD@J!$N\M?=9;;(!C:.K?KWE0R^3G6G&@
M`59Z841AOT:H59LB9[RYE_,>,&:67Z#0*I%\\<;8:K7'E2ME:Y-C'<5BY]<#
M9$L$R,Y&/;6@ZD+4"KJ`4BT8@T<S2.FZ.N90`!+;)M44V(Q!-&C-3KWE=*FN
MG!HC\>H@4Z<]$<H`S1IA,CAYR-RSR-M,I$R[>KQ"6%,<LJ3R`AXYLW>*M>6:
MUIG6-IIJ3YNX.PCF%!KM>:/U$4C*`Z"=2)OT(@8V6>(5Y?(NI(,0O2ABDHD5
M8%0+OWA0`Y2D("I2ID#O`*01[LIC;[$'?IVUE"TE;VFDL!^TP[^;LUSVSIS+
M^YD/X1`4XP9I7GCXC=$@LCXMQ#1;4T6?5BY\KN,=6G&;1R+)TXCIG*T*R<$]
M;`!V1%-4>HFW:7</9T\7PR5BMVV,RJ.[*O/WRX&\.#85D*)MB\.1^SF'#:G4
MW'"=;:J+-XHCNO%=.21X&-ZH"SDSQ,7"W<B'4;I#TMP]C7R>\>"V&7F<Z\.#
M;3S&O/\`O+E^ZS'\XUE)OX.J[`.P4_%>P#L`C4"B/YX^V';JC\$,*A"#-?UD
M_=1D,F[A1\'5>/W(8J_>:7]L-8#X(89'T6[OWD>ZLO1K\Z/@ZKQ^Y#%7[S2_
MMAH_!##.BW=^\CW5EZ-?G1\'5>/W(8J_>:7]L-'X(89T6[OWD>ZLO1K\Z/@Z
MKQ^Y#%7[S2_MAH_!##.BW=^\CW5EZ-?G1\'5>/W(8J_>:7]L-'X(89T6[OWD
M>ZLO1K\ZH;PZ;N*:I!J6+$^\3Z.\+3R@8FYB]1@'VP\H%`=0=X'88X@66U[O
MC(]U9>C=PIF9?ASD*(Y)8XPH:I8:4B;QB',N1%E4J2F#I-_CZV8V@8I(RP2&
M_=JL[DH8P?/:]%+\#\(%VIL@4#A-7QDO=277`;N%/(3PZ+R4#`>H8IZ^H?)3
MBB'3[';[8:X#O`["Q-=`--.[XR?NK+S#=PJ_X.J\?N0Q5^\TO[8:/P0PSHMW
M?O(]U9>C7YU#'G7Q@O&!L-1<TA6*>F^LMTC:VW;5"HIH6-Z*Z7?)(13PCE=S
M'K&6+Z:A?1%/<!UY#O%X6,PR>V1=61E.;&B->LKA8GW<=*GMLCF0XUYA4+A3
MD'*EP=3]X%PK*/ETTSP#9)==".11*5--BBB9)0$2@`=2@%'I%4QC>4=:^Z_A
M9*O$\&:T5Z>577;`'YJ%[V<2?#>DJNXB9HK!G3T69TUT11:))R)W1!`R<D=U
MW`JCW'E*D)2@.X]NOO6"=PL.P)XFD`%L-U:]UAMVZM=&2!DBO>2L1*D'$-8Q
M9P+Q5JEW:CP2%3,\5ZA%5R=,@F*0ZQ]S"&_E'7J;\YKY1L"`A4M]`2E+Y`_,
MU1)$)30:X!(UJNK#4DN%/_V#FO\`N1)__(G&JKI_+X?A3RJ'/AL?Y/C@[_Z*
MF!_[VM?T[]_-_?1DW:%./5J2-"$:$(T(1H0K#^Q^?I'(I"HK1=?TD_\`J5/_
M`(E36AGP?"%CO%2A[X>G^*-C'_NME;^_)D'4[Y_N'<'D"+G_`"!P^4J:>LJU
M(T(1H0C0A&A"-"$:$*$7`8X#@`XAY!R_FT/S_NF6G3Q;T]7D3%:FV7R:SW?T
M.%!K5VKTD:$(T(1H0C0A:SCR?&_GZSR_]_\`X?PK/?/]J=\+X*O_`%U^OT']
MC7R?[0O:7"_('&6"?&.\3^6R&^L+=I8\;<4&46%=I5NN+E1PSBK@9<B[6K0T
MJX9@4%.PRI2%'8=AU\UQ:5,/=VYO`H9:CHBO;8*\'&)\*W5<7(O4!?Q$N,2J
M8$+*Y4(.P#N7!67]_1.!ND>NDG*`&V[>SR:\3<F;226LB[G?!PKT=XL-O@;-
M]*R:.'=D3$0_)#A7'2685I!SDJR5_,UW@\A3]*LG'G)\O5&5FA(6#8>N-(IS
M0114/)3<`WF%C&V,$B7K*/8&MHE7EE,L$.%5:8=(J(HX$OR\S>%!7%@<J0=K
M4/:)J+L4^I^+9D\%YV>A6S1K%S<TJ%"[R0E8])F0J"IQ$4BD*!=@T%N(O@'Q
M(:("N@*+YEW:/1-.:"YUJY<\%+K%2D):*E8K#&34K]L$JRF^,V3))G)6$B)4
M4II\U<T`Z2\EW9"E%;L/W9>C?H,8HFQOHJ!XU#K%VCZ)TT!:EAY:<(K,K5'4
MK6IR4>4$Z!J&XD.,F3E%J<9FBFDP&O*#0C)12,:5$A6Z#=--%/H*;8=MA@95
M[:(&B.^F;Q=32YICI@FUQ_FSA#0KU>\CE"YV"XWJ_P`Q>5;!,\7[\I-5XE@9
M1S:4@*U,ML<MI-C%&48B?Z.JZ74%=<.\*14I4BS>X0C1PJ/6+G79,>!.VVY?
M<(&3-TQ;5NR-VKR):P3ELUXTY10:.89D[/)-HIXS4H[AL\9(2BRBZ:9RB1(R
M@B4`'<1=F]FDFK?5;ILHF+`;*B'69CAO6L_,\U?=CY$3$)7<B7/+M&Q9+\:)
MA2"I^2+^SLC"QSJ-_C\+Q^;+''^KW&4%K$R]G?P[/UI--!HDBT;))HR[R1`T
MCA2,YE0CJ'*I?63F3PON<C`3-NB+99)BI/%I&HRTQQIRC(2-8DURBDI+1#ES
M1S@VD>[#J*H0A.A;8X;"';(2+Y"+<N_4GURZ"AS7$C0%SHOEUPM@9ZTVR!AK
M+%VZYLTVEILC;C)E)&0LQ4DS$(A8%FU+;NI9B94QUE$W"JHK+*B903;`&@W>
M^4:-]2%^N<"++Z=Y,-EN\<%LC42#IM1F\H8.<5BZ0F0JU.XPXMRHK1EGAV\\
MR`9&O7+"5JHEOA5VEH?&.PF(AZV]85(J0I#HH"G&%[=N*8EW:,0VG>"5^",W
M<)\$45O2HZ0R3;US*WIU,VNR<;KXSGI]UE&>-:<B)OF=8QA!5:.A[/.@512-
MB8Z,C")E(4K<.[*.F)=\C2**,Z8EW=IBVO@X=:5]*Y/<.Z-DJ\9,BYO+2DC;
M:[CRF1$4K@?+`0U"I6.(M5A%5&EL$J(5.'@7CQTN_61+N(.E1Z1VVVL=+FN$
M+)!Y4BX13X'\1GB^0ASC)Y4$"D,(@7`V9#&V`!W$"A2Q$=@U1*N<X3`X`DYH
M(+F-$3'5YU$[`_.WCO"Y]YEV%Y(Y'-&7+(^+9"%4:89RH]5,TB\*U&(74=H-
M*HLJQ[QRV,)"J@0PD$.P!W`.I>;C>&2I<TP,6PA3$;X@J1>)4"WG5YO.I:AX
MC/&'[)93^\3F'W&:YKI$V-5/"K)=XE-,><>`<JK\(SQA]B1RH/YF"<PC_,IF
MEL)NX%7=;E9G<2/A&.,0>60RJ'YN",Q!_-I>C83=&HHZW*S.XD?",\8?LEE/
M[Q68?<9HV$W<"CK<KHNXD?",\8?LEE/[Q68?<9HV$W<"CK<KHNXD?",\8?LE
ME/[Q68?<9HV$W<"CK<KHNXD?",\8/LGE+[Q68?<9JQMUO#A$-)&\K&SV.$1$
M*X/$=XP%#;VRRGV?^0G,7N*T^J7CHE/:L4-.??.7`.0^,\K6:TZR0M*.LO\`
M%F4;A(8<RA#LE&]7Y882G91,9&5JS-@FZ]3CCE22.H4ZBABE*`[ZME8?>)K[
M-#:(Q-`\BH??93"1!Q(W9U,@/$:XP&W$LGE,0$Q]A#!.8MAV.8!VWI@#MN&J
MNIWCHE+KLG,[=PK-\(YQA^R64OO%9B]Q>H=7G=$J[;LS%'PCG&'[)92^\5F+
MW%Z3KM.((@:DQ.:3"E8%/$4XOJIG2/)Y3Z%$S)FVP5F0H])R]([&+2P$H[>R
M&J)=UF2S&D\"F\AX(C6FB2Y1\"&\K99Y.D21INY@<MNFAXNY,2EK*FL*P+H3
M+Y*B%5?$6*X,(]>X"/:8#&'JUL_C$66`VLFZ"Q3)+!SWP+17G/&NO/\`,#@[
M9HV<B)VOVV5CK.PB(NQM7_&[*CU&9CJ\)#5YH[2=4A9,Y(-9,BC81*/<J)E,
M780WU'8WS)Y#RJ)-V-;3J&2I)R8Y.\";1&2$/:*5,SD9*.GC^2C)'C%DEXP?
MOWS*+B5I-PW7QZ+?VS""B&L>+@">L':M4BBH````C+OHYQKX4K5T`]$PW@MZ
MP<J.!MF=5%_/4R8FG]%.W-4'$MQBR@_-6!:G070"!%6CF4CDBN&:1^A,Q0[P
M@&]@0&-B]B,(4[Z+=SH-FD:`L;OE9P;?7=/(;RJSCZYH#'BC:W?&3)JEC`80
MKCVD4&8/01?(.HP[U8$%4#I&2*<0$#[ZMEB>T%KHV3FB-=:@\R'.#I8XA\"U
M,,<K.(>%BY)5BK#E^:E,JY1MF6K7-27'_)C>2=3]L<IG-'G/$8\CDG,77H]L
MA'QQEBG<),&Z*2BB@I@84]DQ^2H0W4*]EXEL%(=3H'*GN)XC?&``'_=+*?E]
MG!68@_\``O4!=YN0%7B],>*`:%?\(YQ@^R64OO%9B]Q>CJ\[HE/;LTJPWB,\
M81'?VSRD'D[/N$YB'_P+U'8&U2WGIF<P")C!1)Y:\\..UPAL',X:2R09Q!<L
M.,]I?D>X9RI'`$17LH1,H]4;B^J;?UM91-N9-,B76851`!V#MUHE7*]320V`
M;#+'D5$S$KK+:;0<3H@I8(^(IQ@*DD`R65`'NR#VX*S&0=A*`AZ/VF=FX#JE
MTN>'$.A$:"K1>V/%MMH--2SAXC'&$.SVRRE]XO,?N,U#9SM&HHZPW2K?A&^,
M7V1RG]XO,?N-U6;O>M&HJ`ODHF`#M0Y57X1KC%]DLI?>+S'[C=5NEWEI`,(G
M058+PPY]W"J_",\8_LGE'[QF8_<9J6QO6C4>5/;R]*/A&>,7V3RC]XS,?N,T
M"1>B8"$=X\J-O+TJGPC?&+[)Y2^\7F3W&:EU:^:-1Y4MNS2K#>([QA`-O;'*
M1A,($*3[A>8@$YC;])"B>FE+U&V[-Q#3%VOA<!%HB<L8)B>R!--`40+7SJX[
M.N<F$;FF_P`E)P\%QXY$UN0*KAG*Z,B64F[W@^1:%1B3U$)!=J5O%+=;@J9D
M"&Z"B;<P:[`NE\-R+H`MV@HIC0*X9J(+&[%9#9NR-J.[2I@AXC'&$ODD\I^;
MMP9F01_[S-<AUWO9>8:H'E6W;L+0ZF!5?A&N,7V3RE]XO,GN,TNJWW,-1Y5'
M;LTI+VOG=Q-MT?ZC).<B*F)U&:N7G'O+4B=@J<HD,Y9)NJ48B#KH$0!0/2*`
M]FJIN&&\-A/9%^0PJ5,PRII!<*!NSIL*!R1X,8_56=Q;3(POW"JCA1PK@?,*
MYBKJCNH<ASTOJ'K-Z7;Y#".J[AA<ZY3+;6T9(`A72YTF74V*>]'Q$N,2!2E"
M6RD(%`"@`8'R^4G27R`!2TKV`ULO$B^37VV1`.>)Y%-UYEN=%H(&99_A&.,'
MV2RB'Q`P3F+;_O+T,NMY'\P%W!_:H;=F8J\/$;XP``![992[/_(5F+W%ZGU>
M=T2C;LTJOPCG&'[)92^\5F+W%Z#=YW1*-NS,5R)GQ%>,:\1+(DD<I=XK%R*9
M`-@O,)0ZCLURAN8:9L4-S>4=@#V=%VN-X#;+&EU.95==DQJ=NX5%7@5SSX\T
M+A'Q&I5C=Y+1G:?QXP[5)<K##64)>//-PV/Z^U>-XR4C*LZ82Z'5Z9%VRBJ)
MB?H@-V:MOV&SA/+7%M#ZQ&!B(T4<&^@7Z4:(.B=[E4P?A'.,'V2RE]XK,7N*
MU5U>=T2K=NS2CX1SC!]DLI?>*S%[B]'5YW1*-NS2CX1SC!]DLI?>*S%[B]'5
MYW1*-NS2CX1SC!]DLI?>*S%[B]'5YW1*-NS2CX1SC!]DLI?>*S%[B]'5YW1*
M-NS2K3>(UQ@$/[)92#R_^(K,0_\`@5J+I,P$1!4A.;`F!@M9;Q%N,:A023D,
MJ&46,*"10P3F$`,LHDH!"&.>FD33`WSQA`OG'6B5(G.(:&UT;J%BGWF3"DGB
MY5%SA%SQXZTGC-CZM34GD;VSCY/):CDK'#&5Y!`H/<M7QVB`.&=171$W=J@`
MAU;@8!#5M]NTT3R0(@@5;T$KC>9;I%`-!/EWU*[X1SC!]DLI?>*S%[B]9.KS
MNB5LV[-*/A'.,'V2RE]XK,7N+T=7G=$HV[-*/A'.,'V2RE]XK,7N+T=7G=$H
MV[-*/A'.,'V2RE]XK,7N+T=7G=$HV[-*/A'.,'V2RE]XK,7N+T=7G=$HV[-*
M/A'.,'V2RE]XK,7N+T=7G=$HV[-*"^(YQ@,8I0DLI`)C`4!-@K,12AN.VYC#
M2@`I0W[1'L#3%VG.(:`8E(WA@$8%1%X9<[>.](PJE!SLADDC]?(^7)](K'"V
M5I)+VNE,DV15FHHX85)P@D=0BP;D,8#@/E#6K%,-O#IL!`B`I$3D^!5"_2C3
M!PU<JEN7Q'>,'D]L<I_>)S%[B]89=TFRQ9@2=Y2%]E/,!&/!RJ_X1SC!]DLI
M?>*S%[B]3ZO.Z)5FW9I1\(YQ@^R64OO%9B]Q>CJ\[HE&W9I1\(YQ@^R64OO%
M9B]Q>CJ\[HE&W9I1\(YQ@^R64OO%9B]Q>CJ\[HE&W9I1\(YQ@^R64OO%9B]Q
M>CJ\[HE&W9I6LX\1OC#L7_=#*INLQ$R@G@C,2AA.8P%`O06F=8!N;M,(=(>?
M5,J[3#?P!Z99"&^5GOD^6+JXNB!R<*^,[[J]0^=LW^5O^Z;_`,3K+_Q5^F?V
M-_LM_P!@_P"VOTFOT)U5^<?[2"^5VV_YT5]*_#D3'\:'Q6`[PX]&*N)8`80(
M40!2*MI0(!2%Z3$+W0]H^EVZ^4XN?_\`G;BW.7<0\Z]U@H_]9O$:O.%[>])P
MZ![PP^B/F\X?$UX60]TNZN<VNV/(N]>_]V(563Y58JH=,`$.^4W-T[$`H]/8
M(]9Q';I3#;M'M_,TNLSLP40"<JCGR-Y/4OC-BB>RK;V$W/-8TC9*$K-91]=L
M5NE7Z3EXQBH%L*($56-%1[IXN<XE(U;MCG4V`-7W=\Z:3$5*0<Q@C,A!=F=Y
M/8.J$?C9[><D5*D+Y:CH.1HT99;#'QTI-(SZ47ZFNW8*#ZV,81W--6ZK\4P9
M(JKD*JJ03D`VD->:LBD9L@5PI3;DYM8)B&9W.3[_`$7%;E_:+E!4^.G;[7W[
MRY1=.NB>/GEBC&S#^K"MBVPQVKM,$50C1)U.5"%$!U8R7,(H"R3GL>X;,BI.
M2]Y)8.BK^UQ5,97HT5D=XT!ZC2WEFC2SQ6RD>>6:+.FB9E`8DE8M!5TP[XR9
MG[5(5FX*$W$)B7,<(MI$50;33`P3)T7Q&.)EVQ2TS,.58NGT)Y/V&M(R5\6:
MUEP,I7IF3B13*S<K*K/D99O&&D6JC+ULGM6LBX6[D%`*",B=:LP,2MLJ9);+
M%HB*4MFYOX+IN8Z[B>SW.J03.SX[I]\B+S,W2O1<(_4R):9BK42)CF[E4JDB
MUL;NON^B214,S34*DF(B98HA'8S2VW#FJS;7>,(B*7,ARJX_L,EH8<6RM3?N
MIN9=G`)T1.>9+V`\\\CG,N$$DU;%<%/-MHMJ+M=F)BN4&ABK*$*0Z8GC9F0C
M"A!%W-)A%-7<_$.XCTJ+3F'&8("Q,QR%2,9.PIBY+.O&66^2\E$Q2C\L:55'
MVG;>TKURN[0461!JR<'*)@3'<#9IJ"+-WT;N!/*;DQ@8MX<8U^Z[1SWMK%OY
MAS5B6.-4FFS6+C&\[)(.8],YG#>58P+M)^JR.4'96:A5>[$H[Z)DN<Q@?"@J
MLQC`)28WS)CK,$6ZGL76^(OD!'RJT)(3M:>$?Q+>500374CTWW=I(O'9"+I=
M14A,!>\#<?8US)EZG,,*(14F"T1F3J=(_3#?(^5I=;GY@M/5]*H<@&(<.\4[
M2CY!`![.WR@&X`.W;\35]WO,U\T`@).D"%"A)QQ27#DKSP3%R82)91PT!&Y$
MTTFS038%IZZZ;0I``PHK++B<>OMZA$=:[S>IQ:+439$!&G=4J-A080$3RJ:3
MA4S5$ZQC")2[`(F.DFF0!_1JJJ;%22`?*8=]O-KG,O,^8\MT*Z3):UT7U+"9
MZH0FX[E4V`.[$2")S](',5$P$V4(!!W`_8!M7VI^9:0V1&I8BR1C[?-[*=V#
M<QNZ*1T94QP2!JIZ1%B*E)N!MP#M`/9T6I^9,MNY68SPX$$^QR[%.<X*F12!
M`A2*'*HZ,/45!-0"=@CY^W1:GYDK%WS*T\@1,G6H<Y!W``)L0YU`,4AB'0(D
M4YUDE!/Z)@#MZ1';LT6IZ09(S!8/;=/8@G[Q(QRF$4510(X3$!*``JCU#W(F
MZNSK$HCN4/*;;1:GYDPR0<@6TFX45'TDETPW#TC]`!TB&X&```1V`1`H@.P@
M;</8U(3)HH(6*<(3"&>BMI,043(H4QQ`Y0,'S(=@^3LZ=2$U\*E`5*`WB7HK
M$XF6(P&3,1;-/#Q$W>=8FV6YE8%3.3NRF*B)#(J&#JVZ]Q\NVFV\S6F+:"/[
M%+8!P)HI4_#$$3&'K,'I&[.SSCV>34#-F`P`H0Z0XN)SE5Z1^F&^1\K67K4_
M,%=U?2CI'Z:;Y'RM2EWF<YX:0($I.D0!,:E"G&W.W#N0V_)AZLC9Z6RXL3MD
M99`<6UF@P-)5:LQ:LH[R+6&X*F7EJ2N1FZ13=E+L+AFLGVG((:ZQD3&T.%97
M.%[::HK#1.?F`K%AS'>8\@3Y\%,\EO+C'0M.RV^B8*Y,7U&M<O4K&C,L&SMX
MR8IPSV'.=\N9?U6/`Y"+JD.8`%&2_-2ILO,LGG4-TITW?+#CS'Y'9XC>Y?HJ
M.3'J\&BC1C6..^V$4[1$ISE8=G;E$6Z+*RQ:H+1RJBJ97Y2G*W[Q4AD@KL/A
M&%"T[60#`PCNT+8A.4F`+-<IS'$-EJBO+]6(Z4EK'5$+5#*2L(P@4"K3ZDB4
M5R-T%X`##Z^CWG>L`#J<E2+N(2:QXI(@%3.F2WMLRX6H\2:UASCPE:+MBZJX
MVL\%DR(R'*WV&E+G5K9!+0%'?46FL+N9&86.;NW9IF'DD5$!35(0J*A%A,*9
MRB-IE36BT10L@<,L24LXWF3QCE:E<+U%9TQH^J5$?1#*U6`MOBT8J#+/G,G`
MO95XY[I)E&3PHJ^U[L>IH_!,1;JJ!N()TB:3`"E:)$R4`;9@LLIS)XSP=*A<
MC2F:*&C2;#*2L-#V%*PM';)_)P"@H3\>U%D1P<[VON>E*0(8"%9*F*18Q3"`
M:CU>=&$#&"T;:[YPE)C?/,#E#*66<;0,>N"&+:[AVS)6M*5C).'ML9F2NSMD
MAW$.$<9<"(,&D((&5[Q1)QWI3I&$O:.&\3)LH1;NKY%<&-F>C4GWZ1^F&^1\
MK67K<_,$^KZ5<&VW2)SB/YWD^-K7)G%X%JARGL>;"M0AYO`HE!\>!3641%3F
M7Q01[U,B1UU$W&8JXDY9G,H'H,7#8IBG*7TA$V^NM=II9*>8_%(W:=*Y=XNU
MIS1I"FRF0W07=;;<.K83`.P&](`W$-^P!VUSWSF->012"MLN1_#&\K^@?I_R
M2_*U';LS%6;%(:]Y#JN-*O.W6[3;>`JE7C%YJQS;X%4VD1%-M^]?+B1LH*B1
M1#8>GR:XV(XS+P\_Q3S59,;(EBTZ@*E3R-3[]!15IHUGB;=6YI$%XJ:KTBUD
MV,@F(=0"T6;"9%0=A[0$Y1#;5^'XWA]_8#+>+1R4TG4N<;[=P\2VD$DP&Z"6
M1%#''L,H``.Q^KH`Q3>P`E`#>772V\O,ITK,!3"/]-/_`.U^5J$V\`,)9Z2E
M+:7NLJX"C[*A_D?*UDZW/S!:1=\Y6-8NZ8EZS"!MRF`P`(&*)3;E$0`!+OYP
M[0]C4'WR>(0$#'=E4VR&P.\H.VTBI/$+P`3O=R*<5.1@B42@8Y#)9%P*4`(N
M8.]%/90>PV_DWUVV3YCKK9(@TF,-*XK[N[KD<MDZJ5.4"F\G>&[/S/E:XG6I
MXFN$*-VE=<2(L`RA5Z1^F&^1\K4NMS\P2ZOI1TC],-\CY6CK<_,$=7THZ1^F
M&^1\K1UN?F".KZ4=(_3#?(^5HZW/S!'5]*.D?IAOD?*T=;GY@CJ^E'2/TPWR
M/E:.MS\P1U?2CI-],-\CY6@WN?"H(ZOI7(G"&"#FQ%0W9$2GL%'RL5P`?)[&
MM%SGS)K8OR%5;`AVM0N\-QF<WA_\'UP,D03<4L#[J))BFIL?'T&Y<)II`844
M$U>L-S%],=NT1[-2Q"^3Q,B*W&)\B&W<&`RA3HZ1^F&^1\K67K<_,.)6]7TH
MZ1^F&^1\K1UN?F".KZ4=(_3#?(^5HZW/S!'5]*.D?IAOD?*T=;GY@CJ^E'2/
MTPWR/E:.MS\P1U?2KB^COU*''?R`&WE^-JZ5>'O_`)BFV3!:3U)00ZTU3%(4
MIN\*(_-E`Q%#DVVZ=E$TC%W\H=79KI2G"%._NUK%>)&7=2H=>'N54W$G&BJJ
M@`969RT8"I@/20OW:<BBF7K/U*'$J1BE$1'RAV:HQ.\S!>264@\@1<[M"0*=
MT3K4T.D?IAOD?*USNMS\P6KJ^E'2/TPWR/E:.MS\P1U?2CI'Z8;Y'RM'6Y^8
M(ZOI1TC],-\CY6CK<_,$=7THZ1^F&^1\K1UN?F".KZ4=(_3#?(^5HZW/S!'5
M]*O*4-PW.<>WR#ML/Q![/(.K)=YFN>&D4$J6P:*5"#@6FHI@,JH+J^CE_-I#
M%-L/?E^Z992D!81`1`$`(/=E+L4O9[`:Z-[O$TO+S$FJO0LPN\&V:(1I4V^@
M0'YLX?GA\K7+=?)MJR`K&R!%5Z1^F&^1\K2ZW/S!3ZOI1TC],-\CY6CK<_,$
M=7THZ1^F&^1\K1UN?F".KZ4=(_3#?(^5HZW/S!'5]*.D?IAOD?*T=;GY@CJ^
ME:ZY#;D,"@[`!P-Y`,8#```7<`^9`>W;5MSG/F7R#X1L?"L=_867:$:SY5\'
M/K(?.!_EH?5OF"^7Z9\W\W\7RZ_176-/_A%\H@/\Y?05PU_RT/BN?W+.(W^]
METU\MQ?_`-OW']_R+W^#?\XO.]\(7N*4O48@?I!_FAKQ=T@9!!JM?`O07AMN
M]@?(/E6M))E!J81!(2@8@J&6$2I))`.ZJIC`8!*)$P'I'Y_;5UEF9&QTKSIS
MQQ+F.265I":R9D"T5C&U+QI*UG%<#BF97B;(O:<D0K^NYGLMX%6,,P7?DK8(
M146".PG8/7(IBD<0ZKI5[;=#$,#HZ3D6"_W%]X:UK9A;".0&*;#$W'+DEC"X
MU.T3SG`5T:!QQQMARWV2?G+A'V#&S?%[J[S$:KC2/<4N1A;A5K,_FVR\D>3D
MH$\>X25`2/$T44AU"]LGBT&6:233&)U+$W#9H;9=-C1`1;57$"FJF)2#B?#Z
MOQ,?W")DY7&LED)_@K'6'*]:%V!WC",7O63'F7>63HKE2GH$+'Y%MLDNM'="
M29`341]809'``-L&(!EFS+H$RT::Z(`5<.E;;GA[62RV9,B89O.M[%O`*1KW
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MU>$0K)XAQ(Y-O5BL8)203K<\`BY06(1XL04D;7WV4X@NEP#2XPM4$FJ)T9\J
MRLN#P/YIM&%-G((QRP5Q>!_(VQBZJLE?,-56I0<IS,L=7R?C]"XNLV6',.>X
MR7C\59HL<FO!5QG!6#$[&T'8N(]N\?`Z29-%TY`Q"BV3R.O+;1(;D:"(YH4\
M.[1N9='AK07Q`B:JT]<7QWY!NZKQ-;.J+Q>KDEQRR_!2-@Q]3+1>U<?VK&T!
MBB=IE;F(JV)8I@I=I;XB?L*<ZWB7<0I&BJV%J=]TK'7+#;"P8`Q(,3'.8T"H
M05@N[K8BX0!$!"BB%>4QWTP%*\-G)M;A^0[1^>H3=TR!7,[Q.*<X3.8<UW*P
M)2><'LZQDK>;$4_75\;X$LL%5+$$<=2MNIDTDA$H]94]QVNO&+&>6LV8$AK0
M(1K@(5PRD1^%='8"%=*]E<<XRK^-:34:-6(^)AH2JUR(K[*+B(MK'1C9&/BV
M;%46;=DFT$OK3AF58YU.M4QA'<0W[.-,:V8ZTX*39=EP(-2<ON?TWR`T[+.B
MM.TT*TR?24P]7D*;V`\PZDP,#A`4Q2=-@TDA0EXY=G)GGM_=4PWO]X"D:NG%
MMEM%3?A6<3P039J.=3&DS;-1,!!.)%$C@F42]2@E-V$`IS$34$/+TF$"FVVU
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M(+F46@G,K$-"-$2H*HN"+E4;J*)F!0R+66**3:KSB$1NUH+IP--`AQY>/^Q)
MJY\K<SR9,P<BL=6^FNL#81Y#XEPLRQVK4'LFZRG5+HAAYS8LB?;^E,LGS5ZZ
M3SC'#7#)-08QZ3);UD%16**<6"0X680F628TT:(1T4J3NL-%J,6$^3+5IWUF
MP1R1Y`6EKQ4RI,SE%DL=\UI/*<=2,0M:L^A'.))!C4+SD3&2\AD'UN9E;.S<
MP=%<1MC=N8PWKDL_0<L2-RE*B>4)=-'.;")C7'B$$B9U!C0?@3C8(R[R4R57
M(]I;5HB=N6.N?EDQ+?G^,X!W'TUOB"J5]W)*])74E)N#1,0_G6+-=^Y<'<O'
M!.].DCW@H(Y)Y:V80RD0KTYUOD,+Y8<_TH[@O4:/,`LF_3U=($$I1,/5UE(8
M2@H0WZ),^VY1]D-4ET3&"MV.E05\3'<>(TZ._ESCPXV[`[/\,O`?Q]`<!6%>
M(`0@IZ[#N;M_1&]@/GATK0S)Q;FXU?W/Z;Y`:C9E]%2VFA6F)T%,<.HXD`3`
M0H%`QQ*&_07J$"[FVV[1`-$&"D"E!?:$,Z\9/@],DC>*9/#<Z@RJTYF+)4AR
M+A$1L#V6R/@QYDEOG/$="KZ[ILBU9OZAE2-[J02=$&/=1,H^:$.JFL`:[(Q1
MCS$R@2&BSSCS39@31"@UPHWUQ3AA8V&U.F@4B,8+38\(<^U".1D:,YP%?;38
MZ5RIQ9:8S([Z:8UZFTWD3R#L&7(ZTX\6C,>V%N_?QE9L*+>6KKEG%-YYR@V%
M62(1N/>W3;XR9++MG`.>"($BH4@YXPS4<:PONKVQ8'\ZR1&&^NZ7P^[DVK.5
MJS$6RGRA;+E/@-9:19IA&82FFU8XF$PP6\)RYFB,J,++3QL=R8PZ+%59J0'J
M22S@H'.8F1UZ>7`A@`IRY^3=!4=1+6&$PGT<@R5\=6BN*3R/!?+<R1#&-CLN
M)8;&%)7Y/2%`R5#O):0R_D^<Y$0EP;N6^9*LO7:\G!H5I&Y&&==,;!,OK/W!
M53%CA<"5M-M^-W=M-BTOH%),(`TZ]T5KN=S<9G.F192:A&)T[@E!;.&^=,U4
M>D4G)TW@[%A*K2,NX87?X:?W21?A`6[#D)C*OV-FYEJ?5`=V4LG'.I-Q%O"^
MKQ;95)`CMX9`'!JY>)-E%UF3S7.#H6S1!T859H-X(KJ.N8=#G5"%7G6K)\.L
MY97=IVK+S;CO2;.G'81Q['4S'+BU/Z/-4C&616EWFK!80FJ=6G9+;9/:E)&*
M@$(]=G%HAW8R3OT3ET7?$A9<UTLAL7GTB?2J%(^+7&*Y]_N)<667P=$?%S<*
MT\W\%>0%O)D:.Q[=Z+%TZ\9DRY?'52;Y,RSA$[A._5V")6K'*9!Q1`.[BY/4
M9=K)K2E524:P-@,_W<K`9LB4%,Q"7LFRS*]%H^,81!I.<QTDPX54W"9CW.>)
MT(D_%&7)FHT`<"E9POXQ7#CP\LQK/.UV<0?8-XAXK9K0JDB+D9;C[BF3H-H>
MNT'S%GW<?+2KCOV!_P"FJH&$5")B!0'FWF<R\.M6(&+B:8QB2>(&'&NU<Y!N
MC+!=:JR0J`&FN$3OJ>I4]PWZO9\VL]F7T5LVFA6'+TB/L[;?$U4)(?,)!@!!
M2#HMBO-WQ/\`)#/$6!J1EF2CW$G&XKY(\=,@R$<V4!)>0853*4%+/T4UA36!
M`@,DU#&4Z#B7H^9'7+Q[&IF`W/;,E;:(JM6?@*\[?\6==S$2K0!Z4/@T)FF'
MBOP4DPCG[2B5(Z,BT0=H#]U$J>R#A(JJ/416L)J%/W1@ZBB`;&W#M\NOSEB/
MYBIEUOTV[G"02QY$=N:8?X*\X[OU>)3C*%RB&T1VL(_,72^%,B@'MI%+#8>T
M#962W#X@A]K/E#6+]2,S)@XC_P"8=_HJ'O\`7JKJ/^;_`/;3&\A>=L=G'">2
M\2-82E5Y[?:=*5A%\?)BDCZDYD>KH(9NG!`#HJI1W[3)[`.VO,=X?&[$N\4H
MRAA'5B<O6"^@'-LFK/>>]MXO$ITL2+)=1&U&BOHKQ]PUD:Y8)096*H995PY=
M8=V",RR:3A"U"V]R'0@ZG*:Z<&K-P$_D[QTW%5,!W*H4VQ@\Y@GB=BF#WMDX
M7?:"T(MMPB(U>@8+@R,0O;+TV:VJ(B**1&,*N->QO'OQDJ4_>L:=R%90\=("
M9%(^4<9.DINKO7AQZ")SU2;&<6R%544$`,=!!XS3`1,98"AOK],=U/$J?WD=
M"9<1=X_\6W_U`OHMRQ3K1LOEV#OQUT+V]KUBB[3&QLW`N"2$)+L6LA&RB9B@
MW=M79`43,1,?ZH3/T#\RH0@Z^O2)0<P37&O(O0RY8;_$BE)W/Z;Y`:NLR^BK
M=IH6)5+8H#U>0WF^(.HO$L0-G*ILF5T9%!ZXC_\`[#>/GQ.*O)$/CY'P$.ND
M8=4-']X/(N4^=_WN$,AR[ZG&5/J$=S>P'L?F_*USH,,QT6TKJ;3F@P5_<_IO
MD!IV9?14=IH1W/Z;Y`:+,OHHVFA'<_IOD!HLR^BC::$=S^F^0&BS+Z*-IH1W
M/Z;Y`:+,OHHVFA'<_IOD!HLR^BC::$=U^F^0&@MEP]%&TT+CSX?[AS7;_P#P
M>4]C_L%Q\K2NSP98@(0/PI`C-E4.?#8#_P#U[<'@W_\`-3P2'D\^-*_IWU[1
M-,6Q!?G1$"F"F]W/Z;Y`:+,OHI[30CN?TWR`T69?11M-".Y_3?(#19E]%&TT
M([G]-\@-%F7T4;30CN?TWR`T69?11M-"M%+R>E\C_3UGGAHA9$%(3-"PN?00
M.'E]%0?-Y$E/S?/K1($6QT<BRSYL,BAQX>Y.OB-C#MVVE<K_`!?+F3(`ZMG-
M;M#:$31Y$KK-C*B!"ORE3/[G]-\@-569?16G::$=S^F^0&BS+Z*-IH1W/Z;Y
M`:+,OHHVFA'<_IOD!HLR^BC::$=S^F^0&BS+Z*-IH1W/Z;Y`:+,OHHVFA5!+
M80'J\@@/D#3@P5"E!F1$(*$O`5/_`)`#%ZO)F#-QO)_Y3;3V>76F>]MMQA19
M"C$9E-GH\H;^7XFN>'2W/@6\:<0*8([G]-\@-769?13VFA'<_IOD!HLR^BC:
M:$=S^F^0&BS+Z*-IH1W/Z;Y`:+,OHHVFA'<_IOD!HLR^BC::%@7)L7;?R?$\
M^LTMH&)!S:!LZECOXVEV)J@5\%7=_%_Z:[;R?Z>OONP/2_\`"1J7R6S_`//@
MOH2X:_Y:'Q7/[EG$;_>RZ:^<XO\`^W[C^_Y%[O!O^<7G>^$+W'3^;)_[F;^:
M&O%W3^0?VO@7HIO^\'[!\H5SA`JY2E$1*)#@H4=NH.KI,3TB#Z)PZ3CV#V;[
M#Y0U>K5S%(EN`!UF45ZNY*?O#"(G*V$PM^HVX&[Q'J'I.`@;S[ZHGY,RJFU#
M,HA\^':=;X5\HIHC.-D`B,)9)FTX^>*=>OR<BPJ[T8R,FV1'#3UR.>NQ("B0
MJID5$NQA[>V^[#F@"M9Z@1D4)Y+/')MOG2RNV>2JHQQ'&<\(S@W`8\8XUB'T
MVUA[GA.BVR+R9*7QWZS*N[!1K5+J*-V!R>USYN<4WO4)$Q#I,=+:TAUJAEH"
M,!&CX,NI8[RV:7,L$`%X::(UQITPS:U`'$.8>4F#*30*CBO(U7EYJ\T6<Y17
MB[7VMXEH)<MW!UD:PX\FL=6=Q=I1CULHE"L)/)B=B%232?MFCWIDDQ:E4W/9
M=YCPX&RUHA0<D(QKR$U4KE-O%X:TMK)SC3R*9N7LZY;O]6YH/8GEA3\+36-:
MSGBAUOC_`!%%H;[)4.CB^B0-MDLG)2\ZJ>]G=G0E72ZJJ29H9HU4;.DE$52F
M/K,YC&SQ9)=*@*2<I^&H>5;I3W/D"U_,B?-I28E\Z9`QA+S(-LN4^QS]IX]^
M'749?E/.5FID8QC+-^9^0M6D<A3$5%2R6/II2JMF!48EF)D6!9!RJJ[67(N=
M,M36%_-J@>$PS1S\D%H<0*<AS9-6;E2AIN>N4&5;7CGCYCOD-26:\OEGE'B>
M3Y-Q&)Z?=AR56\!X]QI:ZE;ZU41>I8XC+9&SMQ<Q[HS)-2$6%L?T1<D$A,Y`
M!M9Z89HY_(M;8PLBF$:<\,V[*E!C7F/EZ_Y'X5V>\Y"JU2QQG;#V%G(X^HL)
M1KC)SN9LGQ5K=3+6[-)F58YIQU5E#M&/M!*0;%\Q7,=T>4]29-3NA=EH;`DP
MB4@23DBO;-*/2`I1ZU1ZNA0W>"0QS&`HE+WA@`2CL0PAZ.V^X]HZR+<MLOE#
M\T-"%GT(5BO8FH/Z0W\P=29Z0WU%_HG>4'.-YQ/R8Y["(`'_`"JX;#L_]'^D
M#JR\4`#Y/PK(/1.^/A4U5$2.""F<3`41*(]!NDW8(=F_;V"'8/L"`ZPW=UE^
M^%)K`\P*BW=N(-`R1DIOD6]W/+-E9-Y2H6(N)7E\>I81-;*"1N:GVPV.VR"2
M`3<#),6L@B)7((>V31%R*?>D`=;1-($*/A5FQ!KBMR<XBXEL4%G2N2/VU>U?
M(F]0N1LC`TLCQH]-:8!&CH1KBMOT0*M76)"8]CQ4;(;IK*`J8W:H;1M31F%2
M>Q%.<U[H+LU[C#B^JYTR1R.@4)B-ROEJHT^EWR7;2BY(J6C:.>0]II!M`&ZX
MV+G5&TB*+ET@4AG)$4>\`12*.C:NL6#Z*-B+5K*D%9^#>%;;EMWEZ6>Y&*]F
MK)6+M;Z`PO<NRQ+>KU242-ZA=+=04Q-'R%@@&Z")4SI'017]61,X36,DF)6)
MSA"&1+8`QB:UJ8^X)88QE>)&\U>8R<DNF6\?<_JSV]/'M%PDMDETH\N[O#-4
M6:BPI;N><*=1S[N`0#<B`))G.0S,XF-5->E&P;12:$I^.G$6H\;3WQ2MY-SE
MD`<D61:YV7[L615K^/VWNVK9I)V2),YC&(Q$E,)LD1<@E]`,*1>E,FVJG.+C
M$JUK0UMD*523<J1`(!C&'<3&,(]ISF$3'..^^PF,(CL'9YM14E`KQ,@VXCS@
M?^7'AO\`_EEX#T(4]/9'_5&_UPZ$+8T(5#>0>T0[![0\H=GE#XH:$"M<,\<D
MV2441.810*HJV(NL()HG,0IE=UE>\]!90G483@8"B/H@&I2ZPHS*BOG\?\]\
MUEROR)2J&1&%HIC3&O(2RXRB;O3,<1,KC>RX5O4?1S*/X2HRKZ_/*PI/`XCA
M4M1&ZSH135:$+V)CUI4IK@"XP;::3#ACKT+D37P="`->[3PQT+<R_D[E<PH]
MWI5NY-A6YFGY=X*W!IERM8EI$"M'8ZSY;Z[7;?1;%!N2!$MZY7[.X,H$JN!7
M3IJ0&SD0344-JYCI#;3K-#@[FDQA"J&7G1JR9%%T#"FJ%,(;H9TEK!;["IR#
M0AV6>Z/A.:'GQR2H1,XSD)!KP#U1;P]L(SZMG?5ZQRJ&.I^W2RKXQXY!R/M6
M1N4I"('42$YL<V#Y-EHB0QM%,8Q/P5T5K5*<&S(DB$2(T0HAFWTH);GSGRQX
MSC[RWS)B?#\QBKBE"9^<5J>IT#-$Y66<USR#77$!5$K&^;SD5CBQL::Q13<5
MI$TD9],*IMS"0C4RE)NT#E()A1D5HO,0:HP73R1G+*.6,XXWC9'-]/QPA#<^
M,98JK'&="%K3BZUHD-BIU<$,FN;0V=HSUH4E9"T'</&KE%6OK,HY-)$"+@X,
M-TF46,F!P,+-.FFJ"HG3=HYEDB-K5I)4QN&_(7*_(JZV"&M:]>C4./U)8XQY
M%0\1%Q*RB?+E>:EE[55VDA'2#T6;:EU-E&27<(F.U<A90`P%%N0`RSA#+$&K
M>W4+;))(IK7IFP;F12$BBHJG$P&$VP=FY"@)3'VZEE.H!$QC=NX[>0`UF5Y7
M0`-NP--)8C["8?S`U0)MB>6FHJ4>;!>?OB'TRNW[&6':1;&`RM9N7+/C)6Y^
M-,LHBB_BYO*4%&OV:JB)BJ`BNU,8IB`.Q@,.^JL2P]N)R-D\<P4KF7BX"?0[
MT8Q3-VSP^GSB2<!4?M3B8<BW3&QR=<AS)Q[(A2%;M$U%&YCG*@F`%`QA$1\H
MZ^1WKP1P6^7E][F.:'S'%QJK/`N><$NP,#"TDK\'Q=RCTC+U#L[!WJT&(]GG
M'U7M'53?`?!(@@MAP<BB<$NNA,WR+X<WW%^#LI7R.EH,DI7JFY=1[:$JD3[;
MOI,`V2/'IM69Q4<`40``V'?7)[S^&=RNLK^"P507/.`5F&5>`E?X79+RO8XR
M1OT=*1K=DT*A"UAS&+'F&X*[&45<)^R=?K\I@'IW[/)KQ>'>%-XODX3FRS8:
M8U&KU5*7@//%&5>W7%7PPW+-&*D3Q*-0:-2)*"H9!KZ\X[LQ3=XHJX2%P9<-
MNST^C?RE$-?<NZ_<QN%@/+80W9EWI&&[$Q7O7B_';/'%>0A6KIR[.(HF6754
MZSF%(G0`#V]`$'V0*`!KW`F[.<V0,JZH)LPR)T-;5%85OF/S_P"<.JYE0_:"
MFS+O*#%Q_P`H=Q]_]%;DA_?&P%KIG_:G]L>1<=_^\_=/PJ="?E-^87^?KFC^
M8Y=;X@674TD:$(T(1H0C0A&A"-(U(7"G_P"P<U_W(D__`)$XU5=/Y?#\*>50
MY\-C_)\<'?\`T5,#_P![6OZ=^_F_OHR;M"G'JU)&A"-"$:$(T(5AAVV_T>QK
M->#""D,JTW8[H'_U"O\`\4?6F[>@=[D6.\%0[\/3_%&QC_W6RM_?CR#JV?\`
MS#NR(N?\@;Y\I4T]5+4C0A&A"-"$:$(T(1H0H2\!?^8(_P#=>S?_`'S+3JZ?
M6[]D)J:X>77.E_S.%,U*_6M11H0C0A&A"-"%KKAN`_$`/YNL\O\`W_[GPJB]
MTW8[Z^"7O/B?]-?Y_P#2U^@_L:^3?:%ZG-.<&&N$'B^>)#<,Y1V6O:'(E"XQ
M5NLNL;82RCE%)Y-U:$LKNPBJZJ-<>MVZ3=*6;E`@&.)3=6YAU\VO4B9?\'N\
MJ[PLR03`^D;4!D!!SY*%[FYCJE[FWB/\1^B(K&D9E-4GC_\``(H@867*\=@Z
M0`.&W(<![1WW[:3\37G;OA%Z)-WN['.F5D5GR+;,Q23)?UB]&B$*`!7ON*R_
MR@3@#^L.6/O-^0WN)UJ]W\6]B_4>11]XL,Z1^;RJT?XP!P`/Y6'+'L\W#?D*
M'_@0.JYG=W%#"U)?J/(H.[P86X4N=\WE7&G/'?\`#ILD>O$S<)RKD8QVBY;/
M8YYPSY`.6#]H\:K,W+.09.*(JU?,UD5QZDE2'3,8`$0'8--F!8JP0;)?J*AV
M]A72=\WE7)'QPO#3,L5<:IR>Z_MA0MR_^!1G8/6[8U9(Q[:SN3ACWO3SR+5L
MF4'0&!;I3*`F$I0`)G!L7/\`=/U%1=C>#NK+HP^3RKCSGC1>%K9HV(B+!CKD
M1,Q]>D_;BNM93@MFJ0;P$CWPK`ZAV[S&ZS=BMZ0E$Q"`8Y1'J$1[=+L7%_9/
MU%0[8P7.?F\JVDO&R\,-O./K,E1^2Y;+)QJ,-)6(W"7/"M@D89!155&'?SBM
M`/*O(E$RQBD;*+&1*GL0"@0`+JYF#XT!1)?"G(4^V,'-(<X>KRKGH>,[X6;:
M.6AV^.N1:,,XB/:!S$)<&<VIQSN$!1\L2)>-28Z*F\C4G,L\6(@KUI%6>*G`
MH&-N#['QHNM[%T8YBCM?!X>D[6WE74:>-SX9<<6#)%4_D[$DK$8^AJR6,X39
MW9_:Y%2@)$E&4"9+'X'AT9)-$I%O5Q3,<I2AOL4NT#@>,FDR7QWCR*T8YA(H
M#G0WV\JY;3QGO"R83T'9F&.>1;*=K41[0P$JWX-9P))Q$.9%5JI&,)0<>#)H
M,%6:QD11!;NBICZ)2CVZ#@>,FN2_4>1';N$QH<[6WE3CE_C`/`8A2D*SY6])
M0`H=7#?D08VQ0V#J,:EB8QM@[1'M'1V!B?L)FH\BEVL[(1#]GZZJ'\8!X"[A
MNRY6>4/)PVY#[_\`>6.@]W\3R2)FH\B1Q<MYSR+`KYOUUG_E`?`+]8\L/>;\
MAO<3JOL#%O8/U'D5?O1AG2=J'TUC5_C`7`0R9P(QY7=0E$`ZN'/(,A?)V[G4
MIA$RAM[)A``U9*[O8J9@!DN`C608#?H2/>.Y3@9<@DS35$#Z:C7A_P`:?A72
MLR\K+W+,N39(+*M]QW,U<$.)^<GSE5I5L3UBGRJBJ+.J*J%`TM&J=`=.X%#M
M]G6R\=V<1L6K-H@5",>#FJ+,2?`M=`<ZBC)`U\X4U*1P>/\`\!@_ZSY6?G\-
MN0_N*USAW:Q$&(D38[M"N;B;F&((]7ZZN_E`/`;]9<J_>;<B/<7J?N[B7L9W
M'R*?:[_D^K]=5#^,`<!?98\K/SN&W(CW%:1[NXG[&;NX%;+Q-[XU>K]=5_E`
M'`3]8\KO>:\B/<5I>[V*>QF[N!6]??G'J_65!_C`/`7V&/*S\_AMR(]Q>F.[
MN)^QF\?(J9F*/884>K]=4_E`/`;]9<J_>;<B/<7I^[N)>QG<?(J^UW_)]7ZZ
MJ'\8#X#AV`RY5^\VY#^XO4AW?Q(?W$W5YDNUGYQZOUU7^4!\"/UGRK]YMR']
MQ6CW?Q+V$S4>1':S\X]7ZZBSS-\:+AQG'`TGCND1G)9U87N3^.=G:MY+BIG2
M';&B\<<@,894M"BKMS4#`U5:5:F/5$R*%**ZY2(%W.J76AO=F_N8'%D(Y#&(
MW^:H=K3HFJ&3FZ_C\JE,?Q_^`I3G+ZGRJ-L<P`8G#GD,<I@ZAV$IR4L2F*/L
M"'9JAW=[$FDMV,PPRB,#O4*?:SR:"(?L_75W\H#X#?K+E;[S7D1[BM0[`Q3V
M$S=P+5UY^<>K]='\H"X#?K+E;[S7D/[BM'8&)^PF;N!(W]X$8BCY/UU@/X_W
M`10ATSL>59B'*8AP'AMR'V,4P"4P#_P+\@@.IC`,3;5(F:CR+*[%7NK(]7ZZ
M;4OC.>%J1Y)OR8VS\5S-J%6G%0X(YJ[R:<)I%12<2:OW.N^=+)I@(`)C;#U"
M(@(]NK3@^+EMC8S+.\>19W7MKC:)I_9^LNA->-IX9]A2EF\U4.2LFUGV#*+G
MVC_A'G9ZWFXZ-516C6,H5WC]8SQM&J(]3<AA$$3'$Q-C;"%?86*C^YF\?(HB
M]-RDG]WZRYDGXS'A:3C!]$3..>04K"R?>*2D,_X)9J=QTBZ5CV,.=\[;K8Y/
MUO30D8@R%0!`PM4B$'<"%V8P7%FFT)$R/#R*V7/:\PCDS?66T[\:+PNY%>"=
MRN/N1$L\JRZ;FKNI+@MFYTM7%T%2N&ZL()\=]$<JW7(50IDP*;O"E,(B8H"$
M^R,8A9V+X&N@TQX%;:9&,3J^LL[OQK/#$>V$EO<4;D>K;TO:T$K8MP=SHYL:
M9891=6(+[<.L?+O5`C#NUNXZSF[H%3@78!VTNR,9@6[&99.2'F3#V"!C2-'U
MEQ\4>,YX;F'D+R2M%YCOG>1,F73*=FE9WAWGAW*O)VZ3"\HK'F=M,<,#+0U?
M:*)1T:58%7*$>V12.LJ8G6-;\#Q5]<A^KS+0V]E@@T_-^LG7+_&`.`B8"!&/
M*PH"8QAWX;<B/FC#N(]M+^+J([OXG["9J\RKFXH]I`B*NC]=7?R@/@1^L^5?
MO-N0_N*T_=_$O83-1Y%7VL_./5^NK!_C`/`81W]3Y6>\VY#^XK5#N[%_<^V9
M$Z.[0CM9^<>K]=1OY)>-;PLRI$8C85IGR>,M4^2V`<E2?KW$[.+`B%<QY?HV
MV6!5-%W5$5U%!BXE<"=GS8A['EZMV[N8B)1Y@:7-(@Z,>&C1IWDCC<\.``:6
MQIYN31SC3F4CC>/UP'()B"UY6;AL`BGP[Y!*E#T0^943I9TC[!V"("(;ZP3N
M[6)B8X"7.--;28<'-J4#B3GDO<1:<8^C]=8P\?G@'V;L^5IA[-Q-PVY"B(CY
MQ_X$AVCJ`[N8H/[N\:SR*/7]/S?KK$Z\?+P_'B!FSF,Y3K(F\I%N&/()8HA\
MZ)%J.H00_-`=4WWNI?;^T-GR)L!F_P#A6CMB9\GU?KIM8OQC?#&B+%(VM"J<
MIE9R1$!4?.>&_(54[<H?H6I0HY2I%'\P=:+CW>O^'RMC=[N^R:XM!)T5*(QF
M<#'F>K]=.87Q]?#^(5,A8[E4!$@V(4.&O(8"AM\0*4`:N[%Q4"`D3`-[S*PX
MU-,8V:?D_76R3Q_N`A3;E8\K`#S%X;<A]OC?:5K&[NO?S.%XV,[:#5Y$F8K,
M<ZS1`_)^NLO\H#X#?K+E;[S7D/[BM7=@8I["9NX%?UY^<>K]=8EOXP#P(,F;
MH8<L#F+L8"DX9\B#"(=0%'_ZE@!0V-VF$0`/*.FWN[B,Q[6ODO:":S0!OT*N
M9B4V6PN81']GZZC39?&GX9/>7F*\P(,.2BE+IF#<R8_F'"?%;."LJE8[K<<5
MS<&@G!(U-2359*1]2=B=ST`B0X%*(@)P#6^;W?Q*7=[(9:)<*&Q)JW@N=UYS
MKQM'>C9.3+3DM?"I-)_Q@+@&7?J8\KAWV^9X;<AO8W\N]*'7./=[%+5ILB9$
MZ#R+:,<N\D0O1WH`#RN*R_R@3@#^L.6/O-^0WN)T>[^+>Q?J/(G[Q89TC\WE
M6,_\8#X"[AT,>5P!MV]7#;D-\C:E!J0[OXI\:1,U'D43C4F;SKL>9EB`:>!P
M5O\`*`^!'ZSY5^\VY#^XK3]W\2]A,U'D2[6?G'J_71_*`^!'ZSY5^\VY#^XK
M1[OXE["9J/(CM9^<>K]='\H#X$?K/E7[S;D/[BM'N_B7L)FH\B.UGYQZOUT?
MR@/@1^L^5?O-N0_N*T>[^)>PF:CR([6?G'J_71_*`^!'ZSY5^\VY#^XK1[OX
ME["9J/(CM9^<>K]=<Z4\?C@4\C))HDRY5"JZCWS=+JX;\ARE%5=JLDF!C?:5
ML4!.<.WV-1E]W<2EBRV1-A'-YDQBSXQ)'J_74=.&_C7\-L(<2.,N'[Y%\F6E
MTQ7@W&&/K6WA^*6<+&Q1L50I<1$2[=F]AZJX2>-/6&BG=N2_0A`OGW#6F]=U
MKZXVRTNYU0C]%5,Q>\$0=9!AT8_]89,O$I.?R@/@1^L^5?O-N0_N*U1[OXE[
M"9J/(K.UGYQZOUU4/XP'P'W[67*S\[AKR']Q6D<`Q/V$S5YE)F*/<Z$1ZOUU
M7^4!\!OUERM]YKR']Q6EV!BGL)F[@6CKS\X]7ZZN#^,!\!/T3'E>(?$X:\AP
M_FTD=!P#%<DA^H\B@_%I-W%N\F##F`%/"Y7?R@3@#^L.6/O-^0WN)TO=_%O8
MOU'D5?O%AG2/S>54'^,!<`3?]8<L>S__`(WY#>XG4'=VL6F_W$RC,#R('>/"
MQ\8_-Y5A4\?K@&X`$2MN5"`FVW%SP_SXV*8#F*D)0.YJ"(%#93M/VE(':/L;
M[;KW7Q8@@RBT5<Z(X:&G,JIG>#"797?-Y5'CB5XV?"K#6`J1CFZQW)\EEA'=
MZ?/DHKB5GF69I(6+)EVGHPH/6-.70.J:+?HF.4!W*(_%V"-][O8G+G&S++F&
MH@')#0E*[P87+98:YT/W>520_E`7`']8<L?><<AO</K)V%BOL7ZCR*SWCPSI
M'YOTE:/\8#X`A_UARQ]YOR&]Q&I#`,6(CL7ZCR)CO%AG2/S>5'\H$X`_K#EC
M[S?D-[B=/W?Q;V+]1Y$_>+#.D?F\JQ#_`!@/@/N.S+E8`>P`\-N0^^WQ?^!6
MI#N_B<*9$R.\>10.+VC:ED;,U<WZZI_*`^!'ZSY5^\VY#^XK3]W\2]A,U'D1
MVL_./5^NC^4!\"/UGRK]YMR']Q6CW?Q+V$S4>1':S\X]7ZZJ7^,!<!Q,4!:<
MJB@)B@)C<-N0X%*`B`;B/VE#L`>SH]W\3]A,U'D0,6?&DB'[/UU&OBIXV'#+
M$>)QJEQ9<DVTS]OF2[*=".XIYREDC1UJO$O,0ZI7#2J')WZS-^4QVX=2J0B(
M&`-MQV3>[6($N(;$61GIT#FUJIN,7@@6[(,<C<F3XPTQ4DP_C`7`??M9\K/>
M;<A_<5KGCNWB+3:$B;'=H6AF*O<ZS$>K]=7?R@/@-^LN5OO->0_N*U+L#%/8
M3-W`K^O/SCU?KH'^,!\!MNQERM_/X:\A_<5IC`,3]A,U>95S,1>QL8CU?KJW
M^4!\"/UGRK]YMR']Q6G[OXE["9J/(J>UGYQZOUT?R@/@1^L^5?O-N0_N*T>[
M^)>PF:CR([6?G'J_71_*`^!'ZSY5^\VY#^XK1[OXE["9J/(CM9^<>K]=8%/X
MP!P*,9(OJ_*-,JRJ2!17X=\A40[Q0P@!C*'I0))HE#YHYA``T2N[UX$^W-8Y
MDTB'.H$,_HDKF7[&[V#LY8:9<`?0IC&KTU\N'XQ%%_<KE_\`RC?XT7_-!DG_
M`)LOLC_Q8_LE_P!@_P!/U];ZQ=>E_<6*UX>SB/1;Z=JHUZ]V=?H7.(N.9D6>
M=PV*LH)/6';A-IUJ"=0$R*NUUB%%;N@4V#K,.Q0``]C7Q*[WAUD$.<&$51(7
MUK8:*>!:D,]A9Q$'+(L4];*%34:.&)F;MH];KH).D'39V@0R*J9DE@V$IA`Q
M!*?YDY!'%/Q"?*F0D%Q?H*DVY29M%X`V>\%?-J14.R%ZZ1CV;<JFRSEPDW,1
M-(B:JZHD3$Z9U5A21,!"E`YA-MZ(AOJH8MB.:9ZR?96&Y&MU>9<0)-BFFLHH
M@Q,W(4H)N#IMQ7[]TL!RIN$&K0Y$DFR"Z94E"]XFN(AN?<0ZI,Q3$GU!_K>=
M3[)PO*&Q_96=*2C5C((`A&%5=**LVQQ!IUKR!$EG`-$D53(D4<E9ME%E$TSJ
MBGW2A#=)B"`V]?Q/Y?K>=1[*PSHMCO>9;4H\B6H,DR!$-%Y!91NT2>&:)N7*
MY6XN!2004$AC&12'K.)04`I>T0Z=QT=H8GD#_6\Z;<)PLUAH.\M,TI'G<%:-
MF<8JN5JHJHGWC<%C'`[=-)?N%&Z)?:]0XJ=3@%`3`@%$-^\)L=H8G",'^MYT
M^R,+S-KS<:SQLC%R!E2H,V;KU=14CP46R"1F)DMS`5VV65*\9@NB7O$>\3^C
M)B!R"8ABCJI^*XBPP@_UO.EV3AD:FPAF\R#NF";LK,4XWK+WB1TS>U8.W(D*
M8WK#5$[AN<HI$$%%B"F?9+82;B.H=KXCFF>LAV$X:(0:TQ&:K14N%:+K4J?7
MIJW6$T9&5FM1<I/6"84!%9O'0L3%.Y9[)&;H-U'XLVC=DH*INZ$P``=!5!'L
M.U\1A&#_`%D=DX7&IL-Y+B.3BY)@QD6S-JJVD&;5ZW5*BD!5$':)%T5"@)=P
M`Z:@"&_;VZ9Q;$1DF>LEV5AH^*V.]YEN>U[/]8M?ZW0_4:7:V(9IGK^='4&Y
M`V&\$>U[+V6+7;V=FZ&_^LT=K8AD$SU_.CLYCN:X-LFN@+"+%@4!,:.;@4`$
M1$4T```#M$1'I[``-3[6Q'Y?K)]A8;T6ZO,M%PFQ;)F549-VX`BHJ)Q*T'NS
M@EOW/D)N4I0$QS;@!0\H@';I'%L1(I#X?M*1P7#I<72;-L&BC65JQ*#)VFDX
M[AH"RB30SA-LFW%N)CHJ*EV[@SI!0ANK<1!94-]O2W[--V,XBX!I:^`,1SJ:
M57V>R,1#4N][7L_UBU_K=#]1J':V(9IGK^=/J#<S=01[7L_UBU_K=#]1H[6Q
M#-,]?SHZ@W,W4%8=@U*&Y6+8=A`1`K9MV@'E+Z10`-_/H[6Q#-,]?SI&YB6(
MT:@N;'.(*35D$&!XB05B7AH^3*U!FLHPD"D*L=B[(D4P(.$T52")1]+8>W3[
M5Q#-,]=+JXT:@NK[7M/UBT#_`+70_4:7:V(9IGKIBYA]-&H(]KV?ZQ:_UNA^
MHT=K8AFF>OYT^H-S-U!'M>S_`%BU_K=#]1H[6Q#-,]?SHZ@W,W4$>U[/]8M?
MZW0_4:.UL0S3/7\Z.H-S-U!:KR$CGR`MG+-$[<3D4,@":14SG162<H&.4";&
M%NY1(H3YTY0'V-':M_M6K+[0^5G$/(8(Z@VJB"V0CVFP;M&YQV#<YT$3',/L
MF.82;F,/LCY]`Q6_@0`F0_;1U!NC4%7U!I^L&G];M_U&CM;$,TSUU'JXT:@D
M,M/Q*+U9B"D$9TUD(]N[9G/$>N(,YA988]RJU,LT62]9*T6*U^:]833,<@*G
M`Q"G:V(9IGKIB[`F$!J2@,[@D7R$8L>)2DG#99XC&N?4$7JS%J=,CI\FW`!5
M,BBHX(F)MND##MOOH[6Q#HS/73%Q9F&H+?\`56H*)$.Q:$[W8>GN&HF!00*/
M<%`";GZ"[F,;;L#1VMB'1F>NCJ+<PU!;7M>S_6+7^MT/U&CM;$,TSU_.CJ#<
MS=01[7L_UBT'_M=#]1H[6Q#-,]=!N08(T:@M-^2+CV;A\\0CV;1JF*KEVNDT
M21;(%$.\7545*"94TB[F$1[-@T=JXAFF>NH]7&C4$,B1K]!)XT0CW3-TD1=H
MY039JHKMSE`2+I*)E$ITU@'<HAN&WDT=K8AFF0_;1U?0(;P6R9@U[`*Q:`.^
MX[MD!W*'S0;]&P".^CM;$,TSUT=7&C4%SV"T'(+OVK0\0[=QBY$9%HV-'N%X
MU18@J((O$T`,=NHJD'44#@!A+VZ!BV(PB6S/70VYAXB0([P73]KV?ZQ:_P!;
MH?J-':V(9IGK^=2Z@W,W4%QY-Y`1"L>A(^U4>K+R#:)B?7?4VY)*7=INE6\6
MTZPZU7JR#-4Y2%#J,5,VWD'3[6Q#()D?VT=0;\F.\%T#1;%P3Z(R1$!`.GZ"
M@'04#'$.[$A1`H&`X@.P[B`]NI-QG$6&+6OC^T@X>PYH;P68L<T`-A:(*#N(
MB=1%$YQ$PB/:82;CMOV?$U#M6_B@-F`?MHZ@W1J"N]KV?ZQ:_P!;H?J-':V(
M9IGK^='4&YFZ@CVO9_K%K_6Z'ZC1VMB&:9Z_G1U!N9NH+630;*F52*UCS*D4
M,`@D1!3NT@^9%7Z'Z"@C^A'0<5O_`$9GKIFY-T:@N=&/(":02=Q)XN39JNE&
MA'D>5BZ;'62[SOR`JF!B@+=1N=,P>4#!V]H:.UL0Z,R'[:74&_)U!=KVO:?K
M%H/_`&NA^HT=K8AFF>NCJ0;3S=06-1BT`@[,6P".Q0$K9L(E$P@4#;&)TCTB
M._;H[5Q#-,]?SJ/5QHU!<MFYA)!Z[8-%(TSZ,%L,FR;*MBOH\[M$5VK=XDW]
M,A7+<IC])_FB]NVVF,7O\*6/.^X&&D1RYCD3%T;,$#!=$D.P(H*PLFZJO2*9
M55D&ZJJ:0B`BDFJ9/O"I"(!Z.^W9I=K7_(V8/WT^H-R`:@M1^@V;G:;-6B:2
MJIR+&!@FH8`$@%2,*H`5)%,%CAU=0"8^X`4-]]/M;$,TSUT=FW5P_CAIS4!<
M$LS">HN)4WM3[6I'!079EHA-J@R13!PZ=.7P.U&:B";8IE3'2,84TA`1)U`;
M1VOB,869GK)]D89E#:\RZ-;?05CBVDK$GB9:.?-6LBPDV`,7;*0CI)+UN/?,
MG3456SAFY:'**9RFW,4-Q`!';2[6Q'-,]=+LZ[MHD!MC>"[_`+7L_P!8M?ZW
M0_4:.UL0S3/7\Z.H-S-U!'M>S_6+7^MT/U&CM;$,TSU_.CJ#<S=01[7L_P!8
MM?ZW0_4:.UL0S3/7\Z.H-S-U!<A5-(CLR)V;))(`#90C9L8""4W>E*<3DW%=
MP@&P$`![-Q`=PT=K8AT9GK^='46QJ;J"Y[)ZR==Z5-.)65[QP8B:;9!8?5F3
MKU)<42,C.1<G]8(8#['`R`B`*)E'LT=K8AE;,]='469AJ"4P1[,0[6+3M#M#
MU=`0[0[0W[OM#1VMB&:9Z_G1U!N9NH+51@X]N`%1:D22`J1"()%320222%42
M()))$(0B'T40$@>B(;:GVSB&5KB::W`TF%-.6B@Y$NSVZ%M^U[/]8M/ZW0_4
M:AVMB&:9Z_G3Z@W,W4%HR7M/$Q[R3D"1;!BQ0.Y=O7@,VS5JW3[5%UUUP(BD
MFF7M$3"`:.UL0R"9ZZ1N0:(BS'>"XS%_'/!7=$+%'CVP`<5$R19D3-5VZ2Z+
MU9TFLN!`(0AS`&R0B4X;DVV-H[6Q#HS/72ZOH&H+;C%XJ5CF<LQ]K)"+D6+6
M1CI%D1BLRD&3X!79.VBZ(&*LFY9'(J02[E,4=PT'%L1&29#]M,7*1.-B\`6(
M9A6MQHW;+F+O'MA`4A,?=-ML40.!4U$A(0>]1<;&$#;]G3Y.W1VOB.:9ZRD<
M)PP9&ZO,M"?=P\&BR4=A$L?;!Z2*8>NBU1![+.TE31[!N)]C*.'!D3=*9"G4
M4Z=B@'EU8S%,0()(F>LAN$X83`AL-Y<\SUBN18K8D8Z,W263<HH+QP=X\$3`
MFT5!'U@$D%-A*(',50G3N<O;N%O:=^#HPF1%(YV5/LC"R(0:*<V16).HY!FH
M[;-(\\>4Z1R%3*Q`BHNC-D$Q9.E7*485!=RJ7H/WIDS;[`8QQ`--^*8E--KG
MQA#TJ3!(81A8`H;JJ65N]8KO!CDPAEY1N0HR,<B=LFNQ[\RR+915L+=TX317
M5:J=V8Y@(H8!Z3'#;4.T,3S/]9,83A64-]5:KRP5]DA+.G*T(W1AD3/Y#OU6
M#46$<BF<5%WZCHQ44D3'1/UJ',CW)2B)P*`".JGXKB3'0A,/[R!A.%DP(:.!
M*F.18/F:+HK)BJ14!$BJ`(JI*I]0@14A@3*&RA0`=@W`-^P3!VC'M?$<TSUE
M'LK#.BW5YEO#'L]^QBU_K=#]1H[6Q#-,]?SH.'RQ0P-LY*`M86\>4RACMF9"
M(B<BH';MR$`2ID<&4%02]A4D!W-['LZ?:V(=&9Z_G1U%F9NH+FI*1[CK!D$6
M[4*1N?NTF[)T8$'"@E0>BFR5,H#5TF/4F8=@$I1'2[6Q#HS/7\Z?46?)U!=K
MVO:;=C-L`[?-%;HE,`_/%'HW`0]CS:.UL0RB9#]M+J#<S=06!O#Q[0ADVS)N
MBD90ZYDB(H@F997?OEA3`FPJK"(B8?*8=2=C&(/=:>UY="$;605:D=GMT+F.
MWD"R=L63L\4T=2+Q1A'(+`P26DWR#?UU5BT16`#JK^J^ETEW,!0$=O9U'M;$
M>C-A^VD+DUM-&H+II-FBP`8K%EL&X*;(-S!WFW]+(<"=)P+Y1$-':V(9IGKI
M=7T#4%L>H-!_ZP:!_P!KH?J-':V(9IGKIBZA]%&H(]KV?ZQ:_P!;H?J-':V(
M9IGK^=/J#<S=01[7L_UBU_K=#]1H[6Q#-,]?SHZ@W,W4$>U[/]8M?ZW0_4:.
MUL0S3/7\Z.H-S-U!5]KFFQA*W11,9,Z0G23(F;H/MU`'2'3O\40';6J5?[Q.
ME_QBX&-1,>%3;<;N!_$:"[>"TOM<@_L5'>3?_:#+^F_KG_:_^VOT_EU;UR;[
M1^MW*I=2NG1;5F'(N%DRGH9`H%MI+F6FH)"SPCR'/,5QTT8S[`'A.[!:&>OF
MSQHTD>K8$E#I'Z#B`@&^PZH9S!!E`5UD*+^#\*6#B[QO@<<8V?O<KV>A5%NS
MJS6^S#&KNK)*((-F;:+D)`B,F:NQ"B;00;HKJ/%F+5--N=984P.1,:UC]HT<
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MKQFHXJM.O%LLL%.0Z[LI$AD9)TT;H@DT3$VTWV4YQ,;(`#8BN`((._6(<.6"
MK[+R0CE3R<SE0G[N[/R<QC[69)M?&"PP/#VOL(BVY2@ZIRB5M,J2M.Z!9ZM&
MC'5'*)91&$?>W)2M72<"1PB9P5J*Y#0,]C0TW9Q/.B2<HA3$:]>A1-S$LELR
MHM(HKX.)-_CB*MT/ENE,5J%(SGB-5?D7E2X7&7E(&3+)R.`%L=W%M4_MMS`Z
M29U6:PLZ@Y.)9,8\DD=!K8%&8&0*X(=RFNL$M+7G^"6@"&0Z,JKZHT$.;_,#
MLO%71#=2G0X+6/(6$,[\N'_)S$]QQ+(7M?B<:;L]DN=/R:MD#-EY;7Z#DF%4
M4H;V7,[-+>LH>IH-2J%B(*-;MG1A52%4V=\USH630!11"K/%7BZ2/C-I)$3&
M.>J$-03B<U[OQP><G<!4'),+#4W,L)8<:9"#D6M1KK,RM1H%8R*K+P^-,77V
MKU287CI[*,JT5CY<B3Z/2:1#D%WY%`6;('@'.@79*:-]2-WD^B1E%,3DC#RI
M\;7P"A)&HS-.B[O",S61W?2V`]FQ?#VN!E9"\.K8Y+9WU96L$4T4ME28V0Y8
MV6<.5'#3N-T@*"P@7GMO-[,\M+CLP:*!R+0,/N8$;`B1G/*HU^(;R,RGB/(6
M#<+4?-DU@Z-E:-(HR%VA9"BQ2%>LK:<K,/"6+)*=DQQE51]CN/K!9!91G%HL
MGJBZJ"Q7!TT52:[]S;=IC+<YH<Z)HST$P!B`*<^\LLV6V4?X<6U",2(4Z*Z$
MV3_DMS.:9@Y=LE\X1<.^HN#^35AH>#%*?9)^U=S2<>FD,*Y,HY6^%F5%=HS$
MDFF\4<&N$RG**.R(H,"["4*R_#X-:&<Z@DQR1I!IC1O9%'_U2EPF5T`61'R?
M"MW-6;>:.&://U$,X6N3KA[OB.2N_(B\U)*(FL1U;(V)I*Q2C9"9QIA*^Q+2
M`/E*';1;``JDZZC$I$Z<@N5+H=E`_#@+9;&BH1S[XC1Y$XXFXAMN#:,@IHT"
MB/$EA)9NY7-*%?\`)UMR_D:Q(XNXX8FFTZ[@*CPU?K]RLN4)AY#6+(XRV4L9
MR-D6;TFEF;SSE(K-LI$@V=O5(]T448X=#GX<`"R6T\XQC&@0H^-DXX0H5+;O
M?XD.>>4ZLNE,[CG*V6,E/^)N2,BYMSN>'6OW)'%],>MH6%>UG+C-_1U+'BPF
M4B-<,,VUE0O1TEF+62)&UI@O'I"F`(NMS&<U]P$IPDL%)81&-645Y(1X5.1+
MOLN8)DQQH#LQIR;]*5E8SWFNNR^(ZA'73)&-+:QKW'9CQ_P!5<25QKC7D'%V
M*8BV>>Y.VN2X]0:0?VH&=RJ(>KR-1;Q39DD_,D[!,R2U!FW':$.;&62:8F(S
M"OCX%HVM]<+1?SJ,@IXE*;C;?^1[G+5-L=]R]?;S3LJ6KF'6I>DV"A5V"I6/
M8G$>;;E%8MDJH\BJM%6EM)FK46VCSN)!Y(LIUD8KEN4AQ(JK3,-U=+&R`#P1
M53&BF-.?R)"=?+7I5Z!R))93Y"YQB>54M48?).28V]M<HXQA,8<;F&/(9;$6
M1>.4DVA`RKEZ;OCBJ/WY;+!$=3+M%<+!'%9/XUO$A'NCJ@X5SV0'"HT*9G7H
M@FU!]JB@5:J-?`HP9GY,\JL48KPC..<M\B)#(F5T[;D&/E4ZE0H_'_VRUNX,
M:W'X/)6V^%9VTS9I*LB#Y*(,K&O'XI.WH2[=/N6@:)/50XMG@634?[#QJB:Z
M_O:-FZ!%<`-=2F$SO^;*#@/GGD#%M><?=399,M%DJ3)U7)-Z569D:I553O&D
M&[33D)EC#IO#G*U9E<_1T/5TC.5>HHV&;<G/8'B+0P"LUQKKT`*NSB<"0\UY
MA5J4;<=9/YA9-QGA>%9<M;!+1]MLW)U\XRWB"E(R=C=5O'V)HV?H4!:;)EO`
M=`9M7:=_(N1)TE3VB<HDH+,@B9,5]`?<*8LI@W>C&G+FKIS95-TV_2B`YX(B
MXU:*J1JHI-="4C'D'EK*>9H^A5CE1EW'.7I/BFVG'F)Y+&T`2A/\TSN.DYF,
M-4FTIB%PO%/Z[#MO;J2!]:5FBLJ[(S21`$UD4Y!]P;&+`07T&)B&ZZ::!H5/
M6KZ:=H;0;T6TF.]F69?D#RJY"5BC9'JV2LG8$J.66?(^RP$92Z-4Y60@X[`^
M&X%Q#PSC[<Z7//8M[*YA&;;OTW:1E7Y8H$FHI$6*<8B9<60898<`!$DF)B:3
M7D$*%<'XC.;M!,A&-%EIJ%&3*:-&E(G(7(?F7C['E[:LLT66Q+6/&/$/*4UD
MRVT9"NM\0(Y>LN2X++LA23TG%%RDV5"9H5".%%!>`M4I5P<*.GO?(.$"@G3+
M@71#0UC;5%)M50C3\*&G%*B^@D?%;R*9L1EGDHCX=K?(L?>(S)6;&\#'J&R+
M2:5//EY"JIY";1EEO\71[C5L?S-AGZYC/UY\#=2&C2R#UAWJ#;NSE2',+!F$
M&`9&@:%=MK[`BU3'(!R*#_)CF+?J!BO#LEQUY)<@\F$=1]^ME1R[9J/6089=
M?U>XP;&7I-MIC'`K2<N+VM>V+A)..C&U2[^.:GVD%5P`X[Y!N1E_QY;6NJ%9
MIIR`T55H,R^`T/BT:`/@4@[)ECF%7<C91NU1OMZNK@N8>66+Z!@:9Q[#MJ"O
M!8XQ8QM.*WL:]0JL79/;=6Z%!O[<NIT\5(-7?<@CWA04"ACKBYH#V@.#6QK$
M33'+O+%/?B@)V3C9+W0C`D`0A\6'E4;,<6^S6.Z2]^J5_P`E\@4YS+'A:QSN
M_93Q%&1TN=V3.>=E\@4]-NEC.)9Q$?0)66432DRQJ:M:0<E.$B/HN3#YET@`
M&AI(?&LPC0#7313#*G+.(NF1+R6BS1!HC12*1&DY<FI<5AR`R2WGLB9CF,GY
M^O61*QQ^R1%Y,B28PC*FEQVNLEFVO5]S5\;2SC'"]:"*J=;43DES/D;:^;QK
M<\JF+M,X,RZMI<FRR`QL-I732VS233GIR1J6HOQ*(L/(!;2.;7'>%8WUT\?9
MCSO=GO$?+<YEW.LG)HW3E%0L8,TF$*G6,T2*-)-:\*QF4G3/$44WED<C/&QH
M]I+D9U=DHQ)TIB@[](SF.N)E/$E@B;)%)%&6LT0A'/2B0_$FO&V?%E,1`<%0
MSJ67AR9IY&98A,RO\G9J@,B/&</!+!6&M?O"MGQ+E%ZPG'=GIKR5LV%<)PYX
M2)$T>V9QS=O.'!=!=<\HHDY2(GSWB7:)EB#1NC7NXEL$Z:/C<7F3'5?EWR,R
MY1:5"4K*F18"SL<8\8Z3F"[N,,"@>H9SL%P:US.I%(V<IK=%>=K3(JQ9`S=L
MK%L73ENLF44RF(?3=^J!Q,^6"T6LIS1%1X%GO#[V]@$ET'49!5J7`S3FS.;?
M',]BW)F=\UU.M0]FYG8WJ.0X7%L':[QG>UXQO3*I8<H>1D83&RS1)A8JBJ\7
M%:+C:^E:7!C"UD6(-!!>V2ZXVVS+`CS8@1@(CG$1=GR4FA4%N(0<T.-9@:,]
M%3::-`"K2<Y\N(+D!7\:ER;%4"MUW&T,QI>&INIWYU,WO&<5Q]@9IQ?J_&M,
M-2M=<6E/(CA\DE+2%Z8((E8'26A5!`HJUSW7.B@$EY,0:A$<VOHZ*U$-Q&$;
M9!WAFKJSJ<\+;>1E-X)3N2W&1[IDS-TSCI:_.YF4IL">3K#V8CVJ4NG0,>5N
MNQB:T=34U%'L;%/!DWSI9`45ES=YL6ISKB9U#0)<:LX'#&FK0D!B0;Z9CO#D
M7F58,W9@HM?R'8,)<@+HYQG?<^1J%IY896J<M4)\U)BL3D<4U)%[3>/=[1>+
M6>[E>1Y9,E$;-U@;F2$J)B$66ULF7![`Z9+!F!D(`Y8CY0%6<\:JFG%@^Q+F
MPEQK+0<G[)/%Q*61<[\Y(^W5K$B$LO?K9=L9T_D7'7Z"H):O2S0M4QH^@KGB
M:!&Q1GK#1Q9\WUZ$<+LI/IG0B;FL1#N3,3"BF=G-<'3&@MA`B)%,128$T@1&
M:B.55F9C1!LS#7T6\F51[P7E3DOF"IX6M&0,MQ.;92!YQX:>QL:QJ>0&;['=
MA6PIFI6WTZ[2,QAK#XLX$EL<MFB:+9A+IP1_H2DB^4Z!-GG/N9>6RA8:X$<$
M136::#OA="5-OS98#WVG0$:!2:=`T"A96/+7D6WQS9[%5^0N9K$Z0I%&=Y^<
MW#!U=0D>,V=IK,&/8!YBS&]95IE/4L+.0I\U9"+1BJU@6B?:9!0\@HJN1)20
MFW`O)=+`$3"DTT&NFBF"9FWR$;=)T#D3D)Y;Y,WVOU:!QYR/SZMC14.8%GHN
M;T\8T)CDK+E-Q71*'+8Q/,KR^,30C=LC>9&49MW)*W&+69%(Z***0H=^>R4<
M/@'3&@DM;$0,`2:8<[*--"QSIF*EQ;*?S`3`\VJ'[.J@1.=<C)6>>:-"Q7>5
MV.7;E)EEJCPZR);,I6O'[.";XC0RV^RVRSHE1D*5C*[S$%4ZM'T6'=';OX.T
M2%=(_4564=`H":+CAMMSW,`8VU0(\ZJ&6M0$S&'!K`^#C")@W/E%G@\ZW&67
M^9L_7:E9$N1TY-%HW$?'V;R/,08R.]IV:;@XY`VBJ*(SZV0<40MNDXZ2HS)N
MC*LF+&O2:X$%PV;M0.0ZF<3,/)(+*'&B)/-$-^FG2M7_`*I"F92T=$<ZG>HU
M9*LJE_PE-887*/+^"LV5,JW*Q16=49*2I%_9,PBJC6K77V%BH\M1'S2DUGUR
M/L)';YNY;D=R1$31Q"F[@Z1P<*=/NKF!C0T.LBFGA%?E3#L4A:?,);31!M6I
M0*P[G7)..?MSB:3><_VE.I4#EI<,MX498SA&C?#*,-9$G.&K7CVRV>F,#/K#
M:EY"2.F9S(S;221(90K-N1J8BM[I]R<ZE@A!M,33TA71D.^-*IZU?RVUM274
MT610!#13'-PKC5CF#R.<8=I-DE\U95<1$+RW?42&!C"0BF6\[4`N/<769C#,
M+PMQ_:8\EU(FQW*1.^24@JP5_%LE4&TB1VTW<5O=<0Z#6@MLZ13'?S;J4C>+
M],8XM?"GHCDR);H<E^<ILQ<R"JY/AVLKCZF9LD*_QW&AW*5M]0@*^\A$L77R
MC12F((NFSDD2$67?%ZKQ-)V@[A$$FC(4U4P0=<+5@"@0IX*<M,<M%"K>[%A+
M:_:0>8Q$!G.B`@%(_B-:K*K%\S,AXMO&0^0,BY;5.;Q-<,HU-I797)4ZPQ%(
M%K\<"2%8QTUF&CBUI"Q6<-8N+`0**8IE%$55%-FW;9MEL:!$0-)HIC&N"ONC
ML2?/?:>;%8H%6:,`F+JV?^1UHJ<TTQ?R'S!>DYJU</X*_7BW8G@(Z>PCEK*7
M(N'Q[G;$=,C3XTK4>Y@X&BNCG3!^WE#074D]/(NT5A!(VMR`/,;03GI$*#7G
MAD71++YD=1`9&UY<BGMAFZ2J>!<GQG(F]6BX0V+;[E^ER>4)Z)>U.[6'&U7?
M&393]A0Q[%P2KB9)7WRB2TE`-623H6Z:R"2:ACD)GF393#&40+311F,*81.=
M5SI+IL!>:1$PT:E%OB)CO''([CSCD,:W(]9:X.S7DE=XS-CJ99KD93D^,DUA
M%H>\K04:@I8,;R21%GHLY%T1!\<[9=LY*<VAU[:7$B$+,.'=%9A<[L!Z-1T\
MJ2/.G).1^$W'[C;B/%&0)"D^MFM])=VK&\32ZA/'6I--;#2ITS*VUS),*VKK
M"0=IN+.U;1+B2F"(B5LNV4-U&OD&1/<^;-`@(0K.@B@CS<2BXS+N6R;L2UAB
M844F%%8/#GJTI$1_(KENER4QI1T.1,`]H;:NXY2H[MY%V&VI\J,=*XLA[)DG
M*\$K1<!+4B8M0V<\PU;/BV:M,H]6-ZABW*9"@O>67,4!D3$Y:H<-4-<52+S?
MS29D(`?%&]1S=:UK-GKFUC;$5BEF69;CD"V9#XSXWS([FKACR)C8[#DA+YJ)
M2KA+TIA1<<RTVTBH?'!TW,A%.&-GF(Y<59(4!13,T#/-%W$TM#0&-)JC2(9:
M<ZU2IU[=*!MTD4T-KCFAFS[^9+K%>4>6]L/@`DCR,M%^K$5@?E=F6QRF&*`F
M9YEIQB3*>)H'&]2L-HRIB&C'>3IX>Q230Z32#K8V(YC+-@000,X")V`$;(K%
M!R:BK#.O,3SJ*84#D46JWGG,.8*70[GD'D+R*JF,,8<U<'2CG(S./@%[I!5+
M(V`\@25K@KF^B,$QT#8&-0R(9K"IM4(!9K%N7RB"SQ^<J#A)VI+7$RF@Q::#
MOA,3;U"EUFD`P`J,8T0WD[<WF_+E.KQV4ED_)6"8R0R1S@DL4SN+,,P\@YS/
MF>$Y07)CC'&EY:!C.0BF\-8<?&1>`=).'?V7OE'JLP4[,X.V7,($0#$BC@WT
MA/O9!#GY**!7J4HZ'DSE*^S)1;5<K_?FK*6Y,P^%;5A!K4:JECBO4F<P#;LC
MS<^ZD3U<]S7D(?(5:2:,I$)5-J@T4%JJDNLJ58L7[%K8-:+4#3IC1Q*+9M[C
M$ORC(.2*5>4,Z7.&Y?25.L66,KT",B:77I+`>),?T*+LM=Y%R;N-N3S(J-BF
M9*BRBRL]`RT?%,(]FG.5PL:"Z2RXO"/0%O'^$&Q@"X\$*M.92VUZ--JF.89C
MHJBH7<>N2W*3-S.<JD9F/-D+`V+.V(H0<B2E3I5FO&/ZW;XJWHY+JJ$B&(*=
M5XY:O2D6W8=+F(DDZ[+JE4-(2:)!14LLW8@N:!"!X#NRJ!G7P0!=FR#74N5F
MS-V=IW##.BY;S'E^L-G=3Y)4BD+U?#T?9ICD3?\`&_(^WXRJ\'E$&=`7!L]D
M<25U!^0D0A6DY!X9>31<)H%1:G31*8]KX`B.H0HRYTS.O+VN!="BB@9][,EE
MD'*&3Z8I/UZ3N%]P1B2?R+DZ'D\D8LQ9!/[?+WLN+<:_<:Q[,M'6/[,YL,5<
MCOII)Q,+,5'#L8M-L,LS75*`A,J`,(N@*R<Z@'7F/I44Y!F2!QCR'SK!VW@'
M@^MS>8Z`T=8.X7T2_P!-?0$$A5BU;).'7K.XV^!AG^.K':T+E0Y>,9@,U*61
MLP8.MTCQKWTS:D72X.(`+Z81WX^:"IGF:X-;-)L6Q$Y@>#ABFD@\X\I<88&X
MOT:J<H+71WY@O\'DV]9WA[))NJ]GRL3T!"(\?WB5,XYW9RYKC"(>K/FQ%2H%
MD%C*F3G3$:]TJR^4?2:(VMQKH\JC=Y!SD\S.1#1IJWE[3YG?2KCE+P(B9ER1
MQ%N7^?):Q$9)C]KI[?$XIAUJJ0>^=(JH.?6'[M:-!<IU#")@$H&[0H;,LL=9
MC2`-_.=&9:)UT8+`A"!)XMU="\W.$^`(+$_'%ER"SG$T'#.*)?C&Y@[+7<0Q
MN4*?=,D%FY-I/H95Y)1\%7ZY.-,I1Y(\[!`D?[8.T"RKPAWBR+D4R7/O3K5!
M-!K@*!E`S\.94"Y,LB,(D54UY,Z3,A9SY^X7<;^.6",:W/*\9..<@R>3H"GO
MFF%#4AEC61F4JG#R<WEAM6J:Q2C;Y:(9W'-"*@91_%(&2251[P=3$^Q.?-)(
M&3+FC0H]3:6-;7GIAQE32XM72:R1G#"ECE:H-6LDOPYML)R(J3INB20K>3<*
M9GJE0I\)-(KMR-WI(Z<E+L5@[;'(S=`FJLW,<G=B1/GPEEHKMF'#IX4FW06@
M35"E0W6XJVUS3^<N?4*1BBEH1%)Y[P(SM,K]L5S?G%U;ZHLVAV63T5ZA!$F8
M"F&CN\B$D'LVX?*.E$6PH#U"LG3VVQ:I$&@YJ..*?5`Y@JH)SQIXDM<NYFY&
MX!QM;<?N\QYPEV;>WX74K>9&E:H<*\Q^QO.')ZU*U6:G$,2V:*/CD;A7&L3%
M=%>>SCN0D",'"[8IRO"HND$@EH#:8Z_*F)+VFMQ="BDYET(?EIRF<V6@`TLU
MWOF7K+Q37L=6X^P=)2JT.QR"VQG9IE+(6:8^8H*RL_6)V\1T;'IJP%ICW$<\
MD4FZ\8)5>\31%V$01`QH-)^%:6S;X(!KJ`,PY$\?!?+&:<IXAY%.\DYFB<R-
M64>Z""]49W=C=*)97E1GT[Q4K`]M.%<%G6;Q[LT<FP:L89X:+."X+R#M1P@1
M.-N4#S1#)J,=Y6;:^``A^09!R<.9+3@0UL3&?G5IV#GH=4O&KCN8ZD\UE6W=
MS#>-LZ4DR14DF9!</F:IB%7$2@J8RFYPWV#4Y\QE$!`1.GDWTFWB^D&T_)F`
M^!0RS3FCFS2N.N$KPER3M5/7S5<K[(7S*N0J*2"@<4NJRK8&..:%"P6.L%96
MGX>KV8C%J=PI*1SQ>?=$$J+R,];*FA'_`+O%W,%$(</#DI2$R]F'/$,M`^`'
MR)Q[?R3Y*,<A\A:S`95ON1,B,.',Y;J;5,3T9)*B8VR%7L<5R3+/R]2MV+4K
M3)6:ZV9RH[@U6=@EF@H.#-'<8W6*4`+-W$*`6_VZ=T$;6^&BUSMX<E2Z<WF:
M5Y/9$C)#'\SD*>H"><$HS%5J8TV6J2C5O+\>+":=L%4E[%46CQ,KRPB5FQ<2
M+19)M*I&#98`[O4V/DM:"X?%IX"ATV^$E@?03"H<B:[COG?(M4/P>I,7R+SE
ME=K(QJ-7N>-5JNT9Y,<9'D<B6>%O$AD.0L6%8J!MV+<9QL;ZLK'Q\I`3L:FP
M._*XE$%A*2+S*<YQ>T:#P45&C?4+=Y`$'TY:!R+Z#HP'2PIBZ<@L!$SF-T)D
M;@L?O#H]8H%%<"-S@7K2V4$>WM$0\F-[@UHAZ:UW:9.MDN-$-"[?=)_.A\<?
MEZIMNSK;M'YT=TG\Z'QQ^7HMNSHVC\Z.Z3^=#XX_+T6W9T;1^=5!,@>0/DC\
MO5;VB88OI(4'$NI<J])?-_-T66YE&R$WV3+S5,;TB<N=WD`BZQ$A'HR3\6JC
MT$#S$JQA(\/54BF45%:3D44^P.SJW[-M]24DIVGJZHHKI)I=TY;G=('*0`!5
M%=1-9-4P&`#%.;OS#L/:'4/GTPJIIYB0M]R%3<?2>-XBQ2@1$OEC(!<<T1(K
M*3<A-7(U+N5Y"+%Q'MW#:*#[5J/)N?6'G0T'U;NA-WBB0"UF$8T).V3*F-Z9
M"/+!:KA7H&';OHV$<.7,D0(QO*RSANU8,9!XD!2-W\FY**9!.8H*$`JGS)M]
M1=+=,]&M7,G-D1MU%+%"S0)RR)',W%)N(YD>5=D-)1Y`CT10.<YUBO%6R1V3
M=!0!!RILAZ728P;=M?5YF<JSKTJ$*.+E60L[!`U]88R39RR>LPD5'R<HQ.Q=
M"^(BV;J>LM7YDVR+E4J9$UDRF;FW`B1A.(`-C09(@ZM,/9>!:;2!1N@M<MBA
M%@=-TY.'<&A7*C1VU3?QROM0ZZ!(+=^5F]4(W5%%?J2:K@BY7((B8-RCTO:`
M4@A/9BJ"R^K5RQLXV8<-X><;1DD:6A7)4V,VUCY9$CAH:2A73%=P#5^BFLJ7
MOP/WB0*F)U!VZM88BN@[J5GF"#H"J"P#<ZNT8A(!-Q!(Q-V$:"J$U"H1Y9)1
M86X-O;167)$`_)U&)ZF9;OS[;@3L#:1$35Q>90$1EXQRIE9KD]BNN9)<XCE%
M9@UH;9&Q=BTK=""<.X\;1E^DVJ_4M%NY57.@9F>"IKTSQ?;H35Z2F$/+I&6`
MZT*(QXC`K:!S`="0?(6@\1;H_H>2LT4.@9%=QM_J>,ZK:.Y]O%(:V9!MD5#U
MZ(FE8B<315BD9AX19X1\)V[<ANH"`!C`-@F.8+`)`W:-2YL^`-H@&GETJ51[
M-76<?&NAGH)&'?\`J:$4[2E8AI$KF>*BV9-XHR\@1F\4(<$^Y(0ZH!N`$+OL
M&L)D3+4(Y5T1.99C14K'-HAHUP9*2G63`S;OE70OI!DR7CFZQ4BJ`LW,9F9E
M'K.-C$>.P(4QA`"]ADQ,"0^T(E2$Y@S)"3N;L9U6:G864LX#8ZSC];+,I4H9
MD[L=F=4</;5H>PP<-!QS^Q6%9TZ@W((MF#==Z[4+LDFHF8AAT[-\*`=12VK,
MXXDLFEB@G:[,$9M--ZYB#2`,#N(UM,.XU1<RRSMU#.5T)=@1%8BP+`J@@F@<
MAR*%`2B`1=)>61I&ORP@EM&/YHI/`NY#S$-*KJ%CY1@Z%%<K5^WCY!DX!!TX
M:F=-F\@BT?/2=\\CQ`X=6QQ*0!\@ZSF1-S[M2-F,Q7?79-BH'*D1-,.E,@I]
M72FHBB)CD;=0@<&Z>X]@D`!('D\VK)4M[71B=W`C9#,FIL.2J/"7BGX[D7[<
MUEO$A+MH6';D2?@B\AZVI83+2C=J\,M&%38,U#HF61346.'4F'HF'6B%$<V[
M>1LAP)2(6RNMF8RP6"',W5>LX<[PDVQ-#JO4C@R$B;YL]D#%4!RXZ025,"OS
M)3`7RZJG,<X"S13O5HYLJO*N0AD6FSC>76)(+1I*U8U8!X[LK(]62"68$!<H
M1#NRH,XV79.3'*#==LHHB<VYTU!,F.U!NTQII-*>WEFJ"4K>?@9)P+9E+,'#
MN1(95NW+(D]=>MDSI`9RR14<(O#HHHG!0IDBJ)@0Q%`-LH&[$F8*22%1-`FN
M#FPA!9)L8L8U_P"W"K<L*L@Y1?>V@IIQ:<>H51%V=\Y,LU(BF^*`F%1P<H`/
ML[^1F2_.JS)CI&[<4DZZ&.Z#7JA4J>:L5ZK,HB-@JC%Q\C#EB6T*S`H1D=%-
MTY9-T\5>"`D:=P+H5%0W,(B([HW>8,_'R+1+?+EM$NB(5]CR/2:L>2<S4VB*
M]?8/YQTPCQ3D[09D$>+Y5-E680'EAEB&CT1<^KH)*O50(4_<F*`#I;"83!3V
MTL4T+LMK-77JD<`O&";V7A5)EBS6.W:V`K`K)%191:#>.0GEG)6SDH'(=N4S
M<!`JG0;<NM<"&"$8@;LB1EM?SH5K:+-P1F[Q=.5ACMV9Q2F9)25:$+'+MA.*
MB4V=JJHR:J"90W2DLJB!>K8"AML&&9>K!#!"O+#E0)8K"3,G>:S7(X\DZ=-3
ML@CEY*,8Q_K3^5F&$8S=.&Z4##,$!=3;\S9H<R+)`BQUP3W3./3OJ?5YAIB:
M=V99S>90X-V=;\9<X&P,HATQEB>M3S(KV)C)45HN;]2]4*Y52<PSU$DPE(I,
M7(*F1<(J;=0@(``AJ0N\T$$DIMO4IQ$-W&NLA,PKMP=HVE8J2FHU4J;IBTF$
M';EDJ@0Y1!TDT*J$(?NUC`("FF(=7E`-7[-P-F!B=!I5^U9"L<2TRV&N]P_=
M-YN)=@S67:/56<C"K=PL5<SM5B^='DE8UFN4>HP)*BDH/2(@4.W4C+<RDQ!%
M<8CRA1?,8YEFCB7)L>0:9`U9]=I2QP_M0QBEI5.13D6SLKI@5J[DP4C4329?
M;)T1)`_=D;*JF5$!*0@]@!5M`*B%E)C25T(>_P!<FZA"WU-\FA7K!`Q]EC)"
M572A"C"S+)@\:'>&G7+$\.NY!V&S<ZH=/9OJ3`)ALMKT1/DBKI+P'6G5061Y
M.QK($5%Y=JW,_42315!VS9.9$`*8S9FS(\='?NDSJB*B(L"*E5W$R74([&E8
M)SQWCR*\S6)`I9WQ?*OPB(FT&G?;2Z3V/WAZY%3MIC*U;JU'>V$LSMLO"1CR
M*I[%NS2%11U*K-6HF#H(IU]0!7-DS#`4Y\NXHVTLTDB*7K*U5<QVY22M?5=N
MYCVN%L6<C%Y%"25:D54CSE8OY,IGGJRI%"(E4#Z$J3J$O8)J3=WBM&VEZ%IP
MV4*/8F)';>8-'F-)2\(@RLJ3RL34@]9NA:.4(Z'FF[.4?MEW8]*;ALF=-4NP
MI',';K0R[S&BF)X#PJE\^4#&(UCE2<N>3L:4^"E+#:K96H&MPCQ.-L,XI,PY
M(Z*EI=5*,;QKY0ZRBD:[=2@E;[JD*].ML&W=]8ZF)+W4-KR;VZE5]9E;H<JZ
M[#*%-E$K08'CU-I6I(L=*REBB)6N0YCO"INF)XB:L""3:;CY`O29([`SE,_8
M)0*42[YIDF9&--(5[0)@M"F*OMR6/[HU9P%P2K4\T=R4+*1,%.'CE.^F()\E
M,0YHR*7?LY%V_:24>#IL<$AZ56QC;;$+I=7F98PAP*1E@BD)5.9V-:/8QO(2
MK)!:2="E&'?/8UL1VN5,P@E%D6>H'E7`FW.4A"K'3`0W[-:A(>!EM0T\=%"H
M=>);7%IA0<XY4R\!R(Q[=+IF>@P0SIIKC^LTC;_+)1;].&1EW-=C[X]KT18&
M[59J_D6U;>LU77JY#"5PY%`AQ727(1F1,`%<3O[U4$A>I1-?&.5+JDY.IE[@
M*E;X6802C[K#%L%8;S9VL/9G+(BBI7<@K#O'Q7)BD0`2'!-$ZA`]$_:&P9'7
M:8"1&F.E:1/ED1HAP+O)6*LNV[TZ,U!.8Z&%R5^Y"5AEV+-6+.F+E&0.WD#-
MHQP94BQC`J=``,F/>``AHZO,JI2VLMPLB%(*3./<DU/*4?9I*OO7,@UH>0K-
MCU\LX:K,1^VRC+JLYL\2FLX7:R$>D#CZ`Z1-T+I@80W[!T;)^<P64RC"S\7?
M*4Y[A5Q31E262#.T>'!FU=MYV-73DETSG(I&,SJ.`92[DBA1*8J*AURF]#;<
M=M&QF$V8F.ZNA,#9$S7F@#.KF\Y'F?)PI3IA)'(1ZWB0DHP7S5%J*:9)#VK,
M\"4*F3JW4*9(")*`"8^D.D+M-A6?@0;W*`T\'DBFWE\^XQA+B\I#R0DIB69,
MX9X^"KP<K:V[5>SV@:]&)K'KB4V\CA1D0,#HZI4V[$ANM8Z1!WTQ=IE<2F+Y
M*:XC+#1RKIS.9:1!90KF)'\VV&WV:IW^VQR:;]HJ5O7\=NJ1'V(DHL@H/M,\
M9R.2(PA$CICWZ1Q.90H$Z1.KS2:SNX%9UV4W-#@XZ:UE?9/Q[$6*G5Z1NU>9
MS.0F\F>EQ@R#5?[95ZC&(/K"\BW#?J%9.,;G*G]!6.V$^Y0W4W*,FW5Y%HQH
MANJ49D]LP`-A$'1\!2V^V.`.UE7CBP10,(<ZK:6>.)J+21BGZ"QBB$H<[A`(
MLZIC?,*'2V\G2&^I=2),#&UO'DKSJJ)/]J;C*''K!W(Z'KC/,N/*UDEE59!:
M:JCV33=MUHE[(I$(\=P<A&O6DFS0>H(ID5$BXI.R%*)NLH!JM\WJO,B:4;(/
MI<`2GD@JY`5B&85RMPT7`P$6R:1L9"Q#-"/BHZ/8()M63%BQ:IIMFC5JW2*5
M--,I2E`.P-5]=;&.5!DD@BB!74!DT#NA!ND!D=Q1,!=C(B8``PI'#8R8G`/2
MV$.O]%OJUDT/;:$%H9*@V"H=BT4-U*-TSF[Q%7<X"8>\;"(MS;F$?Z2(CTAY
M`WU/::5+9#,J>HM.].L*!164240.L8RAU115.90Z0*&.)R$$YA$`*(;"/9MI
M;32$;,9ED!L@`"4$P`I@$#%W.!#@*14=CD`W2<.Z(!=A`=MNSMT]I'*$;,9E
M0S-J<H%,@F(!\0=_FB'^:WZ]A.D41[>T0T;2B$0C9C,@&C8I5"%1*4JVW>@3
MJ("@E`"@*G28!.8"E`-Q[=@`-]@TK8SA`E@"`%"O%%(=^H@'W*9,>\$51Z#]
MAB;J"<>@WLAY-/:#.$&6#6%0C9%,>I-/H-T$3W*8Y1[M,O20FX&#<I2_+\NE
M;&<(V8R!6^J-^\!7N_HH'*<%`.H!P$H;`'7U]7=[!VDWZ!]D-%L9PC9C,JF;
M(BF9,$R@0RAE#%+N4#G./4<YP#;K,8WLCOIB8`:PJ9\J+(4UJI44DU!5*790
M4RHB8#'`O=$$PD)T`8"`4HG';L\HZ+8)C$*R1*HI29FZ13[.K7G$_7(J6<5*
MQLK;6UGC8JJT+98]!ZW933%3<#I/FZ$BL0I]Q]%00'3+R,M85\R6***4HR,V
MI!$Q$"%,*RC@3``@<5U0.55;KWZN\.500$=_(.WDTMII"JV8S*JS1LX(9-=!
M)=,RI5S)K%!5,52"0Q%!34ZB=1#)E$O9Z)@`0V'MTMH,X1LQF2?:TFI,K-.7
M)I7HM"U66(A("?GB-B^V<M"UQU,/H*,>N3;G59Q;RP/54B>0#NE![1-I[32$
M;)N9*'U5N.WT(OH@(%'MW*`B([%'?<OI#N&WD'M#MTK8SA&R&96%9-BG[PJ0
M$4!-1(#D,<@E35,B90I.DP=`',W(/9L.Y>SV=%L9PC9C,KUFK==/NEDBJ);@
M($$3`4!`P&`0V$-AZB@._EW_`#1TQ,A40C9C,L2\>R<JD7<-4EUDP`$U52]9
MR%`1,!2F$1$"=0[]/D$0`1#<`V5L9"$&6#6%G,@B?YM,IOF.T=Q'9-0%4P$=
M]Q`B@=0?%T]II"6R;F5I&R"9S*D3`BAQ,8QBF.`B)R)IF$=C>R1(H?$Z>SMT
MC,!RA,2P#$"E9!3(/3N&_2;K+N(B`'V$.K81V$VPCVCV]NGM-(1LP:"*%B!J
MW!,Z7=%[M3K[PHB8>OO#J*'ZC"(F$!.J80#?8-^S8-`F0J(098-864B"6X!T
M!MTD(.XB/H)")DR]HCZ)##N`>0-]&TTA&S&6*S)HHI;]TF1/<I">@`%#I3`0
M(78.P`(`]FE:M98H#6MJ$%ET*2-"$:$(T(1H0HW<L*#:,G\?L@4BF-X]U99<
MM87C4)1XI'L3A"W&O3STRSQ+TT3)L(Q4R>WE4`H>SH0G,M4!.6&G3$#7K6\H
M\]+0:<5&W"&9L9!_69$B1TQDHUG*IJL7ZS90G8FN4Q#;!U`.HNFME"TZJI2:
M(J+&=\)Y!NS3B3&LI=2\NL+9Q"\9(L]B=,:_(3$"7C[G+'JLN+)LB5D]D)>R
MWZ/2.V:E`J"*RBI>GN@UIE7F2XDP$"!D%!%1&JG.L\X0%2\UY?PTYZ'X_&HE
M=X_8=MTH3C_QC->,>R+FI'K&6N0V&)N)=WH9B7M44_9$G)NLF>,4+-*%6.Z;
MG(DJ<R>VV\WV2VDM:(EU30*"(#57OK!+NYO#R2>:(9<L=T$X.6^"-DN.+N1[
MBFXWJ];R/E;-54M31K5)NFQ-CN&"85"!.]P?&VNV5*?J%58.$6;EJ2)D8Y>J
MN7X$6<I'0<F$T1?I`8UI:+0EV=$<YRQTQCF5YPZ)._%)&.X&Y.9L..I:/4E:
M;!8AAVC:^5J[Y+HE]N^5HR2R2>S,L0S$K4:]5<;EJ>#E^ZN$$#>,(R+(,$(U
M`GJQ!*,AB%W)+IK&$D`4-$!"-40:U1-P^<"&R7.:VDUFG?A`4;T5H0/!7*TE
M!2L#,X4Q=B]`M)C:/D^0IN0B]/,"9/F*FW9[FR^NH]"/GF!X6JUN4.V6L!E+
M$HZL*S913N>DHP;?+I:+W,9`NC"R*!"`%7#FHSJ#KC>:`R9,JZ1KCN"G/4^-
M%OJ6!^7&"Z*WKF*XG)UWRPXP*QJ+I.'IM2J=UHM0BX>"91<"P24HD0YMC.6.
MNG'-DE&@.55TB@Y5`PYG7N2'M<0(!H%0`)$:854Y=*UMN4TL+;1C$Y35FII@
M,BA_8.)=YF*KC59AP.P8C3*R&1H*R\51R!C!6A3E]N,'3V%;Y<*KMH-.B2EN
MJ2]6?E00.G[>IHS+IZF;U\I3:CUMMFS1:X*E+J1M6HF&^=WP)5Q/#7D!7+MC
MB6<_:M95J#DOA+9Y*V.;A+K-YAKQ\XUY7QAD6;%O(MRSDJT:W"XLVK)-4/7Y
M-B<RZYC+)J',G7N2XTP`IXSD575[RWFM>3`B$=$:^+?%:8+&W!3DK#U',"MH
MP;B)G]MMZX;Y!<XBC[+0*U1,A2V%\U7^\YJ>(PE/C1KM?8VBKR\6$:I.!(2D
MBDFDUEW#@&Q=I]>DQ!@TPC7#*LO4)Y])QUE=V6X+YH^TJ*CW_&O$-OK\]5<R
M0F.\"R60(+[6N"5FRC8UW]2NV,I1XP)&V$]*B52E.I54XZ28';`6'.0X%'2Z
M\TP/-C$1JIAY.!;>H'.:112:.7A3G9!X47F0AN4$\SQ5AS.63\GY7PLS=RN0
MXFB3ECO&#:+B;`U0N4+'K9(;2%,KDZ%KHTH_1CY0CR.!P1NZ<I*N>Z3`Z]+S
M-W&*.SW](ZTR<9X>F8(^@-HB2P5BZ[Y4G^`N6.-+[)\E9J(2TXKO\C(YA7HI
M/MHE(MQ+3$"]IMXCJT"\*LF2*2;@V%,C`H)%!?FB,(>D#Q*1N+B!&/HPRC+'
MR5)Z9WB!F:>S1,6QMB^@M;&I?8V]MN7BUU:_;[&XV9XLC:FZXMI5\[0EQ-69
MF8C#MW#85R5,S)Z+WU<TD=PH:)OS+))/-AQY^3@1U5\H6XF(.<IZ^*O$BP8%
MMAG$-7*YBV$MO$+%>.+I(T"7;!8I3/M=OU_D;;;9%RE%/VLY8BU:T,"MIQ\B
M[5$R1&JAC(-RD+2Z_P`IQILUQXJH;J8IASJHFK/E_L4G\0\>+3C.T?;.^Y5<
MI<OD2:NVJM/S+;,73-/1<NTS;*"TI&'J-+.7#`J@&24!\9(!`-RG'LTF7N42
M0+-.BK>3#7S*`3$:>1>:ETX2YSD,B9'DZS0<=XWM,\YY3.#\R$KHDGE*_*9T
MISZ#Q8I)5JOP:UK1=4%^9%JLD\$S.'1V-$D[DS@NM3;]*;\5MF`H2-SG&BV^
MO.=W&FK@_#VRG6\#.8&"X\SLQ>76:8B]1%*R_FCC==<9U^U0U0DH>)RW:,<T
M[$%`QG/U-I8I;O7K-NT0NZJC4CQ)\5V@W`-%UOK+9+VL+2(54UQHS$9-2HGW
M*:Z$'O$-)S>0IJ/$'Q+?ZZ$#7\SXUC;_`$[*N3>0DS8V["GMLE4QW&V&!PU7
MV<A%QEIK[Z-H.1ESM)1M6W+Q-Y*Q;/U@R2BG>KBGM;?KL6MBQL6PC0*81.;+
M1OU5+-V?.I@XZRIX0'$DD;<*WR1B<5Q-+D"<A,$9$@WKUE$,LDTWCK4\+-J]
M8<=)Q,2R=&JIO64FB<C78M4"OS-B%5!7U5/IP7N]R3`-#10Z,!`1)C'@%`S9
M%JDRC(;!Y)I!ST03P<L\;Y?Y@<.*K"_:A(4.YS\QCZZY-PJ-JJS28E(:)F"/
MIS%XV6T5VW45>2DFY$UFRLQ&NH3O4"D>D]644UG;>Y3#&`-$*<^?=H5E)RG3
MH464_#QEW%#I,;*8R:'?X[XP2%-PZWS+D*L7FWXJS8GGMUDN(=Q]CI=;KM0K
M:\'`))F:S4+',21B2A6#0Y$"B0;Y-X:0'$"L1HK$(;LZHF2W.),32**:C&/D
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M!'SC^8[$)=86Z0B,>M7.$R,J40XDMBP1!-4=`R0J(4A<[Q::=I,@(1YQW#C4
ML,;\$9.`-4GLCC9)=+'_``8MF),5)9)O%'R9=,<9:LV0LF2#H8RSUNM04!%+
M&J=I:-2R\2P:1K)GU,VZ0%*8#<XWUD8&S0<@&2%>7(M'9QAE)AE-4=WE61IP
M>O,))0F57F/:.^S#C_*7$6Q5JT)3(2]KKF*L4U2(;YFJ=*E&S;V[CG5@*24:
M+,V1T_MD040(N"O=EZ9==EEP]'+D!K,>)'9SFL)IR<28WPE(R%9Y=S5-2V++
M'!Y*<5-&MNLE&QK`U-@^;?;Q;K"9CD:Q)5Z+N=ES`*DP)E9&07=J*Q#9%LKT
M*H@!M$^]R)L+$!6=8J&9HA0,A65LN9\8G=\*NQOP.Y"*2.6T\G8BQ?`PN4I[
M$(7N(J$S0JG3LBR^.\D!/V^ZIQ])03>?:S(U1PNW(:PN5K/)B"B+Y<HF!,93
M+](V9;9!))KIK%%>0')4I,NTQSPTDC-3R)<Y#X.9#",<0%<P#A[+.-&EIYBQ
MN+L82UN@:U2,)-LSSL+)X=R;2*V\AC5^.+7HF-61<,8\4I:"3,`Q0(E<.>O$
M+W)`'-91#(.'A*U=0>8TN@8Y31NW%27SOQ]R!:L(<6*X?#V/^1$?A-2(-EKC
M%=[1#QU/RF6.QP%*8"$Q<$75*L;NBV,4I=DG/-E63L"`43%7*4X.7>I0<XL@
M"X9,E,>#-12J9URFAK0#2#G.:'#"N!B,X(4"K)PNR[/7>`PP;%\'D>V0?#7"
ME4J>:YJQ`LVXDY!+G3.E@;9`QE+SD:@I:[GBYBI&-V80RK:4*U8,2]962VVM
MIO\`(+^:&M;:I$!2(`<<([]*Y@PZ]-:X.>YSK-'.=08\$3#?"D?!\);O6;+D
M=&BX9Q/0HL.0N7<F,;Y6I"HQB^4:QDK"DO6&A+%%0T(QG(I["WR4=L5DG(J"
M9!91R@H)#GWD[$+NX&($++0!"J!^%6R+G>)+3M'$F),8G11P?"DVGX:S>&;J
MOH##6-&$Q6\)<7STE^UEF:SN)Y2XTR9D&:RME=.0(T"0-D"5J,C",#6A<XRS
MYLU*W,N*20%`[0DVS$,V=HGT15"@59#2KMB^%!,=\KI7+BWD5?*6#G=OXL8[
MRU4Z9R1RMG.4R">Y8OB;[4T9F\HRM/)$/;/79&T*U>)BGAYV29PSAN[DWC1!
MMU[E'KK?>F/@99@;(%0A'*3OJ39`-+Z1$Y:<XIW14?%O#^SY98?E.&2,)X&?
MRV4:(S<1D+&H8G@J3FC)M7R2I<V]G]I&D4Z<,&,M77JL4RE[CZQ,L064!XOT
M*[!/K+`8P@0<V2&ZI0ZJ<]?*I,9(XG91?SOVU.>.F,<J8O;90+9I7AY8+ACV
M/HMLKTKAZJ5.KJRA9N%?XW5<X!F8-<(B->-2-%D3**M1^AH"%1F@RPS**S#)
M'72KFLF-)YW-.DZZ##=4N$S\/?("<9#2L]7,>6[)^../W%.G8@MDA8W;]YC'
M(6,\A93GKI&TJ7L*3FQPL="5>T1[9K-@HG)S"+<[9PH<@"GJ8G2XT-HIJ'!N
M&>E*S/Z;M9'PIW>:7&+).:,BC8*GA_'V56\_AI7&V-KY=+1#URP\/[\$Y(/`
MS)2X9['N)%2879KH+HNX4S:3[]D5LN8(\3AK.)D(",#ET[ZB9!(<33$9ZJ?A
M3]X(XR(8H>\O)=&DTB!LV<;])R[2TUV(@8>3NL.XQ148DC^SRD?%H/'+AW>U
M9J0.FLJJ4KQ^X6W$ZRAC,S+1#HTB'$4A(L@MIRPISA><\+P&S.OGW`MSO$/8
MK)%8ZK.%H^.F:)E?&U8B<+3F+T1>W:)D&=OQ9.Y1LT/:Y=JU<+I4F<B4I)%8
MS9Z02BH8UKYX<8P%F)R4F/DT13;(<`8N,89\WE7$IO!CE(13/4Q<,/8E6:Y"
M<XZG;QB2M6"B5''W)B4HV4W=SL%>G3UN-!*.J^0J=("Q;.[821?NCD41DU!*
MH(#-\^60`UM.>%63A@DV1,!C:X^'@4W<6<9LFLN&G)3#D15J9A*TY7N/("PX
M_H-7M9Y2GT:$R,Y6&KU5Q9:V$66(!>..=L\&(,1./14,+("=)`#*'-#J868!
M6.ES"(-)!M'*8`9%$;.G"_-.1\78LJ>)^%N`L)1$2YO+I?'<9-87E97%N0'<
MG3G%8RE7;*$(C6JY''-"OS+$J[9&PB^*W5%<`4=":Z1/ERI@F3($9:%%\A[@
M1:,-^M/LRX17QKDF%RG'PU9JV8'7)"\VFW9JB95I)WM'!]KXZ9"I4=&I/W[<
MTDLQ5RD\AY%S`HJ^H*O6WKIDC*D`VK3B$DML@-+;.85QCFS4*L7:F.6.I-'B
M;A/F6O(E<+\>L-X:(W@^,]?L$74\F,9A+(%TQ+?1F;]EZQ/8B):]3FTLMG[)
M5T52=?N#F"1.)R@(CK[*F-LP:2"ZH`4&H<"9NI!HHH&6-.76N37.&G)"J3M@
MDX#"&)'=MCL(<HJ)8\TVNW5N<E>7^1<FVS%5EJE[R?7"M&KA`L]`TAVP4"?.
M?VO.4J(B1D9,"P;>)8,2(B-4!0(0@FZ[&$!"@9],>!<C"OA[Y,K2.'+!<>/&
M+O6<><ALVRE>@WCS#K]YAS$V7\3T2$J]JHD>TKA<>Q+;&F4()Y-I5R'1:)G<
MG(]1`KIPMN]NTN(%`(;1DH/)0GL2U@$3&))@<\*^&E(NF>'AEBH85SS6;-B6
MZW3)-]F:`ZLC&6SU@"=Q[F.U5&USDVI>RU]_BNO1,N67D3)^W;+(7MI-3L$L
MHR%Z5PBBJF"\<^TV`BXFD4P.ZM/8NSD\W/EW9%[W<=HFU0F'Z!#7EI46%MA:
M?682PQU%9H,J>PEXF)0:OFM8;-CG:MJ^W<%,FT;I"=%JF3NB**`3K'!>-G,?
M$"(TA;KLQS9<'TF.^GOZ2_.A\8-9]FSHC4KX!&P>8/C:D&M%``31L'F#XVB`
M3B4;!Y@^-H@$1*-@\P?&T0"(E&P>8/C:(!$2C8/,'QM$`B)1L'F#XVB`1$HV
M#S!\;1`(B4;!Y@^-H@$1*-@\P?&T0"1IK1L'F#XP:(!`HJ1TE\P?&#3@$XE&
MP>8/C:4`B)1L'F#XVB`1$HV#S!\;1`(B4;!Y@^-H@$1*-@\P?&T0"(E&P>8/
MC:(!$2C8/,'QM$`B)1L'F#XVB`1$HV#S!\;1`(B4;!Y@^-H@$1*-@\P?&T0"
M(E&P>8/C:(!*)5=$`*D(TT(T(1H0C0A&A":#+L_DR"HTZ^Q-4Z?>;PQ9G=1\
M!=;U*X^@'/<*$553D9V&J=TDFFS0#F3(FP6!=4I4CBD10RR8A,=Q+S7DC.V#
M*-FS(N/Z+B[[H=7A[K3JW`92FLCBA1+/78J>B5[G8;!B[&:L%9"&=B608E9O
MDT#@0P/%MQ($'RA.;9-0I4FK1Y5YFS'A6B$R=B[&..,GUZ"7(G:$K5ER7Q8L
MWCYN4BX:NKUIU$XFR@C84@>R(BHJ=W#%33`3;*#L36JZ7)KG``@$U<'"L\^-
MF*:*N\T#UK-ECPGR%K,7CV^JP6&G,83'Y[[E3'C*<S"YR0A'Q$KE5WBRLU^M
M-Y`::S;LUYAK$(.Y5P#8@J"<IQNO5T:9;)C'1:2=%5!HC&M8Y$]UW>^T(5'6
MGSQ/RUP3F.]S6*:19GLA<JPUD))0B\78FT?:FL4_;1]BDL=VR7B&=>R)#UY^
M[1:2"\6Y<),EER$-T[D$<74S"*T=HM!W<B0MBY@FK^/N4^0T:)ZT?C3R%B\"
M(P:,N5L6SI2B6$ERV))<C!XO%*)$S()3H%+Z8LM_T0"`+L20`:]V?0K1>@X.
MCD.7@R<*V9/F_@Y6=RK6JM.2<A<L4L,J)2))^FY,A:,_L^(W?J^0J?'Y$6HT
ME%3T]`ND!]=:0R<D_09BFN+-='HT=3<:8T<O"I&],`I.C4NZ;EWA%2OIS,G;
MB1*C:UGI4RZ23E%HB$N["B1N2;*B24L$/&K.J7$5*4*Y6G58]*-3;F$/0<AW
M19MN5K(:.6&=5OQ!K,HANT)#P/B!<89FIPUCB++;Y`\GD=AB2,K,3BO*Q;H[
MOTW6%KK&PWW.5*JI;XUA(5:,6?,G)VB[08P2K`J5(X!JSLXQ$,H.7)GK59Q%
MHB'5@\>I*`W,W&,Q[;?:2WFK#'Q>587%$C+6>HY+J%'L3V5FWL',HXTG/M!G
MH'(\M#RK-9FN6/$697B2B3MXS.0=`PZ-8X_.LTS$K)C"@GS9DD<5<],-96K[
MRRO$;WBXT&RS!)/HK+%"N=(-(U3#DS"PMKE4%KA76JDG$H/YU@!RQPJ.TW9A
M;@4P(.#!)V&0(TG/YU#M.D@BD;LR=_)/+G"V'&-8E;Q/VLHVRMH7I./@L9WZ
MRS=8Q\9DDZ=Y`OU<@*S89G&M)@A5'UN1ED(YDS5`R;@X*$/M!MPC$45PK%>:
MM;.O`Y#"$<M6>I-;BGDK/Y7SYGV@UBDR"="PM%QT1#VB2KN3(1GD"\35<K]P
M053MTA3EJ$G5GS2S-U"'9/W,T``#X4CLW:0:;K@&CG$`[^G?3&(#(#J\R:>N
M\],@4)]=3<I,0XSQ14:3;1QTXD<4Y<RCGW(5MRD[C&<W#0M,QFRXXX_L%PCW
M5?\`7)!\Z3,F[8@Q,95LH`"N5G#H`'.(\&_%(8@'&R([N!2%B.9O'NQR%>C*
MSD$;'*7Z.J\M5&\=6+$LVM,)<XNPV2%GZR'M>BYF*[%1]7DG4Q)HG<-H%)FN
M1VJW4Z"&A,PT@$$'3NB@7ULT6*H[LRX)>?/''[5++/.)O(#)W6+M`4QY59#$
M.3F.3)N=M46]L-?"F8Q=4,ESN4=/Q,*Z>L7;1@LW=1S5=UWO2B8=5#"XTPX_
M.HEPBG<R_P`EL<8;H<;D*Z$O3>L3Y4E8I_7<<7NW/HF.2BRSDI*VN&K->GY>
MHQ<)'@=5\X>-&X,4TS"H).D3!)F&P=9`-H0C3GX<J8GB3SS54D?B3EO3LV9@
MR]B2H5O(97^&7-*,%ZDZ#;V.-;=!VVDP%Z:OJY;WS%A`+O7459446R:C[UE^
MEW4@@W49""HS-R``.4G/P9]"EU\0.;<<VE):"YG5S[MF><?3].L=6H^)*5/6
MU#*TBY]>KF0I'%L;&/<R0==C0CT#JN*/'3\?W;E-TN>35*^#NT_:\XFL9<X"
M+(D$@:Z!E5$W$($"J$>*N%"5MNYG81HS<QI.P6=ZM(H8]=0%<KM,R+;K?9E,
MK0C^RU1M5H2JP,_+V)ZO`QC]VJS8H**LF[$YU>A,.H+1<WD1A13Q4'*J>THN
M#1Z1A#AX$VH\YJU*76_8[@Z;<6DEC2XXAJDE-Y!I]^J='FTLJE34AWU)M;>E
M6:*L,IW2Z:S=BFJ)W"?>&4=,TTU%"U/N47`.A:@<N;A5\N?MV[3(G$Q5RXPY
MF3(,GCS'LS:7=C"-M,O$.[!1+I7JO:6%)L3*JWV1H\[9(:)K=R3HD[-,6LLB
MQ67<MBO4>\.*IA3"#KD&0!%>D9>%3C&I2<C;QC]=R:`3NE0>S)G;ID:(^V>$
M?RJCP%%#+L#M"/E':JZ)RF+W8D`Y2D`!*&VVJK-D0;&RM+0+(M0BF(M?*O%%
M<RXYPQ,REKKUV-$2,NT<S%(N[7'4RWK%4>WZ8A86^/*Z-(E;.QIS!W*.XR.>
M+281S)90I0,D)00=E'D4X"KX5&:<\2K`K3'@Y&IC'-61$QLN)80L77\'Y7<6
M0T-EP2FI=_@*:]KSBRV>B2D:L<_K,>DNV<G+ZL54CPH`&QET>]MH5$17+FXB
M)<PLIH,-U"WK#STK%&N+&,M=<FEJ\G8\U5]P2AP.4LDWH[K%+2LN.\3HS?'$
M5;&[]*$G%'\TFS0?QD='HK+*R*I2"(R=<G-:2840RC+PZE%F)6WAH!IC4,NI
M.T^YJ<>D+K5Z<C<7[Y>Q-*`X;6^"J%P>XI@395BAF<7Q]QR*%?<8\IKG(+`R
M?M8S?R*$@X]:1,D3J6*`9S<(9*:>*O*MHQ`%MH^C1KA$"I-4/B$82>YG0IL4
MYG%,;ML;7"[2V1EJI>H*(?R]>RYB[$58-5%'==1:Y"QC(NKZ[-]L,89_"E59
M[F6`!W`&'DLM0APZ(YT^OL<X,RU<.I2=DN2>(8NCY4R3*W$4J5A>XVFCY!G%
MH6PF+5[/47\3&V6,,V39GDY=-B]EDD1=1Y%6@&-N`"!!#5(NKC`1.<;RTV=[
MB38->>7&P+A1\?RMDMM8M&1FT.K!0-IQ3D2HDB&US<O&%31OSNVU&(:T!];W
ML*\/%H2YF)I-(O>))J@8HC(7)]<#9&[.HO(E-MT4+1-SQXW,:"YRNO+7>/J1
M;O)4*&!YB3*J<Q>9^-;*'ECXOKKFFI3%XJ47'L!6=S<*B\B6Z""PG.0$S&+:
M</@X,A2:>"K.J!?P11NRYDIR\S<"R=FQ57X^Q3S]/-\74WV-;H6C7`^.IIQ=
MVL@[IE;+?$Z_]J<+:;2E&N#-(J2>M5UUT!)T[@(:4S#S+;%U&ZE0%^:^@")C
M#70,B0B?/SCO*U"#N43+95M$):+?)5ZDL*Y@G+TY8;BO6D&\C8WE,J-=IK:R
MVVN4QJL)9"<9M7D1%NBD(X<@MTD-3U,U)=>8!$U+>Q)S*QW:LX7[!EA.O"WV
M-RM/XXIB80%G7K=F;0&/:%D$I7]N7:.ZW&7QW%VU=<T*+XLB+%$CA1J0.HV@
MW,M%HU;M*MD3VW@&`J4\D03*!A(?<JH]X4H$Z0(4?1Z-P^:$!*.^_;J'5CP;
MM*TB6<@68"$'8>@@[;``]`=@%'<H!V=@%'M#S#J4!*%F*1EPR*AD4C;=221M
MB'2#J3(;9)02B=,-P'9,XD`1+Y!$`W\@:+818T(%%(W5U))CU_-[ID'KV*)0
MZ]P]+8HB';[`[:-II1L]"N!,@=H$(`^3L*4.S<1[=@\XC\?1M-*+&A5$I!$P
MB0HF.``<>D-S@`"``8=MS``#[.L;YCK9A5%&S.97@4O2!>DO3L`=.P=.WFV\
MFV@37)V!F5HE+Y.DNQ1$2AL'HCOON7L[!_,UL$S2E8T+()$_+T$'L`/F0\A=
MQ*'D\A1'L\VDZ8+)I2LC,L($3`!`"$`!\H`0``?*':&VP]@ZQ;1Z>S.9`%('
M5L4H=7S6Q0#?M$>W8.WM,/Q]62RZ8ZP30C9Z%02D$0$0`1#;81)N(;;[;#MV
M;;ZT=7&?=K3V9S<:`33]@A/(`?TLOD#<`#M#R!U#\?3$L2N=%(R]"NZ"[@/2
M7<!W`>D-P';IW`=MP'I[/S.S3MA%C0J"0@B(B0HB;YH1*41-YNK<.W;XNC::
M46-"H*:9C`8R9#&#;8YB%,8.GJZ=C"`F#;K';S;CY]&T&=%C0LJ"::1.A)--
M(@>0B9"D*`;B/84H``=HCIQC2B$%FT(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$
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M2ABZR7>1QL+D7,BF\:)Y1E9ITDDHX*B9P+$R34%#`<`MDF#H@$F"RWMH?+`<
M0!%1WX,89XNXSRSD,V!.1'';*"`QTXA7:'CBO8$<9EHD.[M9I2>-D3+%$G93
M)>7&B%H13224F"-R('5!%0RB@`!;W.?F/'N"PB7(@.<V@T51X3EW5)09#X[4
M&5M68;6ARBAJ]QYL6<J_<>3V#U6]"?1;S.L,;'!6\58,P/9E.;Q:6<+$U!1W
M!"DJN=4S,J9DP<@52`=514-WPJPRVP=%U),35'3'-D.J*4E@X\8<E:[)-I?D
M=!QC17*O,ZRNG3^1H2*",_EQ[8SY.JRAB2R#<RN(S23HCL#@5TV%N<STB(@8
M`FUQS9M2K?+;\9PC$UPKR^?,F[OO%WB?)7VWV2_\D*NG'V7CX;$4W6'60<=P
M<=`.V.-ABYO/<(FYD3GAK"ZQ8X0"1;+$<L5F::+TY2I@(F8>\5@Q2,J03Z38
M;XS;HK7XLX+P!$1N$3X_Y3\>LH/J!GN=M4$]X^4?`.*(.\RLC@6^8]=T28AL
M2SDK'R]IA:1,/K$HY`YI!;U,ZG=$0`PDB"\"HQX5(LD.?$%L,W-"VH7C!CI3
M)>1[G*<OJI.RTKFJEO74-48S&])K%;D:S<96PQ="LM/KMH>1,SF"><R2C%U9
M7+9I/.HYN"!T3*!WI=+)L^@AKH0A0#5GUJ!E2(0M#A(KUI`9,XTX^<X_Q749
M7DECF5QHUY9Y5R0I8K79*!2U:[Q]E$Y]_FW##6<1FGJN2TQ!XZC7D@=1JY8%
M<HN7*:/M>4VD9LZT7/:;9`KC7DH4VRY,``X0CDA5EIK4K^3F"F>4;_,3E<Y+
M$P):7&#YFDYGB%8>E6U_8^.4I99%VO)>HVN08!CD6<PZETT+*8%$FAS'*"1_
M5]M9`Z``:(B/'EI783V\>:#CJE/\M/,=WJ*MD1:;!091Y!0LI"3,=2G<+AC&
M]1B(<DO&.EWKD9BH5Z-E"B\Z!50?)+)`*2J9S-SG&%!K.=1?"P1D@H*<H>/W
M&ZQ,[N\R)R?PACF1?<@4[[!3&9XK!UPI-,N`U(E?=8\L]!RA.H0-Z<24*=1\
MD2260>L3@15L!>D.KH"]WPRPUTJ98L`5.$<QB*N"M<@2Y%J(<`8QR'@@:UW8
M[CU@^?R1@>>C.3E;+?XG$CR&PBGCA+$]-CY;CVRA%8+/C;&%2JLDDB-5R$I-
M1TBK-PI%F];=,H\6AR"D<CBM]ZG;,M,IVSM<Z(=Z5$(FN-5$:4VRF`Q:[G0,
M*JJ8J.]5X>X6KN-\M5FO\]<,/1L+S&$+9+;/TW$%GAX-G`)65A364BP=Y(5>
M(Y#G229@-8596/EEI1@9TWV445`+S?KZ0`V3,!@80:ZJBJC((*!DW?IB'!RJ
M2'+#BO0\@X+Q#4[CRZ5Q#2<:4Z1J#ZZ907JMGKN2X1_CB0HKB?MR5NGZY#R%
MT)$K'F&DJ9PLLR<D,Y[L^X*$Q&?.+G6F&T:X@Q`CIR*1E2"VEPUA/3QZPQ!T
M')N2+#B_/</;*Y8*7AROW:AM6=8M4C"WBG88HU*Q]?I"T1,ZO(1Z=DQ5#1LB
MWBEV16K]-V#U-0R)R'-4"<H-JGRTJ9:R!B19YN;((`ZJ1D*B0KPMX8C(LG$9
MR>;,,N"MGH^7+D;-R#^:NE7ND7?6'(R%)C::R-(X^QBYC&4TY6<R,3#%6@18
MB=4``%`UIES[Q+:;#'.:2*@2`8T5"M5.N]T>0'/:($FD@1S@TK'9^)$.;'=@
MA;3SVH@3]E0PY"O;=><>8>5:1-'J];LT#BR,@ZTMD"*/"6JS1$HV=1]E9R:,
MDXD&)7+3I!04T[)=ZOS98;)ES*S2`XUF)R<"@ZZ7!TRT^;+A11%H^'CRIX"\
M9L<M+C>50Y2F)6"S'%1K,52S/*=.62.RCAU-LWI%GL=]D9QM+V*2S154T$%H
MQVW0%=R51XT*8R@%'#>9DV809K2"(PB",NG3%=*Z2Y,MAV)!!-,"#!.QA+"M
M!IEVP=,U[-\;>%J/BWD)3<;0C-]63+WBIW_(>-K';+8Q]JI)^+MOCR<JS&.%
MRU2603&23*Y.FNJ5,<RUK@5@OAB'S&Q2HBG`M//Y;Q*(QZM7_%[',@9,!X^5
MG7:1HE#[?5,C*+BZ(]*4/6P5%85`W*?;1*FSV-@QLPLRP#B(<"YUY;*=-YQ:
M'0RP30Y"XLXK=\OY3*MFY6PC:XRH7^PUO"4[)T]"YPCR?XY7G&MH9M9J6MI[
M.ZHT;2I9[8$XEO&-63%=BHZ.?I%PJ-POEXV0:R4^Q$0(:81CY8K/LI1,2X6Z
M8TBJ&^NM9.,V,9+';"!K?+)G5)U#%G$BMT6Z-T<?V-./6Q*[C7N*+Z:!=SB+
M2RL,H>J>KA'BN9G)++E]244,!=QEZO`$&RYA;%WQ79:Q5D4W2I!,7N;&`A54
M`(&!-,1P+9M?&:+L-LD)C'W,I&A91"W9WDI$S2J8TL??*WB.@VN4XE_3I&Q(
M"4]2K[9(FY#H+QSA4CER538"G3KU-+;)E/L0:*G9#S:=_6ALJ6'1:\6Z<V44
MY<U>9<)OQ;PGWB3N!Y80[?BHRE,#NLKXP5DZ`^AK5D?'[JI-L.S4IF5O*IRM
M7&VV^-A7*D"F3IF94R`-E4BK>KK6OF3B\.FM-J!A&BO1H&5`9)L%K"(41J-6
M<UTG)4DHWXOXMI5!LK]SR@I^8*4IP_RMCWC?1;C/XWIE,KN!K-9<:3]>DQOL
M7.G4MM4JMMA*XQ4M2WT(OK+5,Y@,LF50,PF,&P=:IKKY89.1+9M`'.BV%%56
MBFJ*D10<+U)+@Q%X8NV98XIFT57XS,&8D9^K2"[_`"VSL<%,9!EYBQ`=C#HR
MLA>RG9*"X%-V'H!T]X(%T]K,VEJP8Y*ZLE'D4=E)LPM"&^*TU>2<.\:E><4#
MD"3Y#<<ZOEZ2;8[0G\/WJN\?[KF2?D*^QG6E(6QO9KK)H9/Q7(S"3[K3-$-7
M(O!0`Q`*)>H7M9[0"UKB`#D=2-X5HL28$6FT[QI^!1UOO%3C63'#R=O_`#@X
M[$4D\VRUGJ%IO=)X]NN.<!9D*[*UBSTUA@FU7;[ELI.&8'.XF%4W+1RI+I`_
M42ZSJE-,WJ]EKF"5,$PM`)`=&&2-%%&52;+DAX<UPK%%'*G47XJX5D,U\9LF
MI\R<<E0KRW'J1H>,8J/Q+%1&1;'CHL\%?=XH1C;<TC:=7\GJ2!CFAZW&N$?Z
MG`J!S@!M1FWF?,DNEOEN:RT8F#J^$5PAE2;*E->'!P+P:!1P9>5.K%<;XAGC
MGB[!8/Y:QM>R9B:D7]CBO*,?"8]R6IE?&\W.593+B*6,G4ZQA9F(:S+2!*M(
M1CH4HYP5N)S"+@4S9;3Z:#$PBF)<FCG"R!15RP^!.C6\+XX;WMW.N\UQBTZ7
MF!+92/!$DJL=<^3U</TJH.\8G10D%%CS7M##H396O0E(IIR`@9N"12*&IFDD
MB(@?@R+9=&M:TAAB(\>5>@:0)E`X$$!^C+"<0'<.\,<1/OMZ('`PCU`'D'RZ
MJ6M;1/)^?_.#0A7Z$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A
M&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(
5T(1H0C0A&A"-"$:$(T(1H0C0A?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
